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Chapter 1 
 
 
 
Introduction, aim and 
outline of thesis
 1.1. The Anatomy of the eye 
 
The human eye is a fluid-filled spherical structure, composed of three layers of tissue 
involved either directly or indirectly in perceiving and processing light. Light rays enter 
the eye through the transparent cornea and travel via the lens to the final destination, the 
central area of the retina, also called the macula. In the retina, conversion of light into 
chemical and then electrical impulses takes place before it is passed on to the optic nerve 
and to the brain. 
The outermost layer of the eye is composed of tough fibrous connective tissue 
called the sclera, which forms the visible white part of the eye. The sclera is connected 
through the limbus to the cornea. The middle layer of the eye consists of three distinct 
and continuous structures: the iris, the ciliary body, and the choroid (Figure 1). The iris is 
the colored portion of the eye that can be seen through the cornea and is composed of two 
sets of muscles that allow size adjustment of the pupil. The ciliary body is a ring of 
tissues that encircles the lens and includes a muscular component called the ciliary 
processes [1]. The choroid is a highly-vascularized layer that extends to the aperture of 
the optic nerve.  
The last innermost layer of the eye is called the retina. The neuronal portion of the 
retina consists of three layers of cells: an outermost layer of rods and cones, a middle 
layer of bipolar cells, and an inner layer of ganglion cells [2]. The axons of the 1.2 
million ganglion cell join together to form the optic nerve. The point of the retina at 
which the optic nerve leaves the eye through the scleral canal to transmit the visual 
information to the brain is called the optic disc (Figure 1) [3] [2, 4].  The scleral canal is a 
passage for the retinal nerve fibers from the retina. The lamina cribrosa consists of a 
series of plates of collagenous connective tissues. A depression in the centre of the optic 
nerve head, which does not have any neural tissue, is called the optic cup. The size of the 
cup is related to the diameter of the disc. Between the outer edge of the cup and the disc 
margin is the neuroretinal rim of an orange and pink color, showing a characteristic 
configuration [4].  
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Figure 1. Structure of the eye (Ref. 3) 
 
The anterior portion of the eye consists of two fluid-filled cavities, which are 
separated by the lens. The anterior chamber, i.e. the space between the lens and the 
cornea, is filled with aqueous humor, providing nourishment to the eye. Aqueous humor 
is produced by ciliary processes of the ciliary body in the posterior chamber of the eye 
and flows into the anterior chamber of the eye via the pupil. A specialized meshwork of 
cells lies at the junction of the iris and the cornea, called the trabecular meshwork (TM). 
The TM consists of three portions: the inner uveal meshwork, the middle cornoscleral 
meshwork, and the inner endothelial meshwork. The outflow of aqueous humor takes 
place via the TM by two main routes: the trabecular route and the uveoscleral route, 
through which 80% and 20% of aqueous humor outflow takes place, respectively. 
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Figure 2. Structures of the eye involved in aqueous humor homeostasis (Ref. 5). 
 
The aqueous humor filters through the TM which is divided into distinct regions: 
the uveal meshwork, the corneoscleral meshwork, and the juxtacanalicular tissue (JCT) 
into Schlemm's canal and drains through the episcleral venous system. The AH exit 
through another route known as the uveoscleral pathway via the interstitial spaces 
between the iris root and ciliary muscle [5] (Figure 2) [1, 6]. Homeostasis between the 
production and drainage of the aqueous humor is very important for maintaining the 
intraocular pressure (IOP) of the eye between 14-21mmHg. If the IOP is higher than this 
limit, this may cause damage to the retinal ganglion cells (RGCs) and the optic nerve, 
causing loss of vision in the case of glaucoma. However, in normal pressure glaucoma 
damage also occur to the optic nerve without an increase in eye pressure from the normal 
range.    
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 1.2. History of glaucoma 
 
Glaucoma is an optic neuropathy causing irreversible blindness, and is characterized by 
initial damage of the RGCs at the periphery, which then progresses to the central part of 
the eye causing vision loss [4]. Glaucoma is also called the silent thief of vision due to 
this initial peripheral loss of the vision. The word glaucoma comes from the ancient 
Greek word “glaukos”, and Hippocrates used the term to refer to a bluish discoloration of 
the pupil [4]. 
 Another meaning of the word is “hue”, describing patients having corneal edema 
and evolution of cataract [7]. Extensive refinement of the concept of glaucoma has 
continued over the years, and definitions of glaucoma have consequently kept changing. 
Glaucoma is now considered as a heterogeneous group of insidious disorders as well as a 
multifactorial disease [8, 9]. Subsequent work provided more insight into the pathogenic 
mechanisms of glaucoma. Damage and cupping of the optic nerve may be due to a 
decrease of nourishment, causing the death of key connective tissues. Ultimately, as 
several studies have highlighted in recent years, damage to the RGCs lead to an impaired 
neurotransmission between the retina and the brain. Their death, due to lack of 
nourishment, is the cause of a communication blackout between the eye and the brain 
and, hence, of loss of vision [4]. 
Glaucoma is now increasingly understood as an optic neuropathy with a variety of 
causes, including an increased IOP. Although efforts have been made to fill the gaps, 
there is still need for research in this area. The majority of treatments are partially 
effective in slowing and eventually arresting the progress of glaucomatous damage, but 
they are unable to reverse the damage due to glaucoma. Blindness due to glaucoma, 
therefore, is irreversible and has many socio-economic consequences in terms of 
treatment cost and loss of productive working hours.  
 
1.3. Pathogenesis of glaucoma 
 
The main factors associated with glaucoma are increased IOP, damage of the optic disc, 
increased ratio of the cup with respect to the disc, changes in the neuroretinal rim present 
between the cup and the disc, and damage of the retinal nerve fiber layer (RNFL) [10]. In 
normal conditions, the rates of aqueous humor production and drainage are in equilibrium 
to maintain a constant IOP. Abnormally high intraocular pressure can reduce the blood 
1
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 supply in the eye and eventually damage the RGCs and cause glaucoma [4]. 
An increase in cup size occurs in glaucoma patients. Normal eyes have a cup-to-
disc ratio (CDR) of up-to 0.5, while at a ratio greater than 0.6 glaucoma should be 
suspected. A large cup is due to a mismatch between the size of the scleral canal and the 
number of the traversing nerve fibers. Pathological cupping is caused by an irreversible 
decrease in the number of the nerve fibers, glial cells, and blood vessels (Figure 3) [4, 11, 
12]. 
 
 
Figure 3. Glaucomatous excavation of the optic nerve. Cupping of the optic nerve head 
due to loss of optic nerve tissue. (A) The CDR within the normal range. (B) 
Glaucomatous cupping with a CDR ratio of 0.8 (Ref. 12). 
 
The spectrum of the disc damage in glaucoma ranges from highly localized tissue 
loss with no thinning or notching of the neuroretinal rim to diffuse concentric 
enlargement of the central cup of the optic disc to form a vertical oval. In addition, RNFL 
defects precede the development of detectable optic disc and visual field changes [12, 
13]. The loss of the RNFL is either localized or diffuse. Localized damage is 
characterized by slit or wedge-shaped defects in the RNFL, but with the progression of 
glaucomatous damage, there is a total atrophy of the RNFL, characterized by complete 
baring of the larger retinal blood vessels and the atrophic area appearing darker (Figure 3) 
[11, 12]. 
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 1.4. Prevalence of glaucoma 
 
Blinding eye diseases are highly prevalent in many developing countries and are 
estimated to be 10-40 times higher than in industrialized countries. Glaucoma is one of 
the most prevalent causes of irreversible blindness worldwide. The prevalence of 
glaucoma is higher in Asia, accounting for 60% of the world’s total glaucoma cases, and 
primary angle closure glaucoma (PACG) in particular was found to be more prevalent in 
East Asia than in other regions of Asia [14]. In 2010 the estimate for the bilateral 
blindness due to glaucoma was 4.5 million in people with primary open angle glaucoma 
(POAG) and 3.9 million for people with PACG, that will be raised in 2020 to 5.9 million 
and 5.3 million for POAG and PACG respectively. Prevalence of POAG is highest in 
Africa, and males develop POAG more often than females. According to the figures for 
2013, the total number of glaucoma cases in Asia was 51.32 million, comprised of 33.45 
million POAG cases, 11.74 million PACG cases, and 6.13 million cases with secondary 
glaucoma. It has been estimated that this number will rise to 59.51 million by 2020 and 
80.87 million by 2040 [14]. Worldwide the number of affected people in 2010 in the 40-
80-year age group, was 64.3 million, which will be 76.0 million by 2020 and 111.8 
million by 2040 [15].  In 2013 it has been estimated that the number of cases aged 40–80 
years with PACG worldwide was 20.17 million, and predicted to increase to 23.36 
million in 2020 and 32.04 million in 2040 [15]. 
Primary congenital glaucoma (PCG) is rather rare, accounting for 0.01-0.04% of 
total blindness worldwide. The incidence of PCG, however, varies with ethnicity: the 
highest rate of 1 in 1,250 has been reported in Slovakian gypsies [16], 1 in 2,500 in Saudi 
Arabians, and 1 in 3,300 in southern Indians [17]; and the lowest rate is 1 in 10,000 to 1 
in 20,000 in Western populations [18]. Exfoliation glaucoma (XFG) is the most common 
form of secondary open angle glaucoma, accounting for up to 25% of glaucoma cases 
worldwide [19]. The prevalence of pseudoexfoliative glaucoma (PEXG) varies in 
different populations, and most studies reported the frequencies based on a selected 
patient cohort ranging from 50-60% in northern Europe, approximately 10% in the USA, 
and lower frequencies in American Blacks and Indians  [20-23]. As the number of elderly 
people is increasing worldwide, glaucoma morbidity will also rise, causing increased 
healthcare costs and economic burden in the future [24]. 
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 1.5. Classification of glaucoma 
 
Glaucoma has been principally classified into two main types, primary and secondary 
glaucoma. The two major clinical forms of primary glaucoma are characterized by 
anatomical changes between the angle formed by the cornea and the iris. Based on the 
anterior chamber angle, primary glaucoma is mainly subdivided into primary open angle 
glaucoma (POAG) and primary angle closure glaucoma (PACG) on the basis of 
gonioscopy analysis. In primary glaucoma, moreover, the optic neuropathy is caused by 
the anatomic disturbances in the anterior chamber angle or conventional outflow 
pathways with either low or elevated IOP. In secondary glaucoma, however, along with 
raised IOP, other pathological causes are also important, such as trauma, inflammation, 
pigment dispersion, deposition of exfoliative material, and neovascularization [25]. 
 
Primary angle closure glaucoma 
In PACG the IOP is elevated due to the obstruction of the TM due to the apposition of the 
peripheral iris to the TM or by a synechial closed angle [26]. PACG is more common in 
small eyes, with shallow anterior chambers, small corneas, and short axial eye lengths. 
Primary pupillary block angle closure is also more common in the elderly; as the 
crystalline lens thickens and the pupil becomes more miotic, there is increased resistance 
to aqueous flow from the posterior chamber to the anterior chamber. Angle closure can 
occur acutely, intermittently, or chronically. Angle closure is more likely to be chronic 
than acute in African-American patients [27].  
PACG is subdivided into acute angle closure and chronic angle closure glaucoma. 
In the case of acute attack the TM is quickly and completely covered by the iris leading to 
a sudden and symptomatic rise in the IOP. This is accompanied by ocular pain, headache, 
and decreased visual acuity. In the chronic form, a peripheral iris is in opposition to the 
TM with a gradual progression leading to peripheral anterior synechiae and consequently 
IOP is raised gradually, with subjective symptoms usually painless but in some cases 
people do have ocular pain and haloes being only rarely present [28, 29]. 
 
Primary open angle glaucoma 
POAG is the most common subtype of glaucoma, accounting for 90% of all types of 
glaucoma. POAG is characterized by alterations to the optic nerve head, such as 
excavation, enlargement of the optic cup with thinning and notching of the neuroretinal 
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 rim and nerve fiber layer. All these changes cause loss of retinal ganglional cells and 
finally axonal death [30, 31], leading to loss of the central visual acuity and visual field 
[25]. 
POAG is principally caused by obstruction of the aqueous outflow deep within the TM, 
resulting in an increase of the IOP to the point where the optic nerves are damaged. 
Depending on the patient’s IOP status, POAG is arbitrarily sub-classified into normal 
tension glaucoma (NTG) and high tension glaucoma (HTG). In patients with HTG, the 
intraocular pressure of the eye rises above 21mmHg, while in NTG the pressure is 
consistently within the normal range (≤ 22mmHg). Patients with NTG have normal 
anterior chamber angles with characteristic glaucomatous optic nerve damage and visual 
field defects [32]. It is believed that about 30% of patients with POAG and glaucomatous 
visual field defects have NTG [33]. NTG is more common in Japan than in European and 
American countries [34]. Risk factors for NTG are female gender, primary vascular 
dysregulation, and low blood pressure [35, 36]. Patients with NTG commonly present 
with disk hemorrhage, which occurs approximately 2 to 5 times more frequently 
compared to HTG [37].  
When POAG damages one eye, the probability of subsequent damage to the other 
eye is increased; therefore, POAG is a bilateral disease though it is frequently 
asymmetrical [38]. Damage in one eye significantly increases the risk of having glaucoma 
in the other eye. On the basis of age of onset, primary glaucoma is further divided into 
primary congenital glaucoma (PCG) [39], juvenile onset POAG (JOAG) [40, 41], and 
adult or late onset glaucoma. 
 
Primary congenital glaucoma 
PCG (OMIM 231300), also referred to as infantile, neonatal, or developmental glaucoma, 
affects children. The age of onset of the disease is from birth to 2 years of life. The 
majority of patients (60%) are diagnosed within 6 months of birth, and 80% are 
diagnosed within the first year of life. It accounts for approximately one-tenth of pediatric 
blindness [42]. In 70-80% of cases, PCG affects both eyes, leading to permanent visual 
impairment [43]. PCG is caused by the degeneration of the RGCs and dysgenesis of the 
TM. The mode of inheritance of the disease is autosomal recessive due to frequent 
consanguineous marriages [16].  
PCG is characterized by an elevated IOP, which leads to damage of the optic disc, 
buphthalmos (enlarged eyeball), breaks in the Descemet membrane with corneal 
1
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 opacification and edema, thinning of the anterior sclera, iris atrophy, and an anomalously 
deep anterior chamber [44]. The other less common signs include epiphora found in 3.3% 
of patients, blepharospasm (inflammation of the eyelids), and photophobia 
(hypersensitivity to light) present in about 7.5% of patients [45]. 
 
Juvenile and adult onset glaucoma 
JOAG is a rare disorder that manifests itself at age of onset from 3 years till 35 years of 
age and results in high IOP [40, 41]. JOAG is inherited in both an autosomal dominant 
and recessive pattern [46]. Clinical heterogeneity has been observed both within and 
between families, with congenital to juvenile and adult age of onset [47-49]. 
The incidence of JOAG was reported to be 0.38 per 100,000 individuals between 
the ages of 4 to 20 years in a population-based study [50]. Another study, based on the 
Dallas Glaucoma Registry, reported that JOAG comprised about 4% of all the patients 
included in the study [51]. The disease is severe and tends to progress rapidly with high 
IOP and glaucomatous optic neuropathy [52]. Initially, the disease remains asymptomatic 
and, if left untreated, may lead to irreversible blindness. Controlling IOP is very 
important to minimize loss of visual function and to delay disease progression [53, 54]. 
 
Pseudoexfoliative glaucoma 
PEXG is the most common type of secondary OAG, characterized by the deposition of 
white and gray fringes and flakes in the anterior segment of the eye, particularly produced 
by the anterior lens capsule, ciliary body, corneal endothelium, zonules, iris, and TM [19, 
55]. PEXG is mostly bilateral, and patients usually present with worse symptoms due to 
IOP fluctuation and severe optic nerve damage, leading to visual field defects and loss of 
vision. The accumulation of exfoliative material impairs drainage of the aqueous humor 
outflow pathway by causing a resistance; hence, IOP is raised. PEXG patients are 
clinically diagnosed with the gold standard procedure of slit lamp examination including 
gonioscopy and pupillary dilation and presence of white material in the anterior segment 
of the eye [56]. 
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 1.6. Genetic studies in glaucoma 
Glaucoma is a disease with a complex inheritance pattern, while some forms have a 
classic Mendelian inheritance, caused by single gene mutations. The pathogenesis of 
glaucoma involves both genetic and environmental factors which could affect the genetics 
of the disease. In typical Mendelian diseases, linkage and candidate gene analysis 
techniques have been used for several years now to elucidate the genetic cause of the 
disease. However, these techniques provide less insight into complex diseases. Patients 
are both clinically and genetically heterogeneous, and genetic heterogeneity indicates the 
involvement of different genes in different pathways. Therefore, multiple genetic factors 
are indicated to be responsible for the disease [57]. 
Three main methods have been used so far in different studies to identify 
susceptibility genes for different types of glaucoma: 
1. Case-control association studies: single nucleotide polymorphisms (SNP) and 
genome-wide association studies (GWAS); 
2. Genome-wide linkage studies; 
3. Whole exome sequencing (WES) and whole genome sequencing (WGS). 
  
Case-control association studies 
Association studies are based on the investigation of cases and controls that are unrelated 
individuals within a particular population. Single nucleotide polymorphisms (SNPs) are 
analyzed in patients and controls to determine the difference in allele or genotype 
frequencies between patients and controls. On average, the frequency of SNPs in the 
genome is 1 base pair change per 1000 base pairs [58]. The single nucleotide change can 
be present in the coding or noncoding region of a gene. These changes may have an effect 
on the expression of the gene and/or on the function of the encoded protein and their 
presence is considered a risk factor for the disease. In some instances, the associated SNP 
may not be the causative variant, which may rather be another variant in close proximity 
or in high linkage disequilibrium of the SNP. 
In glaucoma, many SNPs have been reported for their association with the disease 
and are in or near genes of different pathways, for example involved in oxidative stress 
regulation (eNOS), apoptosis (P53, P21) [59, 60], neurodegeneration (apolipoprotein E 
gene), cardiovascular risk factors (MTHFR) [61], immune system (IL-6) [62], and 
metalloproteinases involved in extracellular matrix (ECM) remodeling (MMPs) [63]. The 
1
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 association of many SNPs with glaucoma have not been consistently replicated, and 
opposite results have been reported for different populations. Table 1 shows the genes 
that have been identified for their association with glaucoma and that are considered risk 
factors [59, 60, 63-123].  
 
Genome-wide association studies 
Taking into account the multifactorial/polygenic and complex nature of glaucoma, many 
genome-wide association studies (GWAS) and replication studies have been performed in 
different populations to identify additional loci associated with different types of 
glaucoma (Table 2)[124-148]. This technique enables one to map the genes and loci 
playing a role in the disease. The GWAS approach has been exploited to analyze millions 
of SNPs for their association with the disease, by genotyping tag SNPs (genetic markers 
that tag SNPs in high linkage disequilibrium with each other) in cases and controls. 
Typically, over 500,000 SNPs spanning the entire human genome are evaluated using an 
unbiased approach [149-151].  
 
Genome-wide linkage studies 
In genome-wide linkage analysis, genes are mapped by typing genetic markers that flank 
the disease gene in families to identify regions that segregate with the disease or trait 
within pedigrees. Gene mapping through linkage studies in families assumes that a rare 
variant is present in a gene within the linkage interval, which segregates with the disease 
and is fully penetrant. This technique has been commonly used for Mendelian monogenic 
disorders. Markers in the disease-linked regions (usually 10-20 centimorgan (cM) in size) 
segregate with the disease [150]. Candidate genes or candidate regions for different types 
of glaucoma have been identified using genome-wide linkage analysis (Table 3)[95, 146, 
147, 152-194]. In the case of complex diseases such as glaucoma, however, linkage 
analysis has achieved only limited success, and only few candidate genes have been 
identified that contribute to the heritability of the disease. According to the genetic 
nomenclature, glaucoma loci have been classified into three groups: GLC1 refers to loci 
involved in primary open angle glaucoma, GLC2 to loci involved in primary closed angle 
glaucoma, and GLC3 to loci involved in congenital glaucoma. 
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 Whole exome sequencing and whole genome sequencing 
Whole exome sequencing (WES) and whole genome sequencing (WGS) techniques have 
gained much attention recently to find rare variants causing monogenic or complex 
diseases. Linkage studies can help to identify the region encompassing the causative 
gene, but this region usually contains hundreds of genes, which makes it difficult to 
pinpoint the gene responsible for the disease. The same is true for GWAS studies, as 
many SNPs or loci have been identified for their association with the disease but only few 
of these have a functional effect. Therefore, a combination of linkage and WES or WGS 
is now used to identify the gene involved in the disease etiology. 
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 In WES, fragments of DNA covering the coding regions of all genes in the genome are 
aligned against a reference genome. WES is less laborious than Sanger sequencing and 
less costly than WGS. Variants localized in the noncoding regions of genes are covered 
by WGS but missed by WES. Both WES and WGS techniques are now routinely used to 
identify rare variants causing disease in a research or a diagnostic setting. 
1.7 Genetic causes of primary congenital glaucoma 
Three chromosomal locations have been mapped for their association with PCG: 2p21 at 
locus GLC3A [183, 196], 1p36.2-1p36.1 at locus GLC3B [184]; and 14q24.3 at locus 
GLC3C [197]. So far, the causative gene (CYP1B1, LTBP2) has been identified for two of 
these loci [186, 198-201]. A third gene (TEK) has recently between identified as a 
causative gene for PCG [202].  
 
CYP1B1 
The CYP1B1 gene (MIM 601771) encodes a 543-amino acid protein of the cytochrome 
p450 superfamily. CYP1B1 consists of two coding exons and one noncoding exon that 
span 8.5 kb of genomic DNA localized on chromosome 2 [183, 203]. The CYP1B1 
protein is expressed in different ocular tissues, especially in the iris, TM, and ciliary body 
[183, 204]. The CYP1B1 gene is frequently mutated, ranging from 20-100% in PCG cases 
from Japan, Saudi Arabia, and Slovakian gypsies [205-207]. 
LTBP2 
The LTBP2 gene (MIM 602091), present on chromosome 14, encodes the 1821-amino 
acid protein latent transforming growth factor beta binding protein 2 [186, 198]. LTBP2 
is an extracellular matrix microfibril protein and highly expressed in the anterior segment 
of the eye, in the TM, ciliary processes, as well as essential in the development of the 
ciliary zonule microfibril. Pathogenic mutations in LTBP2 have been identified in 
Pakistani [186, 208] and gypsy PCG families.  
TEK  
The TEK gene (MIM 600221) encodes the endothelial cell tyrosine kinase receptor for the 
angiopoietins (ANGPTs), also known as Tie2 (tunica interna endothelial cell kinase). The 
protein contains 1124 amino acid residues and the gene is localized on chromosome 9 
[209]. The expression of the TEK receptor in the eye has been reported in Schlemm’s 
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 canal endothelium and is essential for the development of Schlemm’s canal in mice [210-
212]. Pathogenic mutations in PCG are inherited in an autosomal dominant manner and 
result in haploinsufficiency due to loss of protein function [202]. 
 
1.8 Genetic causes of primary open angle glaucoma 
 
MYOC/TIGR 
The TIGR/MYOC gene (MIM 601652) is located on chromosome 1q24.3 - q25.2 at the 
GLC1A locus. The gene encodes the Trabecular Meshwork Induced Glucocorticoid 
Response protein, a glycoprotein of 504 amino acid residues containing an olfactomedin 
domain. This particular domain, comprising residues 246 to 501 (encoded by exon 3), 
carry 90% of the reported mutations [213]. Worldwide, the average reported mutation 
frequency for the MYOC gene is 1.4-4.6% among glaucoma patients. MYOC is 
responsible for about 36% of juvenile onset and 2-4% of adult onset in POAG cases [214-
218]. The MYOC/TIGR protein is highly expressed in the iris, ciliary body, TM, sclera, 
and mouse and human retina [219, 220]. 
 
OPTN 
The OPTN gene (MIM 137760) is localized on chromosome 10p14-p15 at the GLC1E 
locus [162]. The gene encodes optineurin, a protein of 577 amino acids comprised of 
distinct domains such as the LC-3 interacting region, a zinc finger domain, the ubiquitin 
binding domain, and a leucine zipper domain [221]. Optineurin is expressed in the ocular 
tissues, including the TM, non-pigmented ciliary epithelium, the retina as well as in brain, 
lymphocytes, and fibroblasts [161]. Mutations in OPTN have been identified in 16.7% of 
familial cases of NTG and 13.6% of sporadic glaucoma cases. The most common variant 
rs11258194 is prevalent in 6-10% of NTG and 0-4% of POAG patients [222-225]. 
 
WDR36 
The WDR36 gene (MIM 609669), encoding a member of the WD40 repeat protein 
family, is located on chromosomal position 5q22.1 at the GLC1G locus. The WDR36 
protein is comprised of numerous guanine nucleotide-binding WD40 repeats (WDR), an 
AMP-dependent synthetase and ligase, and a cytochrome cd1-nitrite reductase-like 
WD40-associated domain [226]. The gene is expressed in ocular tissues such as sclera, 
iris, lens, ciliary muscles, ciliary body, TM, retina, and optic nerve. Pathogenic variants in 
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 WDR36 were initially identified in about 6% of unrelated POAG patients, and, when later 
results were replicated in other studies, on average 3.7% of POAG cases were found with 
variants in the WDR36 gene [116, 165, 227-232]. However, other studies were unable to 
find any association of WDR36 with glaucoma [233-235]. 
 
EFEMP1 
The EFEMP1 gene (MIM 601548) is located on chromosomal region 2p15-p16 at the 
GLC1H locus associated with POAG [168]. EFEMP1 encoding epidermal growth factor–
containing fibulin-like extracellular matrix protein 1, or fibulin-3, is a member of the 
multifunctional secreted ECM fibulin family. It is comprised of 493 amino acids with 
multiple repeats of calcium-binding EGF-like domains (cbEGF) at the N-terminus and a 
C-terminal fibulin-type module shared with the fibrillins [236, 237]. EFEMP1 is highly 
expressed in the ciliary body and cornea, and is expressed at lower levels in the inner 
nuclear layer of the retina and the optic nerve head region. Mutations in EFEMP1 are 
associated with glaucoma as well as with retinal dystrophy [167, 238]. 
 
ASB10 
The ASB10 gene (MIM 615054) at the GLC1F locus at the chromosomal position 7q35–
q36 encodes the ankyrin repeats and suppressor of cytokine signalling (SOCS) box-
containing protein 10 [163]. High expression of ASB10 was observed in the iris, followed 
by moderate amounts in the TM, the lamina, and the optic nerve; lower expression was 
revealed in the ciliary body, retina, and choroid. As ASB10 is expressed in the 
juxtacanalicular region and cells of Schlemm's canal, the effect of decreased ASB10 
protein was determined using short hairpin RNA (shRNA)-containing lentivirus in the 
human eyes in the anterior segment perfusion culture. The results revealed a 50% 
reduction in outflow facility, strengthening the role of ASB10 in glaucoma as identified 
by various studies [163, 239]. In addition, it has also been suggested that ASB10 is 
involved in the ubiquitin-mediated degradation pathways in TM cells [239]. 
 
NTF4 
The NTF4 gene (MIM 162662) is located on chromosome 19 at the GLC1O locus and 
encodes a member of the neurotrophin protein family. Heterozygous missense mutations 
have been identified in 1.7% of patients from Germany and the Netherlands with high to 
normal pressure glaucoma [178]. It has been suggested that NFT4 plays an important role 
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 in preventing the degeneration of neurons in humans. It is also involved in activating the 
receptor TrkB on RGCs and prevents their death. In addition, it has been reported in 
rodents that a decreased level of TrKB leads to a progressive loss of RGCs, and that 
TrKB activation resulting from mutated NTF4 also leads to RGC loss [178, 240-242].  
 
TBK1 
The TBK1 gene (MIM 604834) was identified by linkage analysis in a large African-
American family with NTG to the GLC1P locus located at chromosomal position 12q14 
[180]. Later on, TBK1 gene duplications were also confirmed in Japanese, White, 
Australian, and Indian NTG patients [181, 243-245]. TBK1 encodes a protein kinase and 
is expressed in human RGCs, the nerve fiber layer, and in microvasculature of the eye 
[180].  
 
1.9 Developmental glaucoma and anterior segment dysgenesis 
Childhood or developmental glaucoma can also be associated with malformation of the 
anterior segment of the eye due to the mesodermal dysgenesis of the neural crest. 
Anterior segment dysgenesis (ASD) affects the development of multiple tissues and 
structures of the eye such as the iris, cornea, lens, TM, and Schlemm's canal. Since both 
the TM and Schlemm’s canal are important for the outflow of aqueous humor, 
developmental defects could lead to a raised IOP [246, 247].  
Typically, ASD is clinically divided into different subtypes based on the 
phenotypic characteristics. These subtypes include Axenfeld-Rieger anomaly (MIM 
180500), Peters anomaly (MIM 604229) (or called Peters Plus syndrome in the presence 
of systemic abnormalities), aniridia (MIM 106210), iridogoniodysgenesis (MIM 601631), 
Marfan syndrome (MIM 154700), and Weill-Marchesani syndrome (MIM 277600) [248]. 
There is a phenotypic overlap between these diseases, and clinical heterogeneity is 
sometimes present in different individuals of the same family. 
 
Axenfeld-Rieger anomaly 
Axenfeld-Rieger anomaly is inherited as an autosomal dominant developmental disorder 
with a prevalence of 1:200,000 [249]. Clinically, Axenfeld-Rieger anomaly is 
heterogeneous and characterized by ocular features of glaucoma, corectopia (eccentric 
pupil), polycoria (iris tears), iris hypoplasia, iridogoniodysgenesis, peripheral anterior 
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 synechiae, and posterior embryotoxon [249, 250]. Axenfeld-Rieger anomaly is called 
Axenfeld syndrome (ARS) in the presence of additional systemic or non-ocular features, 
including facial (hypertelorism, telecanthus, maxillary hypoplasia with flattening of the 
mid-face, prominent forehead, and a broad, flat nasal bridge), dental (microdontia or 
hypodontia), and umbilical abnormalities. ARS patients also rarely have hearing and 
cardiovascular defects [251].  
 
Peters anomaly 
Peters anomaly is a rare disease, diagnosed clinically by the presence of congenital 
central corneal opacity; the extent of opacity may vary among patients. In addition, other 
features include iridocorneal adhesions, corneo-lenticular adhesions, and defects in the 
posterior stroma, Descemet's membrane, and endothelium [252]. Glaucoma is present in 
50% of patients. The mode of inheritance of the disease is either dominant or recessive, 
and the disease is both clinically and genetically heterogeneous. Mutations in PAX6, 
PITX2, and CYP1B1 are known to be associated with Peters anomaly [253-255]. 
  If systemic features are present in addition to Peters anomaly, such as short 
stature, cleft lip or palate, broad hands and feet, growth delay, and mental delay, the 
disease is called Peters syndrome. About 75% of patients with Peters Plus syndrome also 
have Peters anomaly [256]. The mode of inheritance of Peters Plus syndrome is recessive. 
With a prevalence below 1:1,000,000, it is very rare.  
 
Aniridia 
Aniridia is a rare sight-threatening congenital disorder typically characterized by defects 
in the iris. The iris tissue can be absent completely in the severe phenotype, or it can be 
partially absent in iris hypoplasia [257]. However, other ocular manifestations are also 
associated with aniridia in the anterior or posterior segments of the eye, such as dry eye 
and keratopathy of the cornea [258], glaucoma due to defects in the drainage of the 
aqueous humor, lens opacities, nystagmus, amblyopia, optic nerve hypoplasia, cataract, 
strabismus, and decreased visual acuity [257, 259-262]. 
The estimated prevalence of aniridia is between 1:64,000 and 1:100,000, and the 
incidence of glaucoma in congenital forms ranges from 6% to 75%. Two-thirds of cases 
have a familial history of disease with autosomal dominant inheritance while the rest is 
sporadic[263]. 
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 Marfan syndrome 
Marfan syndrome (MFS) is a relatively common systemic disease with an autosomal 
dominant mode of inheritance and a prevalence ranging between 1:3,000-5,000 
individuals [264, 265]. Multiple systems are affected in MFS, including the 
cardiovascular, ocular, and musculoskeletal systems [266]. In childhood, MFS is rare as 
well as severe due to the presence of mitral valve prolapse, and aneurysm of the aortic 
root responsible for the dysfunction of the cardiovascular system and leading to death in 
both adults and children [267]. Due to defects in the musculoskeletal system, such as the 
presence of long limbs, fingers, face, toes, as well as deformities of the chest, spine, hip, 
and foot, it is also known as a connective tissue disorder [268]. Among the ocular 
features, ectopia lentis is a major feature characterized by the displacement of the lens 
from the center of the pupil, which has been reported in almost 80% of MFS patients 
[269]. Other minor ocular features include myopia, which is most common, retinal 
detachment, abnormally flat cornea, glaucoma, and cataract [265]. 
 
Brittle cornea syndrome 
Brittle cornea syndrome [(BCS) BCS; MIM 229200] is a rare autosomal recessive 
disorder characterized by severe ocular abnormalities. Typically, BCS patients present 
with an extremely thin and fragile cornea that can be ruptured/perforated either 
spontaneously or from minor trauma to the eye, leading to blindness [270, 271]. Other 
ocular features are keratoconus, high myopia, keratoglobus, and blue sclerae. In addition 
to ocular features, BCS patients also present with non-ocular symptoms, such as skin 
hyperelasticity, joint hypermobility, and kyphoscoliosis [272]. BCS is also known as a 
connective tissue disorder, and can be caused by pathogenic mutations in the PRDM5 and 
ZNF469 genes [273, 274]. 
 
1.10 Genetics of developmental glaucoma and anterior segment dysgenesis 
In addition to clinical heterogeneity, genetic heterogeneity is also present among different 
forms of ASD. The mode of inheritance is autosomal dominant. Incomplete penetrance 
and variable expression point towards a complex disease etiology. Many genes and 
genetic loci have been identified to be associated with ASD (Table 4).  
 
 
 
32
 PXDN 
The human PXDN gene (MIM 605158) encoding peroxidasin belongs to subfamily 2 of 
the peroxidase-cyclooxygenase superfamily. The PXDN protein is comprised of a domain 
with enzymatic activity known as peroxidase, leucine rich repeats, immunoglobulin 
domains, and a von Willebrand factor domain. In humans, high expression of PXDN was 
observed in corneal and lens epithelium layers. Pathogenic mutations in the PXDN gene 
have been identified in patients with development glaucoma and anterior segment 
dysgenesis [275, 276]. Early-onset glaucoma and progressive retinal dysgenesis were 
observed in mice mutated for Pxdn [277]. 
 
PITX2 
Pathogenic mutations in the PITX2 gene (MIM 601542) were first identified in patients 
with ARS and later in patients with other diseases, such as ring dermoid of the cornea 
[278], Peters anomaly [254], iris hypoplasia [279], and iridogoniodysgenesis syndrome 
[280]. The PITX2 gene, encoding pituitary homeobox 2, is localized at the 4q25 
chromosomal region [281]. PITX2 is a member of the bicoid-like homeobox transcription 
factor family. Pathogenic mutations in PITX2 have been identified in 40-60% of probands 
affected with ARS [282, 283]. The majority of the mutations revealed in PITX2 are 
located in the homeobox region of the homeodomain. Haploinsufficiency due to null 
alleles in PITX2 has been reported as well as mutations that affect the transactivation of 
reporter genes by either increasing or decreasing the activity of PITX2 [53, 284]. In 
addition, loss of function mutations in PITX2 have been associated with congenital heart 
defects in patients with or without ARS [285]. The gene is highly expressed in neural-
crest-derived cells that are important in the development of ocular and non-ocular tissues 
[188, 286].  
 
FOXC1 
Mutations in the FOXC1 gene (MIM 601090), previously known as FKHL7, have been 
identified in ARS. The gene is located at chromosomal position 6p25 [189, 190]. FOXC1 
is comprised of only one large exon, which encodes for a protein of 533 amino acids. 
FOXC1 is expressed in the anterior segment of the eye and is involved in embryogenesis 
and early development of the eye [287, 288]. It belongs to the family of forkhead/winged-
helix transcription factors [189, 190, 289]. A characteristic and highly conserved 
forkhead DNA-binding domain (FHD) is present in all members of the forkhead family. 
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 This domain is composed of alpha-helixes and beta-sheets, and their arrangement gives 
the wing-like structural appearance to the FHD. FOXC1 uses the 110-amino-acid FHD 
for the recognition and binding to specific DNA sequences for the activation of its target 
genes [290]. In addition to ARS, deleterious mutations in the FOXC1 gene have also been 
reported in patients with congenital and adult-onset glaucoma, aniridia, and Peters 
anomaly [291-293]. 
 
PAX6 
The PAX6 gene (MIM: 607108) is located at the chromosomal position 11p13, encoding 
a protein of 422 amino acids and identified initially for its association with aniridia [192]. 
Later, mutations were revealed in patients with Peters anomaly, ARS, corneal 
dystrophy, and foveal hypoplasia [294-297]. PAX6 is comprised of two DNA-binding 
domains (the paired domain and the homeodomain), and a transactivation domain rich in 
proline, serine, and threonine residues at the C-terminus of the protein [191, 298]. In 
aniridia patients without any other disease manifestations, heterozygous mutations have 
been identified in approximately 40% to 80% of cases [298-300]. Most mutations 
reported in the literature are nonsense mutations, while missense mutations are less 
common [257]. In addition, large chromosomal deletions and rearrangements have been 
reported in patients with aniridia [301, 302]. 
 
B3GALTL 
The B3GALTL gene (MIM 610308) (also referred to as B3GTL) is localized on 
chromosome 13, contains 15 coding exons, spans 132 kb of genomic DNA, and encodes a 
498-amino acid protein [303]. Complete deletion of the B3GALTL gene and homozygous 
or compound heterozygous mutations are associated with Peters syndrome [304, 305]. 
B3GALTL plays an important role in O-glycosylation. It has been observed that patients 
with Peter Plus syndrome do not have Glc-ß1,3-Fuc-O-disaccharide, and therefore the 
pathogenic mutations could affect glucosyltransferase activity of B3GALTL and interrupt 
synthesis of the Glc-ß1,3-Fuc-O-disaccharide [306, 307]. Histological analysis of corneal 
samples of patients with Peters Plus syndrome revealed abnormal stromal connective 
tissue, corneal thickening, and absence of the endothelium, Descemet and Bowman layers 
[308]. 
 
 
34
FBN1 
The FBN1 gene (MIM 134797) is located at chromosome 15q-21.1 and is comprised of 
65 coding exons, which encode the fibrillin 1 protein [309]. Fibrillin 1 is comprised of 47 
epidermal growth factor (EGF)-like motifs, seven transforming growth factor (TGF)-β-
binding domains, and proline and cysteine rich modules. The cysteine residues contained 
by the EGF-like and TGF-β-binding domains are important for the formation of the 
disulfide bridges that maintain the stability and structure of the protein. Fibrillin 1 
monomers polymerize to form the microfibrils, the key structural and regulatory elements 
of the ECM of both non-elastic and elastic connective tissues [310]. More than 2000 
pathogenic mutations have been identified throughout the FBN1 gene [311-313]. Most 
mutations that have been reported are located in the 47 tandemly repeated EGF-like 
domains, converting cysteine to another amino acid. Pathogenic mutations have been 
revealed in more than 90% of patients with MFS [314]. FBN1 mutations are present in 
patients with ocular symptoms such as ectopia lentis and glaucoma, and in MFS patients 
without ocular symptoms, mutations have been identified in the TGFBR1 and TGFBR2 
genes [315]. 
ZNF469 
The ZNF469 gene (MIM 612078), also known as KIAA1858, encodes a protein of 3925 
amino acids; it is located at chromosomal region 16q24. Pathogenic mutations have been 
identified by homozygosity mapping and Sanger sequencing in Jewish families 
of Tunisian origin, in a Palestinian family, and in Norwegian and Syrian families 
[316-319]. ZNF469 is expressed in the anterior segments of the eye, such as the cornea. 
PRDM5 
The PRDM5 gene (MIM 614161) (also known as PFM2) is localized at chromosomal 
position 4q25-26 and encodes a PR domain-containing protein. PRDM5 belongs to 
the PRDM (PRDI-BF1 and RIZ domain containing) family of transcription factor 
proteins. Pathogenic mutations have been identified in familial patients with BCS from 
Pakistan and Saudi Arabia [273, 320]. It is expressed in the corneal epithelium, retina, 
and Bruch’s membrane and is involved in corneal development and structural 
maintenance. It has been reported that PRDM5 is involved in the regulation of 
components of the basement membrane, such as collagen and integrin [321]. 
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 1.11 The aim and outline of this thesis 
Glaucoma is the leading cause of the irreversible blindness worldwide, and the molecular 
causes of glaucoma are currently poorly understood, complicating the design of therapies 
based on the underlying disease mechanisms. Current treatment based on topical 
application of drugs aiming to reduce intraocular pressure (IOP) is an important route for 
prevention but fails to reduce glaucoma progression in a significant proportion of 
patients. This requires new therapeutic strategies and a better understanding of the disease 
pathology. 
 Only a small number of genes have been identified for different types of 
glaucoma in that are inherited in a typically Mendelian manner. As glaucoma is a 
complex disease, the associations of SNPs with modest effects have also been reported, 
and novel loci have been identified through genome-wide association studies. However, 
the genetic causes of glaucoma are still largely unsolved and remain to be determined. 
Improving our understanding of the molecular pathogenesis of glaucoma would be an 
important step towards clinical translation, allowing early screening and intervention 
based on molecular evidence. The aim of this thesis, therefore, was to search for new 
genetic variants involved in the glaucoma in order to further improve discrimination of 
high-risk groups and to identify targets for treatment. 
 
Chapter 1: This chapter describes the structure of the eye and the mechanism of 
manifestation of different types of glaucoma. In addition, it describes the genetic causes 
and genes responsible for causing several types of glaucoma in a Mendelian fashion and 
the association of SNPs in the complex forms. 
 
Chapter 2: Considering the multifactorial nature of glaucoma, in this chapter the 
association of SNPs in genes involved in pathways known for glaucoma have been 
replicated for their involvement in Pakistani glaucoma patients, using a case-control study 
design.  
 
Chapter 3: Genes previously shown to be involved in glaucoma were screened by Sanger 
sequencing in families and patients with various forms of glaucoma. In a number of 
recessive glaucoma families, a combination of Sanger sequencing and homozygosity 
mapping was used.  
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 Chapter 4: Whole exome sequencing was performed in families with various forms of 
glaucoma to find the pathogenic cause of the disease. In a number of recessive glaucoma 
families, a combination of whole exome sequencing and homozygosity mapping was 
used.  
 
Chapter 5: This chapter places the results of this thesis in context of current literature. 
The pathogenic mechanisms of glaucoma are discussed, as well as the potential clinical 
translation of genetic studies in glaucoma. Finally, a view on future perspectives is 
provided.  
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 Abstract: 
Purpose: Despite the different etiology of primary open angle glaucoma (POAG), 
primary angle closure glaucoma (PACG) and pseudoexfoliative glaucoma (PEXG), 
several studies have suggested overlapping genetic risk factors for these forms of 
glaucoma. Therefore, the aim of this study was to evaluate the role of genetic variants 
recently associated with POAG in different types of glaucoma in POAG, PACG and 
PEXG patient cohorts from Pakistan. Methods: Six variants in CDKN2B-AS1 
(rs4977756), CDKN2B (rs1063192), ATOH7 (rs1900004), CAV1 (rs4236601), TMCO1 
(rs4656461) and SIX1 (rs10483727) were genotyped using Taqman assays. A total of 513 
unrelated glaucoma patients (268 POAG, 125 PACG and 120 PEXG) and 233 healthy 
controls were included in the study. Genotypic and allelic associations were analyzed by 
Chi-square test.  
Results: The frequency of the G allele of TMCO1 rs4656461 was significantly lower in 
POAG (p=0.003; OR 0.57), PACG (p=0.009; OR 0.52) and PEXG (p=0.01; OR 0.54) 
patients compared to control individuals. The T allele of ATOH7 rs1900004 was observed 
less frequently in PACG patients (p=0.03; OR 0.69) compared to control individuals. The 
A allele of CAV1 rs4236601 was found more frequently in POAG (p=0.008; OR 1.49) 
compared to control individuals. This study demonstrates that the TMCO1 rs4656461 
variant is associated with POAG, PACG and PEXG in the Pakistani population. Our 
study was unable to confirm previous associations reported for variants in CDKN2B-AS1, 
CDKN2B and SIX1 with any type of glaucoma.  
Conclusions: In conclusion, we found consistent evidence for significant association of 
three common variants in TMCO1, ATOH7 and CAV1.  
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 Introduction 
Glaucoma encompasses a group of neurodegenerative disorders, which involves apoptotic 
death of retinal ganglion cells. Retinal ganglion cell degeneration inevitably causes 
atrophy of the optic nerve and progressive visual field damage leading to irreversible 
vision loss [1, 2]. In a recent survey by Tham et al it is estimated that worldwide 64.3 
million people between age of 40-80 years have glaucoma, which will increase to 76.0 
million in 2020 and 111.8 million in 2040. Primary open angle glaucoma (POAG) is the 
most common type of glaucoma with a higher prevalence in individuals of African 
ancestry. In contrast to European or African populations, primary angle closure (PACG) 
is the leading cause of bilateral blindness in the East Asian population [3-5]. 
In both open-angle and closed-angle glaucoma individuals often remain unaware they 
have the disorder until advanced visual loss has occurred due to the degeneration of the 
retinal ganglion cells (RGC) [6]. This RGC death and damage to the optic nerve is related 
to an imbalance between the secretion and drainage of the aqueous humor produced in the 
posterior chamber of the eye by the ciliary body and drained into the anterior chamber of 
the eye. Due to this imbalance the increased intraocular pressure (IOP) of the eye can 
cause mechanical stress to the posterior structures of the eye, remarkably the lamina 
cribrosa and adjacent tissues [7].  Stress induced by IOP might result in compression, 
deformation, and remodeling of the lamina cribrosa with consequent mechanical axonal 
damage and disruption of axonal transport [8, 9].  
Pseudoexfoliative glaucoma (PEXG) is considered a major type of secondary glaucoma, 
characterized by the production, aggregation and accumulation of abnormal extracellular 
fibrillar material in the anterior segment of the eye [10]. PEXG is a secondary type of 
OAG and in this case pigment and abnormal basement membrane material from the 
anterior segment of the eye deposits in the trabecular meshwork (TM), and because of 
malfunction of the TM an increase in IOP occurs and causes damage to RGC similar to 
POAG. The deposition of pseudoexfoliative material also affects the cornea and the lens, 
and results in a significant loss in the number of axons. Also oxidative stress caused by 
reactive oxygen species (ROS) is important in both POAG and PEXG [11, 12]. In a study 
by Izotti et al it was observed that in POAG and PEXG oxidative damage arising from 
mitochondrial failure plays a role in the functional decay of the TM [13].  
Glaucoma is a complex disease influenced by a combination of genetic and 
environmental risk factors. Recently a number of genome-wide association studies 
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 (GWAS) have been performed for POAG, which revealed several genetic variants 
associated with the disease. Among them are variants in or near the cyclin-dependent 
kinase inhibitor 2B antisense RNA (CDKN2B-AS1) gene, the CDKN2B gene, the 
transmembrane and coiled-coil domains 1 (TMCO1) gene [14, 15], the caveolin 1 (CAV1) 
and caveolin 2 (CAV2) genes [16], the SIX homeobox 1 (SIX1) gene [17, 18], and the 
Atonal homolog 7 (ATOH7) gene [19].   
Despite the different etiology of POAG, PACG and PEXG, several studies have 
suggested overlapping genetic risk factors for these forms of glaucoma [20, 21]. 
Therefore, the aim of the current study was to evaluate the role of the genetic variants 
recently associated with POAG, in different types of glaucoma in POAG, PACG and 
PEXG patient cohorts from Pakistan.  
 
Methods 
Patients and clinical data 
The present case-control study included 513 glaucoma patients (268 POAG, 125 PACG, 
120 PEXG) and 233 ethnically-matched healthy controls. Patients were recruited from the 
Al-Shifa Trust Eye Hospital in Rawalpindi, Pakistan. Complete ophthalmic examinations 
were performed for patients and controls. Briefly, for POAG patients the inclusion criteria 
were high intraocular pressure (IOP) (>21 mmHg) measured using Goldmann applanation 
tonometry, a cup-to-disc ratio (CDR) >0.7 with thinning or notching of the disc rim, and 
nerve fiber layer defects. Visual field defects typical of glaucoma such as arcuate 
scotoma, nasal step, paracentral scotoma, and generalized depression were determined 
with a Humphrey Field Analyzer (Zeiss Humphrey Systems, Dublin, CA, USA), and an 
open anterior chamber angle was confirmed with gonioscopy. Only individuals affected 
with advanced primary open angle glaucoma were included in the study while normal 
tension glaucoma patients were excluded. Presence of symptoms such as eye pain, 
headache, blurred vision, and vomiting with history of colored haloes were considered to 
be suggestive of PACG. On ocular examination conjunctival congestion, a mid-dilated 
unreactive pupil, corneal edema and a gonioscopically closed anterior chamber angle 
(presenting eye) and occludable angles (fellow eye in unilateral cases) were considered to 
be imperative for diagnosis of PACG. PEXG was diagnosed in patients who presented 
with an accumulation of microfibrillar deposits or exfoliative material on the pupillary 
ruff, a clear annular zone, or flakes of exfoliative material with a grayish central disc on 
the anterior lens capsule, iris, or corneal endothelium in one or both eyes. Controls and 
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 cases were matched for age, gender and ethnicity. The same detailed ophthalmological 
examination was done for the controls as was done for glaucoma patients, and only 
control individuals without any eye disease were selected.  
Genomic DNA and genotyping 
The current study was approved by the institutional review board of the Al-Shifa Eye 
Trust Hospital and adhered to the tenants of the Declaration of Helsinki. Whole blood 
samples of patients and controls were drawn after obtaining written informed consent. 
Genomic DNA was obtained from peripheral blood leukocytes using a standard phenol 
chloroform extraction method [22]. 
Molecular genetic analysis 
Six SNPs (rs4977756, rs1063192, rs1900004, rs4236601, rs4656461, rs10483727) were 
genotyped using TaqMan assays in an ABI PRISM 7900 real-time sequence detection 
system (Applied Biosystems, Foster City, CA), using 384-well microtiter plates . The 
384-well plates contained 5 µl of final volume for each reaction in every well consisting 
of 2.5 µl Taqman Universal PCR Master Mix (Applied Biosystems), 0.6 µl of each 
primer, and 10 ng of genomic DNA.  The PCR cycling conditions were an initial 
denaturation step at 95°C for 12 minutes and 40 cycles of 92°C for 15 seconds and 60°C 
for 1 minute. Fluorescent signals were measured at 60°C. The genotype of each sample 
was determined by measuring allele-specific fluorescence using SDS 2.3 software for 
allelic discrimination (Roche). The concordance for duplicate samples included in the 
384-wells plates was >97%. 
Statistical Analysis 
The detected genotypes of the 6 SNPs were assessed for Hardy-Weinberg equilibrium 
(HWE) using the χ2 test. The difference between the genotype frequencies in patients and 
controls was analyzed by computing the Pearson chi-square (c2) and odds ratio (OR 95% 
CI) using the statistical software StatCalc EpiInfo package v.6 (Atlanta, GA).  
 
 
 
 
 
72
 Results 
The POAG patients had a mean age of 54.6±1.4 years (52% males and 48% females), 
PCAG patients had a mean age of 53.6±1.5 years (males: 48.8%, females 51.2%), PEXG 
patients had a mean age 52.4±2.6 years (males: 49%, females 51%), and control subjects 
had a mean age of 54.1±1.3 years (males: 49.5%, females 50.5%). The p-values for age 
and gender differences are >0.05.  Association of genotype and allele frequencies of 6 
polymorphisms with different forms of glaucoma was determined. Genotype frequencies 
of all tested polymorphisms were in Hardy-Weinberg equilibrium.  
Overall a highly significant (p <0.001) protective effect of the AG genotype of rs4656461 
in the TMCO1 gene was observed for glaucoma (Table 1). The association remained 
significant when the data were grouped based on the type of glaucoma (POAG p=0.005; 
PACG p=0.02; PEXG p=0.03) (Table 2). The frequency of the minor allele G was 
significantly lower in POAG (p =0.003; OR 0.57 [95% CI 0.38-0.89]), PACG (p=0.009; 
OR 0.52 [95% CI 0.30-0.88]), and PEXG (p 0.01; OR 0.54 [95% CI 0.32-0.98]) patients 
compared to controls (Table3). Therefore, the G allele may be protective for the disease.    
The homozygous AA genotype of CAV1 rs4236601 was found to be significantly 
associated with glaucoma (p=0.02, OR 2.46 [95% CI 1.01-6.24]). When grouped by 
glaucoma type, the AA genotype of the CAV1 SNP was found to be significantly 
associated with POAG (p=0.02), but not with PACG and PEXG. A significant difference 
was found for the minor allele (A) frequency of rs4236601 between controls and POAG 
patients only (p=0.008; OR 1.49 [95% CI 1.09-2.04]) (Table 2). 
A significant difference in genotype and allele frequencies was observed between PACG 
patients and controls for the ATOH7 SNP rs1900004 (p=0.03) (Tables 2, 3). The minor 
allele (T) was found to be protective for the disease (OR 0.69 [95% CI 0.48-1.00]). No 
significant difference in genotype and allele frequencies was observed for the rs49777756 
polymorphism in the CDKN2B-AS1 gene, rs1063192 in CDKN2B, and rs10483727 in 
SIX1, between controls and glaucoma patients.  
2
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Discussion 
In the current study we identified an association of the ATOH7 polymorphism rs1900004 
with the PACG type of glaucoma. To the best of our knowledge this is the first study in 
which an association of a SNP in ATOH7 was determined in PACG patients. In a 
previous study only POAG patients were genotyped and a marginal association was 
observed [16]. ATOH7 is involved in the development of the eye, and it has been 
reported that targeted deletion of ATOH7 causes optic nerve agenesis in mice [23]. The 
rs1900004 SNP in ATOH7 has also been associated with other eye diseases such as optic 
nerve hypoplasia [24, 25].  
The CAV1 SNP rs4236601 was found to be associated with the POAG type of glaucoma 
in the current Pakistani patient cohort. The results of present study are consistent with a 
previous study by Thorleifsson et al in which the A allele was found to be associated with 
POAG susceptibility in the Icelandic, Australian and Chinese populations [16]. The minor 
allele frequencies identified in the Icelandic population (POAG 28.7%, controls 22.8%) 
are similar to those observed in this study in the Pakistani population (POAG 26.3%, 
controls 19.3%).  
However, in a study of the US population no association was observed with the CAV1 
variant (POAG 28.5%, controls 26.9%) [26]. No association was observed with PACG 
and PEXG glaucoma in the present study, which is in agreement with negative findings 
for PEXG in Icelandic and Swedish cohorts [16]. In a meta-analysis done by Huang et al., 
[27] allele A in rs4236601 SNP was found to be a significant risk factor in POAG P < 
0.001; [OR = 1.23; 95% CI, 1.12–1.34]. Upon the stratification of data for ethnicity A 
allele was found to confer a higher disease risk among Caucasians P < 0.001 [OR = 1.25; 
95% CI, 1.18–1.33] and Asians P = 0.003 [OR = 3.33; 95% CI, 1.56–7.08]. The findings 
of the current study also supports the results of meta-analysis as A allele is significantly 
associated with POAG P=0.008 [OR = 1.49; 95% CI, 1.09–2.04] .  
CAV1 is involved in the regulation of endothelial nitric oxide synthase (eNOS), an 
enzyme that produces nitric oxide, and transforming growth factor beta (TGF-β). eNOS is 
involved in the regulation of blood flow to ocular tissues and nitric oxide levels in plasma 
[28]. Excessive production of nitric oxide causes cytotoxicity, neurodegeneration and 
apoptotic cell death [29, 30]. Therefore, a functional change in CAV1 that might cause an 
imbalance in eNOS levels could potentially result in retinal ganglion cell (RGC) 
degeneration, an important process in glaucoma.  
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We observed a significant association of the TMCO1 gene polymorphism rs4656461 in 
Pakistani POAG, PACG and PEXG patients. In previous studies a higher frequency of G 
allele was found in patients compared to controls of Australian and European descent, 
whereas in the present study the A allele was found more frequently in patients compared 
to controls [14, 15]. The contradictory association observed for this variant in the TMCO1 
gene suggests that either the G allele has a different effect in different populations, 
possibly by the involvement of other contributing factors, or that it might be in linkage 
disequilibrium with a yet unidentified causative variant in or near the TMCO1 gene. The 
rs4656461 polymorphism is located downstream of the TMCO1 gene [14, 15] in the same 
linkage disequilibrium block as a second polymorphism, rs7518099, located within intron 
2 of TMCO1, which have both been associated with increased IOP in POAG [31]. In an 
expression study on ocular tissues and human retina, predominant expression of TMCO1 
was observed in the ciliary body, which is responsible for the production of the aqueous 
humor, and in the trabecular meshwork (TM), a crucial determinant of the IOP due to its 
resistance during the drainage of aqueous humor from the eye [32, 33]. Therefore, might 
be TMCO1 is also involved in regulation of IOP levels together with ciliary body and TM 
as rs4656461 polymorphism is also associated with increased IOP in various studies 
[14,15,31].  
No association of rs4977756 in CDKN2B-AS1, rs1063192 in CDKN2B and rs10483727 in 
SIX1 was observed. The results of the present study are surprisingly different from 
previous studies, in which strong association for rs4977756 was observed for Australian 
POAG patients of European decent, and for rs1063192 in POAG patients of the Afro-
Caribbean population of Barbados. In a meta-analysis by Ramdas et al, taking into 
account the data of six independent studies, a significant association of rs1063192 in 
CDKN2B and rs10483727 in SIX1 was observed with POAG [16]. Similarly, in a GWAS 
study by Burdon et al, rs4977756 in CDKN2B-AS1 was found to be a highly associated 
with POAG [6]. Similar to our study, no association of rs10483727 in the SIX1 gene was 
observed in POAG patients of Afro-Caribbean population of Barbados, while strong 
association was observed in POAG patients from a US Caucasian population [34].  
In conclusion, the results of present study revealed that the TMCO1 rs4656461 SNP is 
significantly associated with glaucoma, irrespective of the type (POAG, PACG, PEXG). 
The ATOH7 rs1900004 polymorphism was found to be protective for PACG in Pakistani 
patients, while the CAV1 rs4236601 SNP was found to confer increased risk of POAG. 
Further replication studies of these polymorphisms in different types of glaucoma of 
2
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various populations are required, along with functional studies to better understand their 
disease mechanisms.  
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2.2. Association of a polymorphism in the BIRC6 gene with 
pseudoexfoliative glaucoma. 
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Abstract 
Recently an association was observed between alleles in genes of the unfolded protein 
response pathway and primary open angle glaucoma (POAG). The goal of the current 
study is to investigate the role of these two genes, protein disulphide isomerase A 
member 5 (PDIA5) and baculoviral IAP repeat containing 6 (BIRC6), in different forms 
of glaucoma. 278 patients with POAG, 132 patients with primary angle closure glaucoma 
(PACG) and 135 patients with pseudoexfoliative glaucoma (PEXG) were genotyped for 
single nucleotide polymorphisms (SNPs) rs11720822 in PDIA5 and 471 POAG, 184 
PACG and 218 PEXG patients were genotyped for rs2754511 in BIRC6. Genotyping was 
done by allelic discrimination PCR, and genotype and allele frequencies were calculated. 
Logistic regression analyses were performed using R software to determine the 
association of these SNPs with glaucoma. The allele and genotype frequencies of 
rs11720822 in PDIA5 were not associated with POAG, PACG or PEXG. The TT 
genotype of rs2754511 in BIRC6 was found to be protective for PEXG (p = 0.05, OR 0.42 
[0.22–0.81]) in the Pakistani population, but not for POAG or PACG. This study did not 
confirm a previously reported association of risk alleles in PDIA5 and BIRC6 with 
POAG, but did demonstrate a protective role of the T allele of rs2754511 in 
the BIRC6 gene in PEXG. This supports a role for the unfolded protein response pathway 
and regulation of apoptotic cell death in the pathogenesis of PEXG. 
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Introduction 
Glaucoma is an optic neurodegenerative disorder [1] that leads to gradual loss of vision 
due to degeneration of the retinal ganglion cells [2]. Two subtypes of primary glaucoma 
can be distinguished, primary open angle glaucoma (POAG) and primary angle closure 
glaucoma (PACG), which are associated with different anatomical defects [3]. The most 
common form of secondary glaucoma is pseudoexfoliative glaucoma (PEXG), which is 
generally characterized by the appearance of dandruff-like grayish white flakes deposited 
over the iris, lens, and ciliary epithelium.  This material collecting in the anterior angle 
has been related to raised intra ocular pressure (IOP) and ultimately glaucoma [4-6].  
With advancing age, the exposure of the eye to various stress-inducing factors increases, 
which can damage the integrity of the trabecular meshwork. These majorly include free 
radicals, reactive oxygen species (ROS) [7, 8] and protein aggregation [9], which elevate 
oxidative stress in the eye. In PEXG and POAG the damage due to oxidative stress [8] 
can also succumb into mitochondrial damage and neuronal death of retinal ganglion cells 
eventually leading to vision loss [10-12]. 
A previous genome-wide analysis in a Drosophila ocular hypertension model identified 
transcripts with altered regulation and showed induction of the unfolded protein response 
(UPR) upon overexpression of transgenic human glaucoma-associated myocilin [13, 14]. 
Single nucleotide polymorphisms (SNPs) in two genes involved in reduction of 
endoplasmic reticulum (ER) stress, protein disulphide isomerase family A member 5 
(PDIA5) and Baculoviral inhibitor of apoptosis repeat-containing 6 (BIRC6), have been 
recently shown to be significantly associated with POAG [15, 16]. Since no other studies 
have yet attempted to replicate this finding, we investigated both SNPs in a cohort of 
POAG patients from Pakistan. In addition, we extended the analysis to patients with 
PACG and PEXG, as recent studies have suggested that common genetic factors might 
contribute to various forms of glaucoma [17]. The aim of this study was to investigate the 
role of rs11720822 in PDIA5 and rs2754511 in BIRC6 in POAG, PACG and PEXG 
patients from the Pakistani population. 
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Methods 
Ethics statement 
This study has been approved by the Department of Biosciences, Ethics Review 
Committee and conforms to all of the norms of the Helsinki Declaration. Written 
informed consent was obtained from all participants.  
 
Patients and control individuals 
In the present study 471 POAG, 184 PACG and 218 PEXG patients were recruited from 
different ophthalmological centers in Pakistan. The diagnosis of POAG and PACG was 
made as described previously [18]. PEXG was diagnosed on the basis of clinical history, 
cup-to-disc ratio (CDR) and intraocular pressure (IOP) measurements. In order to detect 
the exfoliative deposits on the pupillary border and the iris, slit lamp biomicroscopy was 
initially performed without dilation of the pupil, and subsequently after pupil dilation the 
patients were re-examined to detect the presence of white deposits on the anterior lens 
surface. Angles were measured with gonioscopy to discriminate between narrow and open 
angles. 160 unaffected controls, belonging to the same ethnic background as the patients, 
were classified on the basis of absence of any exfoliate deposits, normal gonioscopic 
observations and normal CDR and IOP values. The processing and DNA isolation from 
whole blood was performed as described previously [18]. 
 
Genotyping 
Two intronic SNPs, rs11720822 in PDIA5 and rs2754511 in BIRC6, were genotyped in 
the POAG, PACG, PEXG patients and control individuals using Taqman allelic 
discrimination assays performed by Real-time PCR (Applied Biosystems 7900HT Fast 
System and Sequence Detection Systems Software v2.3, Foster City, CA). The 
polymerase chain reaction (PCR) amplification was performed according to the protocol 
of the manufacturer using 10ng of DNA in a reaction mixture of 4µl. After an initial 
denaturation step of 12 minutes at 95oC, 50 cycles of amplification were performed for 15 
seconds at 92oC and termination for 90 seconds at 60oC.  
2
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Statistical Analysis 
Allele frequencies between the unaffected controls and the three patient groups (POAG, 
PACG and PEXG) were compared with the Pearson χ2 test using online free link 
available (http://statpages.org/ctab2x2.html). The Genotype frequencies were calculated 
by logistic regression analysis keeping age and gender as covariates. The data was 
statistically analyzed by using R software (R Core Team (2012). R: A language and 
environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/). Moreover, Bonferoni 
correction was applied to the individual p-values generated from logistic regression 
analysis. 
 
Results & Discussion 
Patients and controls included in the current study were age and gender matched (table 1). 
The mean age (± standard deviation) of the controls was 48.1±13.2 years, of patients with 
POAG 48.3±16.5 years, PACG 45.5.±16.5 years and PEXG 50.09±14.1 years. In total 
321 healthy subjects (52% males and 48% females), 471 patients with POAG (51% males 
and 49% females), and 184 patients with PACG patients (49.5% males and50.5% 
females) and 218 PEXG (48% males and 52% females) were enrolled in the study. The 
majority of the patients was treated with medications such as β-blockers or underwent 
surgery (trabeculectomy) to lower IOP. 
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Table 1. Demographic and clinical features of the control, POAG, PACG and PEXG 
cohorts  
 
The allele and genotype frequencies of rs11720822 in PDIA5 were not significantly 
different between POAG, PACG and PEXG compared to control individuals (Table 2). 
The T allele of rs2754511 in BIRC6 was found on 35% of control alleles, while it was 
found on 32% of POAG alleles, 35% of PACG alleles, and 28% of PEXG alleles. The 
frequency of the T allele is significantly lower in PEXG patients as compared to controls 
(p=0.01; OR 0.72 [95% CI 0.55-0.94]), suggesting it has a protective effect (Table 2), 
however this association did not remain significant when Bonferoni correction was 
applied to the data (p=0.06).  
“Logistic regression analysis was conducted to adjust for age and gender which showed 
that the homozygous TT genotype of the studied BIRC6 polymorphism is protective for 
PEXG (p=0.009), which remained significant even after the Bonferoni correction 
(p=0.05).”
 Controls POAG p-value PACG p-value PEXG p-value 
Age 48.1±13.2 48.3±16.5 >0.05 45.5±16.5 >0.05 50.09±14.1 >0.05 
Gender 
 Males 
Females 
 
52% 
48% 
 
51% 
49% 
 
>0.05 
 
49.5% 
50.5% 
 
>0.05 
 
48% 
52% 
 
>0.05 
IOP 16.4±2.3 30.5±11.6 <0.05 26.4±10.2 <0.05 28.4±10.5 <0.05 
CDR 0.39±0.18 0.85±.63 <0.05 0.67±.27 <0.05 0.76±.23 <0.05 
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The two SNPs in PDIA5 and BIRC6 were previously associated with POAG in the Salt 
Lake City and San Diego populations [16]. Since recent studies have suggested that 
common genetic factors might contribute to various forms of glaucoma, we extended our 
study to PACG and PEXG. We did not find an association of these SNPs with either 
POAG or PACG in our population, nor did we find an association of the PDIA5 gene 
polymorphism with PEXG. According to the dbSNP database, occurrence of the T allele 
of rs11720822 in PDIA5 is very rare in various populations of the world including the 
Asian and African populations 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=rs11720822), which supports 
our finding, as we also do not see high occurrence of the allele in our population. Our 
study did detect a moderate association of the BIRC6 rs2754511 polymorphism with 
PEXG in the Pakistani population (p=0.05). In agreement with the previous findings in 
the Salt Lake City and San Diego populations, demonstrating a protective effect of the T 
allele of rs2754511 on the development of POAG [16], this allele in homozygous form 
(TT) was also found to be protective for PEXG in our study. In this study, we investigated 
only the SNPs that were significantly associated with POAG in both the San Diego and 
Salt Lake City cohorts. We therefore cannot exclude that other SNPs in BIRC6 or PDIA5 
may be associated with glaucoma in the Pakistani population.  
BIRC6 is ubiquitin carrier protein involved in the protection of the cell against apoptosis 
and reduces cellular stress [16, 19]. Increased intraocular pressure, ROS and free radicals 
create a stressful environment in the eye [8, 20]. In the ER, stress can be accompanied by 
the aggregation of misfolded proteins. The accumulation of misfolded proteins can 
activate a cytoprotective signal response known as unfolded protein response (UPR), 
which triggers the activator functions like adaptation, alarm and apoptosis [12]. When 
stress is prolonged and adaptation and alarm fail to pull the cell back to normal condition, 
the UPR results in activation of apoptosis [21] and also elicits an inflammatory response 
in order to restore the normal environment of the cell. This mechanism has been found to 
be involved in the pathogenesis of many neurodegenerative disorders like Alzheimer’s 
disease, Parkinson’s disease and cerebral ischemic insults [22]. 
In PEXG and POAG the damage due to oxidative stress can succumb into mitochondrial 
damage [8, 10, 11]. The extracellular matrix of the trabecular meshwork is disrupted as a 
consequence of damage to the mitochondria, a characteristic mechanism involved in the 
pathogenicity of POAG and PEXG [8]. Konstas et al. [23] have observed excessive 
mitochondrial alterations in PEXG. The highest level of mitochondrial damage and 
2
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mitochondrial loss per cell was seen in PEXG as compared to POAG, which justifies its 
more aggressive nature. 
Zenkel et al have reported differential expression of ECM proteins and stress response 
genes in eyes of PEXG patients compared to eyes of normal healthy controls [24]. The 
expression of ECM genes is upregulated, resulting in aggregation of ECM proteins. 
Glutathione S-transferase 1, which is involved in protection from oxidative stress, is 
downregulated [24]. In addition, clusterin, an efficient extracellular chaperone, is 
downregulated in PEXG eyes, resulting in aggregation of pathologic ECM proteins [25]. 
Consequently, abnormal proteins accumulate, resulting in the formation of 
pseudoexfoliative material [25]. In the anterior chamber this hinders the outflow of 
aqueous humor by clogging the trabecular meshwork, which results in elevation of the 
IOP [26, 27]. All these stresses succumb in severe degenerative changes in PEXG.  
Apoptosis might be one of the various mechanisms that is involved in the degeneration of 
retinal ganglion cells in PEXG. BIRC6 is an anti-apoptotic protein, which promotes cell 
survival by inhibiting caspases [28]. Downregulation of BIRC6 by various 
polymorphisms and mutations leads to upregulation of p53, resulting in mitochondrial-
mediated apoptotic cell death [29]. As a consequence of stress, cytochrome C is released 
from mitochondria, which activates caspases and thus resulting in the degeneration and 
death of the cells [30]. 
In conclusion, our study demonstrates that the T allele of the rs2754511 in the BIRC6 
gene plays a protective role in PEXG patients of the Pakistani population. This supports a 
role for the UPR pathway and regulation of apoptotic cell death in the pathogenesis of 
PEXG.  
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Abstract 
Purpose: Matrix metalloproteinases (MMPs) play an important role in remodeling of the 
extracellular matrix during development and growth of various tissues including the eye. 
Various functional polymorphisms in MMPs have been implicated in the pathogenesis of 
different types of glaucoma. The aim of the present study was to investigate the role of 
various polymorphisms in Pakistani glaucoma patients. 
Methods: The present case-control study included 112 patients with primary open-angle 
glaucoma (POAG), 82 patients with primary angle closure glaucoma (PACG), and 118 
control subjects. Genotyping of polymorphisms was done using polymerase chain 
reaction followed by restriction fragment length polymorphism analysis.  
Results: A significant difference in genotype frequencies of MMP1 rs1799750 (-1607 
1G/2G) was observed between POAG patients and control subjects (p = 0.001), This was 
attributed to female subjects (p<0.001), while the association was not significant in male 
subjects (p>0.47). In addition, a significant difference was observed in genotype 
frequencies of MMP9 rs17576 (c.836A>G) in PACG patients as compared to control 
subjects (p < 0.001), which after gender stratification remained significant in males 
(p=0.009) but not in females (p=0.14). No significant associations were found for MMP7 
(c.-181T>C) and MMP9 (c.-1562C>T) polymorphisms.  
Conclusions: Our data suggest that the MMP1 rs1799750 (-1607 1G/2G) and MMP9 
rs17576 polymorphisms are gender-dependent risk factors for the development of POAG 
and PACG, respectively, in Pakistan.  
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Introduction 
Matrix metalloproteinases (MMPs) are endopeptidases involved in the proteolysis of 
extracellular matrix (ECM) proteins [1]. The ECM is considered an important determinant 
for the axial length of the eye. The enhanced activation of collagen degrading enzymes, 
particularly MMPs, might play a role in the remodeling of the ECM during ocular growth 
and development. Abnormal expression of MMPs in the eye has been implicated in many 
disorders including glaucoma [2, 3], proliferative vitreoretinopathy [4-6], cataract 
formation [7] and pterygia [8, 9]. It has been observed by Scholtzer Schrehardt et al. [10] 
that decreased activity of MMPs in the aqueous humor might be involved in the abnormal 
accumulation of the matrix found in pseudoexfoliation glaucoma (PEXG) and POAG. 
Twenty-six MMPs have been discovered, which are grouped into five main classes 
(collagenases, gelatinases, stromelysins, membrane-type and others, including matrilysin), 
based on substrate specificity, homology and subcellular localization [11]. These MMPs 
are regulated by activation of latent MMPs and their inhibitors, commonly known as 
tissue inhibitors of metalloproteinases (TIMPs), but it is believed that regulation at the 
transcriptional level has a greater impact on the expression of these MMPs. Expression 
studies revealed that most MMP genes are expressed at the time of tissue remodeling [11]. 
MMP1, -2, -3, -9, and -14 have been shown to be expressed in the human sclera.  
A cluster of MMP genes (MMP1, MMP3, MMP7, MMP8, MMP10, MMP12, MMP13, 
MMP20, MMP27) is localized on 11q22. Single nucleotide polymorphisms (SNPs) in the 
promoter region of various MMPs have been shown to affect transcription levels [12]. 
Insertion of a G nucleotide at position -1607 in the MMP1 promoter region has been 
observed in the core recognition sequence of a transcription factor binding site, which 
consequently modifies the level of MMP-1 expression [13]. It has been demonstrated that 
the promoter containing the 2G allele has a significantly higher transcriptional activity 
than that with the 1G allele [14]. Similarly, a transition from A to G at position -181 in the 
promoter region of the MMP7 gene has been reported to result in abnormal activity of 
MMP-7 [15]. Various functional variants have been identified in the MMP9 gene, located 
on 20q11.2-q13.1 [16-18]. The -1562C>T polymorphism in the promoter region exerts a 
functional effect on gene transcription. Another polymorphism in MMP9, 836A>G 
(rs17576), affects the substrate-binding domain of the MMP-9 enzyme, substituting an 
uncharged amino acid (glutamine) by a positively charged amino acid (arginine). This 
polymorphism likely alters the protein conformation, leading to a change in the substrate-
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binding and enzyme activity [13]. These four SNPs in MMP1, MMP7 and MMP9 have 
been studied in various types of glaucoma in different populations [19, 20].  
The aim of the current study was to determine whether the polymorphisms in the 
promoter and coding regions of MMP1, MMP7, and MMP9 are associated with POAG 
and PACG in the Pakistani population.  
 
Methods 
Patients 
All the patients were recruited from the glaucoma clinic of Al-Shifa Trust Eye Hospital in 
Rawalpindi. Patients were Punjabi in ethnicity (from the Punjab province, located in 
central Pakistan). Venous blood of patients and healthy individuals of the was drawn by 
venipuncture and collected in acid citrate dextrose vacutainers (Becton Dickinson, 
Franklin Lakes, NJ). All subjects were briefed about the study in their local language and 
written informed consent was obtained before obtaining their blood samples. 
The study group consisted of 312 individuals; 112 POAG cases, 82 PACG cases and 118 
control subjects. The POAG patients had a mean age of 52.6±1.4 years (69.6% males and 
30.4% females), PCAG patients had a mean age of 53.6±1.5 years (males: 48.8%, females 
51.2%) and control subjects had a mean age of 50.1±1.3 years (males: 60.2%, females 
39.8%).  
This study conforms to the tenets of the Helsinki declaration and has been approved by 
the Departmental Review and Ethics Committee. The inclusion criteria for patients and 
controls, clinical examinations, and collection and processing of blood samples have been 
described previously [21]. Briefly, for POAG patients the inclusion criteria were high 
intraocular pressure (IOP) (>21 mmHg) measured using Goldmann applanation 
tonometry, a cup-to-disc ratio greater than 0.5, visual field defects typical of glaucoma, 
which were determined with a Humphrey Field Analyzer (Zeiss Humphery Systems, 
Dublin, CA, USA), and an open anterior chamber angle. The diagnosis of angle closure 
was made by gonioscopy which aids in the identification of regions of apposition of the 
iris to the trabecular meshwork. IOP, cup-disc ratio and visual field defects criteria for 
PACG were similar to POAG.   
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Genotyping of SNPs 
After collection blood was stored at 4°C prior to extraction of genomic DNA. Genomic 
DNA was extracted from whole blood using a standard phenol chloroform method [22] 
and used for genotyping. DNA was stored at -20°C until further use. Genotypes were 
determined by PCR-restriction fragment length polymorphism (PCR-RFLP) analysis of 
the four SNPs studied in MMP1 rs1799750 (c.-1607-1606insGG), MMP7 rs11568818 (c.-
181T>C), and MMP9 (rs3918242 c.-1562C>T and rs17576 c.836A>G; p.Gln279Arg). 
Sequences of the primers used for amplification of the four SNPs are given in Table 1. In 
the case of MMP1 a restriction enzyme site for AluI (AGCT) was introduced in the 
reverse primer by replacing a T with a G at the penultimate position. The 1G allele has 
this recognition site, whereas in the 2G allele this site is abolished due to the insertion of 
an additional guanine [23].  In the MMP7 reverse primer a mismatch was introduced at 
the fourth-to-last base [15]. Annealing temperatures, sizes of PCR products, enzymes 
used for RFLP, and product sizes obtained after digestion are presented in Table 1 [23, 
15, 24, 25].  
For genotyping of four SNPs MMP1 rs1799750; MMP7 rs11568818, MMP9 (rs3918242 
and rs17576) 16 µl aliquot of PCR product was subjected to restriction enzyme digestion 
at 37 °C overnight with 10 U of AluI, EcoRI, SphI and MspI restriction enzymes, 
respectively according to the manufacturer’s instructions (Fermentas, Burlington, 
Ontario). The resulting digested products were resolved on 3% agarose gels (Table 1). 
 
Statistical analysis 
The associations between the genotype and allele frequencies in patients compared to 
controls were analyzed by computing the Pearson chi-square (c2) and odds ratio (OR 95% 
CI) using statistical software StatCalc EpiInfo package v.6 (Atlanta, GA). Power analysis 
was performed with G*Power software version 3.0.8. 
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Results 
Patients and controls included in the current study were age-matched. The mean age of 
controls was 37.9±10.8 years, of POAG 39.5±12.4 years, and of PACG 40.9±16.4 years. 
In total, 118 healthy subjects (71 males and 47 females), 112 POAG patients (78 males 
and 34 females) and 82 PACG patients (40 males and 42 females) were enrolled in this 
study. The majority of the patients were using medications such as β-blockers to lower the 
IOP. Power calculation indicated that this study had sufficient sample size of controls and 
cases to detect the previously described effect sizes. Three upstream promoter 
polymorphisms in MMP1, MMP7, MMP9 and one non-synonymous SNP in MMP9 were 
genotyped. Genotype frequencies were consistent with the Hardy–Weinberg equilibrium 
(HWE) for all four SNPs. A significant difference in genotype frequencies was found for 
the MMP1 (rs1799750; c.-1607-1606insGG) SNP in POAG and PACG patients as 
compared to controls (Table 2). The homozygous 2G/2G genotype was found at a 
significantly higher frequency in POAG (OR 3.53 [95% Confidence Interval (CI) 1.63-
7.73]; p <0.001), and PACG patients (OR 2.23 [95% CI 0.96-5.21]; p = 0.04). A highly 
significant association was observed for the 2G allele and POAG (OR 2.04 [95% 
CI=1.38-3.01); p <0.001]. A weaker association was observed between the 2G allele and 
PACG (OR 1.61 [95%CI 1.05-2.47]); p = 0.02) (Table 3). 
A significant association was observed between the GG genotype of the non-synonymous 
MMP9 variant (rs17576; c.836A>G; p.Gln279Arg) and PACG (OR 3.73 [95% CI 1.59-
8.86]; p <0.001), and to a lesser extent with POAG (OR=2.34 [95% CI=1.09-5.05]; p = 
0.01) (Table 4). Similarly, the G allele was significantly associated with PACG patients 
(OR 2.12; [95%CI 1.39-3.26]; p-value <0.001) with a higher level of significance as 
compared to POAG (OR 1.60 [95%CI 1.09-2.35]; p = 0.01) (Table 5).  
No significant associations were observed for the MMP7 (c.-181T>C) and MMP9 (c.-
1562C>T) promoter polymorphisms.  
Data were further stratified by gender to study gender-specific associations. The MMP1 
(c.-1607-1606insGG) SNP was found to be significantly associated with both POAG 
(p<0.001, χ2=17.20) and PACG in female patients (p=0.03, χ2=6.94) (Table 6). For 
MMP9 a significant association of the rs17576 SNP was observed with PACG in males 
(p=0.009, χ2=9.21) (Table 7).  
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Discussion 
In the current study we detected significant associations of MMP1 (c.-1607-1606insGG) 
and MMP9 polymorphisms (c.836A>G; p.Gln279Arg), with POAG and PACG. Both 
polymorphisms have been studied previously in POAG and PACG patients of different 
populations. A significant association has been described between the homozygous 
2G/2G genotype and POAG in the Polish population (OR 1.73; [95% CI 1.05-2.86] p = 
0.019) [26]. This is consistent with the current study, although the association detected in 
Pakistani POAG patients is stronger (OR 3.53 [95% CI 1.63-7.73]; p <0.001). The current 
study is the first to describe a significant association of this polymorphism with PACG, 
but the association is weaker than in POAG patient.  
Previous studies observed significant associations between the MMP9 polymorphism 
(rs17576) and PACG in the Taiwanese and Australian populations [27, 28]. It has been 
proposed that the short axial length in PACG is perhaps due to an alteration in the activity 
of MMP-9 in the remodeling of ECM during ocular growth and development.  
In a southern Chinese population, no significant association was observed with PACG for 
rs17576, while a significant association was detected between rs2250889 in MMP9 and 
PACG (p=0.004). The MMP9 rs17576 polymorphism substitutes a positively charged 
arginine by an uncharged glutamine in a highly conserved gelatinase-specific fibronectin 
type II domain (FN2), which is one of three types of internal repeats that combine to form 
larger domains within fibronectin. This domain in MMP9 is responsible for the collagen 
affinity of MMP9 and presumably enhances substrate binding. These residues might have 
significant interactions with the surrounding residues, so variations in this amino acid 
could affect protein stability and function [29-31]. In the present study a significant 
association of rs17576 SNP was found with males of PACG patients. Naturally occurring 
sexual dimorphism has been implicated in the risk and progression of neurodegenerative 
diseases schizophrenia, Parkinson's disease (PD), and Alzheimer's disease (AD) [32, 33]. 
Various previous studies suggest that these differences between men and women could 
result from estrogens that down-regulate the production and/or release of pro-
inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) [31]. The 
transcription of MMP genes in-turn is enhanced by pro-inflammatory cytokine TNF-α 
[34]. This male specific association could also be reconciled with evidence that females 
have constitutively a lowered innate immune response [35].  
MMP levels in the aqueous humor has previously been found to be significantly raised in 
patients with POAG and PEXG [36]. Experiments have been performed by Ito et al [37] 
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to determine the effect of antiglaucoma drugs on metabolism within the extracellular 
matrix of the ocular surface, including the corneal, conjunctival, and subconjunctival 
areas in rat. Those study suggests that α/ß-blockers, α1-blockers, α2-agonists and 
prostaglandin derivatives may stimulate ECM degradation of the ocular surface tissue by 
modulating the balance between MMPs and their inhibitors in the progression of 
glaucoma, when they are not functioning properly [37]. The precise impact of these 
polymorphisms on the function of the protein is still unknown but they could be involved 
in the partial loss of function of the ECM remodelling during the development and growth 
of the eye.   
In conclusion our results revealed a significant association of MMP1 rs1799750 (-1607 
1G/2G) and MMP9 (rs17576) polymorphisms with POAG and PACG, respectively in the 
Pakistani population. Additional studies are required to understand the exact role of these 
polymorphisms in the pathogenesis of glaucoma. 
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Abstract 
Purpose: Single nucleotide polymorphisms (SNPs) rs1048661 (p.R141L) and rs3825942 
(p.G153D) in the lysyl oxidase-like 1 (LOXL1) gene have been previously reported to be 
associated with pseudoexfoliation glaucoma (PEXG) in various Asian and 
European populations, but these SNPs have not yet been studied in the Pakistani 
population. Therefore, the aim of the present study was to investigate the association 
of these two coding LOXL1 SNPs in Pakistani PEXG patients. 
Methods: 128 Pakistani patients diagnosed with PEXG and 180 healthy controls 
were recruited for the study. Genomic DNA was extracted and both SNPs were 
genotyped by direct sequencing. Associations of genotype and allele frequencies 
with PEXG were analyzed using the Chi-square (c2) test. 
Results:  Genotype and allele frequencies of both rs1048661 and rs3825942 were found 
to be significantly associated with PEXG. The GG genotypes of both LOXL1 SNPs were 
associated with an increased risk of developing PEXG. In addition, the G alleles 
of rs1048661 and rs3825942 confer an increased risk for PEXG with an odds ratio 
(OR) of 2.98 [95% CI 1.94-4.57] and OR 6.83 [95% CI 2.94-16.67], respectively. 
Conclusion: A significant association was found for the G allele of rs1048661 
and rs3825942 in PEXG patients of Pakistani.  
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Introduction 
Pseudoexfoliative glaucoma (PEXG) occurs when pigment and abnormal basement 
membrane material from the anterior segment of the eye deposit in the trabecular 
meshwork (TM), which raises the intraocular pressure of the eye causing a degeneration 
of the optic nerve. In addition the presence of pseudoexfoliative material causes changes 
to the cornea, camerular angle, lens and zonules as well as a significant loss in the number 
of axons [1,2]. The accumulation of exfoliative material in the juxtacanalicular tissue 
(JCT) results in the disorganization of the JCT and Schlemm’s canal followed by 
dysfunction of endothelial cells, which appear to be the causative factor in the 
development of PEXG [3]. 
The precise etiology and pathogenesis of pseudoexfoliative glaucoma still remains 
unknown. Previous molecular, biochemical and immnunohistochemical studies have 
elucidated that proteins of the extracellular matrix (ECM) metabolism and cellular stress 
are differentially expressed in tissues of PEXG patients. It has been observed that the 
pathophysiology of PEXG involves an excessive production of elastic microfibrillar 
components, changes in the enzymatic cross linking processes, a proteolytic imbalance 
between matrix metalloproteinases and their inhibitors. It is also conceivable that lack of 
antioxidants and increased cellular and oxidative stress may play an important role in the 
progression of PEXG as a stress-induced elastic microfibrillopathy [4, 5]. A family of 
five lysyl oxidase enzymes (LOX, LOXL1, LOXL2, LOXL3, and LOXL4) play an 
important role in cross-linking between collagen, elastin and fibrillin, which are the 
substrates of the LOXL1 enzymes in the connective tissues. This cross-linking reaction 
provides additional mechanical strength to the ECM and makes it more resistant to 
degradation [6]. It has been reported in a recent study that greater cross linking in the 
tissues of TM and ECM will make the tissues stiffer in glaucomatous eyes as compared to 
the non-glaucomatous eyes [7]. LOXL1 expression is enhanced in the TM by the cytokine 
tumor growth factor beta1 (TGF β1). This changes the crosslinking ability of LOXL1 in 
PEXG, which results in the deposition of exfoliative material and increased resistance in 
the aqueous outflow pathway [8]. 
A recent genome-wide association study in PEXG patients from Iceland and Sweden 
identified a strong association with two non-synonymous polymorphisms in the LOXL1 
gene [9]. Similarly, in German and Italian populations a strong association has been 
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observed between PEXG and polymorphisms in the LOXL1, which support an important 
role of this gene in the progression of PEXG in various populations [10]. In a meta-
analysis of LOXL1 polymorphisms in different populations including Caucasian, 
Japanese, Indian and Chinese it has been observed that the G allele of rs3825942 is a 
common disease associated allele, with an overall odds ratio of 10.89 (95% CI 7.20-
16.45). However, only in the Caucasians case the G allele of rs1048661 was found to 
impart an increased risk to the disease (OR 2.35) while in the Japanese population the G 
allele was found to have a highly protective role (OR 0.03). In the Chinese and Indian 
populations this polymorphism was not found to be significantly associated with PEXG 
[11]. 
Although SNPs in the LOXL1 have been studied in many populations, an analysis of 
PEXG patients from Pakistan has not yet been performed. Therefore, the aim of the 
present study was to analyse two non-synonymous polymorphisms (rs1048661 and 
rs3825942) in the LOXL1 gene in PEXG patients from Pakistan. 
Materials and Methods: 
Patients 
The present case control study included 128 patients diagnosed with PEXG and 180 
healthy controls of Pakistani origin who were recruited from the Al-Shifa Eye Trust 
Hospital in Rawalpindi. Complete ophthalmic examinations were performed for both 
patients and controls as reported previously [12]. PEXG was diagnosed in patients who 
presented with an accumulation of microfibrillar deposits or exfoliative material on the 
papillary ruff, a clear annular zone, or flakes of exfoliative material with a grayish central 
disc on the anterior lens capsule, iris, or corneal endothelium in one or both eyes. 
Controls and cases are matched for the age, gender and ethnicity (Punjabi). 
Genomic DNA and genotyping 
The current study was approved by the institutional review board of the Al-Shifa Eye 
Trust Hospital and adhered to the tenants of the Declaration of Helsinki. Whole blood 
samples of both patients and controls were drawn by venipuncture after obtaining 
informed written consent. The blood samples were collected in EDTA vacutainer tubes 
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(Becton Dickinson, Franklin Lakes, NJ) and stored at 4 °C till further processing. 
Genomic DNA was obtained using a standard phenol chloroform method [13]. 
Genomic DNA was genotyped for two non-synonymous SNPs located in exon 1 of 
LOXL1: rs1048661 (c.758G>T; p.Arg141Leu) and rs3825942 (c.794G>A; p.Gly153Asp). 
The following primers were used to amplify a 259 bp product, which spans both 
polymorphic sites in exon 1 of LOXL1: forward primer 5′-
ATTCGGCTTTGGCCAGGTGC-3′and reverse primer 5′ 
GTACACGAAACCCTGGTCGT-3′. The polymerase chain reaction (PCR) mixture 
contained 2.5U Taq polymerase (Roche, Mannheim, Germany), 1x PCR buffer, 1.5mM 
MgCl2, 10µM each primer, and 50ng DNA. PCR amplification was performed with an 
initial denaturation at 95 0C for 5 min, followed by 35 cycles of denaturation at 950C for 
45 s, primer annealing at 650C for 45 s, extension at 720C for 45 s, followed by a final 
extension for 7 min at 720C. PCR products were separated on a 2% agarose gel and 
purified by using PCR clean-up purification plates (NucleoFast® 96 PCR, Macherey-
Nagel, Duren, Germany), according to the manufacturer’s protocol. Purified PCR 
products were analyzed by Sanger sequencing using an automated DNA sequencer (Big 
Dye Terminator, version 3 on a 3730 DNA analyzer; Applied Biosystems, Inc., Foster 
City, CA). 
Statistical Analysis 
Data were analyzed using the SPSS statistical package (SPSS version 16.0, Chicago, 
Illinois).  Odds ratios (OR) for genotype and allele frequencies of patients compared to 
controls were calculated using the Chi-square (c2) test, taking a 95% confidence interval 
(95% CI) into account. A p-value <0.05 was considered as statistically significant. 
Results 
All PEXG patients and control individuals originated from the Punjab region of Pakistan. 
The PEXG patients had a mean age of 47.3±10.3 years and included 54% males and 46% 
females, whereas the controls had a mean age of 45.2±10.8 years with 52% males and 
48% females.  
The distribution of the LOXL1 genotype and allele frequencies of SNPs rs1048661 and 
rs3825942 were analyzed in PEXG patients and control individuals. Figure 1 shows the 
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normal, heterozygous and homozygous variant sequences for the two SNPs studied. The 
genotype frequencies were consistent with the Hardy-Weinberg equilibrium (HWE) for 
both SNPs in controls and PEXG patients. Table 1 gives the detailed count of the 
genotype and allele frequencies of rs1048661 and rs3825942 polymorphisms of LOXL1. 
For both SNPs a significant association was identified for the genotype (p-value <0.001) 
and allele frequencies (p-value <0.001) in PEXG patients compared to controls. The G 
allele of rs1048661 was found in 85.2% of the patient alleles compared to 65.8% of 
control alleles, demonstrating that it confers an increased risk for PEXG (OR 2.98 [95% 
CI 1.94-4.57]). The G allele of rs3825942 had an even stronger association with PEXG, 
as it was found in 97.3% of patient alleles compared to 83.9% of control alleles (OR 6.83 
[95% CI 2.94-16.67]). 
 
 
Figure 1. Sequence chromatograms of the two LOXL1 SNPs of Exon 1. A-C represent 
the corresponding normal (GG), heterozygous (GT) and homozygous variant (TT) 
sequences for rs1048661 while D-F shows normal (GG), heterozygous (GA) and 
homozygous variant (AA) sequences for rs3825942. 
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Discussion 
SNPs in the LOXL1 gene have previously been associated with PEXG in various 
European and Asian populations, to date have not been studied in the Pakistani 
population. The current study is the first to demonstrate that LOXL1 SNPs are associated 
with PEXG patients from Pakistan. The highest association was observed with the G 
allele of rs3825942 (OR 6.83), which was present in an overwhelming majority of the 
cases with PEXG. A significant but lower association was noted with the G allele of 
rs1048661 (OR 2.98).  
A recent meta-analysis, a number of studies from different populations demonstrated a 
strong association between PEXG and the G allele of SNP rs3825942 in Caucasian and 
Asian populations (overall OR 10.89), while the G allele of SNP rs1048661 was found to 
confer an increased risk in only the Caucasian populations (OR 2.35), whereas in the 
Japanese population it has a protective role (OR 0.03). This suggests that rs1048661 is not 
directly implicated in the disease etiology of PEXG. It is more likely that rs3825942 is the 
common disease-associated polymorphism and may have functional impacts on the 
LOXL1 protein. [11]. This is in line with our findings in the Pakistani population as we 
found a higher OR (6.83) for rs3825942 as compared to rs1048661 (2.98). Similar results 
were obtained in recent studies of Latin American and Uygur populations, which were not 
included in the meta-analysis of LOXL1 polymorphisms [14, 15].  
Not surprisingly our results differ from those reported in the Indian population; the G-
allele of the rs1048661 polymorphism was found less frequently in Indian cases and 
controls (allele frequencies of 72.1% and 63.4%, respectively) and was not found to be 
significantly associated with PEXG [16]. The allele frequencies in our Pakistani cases and 
controls (85.2% and 65.8%, respectively) resembled more closely the frequencies in 
American and European cohorts, rather than the Indian population, which is in agreement 
with our population genetics data where we see a cline passing through Pakistan and 
diminishing in intensity towards India [17, 18, 19]. The frequency of the G-allele of 
rs3825942 in Indian patients and controls (92.3% and 74.2%, respectively) was also 
somewhat lower than in our Pakistani cohorts (97.5% in PEXG and 83.9% in controls), 
and the OR was slightly lower in the Indian cohort (4.17) compared to our Pakistani 
cohort (6.98). The lower association of rs3825842 in the Indian and Pakistani populations 
compared to other populations from America, Europe and Asia (overall OR 10.89), 
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suggests that additional genetic factors may play a role in PEXG in Indian and Pakistan, 
either within the LOXL1 gene or in other genes. This is supported by a recent study 
demonstrating that neither rs1048661 (R141L) nor rs3825942 (G153D) affect the amino 
oxidase activity of LOXL1, suggesting that other unknown genetic factors or molecular 
mechanisms may be more relevant to the development of PEXG [20].  
In previous studies we have identified significant associations with polymorphisms in the 
glutathione S-transferase (GSTT1 and GSTM1) [21] and tumor necrosis factor alpha 
(TNF-α) [12] with PEXG. Among these higher OR was observed for TNF-α (8.37) as 
compared to LOXL1 (6.98), GSTT1 (4.26) and GSTM1 (3.81), the combined effect of all 
these genes probably have a significant contribution in causing PEXG in Pakistani cohort. 
The present study confirms the involvement of the two LOXL1 coding polymorphisms in 
PEXG in the Pakistani population. Further studies on the functional level are required to 
better understand the involvement of LOXL1, glutathione S-transferase and tumor 
necrosis factor alpha in PEXG, which could potentially aid the development of 
therapeutic approaches for the disease. 
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Abstract 
Purpose: The aim of the present study was to investigate the association of glutathione S-
transferase GSTT1 and GSTM1 genotypes with pseudoexfoliative glaucoma (PEXG) in 
a group of Pakistani patients.  
Methods: Multiplex polymerase chain reaction was used to study the GSTT1 and 
GSTM1 polymorphisms in 165 PEXG patients and 162 unaffected controls. 
Results: In the current study we describe a significant gender-specific association of 
GSTT1 and GSTM1 null genotypes with PEXG. The three null genotype combinations 
(i.e., T1M0, T0M1, and T0M0) were found at significantly higher frequencies in the 
PEXG patients as compared to the controls (χ2=21.82, p<0.001). This association was 
specifically related to the female patients (χ2=35.63, p<0.001); no such association was 
seen in the male patients (χ2=2.28, p>0.05).  
Conclusions: The results suggest that there is a significant involvement of the GSTT1 and 
GSTM1 polymorphisms in female Pakistani patients having PEXG, which suggests 
a possible gender-specific impairment of detoxification in this group. 
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Introduction   
Xenobiotic compounds of exogenous and endogenous origin are a substantial threat to the 
human cells as they lead to the production of highly reactive oxygen species (ROS). The 
cells produce numerous antioxidants that counter the effects of these compounds by 
reducing their accumulation. Glutathione (GSH) is an important antioxidant that protects 
against cellular damage caused by environmental toxins as well as from ROS-mediated 
injury. GSH works by neutralizing ROS and xenobiotics with the help of glutathione S-
transferase (GST); this enzyme catalyzes the conjugation of these compounds with GSH, 
which being water soluble can thus be easily eliminated from the body [1-3]. 
Mammalian GSTs are made up of a supergene family of catalytic and binding proteins 
located on at least seven different genes, which are divided into three major classes: 
cytosolic, mitochondrial and microsomal GSTs. Tissue expression studies have shown 
that most of the cytosolic GSTs are expressed in the kidneys and the liver, where they 
play an important role in the detoxification of various endogenous and exogenous toxic 
chemicals in the body [4-6].  
Of the cytosolic GSTs, the Mu (µ), Theta (σ), and Pi (π) genes have been found at 
different frequencies in various ethnic groups. In the Mu class of GSTs the M1 null 
genotype (M0) is common in the Chinese, Japanese, French, and English, with a 
frequency between 43% and 58% [7-11]. In the Theta class of GSTs the T1 null genotype 
(T0) has been found at varying frequencies in different ethnic groups: 64.4% in Chinese, 
60.2% in Koreans, and 20%–24% in African-Americans [12]. Biochemical studies have 
associated these allelic variations to intra-individual differences in the ability to 
metabolize environmental and cellular toxins [13]. 
It has been shown that individuals carrying the null genotypes of GST may have higher 
levels of intermediates of oxidative metabolism because the detoxification pathways have 
been disrupted, and this then directly or indirectly exacerbates the pathological effects of 
ROS. 
This has important implications in a range of diseases; for example, various types of 
cancers, asthma and others, and has also demonstrated involvement in causing neuronal 
cell death in neurodegenerative diseases, such as Alzheimer, motor neuron disease and 
Parkinson [14-17]. GSTs have also been reported to be widely expressed in different 
ocular tissues. Thus, for individuals carrying the null genotypes, the body’s defense 
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against oxidative damage may be impaired, contributing to manifestation of the ocular 
diseases in question [18-23].  
Polymorphisms of GST have previously been shown to be associated with glaucoma, 
cataract, exudative age-related macular degeneration as well as various spontaneous optic 
neuropathies [13, 24-27]. Several studies have been conducted in different populations to 
determine the association of GSTT1 and GSTM1 polymorphisms with primary open-angle 
glaucoma [13, 26, 28]], but to date only three studies have been reported on pseudo-
exfoliative glaucoma (PEXG) in populations of Arabs, Turks and Swedes [29-31]. There 
was no significant association found between PEXG and the null genotypes 
of GSTT1 and GSTM1in the Turks and Swedes, whereas in the Arab glaucoma patients 
(n=107), in a study that included POAG, PCAG and PEXG, a significant association of 
all the deletion genotypes was observed [29]. However, after stratification of patients by 
glaucoma type the T0M0 genotype was not found to be significantly associated with any 
type of glaucoma. 
The aim of the present study was to determine if there was a significant association of 
the GSTT1 and GSTM1 polymorphisms with PEXG in a Pakistani cohort. The study was 
approved by the Departmental Ethics Committee of COMSATS Institute of Information 
Technology, Islamabad and the relevant Hospitals’ Ethics Committee and conformed to 
the principles of the Declaration of Helsinki. Informed written consent was taken from all 
patients and unaffected control individuals before sampling. PEXG patients were 
recruited from the out-patients Department of the Al-Shifa Trust Eye Hospital, 
Rawalpindi and Christian Eye Hospital, Taxila. 
 
Methods 
Criteria for patient selection, sample collection and DNA extraction 
Complete ophthalmic examinations were performed on the PEXG patients, including 
measurement of cup-to-disk ratio, tonometeric assessment of intra-ocular pressure and slit 
lamp biomicroscopy was performed to detect any presence of exfoliative material along 
the papillary border and on the iris. Following this, the pupils of the patients were dilated 
and the anterior of the lens surface was examined for any deposits of white material. 
Angles were measured in all the patients with the help of gonioscopy. All of the healthy 
control individuals were also examined and they were found to have normal visual fields, 
no exfoliation material in the eye or any other evidence of glaucoma. Blood samples from 
2
129
  
all the patients and controls were collected by venipuncture; genomic DNA was extracted 
by a conventional phenol chloroform method, as described previously [32]. 
Genotype analysis of GSTT1 and GSTM1 polymorphism 
To determine the GSTT1 and GSTM1 genotypes of the subjects, multiplex polymerase 
chain reaction (PCR) amplification was performed using the following 
primers: GSTT1 forward primer 5′-TTC CTT ACT GGT CCT CAC ATC TC-
3′; GSTT1 reverse primer 5′-TCA CCG GAT CAT GGC CAG CA-3′; GSTM1forward 
primer 5′-GAA CTC CCT GAA AAG CTA AAG C-3′; and GSTM1 reverse primer 5′-
GTT GGG CTC AAA TAT ACG GTG G-3′. Beta globin gene sequence amplification 
was used as an internal control in the PCR reactions, for which the primers were: forward 
primer 5′-CAA CTT CAT CCA CGT TCA CC-3′; reverse primer 5′-GAA GAG CCA 
AGG ACA GGT AC-3′. Each 25 µl PCR reaction contained 1× Taq Buffer (10 mM Tris-
HCl, pH 9.0, 50 mM KCl, 0.1% Triton X-100, 0.01% gelatine; Fermentas, Burlington, 
Ontario), 30 pmol of each primer, 1.5 mM MgCl2, 0.3 mM dNTP, 1.5 U of Taq DNA 
polymerase (Fermentas) and 100 ng of genomic DNA. 
Amplification was performed with initial denaturation at 95 °C for 5 min, followed by 30 
cycles at 95 °C for 1 min, 65 °C for 1 min and 72 °C for 1 min, with a final extension at 
72 °C for 7 min. PCR products were electrophoretically separated on 2% agarose gels and 
the bands were visualized by UV transillumination. For the T1M1 genotype three bands 
were obtained: a 459 bp band of GSTT1, a 209 bp band of GSTM1 and a 268 bp band of 
the internal control (β-globin gene; Figure 1). The T1M0 genotype produced two bands of 
459 bp and 268 bp; the T0M1 genotype produced two bands of 209 bp and 268 bp. In the 
case of the T0M0 null genotype only, the β-globin gene internal control band (268 bp) 
was observed. To confirm the null results, confirmatory PCR tests were performed 
separately for the GSTT1 as well as the GSTM1 genotypes, using β-globin gene 
amplification as the internal control, under identical conditions as those described above, 
but using only the GSTT1 and β-globin or the GSTM1 and β-globin primers, respectively. 
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Figure 1. Multiplex PCR amplification product of the GSTT1, GSTM1 and internal 
control β-globin genes. The amplified products were separated by electrophoresis on 2% 
agarose gel. Lane L, 100bp DNA ladder; lane 1, 4, 9, and 10, T1/M0 genotype (459 bp 
and 268 bp fragments); lane 2, 3, and 8, T1/M1 genotype (459 bp, 268 bp, and 209 bp 
fragments); lane 5, T0/M1 genotype (268 bp and 209 bp fragments); lane 6, 7, and 11, 
T0/M0 genotype (268 bp fragments). 
 
Statistical analysis 
Statistical analysis of the genotype frequencies of both the PEXG patients and controls 
was performed using the chi-square test (χ2). To prevent any false positive inference, 
Bonferroni correction (p′b) was applied to the genotype data. Correction involved 
multiplying the p value obtained after each single test with the total number of 
independent tests (k) performed during the study [33, 34]. The Sidak correction (p′s), an 
approximation of Bonferroni, was also applied to correct the p value as some Bonferroni 
corrected values were >1 [35, 36]. Note that for the Bonferroni corrected values, the level 
of significance remained 0.05; i.e., the association of any genotype group/variable with 
k×p<0.05 was considered as statistically significant [33]. The formulae for the calculation 
of the Bonferroni and Sidak values are as follows: 
p′b  =  k  ×  p 
p′s  =  1 − (1−p)k 
2
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where k is the number of genotype groups tested and p is the raw value obtained from the 
χ2 test. All analyses were performed using SPSS v.16 statistical analysis software (SPSS 
Inc., Chicago, IL) and StatCalc EpiInfo package v.6 (Atlanta, GA). 
Results 
The case-controlled study included 165 patients with glaucoma (53% males, mean age 
45.8±10.1 years and 47% females, mean age 46.31±11.6 years), as well as 162 unaffected 
controls (52% males, mean age 43.8±13.9 years and 48% females, mean age 43.1±10.9 
years); there was no statistically significant difference (p>0.05) in the mean age of 
male/female patients and controls.  
There was a significant difference in the overall distribution of the GSTT1 and 
GSTM1 genotypes in the PEXG patients and controls (χ2=21.82, p<0.001; Table 1). The 
difference between individual genotypes remained significant even after the application 
of Bonferroni and Sidak corrections (p’b & p’s<0.05). When the subjects were stratified 
according to gender the overall genotype distribution of the female patients was found to 
be significantly associated with the disease (χ2=35.63, p<0.001; Table 1); this remained 
significant even after applying the Bonferroni correction (p’b & p’s<0.001). Interestingly, 
the T0M0 null genotype was exclusively present in the PEXG female patients (χ2=20.12, 
p, p’b & p’s<0.001). In the male patients 8.2% of the controls had the T0M0 null genotype 
as compared to 6% of the PEXG male patients (χ2=0.11, p, p’b & p’s>0.05, OR=0.81 
[95% CI=0.20–3.24]; Table 1). 
The gender distribution of the null genotypes GSTT0 and GSTM0 were also compared 
between patients and contols; these genotypes were found at a significantly higher 
frequency in the female patients than in the female controls (χ2=19.90, and χ2=18.7, 
respectively, p<0.05; Table 2); whereas in males the frequency of the null genotypes did 
not differ significantly between the groups (χ2=0.43, χ2=0.01, respectively, p>0.05). 
However, the male control samples as compared to the female controls had a significantly 
higher frequency of both the null genotypes GSTT0 and GSTM0 (χ2=12.13, χ2=14.41, 
respectively, p<0.001; Table 3), whereas in patients in both these groups these genotypes 
were not statistically different from each other (χ2=0.44, χ2=0.53, respectively, p>0.05). 
132
  
  T
A
B
L
E
 1
. O
ve
ra
ll 
an
d 
ge
nd
er
 se
gr
eg
at
ed
 d
at
a 
of
 G
ST
 g
en
ot
yp
es
 in
 u
na
ffe
ct
ed
 c
on
tro
ls 
an
d 
PE
X
G
 p
at
ie
nt
s.
 
G
ro
up
 
G
en
ot
yp
e 
C
on
tr
ol
s 
Pa
tie
nt
s 
p 
(χ
2 )
 
p 
(χ
2 )
 
p b
 
p s
 
O
R
 (9
5%
 C
I)
 
To
ta
l 
T1
M
1 
95
 (5
9%
) 
57
 (3
4.
5%
) 
<0
.0
01
 (2
1.
82
) 
R
ef
er
en
ce
 
 
 
 
 
T1
M
0 
51
 (3
1%
) 
69
 (4
1%
) 
 
0.
00
1 
(1
0.
79
) 
<0
.0
5 
<0
.0
5 
2.
25
 (1
.3
4–
3.
79
) 
 
T0
M
1 
9 
(6
%
) 
23
 (1
4%
) 
 
<0
.0
01
 (1
2.
71
) 
<0
.0
01
 
<0
.0
01
 
4.
26
 (1
.7
3–
10
.7
4)
 
 
T0
M
0 
7 
(4
%
) 
16
 (9
.5
%
) 
 
<0
.0
5 
(8
.4
5)
 
<0
.0
5 
<0
.0
5 
3.
81
 (1
.3
7–
10
.9
6 
 
To
ta
l 
16
2 
16
5 
 
 
 
 
 
Fe
m
al
es
 
G
en
ot
yp
e 
C
on
tro
ls
 
Pa
tie
nt
s 
p 
(χ
2)
 
p 
(χ
2)
 
pb
 
ps
 
O
R
 (9
5%
 C
I)
 
 
T1
M
1 
60
 (8
0.
5%
) 
26
 (3
3.
8%
) 
<0
.0
01
 (3
5.
63
) 
R
ef
er
en
ce
 
 
 
 
 
T1
M
0 
16
 (2
0.
8%
) 
31
 (4
0.
2%
) 
 
<0
.0
01
 (1
5.
84
) 
<0
.0
01
 
<0
.0
01
 
4.
47
 (1
.9
6–
10
.2
9)
 
 
T0
M
1 
1 
(1
.2
%
) 
9 
(1
1.
7%
) 
 
<0
.0
01
 (1
3.
81
) 
<0
.0
01
 
<0
.0
01
 
20
.7
7 
(2
.4
5–
46
0.
38
) 
 
T0
M
0 
0 
(0
%
) 
11
 (1
4.
3%
) 
 
<0
.0
01
 (2
0.
12
) 
<0
.0
01
 
<0
.0
01
 
N
/A
 
 
To
ta
l 
77
 
77
 
 
 
 
 
 
M
al
es
 
G
en
ot
yp
e 
C
on
tro
ls
 
Pa
tie
nt
s 
p 
(χ
2)
 
p 
(χ
2)
 
pb
 
ps
 
O
R
 (9
5%
 C
I)
 
 
T1
M
1 
35
 (4
1.
2%
) 
31
 (3
5%
) 
>0
.0
5 
(2
.2
8)
 
R
ef
er
en
ce
 
 
 
 
 
T1
M
0 
35
 (4
1.
2%
) 
38
 (4
3%
) 
 
>0
.0
5 
(0
.3
6)
 
>0
.0
5 
>0
.0
5 
1.
23
 (0
.6
0–
2.
52
) 
 
T0
M
1 
8(
9.
4)
 
14
 (1
6%
) 
 
>0
.0
5 
(1
.8
3)
 
>0
.0
5 
>0
.0
5 
1.
98
 (0
.6
6–
6.
01
) 
 
T0
M
0 
7 
(8
.2
%
) 
5 
(6
%
) 
 
>0
.0
5 
(0
.1
1)
 
>0
.0
5 
>0
.0
5 
0.
81
 (0
.2
0–
3.
24
) 
 
To
ta
l 
85
 
88
 
 
 
 
 
 
pb
 in
di
ca
te
s B
on
fe
rr
on
i c
or
re
ct
ed
 v
al
ue
 a
nd
 p
s i
nd
ic
at
es
 S
id
ak
 c
or
re
ct
ed
 v
al
ue
. A
 p
<0
.0
5 
w
as
 c
on
si
de
re
d 
to
 b
e 
st
at
is
tic
al
ly
 si
gn
ifi
ca
nt
 
 
   
 
2
133
    
         
T
ab
le
 2
. C
om
pa
ri
so
n 
of
 G
ST
T1
 a
nd
 G
ST
M
1 
nu
ll 
ge
no
ty
pe
s 
ac
co
rd
in
g 
to
 g
en
de
r d
is
tr
ib
ut
io
n 
in
 p
at
ie
nt
s 
an
d 
co
nt
ro
ls
. a
 p
<0
.0
5 
w
as
 
co
ns
id
er
ed
 s
ta
tis
tic
al
ly
 s
ig
ni
fi
ca
nt
. 
G
en
ot
yp
e 
G
ro
up
 
C
on
tr
ol
s 
(n
=1
62
) 
Pa
tie
nt
s 
(n
=1
65
) 
p 
(χ
2 )
 
T0
 
To
ta
l 
16
 (1
0%
) 
39
 (2
4%
) 
<0
.0
5 
(1
1.
06
) 
T1
 
 
14
6 
(9
0%
) 
12
6 
(7
6%
) 
 
M
0 
To
ta
l 
58
 (3
6%
) 
85
 (5
2%
) 
<0
.0
5 
(8
.2
0)
 
M
1 
 
10
4 
(6
4%
) 
80
 (4
8%
) 
 
G
en
ot
yp
e 
 
C
on
tr
ol
s 
(n
=7
7)
 
Pa
tie
nt
s 
(n
=7
7)
 
p 
(χ
2 )
 
T0
 
Fe
m
al
es
 
1 
(1
%
) 
20
 (2
6%
) 
<0
.0
5 
(1
9.
90
) 
T1
 
 
76
 (9
9%
) 
57
 (7
4%
) 
 
M
0 
Fe
m
al
es
 
16
(2
1%
) 
42
(5
5%
) 
<0
.0
5 
(1
8.
70
) 
M
1 
 
61
(7
9%
) 
35
(4
5%
) 
 
G
en
ot
yp
e 
 
C
on
tr
ol
s 
(n
=8
5)
 
Pa
tie
nt
s 
(n
=8
8)
 
p 
(χ
2)
 
T0
 
M
al
es
 
15
(1
8%
) 
19
(2
2%
) 
>0
.0
5(
0.
43
) 
T1
 
 
70
(8
2%
) 
69
(7
8%
) 
 
M
0 
M
al
es
 
42
(4
9%
) 
43
(4
9%
) 
>0
.0
5(
0.
01
) 
M
1 
 
43
(5
1%
) 
45
(5
1%
) 
 
Ta
bl
e 
3.
 C
om
pa
ris
on
 o
f G
ST
T1
 a
nd
 G
ST
M
1 
nu
ll 
ge
no
ty
pe
s 
be
tw
ee
n 
m
al
e 
an
d 
fe
m
al
e 
co
nt
ro
ls
 a
nd
 p
at
ie
nt
s.
 a
 p
<0
.0
5 
w
as
 c
on
si
de
re
d 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t. 
 
C
on
tr
ol
s 
 
Pa
tie
nt
s 
 
G
en
ot
yp
es
 
(M
al
es
) (
n=
85
) 
(F
em
al
es
) (
n=
77
) 
p 
(χ
2 )
 
(M
al
es
) (
n=
88
) 
(F
em
al
es
) (
n=
77
) 
p 
(χ
2 )
 
G
ST
T1
 n
ul
l 
15
 (1
8%
) 
1 
(1
%
) 
<0
.0
01
 (1
2.
13
) 
19
 (2
2%
) 
20
 (2
6%
) 
>0
.0
5 
(0
.4
4)
 
G
ST
M
1 
nu
ll 
42
 (4
9%
) 
16
 (2
1%
) 
<0
.0
01
 (1
4.
41
) 
43
 (4
9%
) 
42
 (5
5%
) 
>0
.0
5 
(0
.5
3)
 
134
  
Discussion  
Oxidative stress along with cellular senescence is one of the major factors affecting 
cellular processes. The inability of the cells to cope with oxidative stress is due to a 
breakdown of the body’s antioxidant defenses due to excessive production of ROS; this in 
turn leads to damage to the cellular macromolecules, including DNA, proteins and lipids. 
To counteract the stress-induced damage, the cells upregulate antioxidant enzymes, such 
as GST [37]. 
In the eye a system of trabecular meshwork (TM) regulates the outflow of aqueous 
humor, and maintains normal intraocular pressure (IOP); therefore, any challenge to the 
structural and functional integrity of TM results in the development of glaucoma. Several 
lines of evidence suggest that one effect of the generation of oxidative free radicals in the 
glaucomatous eye is the progressive loss of TM [38]. In an experimental rat model of 
glaucoma the retinal ganglion cells (RGC) and glial cells showed extensive protein and 
lipid oxidation, which appears to lead to apoptosis of these and other neuronal cells 
[37,39]. Thus, to maintain the homeostatic balance between the production of ROS and 
their clearance, the eye, under stress, is required to produce higher levels of antioxidants. 
Indeed, the glaucomatous eye upregulates several stress-related genes, including GST, 
which are involved in the detoxification of ROS and other related compounds [39,40]. 
Although, under stress, GST and other antioxidants are demonstrably upregulated, the 
glaucomatous eye fails to prevent oxidative damage, a fact that points to an underlying 
molecular or genetic defect. One such genetic risk factor is the presence of the GST null 
genotype in patients having oxidative, stress-related diseases. 
A potent antioxidant 8-hydroxy-2′-deoxyguanosine (8-OH-dG) has been shown to be 
present at 3.6 fold higher levels in the TM of POAG patients, as compared to controls 
[41]. In these patients there was a positive correlation between oxidative DNA damage 
and intraocular pressure as well as visual field defects. The GSTT1 null genotype was 
found to be more common in POAG cases, who also showed 2.2 fold higher levels of 8-
OH-dG as compared to the other genotypes [41,42], resulting in oxidative DNA damage 
in the TM of these patients. A higher level of oxidative damage to the trabecular 
meshwork has also been seen in POAG patients with the GSTM1 null genotype, 
indicating the possible involvement of these genotypes in the manifestation of disease 
[42]. 
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In primary cultures of human optic nerve head astrocytes from glaucomatous eyes it has 
been observed that the basal levels of GSH antioxidants were well below those of primary 
cultures from normal astrocytes; these data combined with all the other evidence indicates 
that oxidative stress plays a significant role in the manifestation and progression of 
glaucoma [40]. 
Recently, using cDNA arrays, the involvement of several stress-related candidate genes 
was studied in PEXG. The authors found that a large set of cytoprotective gene products, 
including antioxidant defense enzymes (e.g., GST) and stress-inducible transcription 
factors, were consistently down-regulated in PEXG at both the mRNA and protein levels; 
this finding supports the conjecture that GSTs play an important role in protecting the eye 
against the development of PEXG [41]. 
The present study was based on the hypothesis that inadequate expression of GST in 
PEXG correlates with the null genotypes. This hypothesis has been tested in Swedes [31] 
and Turks [28], but in those populations no significant contribution of the polymorphic 
variants of GSTs with PEXG was found. To the best of our knowledge, the investigators 
in all of those studies did not stratify their data according to gender. This may be 
significant considering our knowledge that in mice there is a higher expression of some 
types of GSTs in females as compared to males [6]. This indicates that any defects in the 
relevant genetic pathways in females could exacerbate the risk of disease to a 
significantly higher level than for males. 
The importance of the present study is that an association between PEXG and all the GST 
null genotype combinations was observed and this remained significant even after 
Bonferroni correction. In addition, after stratifying the data according to gender, a clear 
association of the null genotypes with only the female PEXG patients was found; this 
occurred because a large number of female PEXG patients were found to carry the null 
genotypes, in different combinations, as compared to the female controls (Table 1). 
The GSTT1 and GSTM1 null genotypes in the total data set of the patient cohort was also 
compared, as well as in the data stratified according to gender. Although an overall 
statistically significant difference in the null genotype distribution between patients and 
controls was observed, this was due to the significantly higher distribution of the null 
genotypes in the female patients, as compared to female controls (Table 2). In addition it 
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must be pointed out that the significantly higher frequency of the T1 and M1 in the 
female unaffected controls as compared to the males (Table 3) could be a result of a 
gender-specific protective effect of these genotypes in the females only. 
The association of the GSTM1 null genotype with female PEXG patients in the current 
study is in accordance with the data of a group of Greek patients with multiple sclerosis 
[42]; using this data we calculated and compared the gender-wise distribution of the null 
genotypes of GSTT1 and GSTM1 between the Greek controls and patients. We found that 
the female patients had a significantly higher frequency of the GSTM1 null genotype 
(65.5% versus 41.7% in controls; χ2=4.91, p=0.02) while in males there was no difference 
in the distribution of any of the null genotypes. 
Another interesting aspect of the present study is that, in addition to the GSTM1 null 
genotype, the frequency of the GSTT1 null genotype in the female PEXG patients 
occurred also at a significantly higher level than in the control females (Table 2), while in 
the Greeks there was no significant difference in this group (χ2=0.05, p=0.82). Also, in 
contrast to our data, in the Greeks the T0M0 combined null genotype was not found to be 
associated with the females, which points to the possible association of the GST T0M0 
genotype with PEXG only in the Pakistani female patients; the resultant vulnerability to 
cellular and oxidative stress conditions may therefore be a contributing factor in the 
disease pathology that possibly has ethnic as well as gender associations. 
In conclusion, we would like to emphasize the importance of conducting further studies in 
different populations to further ascertain the association of GST with PEXG; this will 
allow the development of a consensus regarding the involvement of GST in glaucoma. 
There is also a need to better understand the mechanisms associated with the null 
genotypes in female patients. 
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2.6. Association of tumor necrosis factor alpha gene polymorphism G-
308A with pseudoexfoliative glaucoma in the Pakistani population. 
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Abstract 
Purpose: The purpose of the present study was to determine the role of the tumor 
necrosis factor alpha (TNF-α) gene polymorphism G-308A and total serum 
immunoglobulin E (TsIgE) levels in the onset of pseudoexfoliation glaucoma (PEXG) in 
Pakistani patients. 
Methods: The TNF-α polymorphism G-308A was analyzed in 122 patients with PEXG and 
126 healthy unrelated controls by using polymerase chain reaction (PCR) and restriction 
fragment length polymorphism (RFLP). TsIgE levels were determined by solid-phase 
enzyme-linked immunosorbent assay (ELISA). 
Results: The AA and GA genotypes were strongly associated with PEXG (p<0.001), 
with an odds ratio (OR) of 0.07 (95% confidence interval [CI]=0.02-0.27) and 0.24 (95% 
CI=0.12-0.51), respectively, while the GG genotype was found at a higher frequency in 
controls as compared to patients (p<0.001) OR=8.95 (95% CI=4.55–17.81). No 
significant difference was found in TsIgE levels of both patients and controls (p=0.86). 
Conclusion: The present study concludes that the TNF-α polymorphism G-308A is 
strongly associated with PEXG. To our knowledge this is the first study in southeast Asia 
which demonstrates a strong association of a TNF-α polymorphism with PEXG. 
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Introduction 
Pseudoexfoliation syndrome (PEX) was first described by Lindberg in 1917 and involves 
excessive production and progressive accumulation of fibrillar extracellular material in 
various tissues [1,2]. Although the syndrome is recognized to be a systemic disorder, it is 
the most common identifiable cause of glaucoma that has now been termed 
pseudoexfoliation glaucoma (PEXG) [2–4]. 
PEX syndrome occurs worldwide but its prevalence varies among different age groups, 
races, and geographical locations. The highest prevalence of 20–70% has been reported in 
elderly people (70–80 years) and it is estimated that PEXG affects 10– 20% of all 
individuals above 60 years of age. Moreover, prevalence varies in different countries with 
the highest rate of about 46.9% in Greece [5]. Comprehensive data on the prevalence of 
PEXG in Pakistan is not available. However, a recently conducted hospital-based study 
did reveal a high rate of PEXG (6.45%) among patients with ocular ailments [6]. The 
mechanism underlying the development of PEX syndrome and its subsequent progression 
to PEXG is still unclear [4,7]. Studies have focused on immunological changes during 
glaucomatous pathogenesis and possible preventive therapies based along those lines 
have been proposed. The major targets of interest are cytokines, as recent advances reveal 
that they play an important role in the pathogenesis of glaucoma and may regulate retinal 
ganglion cell (RGC) survival or death [8]. 
Tumor necrosis factor alpha (TNF-α), a proinflammatory cytokine, is upregulated in 
several neurodegenerative disorders including multiple sclerosis, Parkinson’s disease, 
Alzheimer’s disease [9,10] and in optic nerve microglia and astrocytes in glaucoma 
patients [11,12]. It has been observed that both mRNA and protein levels of TNF-α or 
TNF-α receptor-1 (TNF-R1) are raised in the retina of glaucomatous eyes as compared to 
normal eyes, and therefore it was suggested that cell death mediated by TNF-α is a 
contributing factor in the neurodegeneration in glaucoma [13]. Using animal models, 
Nakazawa et al. [14] showed that ocular hypertension or increased intraocular pressure 
induces TNF- α upregulation in the retina, which in turn leads to RGC degeneration. 
Moreover, it has been observed that anti-TNF- α antibodies can prevent death of RGCs by 
reducing ocular hypertension, suggesting that reducing the expression of TNF- α would be 
beneficial in treating glaucoma [14]. 
Several polymorphisms have been identified in the upstream regulatory region of TNF-α. 
Among these is a common biallelic G (TNF1 allele) transition to A (TNF2 allele) 308 
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(rs1800629) nucleotide upstream from the transcription initiation site in the TNF-α 
promoter. This transition is considered to be an important enhancer of transcriptional 
activation associated with elevated levels of TNF-α [15], which have been shown to be 
involved in increased susceptibility to different eye diseases including diabetic 
retinopathy and glaucoma [16–18]. Association studies of the G-308A polymorphism in 
different populations have shown contradictory results [19,20]. Therefore, additional 
comprehensive studies involving different populations are warranted to better understand 
the role of TNF-α polymorphisms in different diseases. The aim of the present study was 
to study the association of the TNF-α polymorphism G-308A with PEXG in the Pakistani 
population. 
Methods 
This was a multicenter case-control study that included 122 PEXG patients and 126 
controls. The study was approved by the Departmental Ethical Committee of COMSATS 
Institute of Informational Technology and the relevant hospital ethics committees and 
conformed to the principles of the Declaration of Helsinki. PEXG patients were recruited 
from the outpatient departments of two major eye clinics including Al-Shifa Eye Trust 
Hospital, Rawalpindi, and Christian Eye Hospital, Taxila. The healthy control individuals 
did not have any exfoliation material in the eye or any other evidence of glaucoma, and 
had normal visual fields. 
All the PEXG patients underwent a complete ophthalmic examination including 
tonometric assessment of intraocular pressure (IOP), measurement of cup to disk ratio 
(CDR), and slit lamp biomicroscopy. Patients were evaluated by slit lamp biomicroscopy 
for the presence of exfoliative material along the papillary border and on the iris without 
dilating the eye. After pupil dilation the patients were also analyzed for the presence of 
white material deposits on the anterior lens surface. Gonioscopy was performed in all 
patients with a high magnification lens for determination of the angle. Approximately 4–6 
ml of venous blood was obtained in vacutainers (product no 364606, Becton Dickinson, 
Franklin Lakes, NJ) containing acid citrate dextrose (ACD) as anticoagulant, after 
obtaining informed written consent from the subjects. For the ELISA assay, serum was 
obtained from clotted blood collected in Z-serum sep clot-activator vacutainer tubes 
(Greiner Bio-One, Munich, Germany) by centrifuging the vacutainers at 3,000 rpm for 10 
min. 
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Genomic DNA was isolated by a standard phenol– chloroform extraction method. A 212 
bp DNA sequence corresponding to the promoter region of TNF-α was amplified using the 
forward primer 5′-AGG CAA TAG GTT TTG AGG GCC AT-3′ and the reverse primer 5′-
GTA GTG GGC CCT GCA CCT TCT-3′ [21]. The forward primer contains a C (bold 
italic) which is not present in the genomic sequence and was introduced to create the NcoI 
enzyme recognition site (i.e. CCATGG) in the normal sequence. A transition from G to A 
abolishes the NcoI site in the mutant allele. 
PCR was performed in a final volume of 25 µl containing 40–50 ng of genomic DNA, 0.2 
mM deoxynucleotide triphosphates (dNTPs), 1.5 mM MgCl2, 0.2 µM each of reverse and 
forward primer, 1× Taq buffer, and 1 U of Taq polymerase. Polymerase chain reaction 
(PCR) was performed in a thermal cycler by initial denaturation of the genomic DNA at 95 
°C for 7 min, followed by 35 cycles of denaturation at 95 °C for 30 s, primer annealing at 
60 °C for 30 s, and chain extension at 72 °C for 45 s. A final extension step was 
performed at 72 °C for 10 min. 
The PCR product (12 µl) was subjected to restriction enzyme digestion at 37 °C overnight 
with 10 U of NcoI restriction enzyme according to the manufacturer’s instructions 
(Fermentas, Burlington, Ontario). The resulting digested products were resolved on 4% 
agarose gels. PCR products carrying the variant A allele remained uncut (212 bp), while 
PCR products carrying the wild-type G allele were digested into two fragments of 192 bp 
and 20 bp. 
TsIgE levels of patients and controls were determined using the immunoglobulin (IgE) 
enzyme immunoassay quantitative test kit BC-1035 (BioCheck Inc., Foster City, CA). 
TsIgE levels of all the patients and healthy control individuals were measured in 
duplicate. 
A contingency table analysis (χ2 test) was performed to determine the level of statistical 
association between genotype and allele frequencies in patients and controls using 
StatCalc from Epi Info, Version 6. TsIgE levels were expressed as arithmetic or geometric 
means in IU/ml. To obtain a Gaussian distribution, TsIgE levels were normalized by 
logarithmic transformation (Log10). Statistical computations were also performed using 
Statistical Package for the Social Sciences (SPSS version 16). A p-value <0.05 was 
considered statistically significant. 
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Results 
A total of 248 individuals (122 PEXG patients and 126 unrelated healthy control 
individuals) were included in the present study. The PEXG patients had a mean age of 
45.3±12.7 years and included 67% males and 33% females, whereas the controls had a 
mean age of 44.2±12.3 years with 64% males and 36% females (Table 1). 
The GG wild-type genotype was found at a frequency of 87% in the controls and 43% in 
the PEXG patients with an odds ratio (OR) of 8.95 (95% confidence interval [CI]=4.55– 
17.81; Table 1), whereas the number of heterozygous and homozygous variant 
individuals was higher in patients as compared to controls (p<0.001, χ2 54.97). Of the 
PEXG patients, 25% contained the AA variant genotype while in the controls this 
genotype was present at only 2%, with OR=0.07 (95% CI=0.02–0.27). The GA 
heterozygous genotype was present in 32% of the PEXG patients, whereas only 10% of 
the controls were heterozygous (OR=0.24 [95% CI=0.12– 0.51]). The distribution of 
allele frequencies (Table 1) of the patients and controls showed that the A allele was more 
prevalent in the PEXG patients (41%) as compared to controls (8%) and was strongly 
associated with the disease condition, OR=8.37 (95% CI=4.78–14.81; p<0.001, χ2 74.6). 
The genotype distribution data were also stratified with respect to gender to determine any 
gender bias (Table 1). Even while considering the data of males and females separately, 
the GA and AA genotypes remained significantly associated with PEXG, (p<0.001, 
χ2=33.30 and p<0.001, χ2=23.09, respectively). In addition, the variant A allele was found 
to be more prevalent in the PEXG male patients as well as female patients when compared 
to the appropriate controls (p<0.001; χ2=44.74, χ2=30.22, respectively). The frequency of 
the A allele was found to be nearly the same in both sexes (40% and 43%, respectively; 
Table 1). 
TsIgE values were found to follow a log normal distribution in both the cohorts: controls 
and PEXG patients (Table 2). No significant difference was found between the TsIgE 
levels of PEXG patients and controls (Table 2A). In addition, no significant difference 
was found when the Log10 TsIgE values of the different genotypes of the G-308A 
polymorphism (GG, GA, and AA) of patients and controls were compared (Table 2B). 
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Discussion 
During the last few years, several immunological components have been shown to be 
involved in the pathogenesis of various types of glaucoma. It has been observed that these 
components are not usually the primary causative agents but are involved in the 
progression of the disease [21,22]. In addition, it has been reported that components 
of the immune system involved in the pathogenesis of glaucoma are also involved 
in neurodegeneration following brain injury. In such cases inflammation occurs in 
response to glutamate, reactive oxygen species (ROS), nitric oxide (NO), and cytokines 
including tumor necrosis factor (TNF)-α, which are released from activated 
microglia or macrophages [23]. As glaucoma is a disease of old age and 
involves optic nerve neuropathy, it has been proposed that both genetic as well as 
epigenetic factors are involved in the progression of the disease. Such factors cause a 
decrease in the cellular viability and self- renewal capacity, which results in the 
generation of dysfunctional microglia. Such age-related attrition may contribute 
to the development of neurodegenerative diseases by diminishing glial 
neurosupportive functions. Secondary degeneration by the immune components 
leads to the neurodegenerative injury in glaucoma [24]. 
TNF-α is considered to be a neuroprotective component of the immune system, because it 
activates the ubiquitous transcription factor NF-κB through binding to the high affinity 
TNF receptor (TNF-R2), which in turn mediates the expression of a wide range of 
genes essential for neuronal survival. Contrary to its neuroprotective role, TNF-α can 
also serve as a neurodegenerative factor when it binds to the low affinity death receptor 
TNF-R1 and induces the mitochondria- mediated apoptotic pathway [25–29]. Thus a 
delicate balance between the two pathways determines the survival of the cell, and any 
shift in equilibrium might have deleterious effects. An increased expression of TNF-α 
can shift the balance toward TNF-R1 signaling, as seen in glaucoma, and thus 
promote retinal ganglion cell death. Based on the latter observation, an 
antiglaucoma drug, GLC756, has been developed that inhibits TNF-α release from 
activated rat mast cells and thus promotes cell survival. This can be attributed to the 
potential neuroprotective role of the compound (GLC756), which can therefore serve 
an important role in the management of glaucoma [30,31]. 
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In the present study we found a strong association of GA and AA genotypes with PEXG, 
suggesting a role of the A allele in the pathogenesis of the disease. However, our results 
are in contradiction with previous studies, which have shown no significant association of 
the TNF-α polymorphism G-308A with PEXG in both Turkish and Caucasian populations 
[32,33]. Agarwal et al. [34] reported that the G to A transition at position −308 results in a 
six- to sevenfold increase in transcription of TNF-α as compared to normal basal level 
transcription, as a result of which increased levels of TNF were observed. Recently, a 
significant association has been observed for the G-308A polymorphism between PEXG 
patients and controls in the Iranian population (p<0.005) [35], which is in agreement with 
our results. This similarity with the Iranian population has also been observed for the 
association of the ABO blood groups with different types of glaucoma. Blood group B 
was strongly associated with different types of glaucoma [36], which is in agreement with 
the study of Zaree et al. [37] in the Iranian population. Genetic relatedness was also 
demonstrated previously in studies of the Y chromosomal markers, which have shown that 
the Pakistani populations share a significant similarity in their genetic makeup with 
different Iranian ethnic groups [38]. 
Our results are in accordance with the findings of Razenghinejad et al. [35], and are 
interesting for several reasons. In our study the statistically significant differences 
between patients and controls are more pronounced as compared to the Iranian population, 
(<0.001 versus p=0.002). We attribute this difference to the fact that we not only observed 
a very high frequency of the heterozygous GA allele compared to the Iranian study (32% 
versus 17%), but also found the derived AA allele at a much higher frequency (24.6% 
versus 1.7%). Razenghinejad et al. [35] also noted that when the data was stratified 
according to gender, the genotype frequency became statistically insignificant for females, 
an observation that they attributed to the unequal gender distribution in the study subjects. 
As opposed to the Iranian study, we find that both the genotype and allele frequencies 
remain significantly associated with the disease even after gender-wise stratification 
(Table 1). A likely explanation is that gender matching was better in our study than in the 
Iranian study, thus emphasizing the importance of careful design of genetic association 
studies. 
A strong association of this polymorphism has also been observed in the Chinese 
population, but that study was performed in patients with primary open-angle glaucoma 
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(POAG) and with a very small sample size [20]. Although several investigators were 
unable to show a significant difference in genotype distribution and allele frequency 
between patients and control groups, some investigators have successfully demonstrated 
the functionality of this polymorphism in the reporter gene assays with a significant 
upregulation of up to fivefold in the constructs of TNF1 and TNF2 alleles [39]. This 
suggests that transcriptional regulation of TNF-α is essential to circumvent the deleterious 
effects of overexpression by transcriptional upregulation. Thus, excessive production of 
TNF associated with the G-308A polymorphism may have an important role in the 
development of TNF2-associated autoimmune diseases and may act as a genetic 
susceptibility factor driven by a high TNF-α expression, which would subsequently lead to 
immune responses causing the onset of different diseases. A recent study by Sawada et al. 
[40] also demonstrates that TNF-α levels were significantly elevated in the aqueous 
humor of PEXG patients as compared to controls and other glaucoma subtypes, including 
POAG and normal tension glaucoma. We believe that this is in line with our conjecture 
that TNF-α is significantly involved in the pathogenesis of the disease in the Pakistani 
population. 
It is worth mentioning here that the greater number of carriers with a GA genotype in the 
PEXG patients also points toward the possibility of a dominant mode of inheritance of the 
genetic defects responsible for PEXG. However, due to the presence of such carriers in 
normal individuals, although at much lower frequency, it is likely that environmental 
influences and other genetic factors contribute to the development of the disease. 
On the basis of different evidence it has been suggested that autoimmune damage to the 
optic nerve may occur directly by autoantibodies or indirectly by a “mimicked” 
autoimmune response to a sensitizing antigen, which in turn injures retinal ganglion cells 
[41]. In a recent study by Joachim et al. [22], IgG antibody levels were found to be 
significantly higher in the aqueous humor of patients with POAG and PEXG as compared 
to controls, due to which it was concluded that multiple factors contribute to the immune 
status of the eye [22]. Therefore, we also investigated the role of TsIgE levels in 
glaucoma and its association with the G-308A polymorphism, as previously in a different 
disease it has been shown that IgE levels were associated with this single nucleotide 
polymorphism [42]. However, we did not find any association of IgE levels with PEXG in 
our study population, which could be because there is no significant involvement of TsIgE 
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levels in the manifestation and onset of the disease. This warrants further investigation 
simultaneously in the serum and aqueous humor of patients, as previously pointed out by 
Joachim et al. [22]. 
In conclusion, we find the A allele of the TNF-α polymorphism G-308A to be strongly 
associated with the pathogenesis of PEXG, and thus propose that the GA and AA 
genotypes of the TNF-α regulatory region can be considered genetic markers for the 
stratification of PEXG patients in Pakistan. Mutations in TNF-α might be involved in 
causing different neurodegenerative disorders, therefore it is important to consider it as a 
novel therapeutic target for the treatment of neurodegenerative diseases like glaucoma. 
We expect that our study will prove to be a helpful tool in the treatment and management 
of PEXG by opening up new horizons in the field of target discovery to develop novel 
therapeutics. 
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Abstract 
Background: Recently nonsynonymous coding variants in the ankyrin repeats and 
suppressor of cytokine signaling box-containing protein 10 (ASB10) gene were found to 
be associated with primary open angle glaucoma (POAG) in cohorts from Oregon and 
Germany, but this finding was not confirmed in an independent cohort from Iowa. The 
aim of the current study was to assess the role of ASB10 gene variants in 
Pakistani glaucoma patients. 
Methods: Sanger sequencing of the coding exons and splice junctions of 
the ASB10 gene was performed in 30 probands of multiplex POAG families, 208 
sporadic POAG patients and 151 healthy controls from Pakistan. Genotypic associations 
of individual variants with POAG were analyzed with the Fisher's exact or Chi-square 
test. 
Results: In total 24 variants were identified in POAG probands and sporadic patients, 
including 11 novel variants and 13 known variants. 13 of the variants were 
nonsynonymous, 6 were synonymous, and 5 were intronic. Three 
nonsynonymous variants (p.Arg49Cys, p.Arg237Gly, p.Arg453Cys) identified in the 
probands were not segregating in the respective families. This is not surprising 
since glaucoma is a multifactorial disease, and multiple factors are likely to be involved 
in the disease manifestation in these families. However a nonsynonymous variant, 
p.Arg453Cys (rs3800791), was found in 6 sporadic POAG patients but not in controls, 
suggesting that it infers increased risk for the disease. In addition, one synonymous 
variant was found to be associated with sporadic POAG: p.Ala290Ala and the association 
of the variant with POAG remained significant after correction for multiple testing 
(uncorrected p-value 0.002, corrected p-value 0.047). The cumulative burden of rare, 
nonsynonymous variants was significantly higher in sporadic POAG patients compared to 
control individuals (p-value 0.000006). 
Conclusions: Variants in ASB10 were found to be significantly associated with sporadic 
POAG in the Pakistani population. This supports previous findings that 
sequence variants in the ASB10 gene may act as a risk factor for glaucoma. 
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Introduction 
Glaucoma is a group of heterogeneous optic neuropathies and a leading cause of 
irreversible blindness, affecting approximately 70 million individuals worldwide [1, 2]. 
One of the major risk factors for glaucoma is an abnormal elevation of intraocular 
pressure (IOP). Glaucoma causes an irreversible destruction of the optic nerve, which 
ultimately affects the central visual pathway. This involves the degeneration and death of 
the retinal ganglion cells, which leads to a progressive deterioration of the visual field [3]. 
The cellular and molecular mechanisms underlying glaucoma are not yet fully 
understood. Family-based linkage analysis and case-control studies have shown that 
genetic variants contribute to the pathogenesis of POAG [4-8]. At least 16 chromosomal 
loci for POAG have been reported [4-6]. To date, several causative genes and 16 POAG-
associated loci have been identified, including myocilin (MYOC/GLC1A; MIM 601652) 
[7, 8], optineurin (OPTN/GLC1E; MIM 137760) [9], WD repeat domain 36 
(WDR36/GLC1G; MIM 609669) [10, 6], cytochrome P450 1B1 (CYP1B1; MIM 231300) 
[11, 12]. In addition, genome-wide association studies have detected several POAG-
associated gene variants, some potentially acting at the level of the trabecular meshwork 
(associated with elevated IOP), and others possibly at the level of the retinal ganglion 
cells [13-16]. 
Recently, ankyrin repeats and suppressor of cytokine signalling (SOCS) box-containing 
protein 10 (ASB10) has been identified as a novel POAG candidate gene (MIM 603383) 
located at chromosome 7q35–q36, the GLC1F locus. Further support was provided by the 
additional screening of the POAG patients from Oregon and Germany [17], but this was 
not confirmed in an independent POAG cohort from Iowa [18]. In the current study we 
further investigated the role of the ASB10 gene in glaucoma families and sporadic POAG 
patients from Pakistan. 
  
3
161
 
 
 
 
Materials and Methods  
Subjects 
Thirty families with juvenile- and adult-onset POAG, 208 sporadic Pakistani POAG 
patients with a mean age of 55.3±1.2 years (51% male and 49% female), and 151 healthy 
controls with a mean age of 53.7±1.1 years (53% male, 47% female) were included in 
this study.  
Ethics statement 
The study adhered to the guidelines of the Declaration of Helsinki and was approved by 
the Institutional Review Board of Al-Shifa Eye Trust Hospital. After signed informed 
consents were obtained, blood samples were collected for DNA isolation.  
 
Clinical evaluations 
Complete ophthalmic examinations were performed for patients and controls. Juvenile-
onset POAG was diagnosed between age 3 years and early adulthood (<35 years). Adult-
onset POAG was diagnosed at adulthood, usually after 35 years of age. Briefly, for 
POAG patients the inclusion criteria were high IOP (>21 mmHg) measured using 
Goldmann applanation tonometry, a cup-to-disc ratio (CDR) >0.7 with thinning or 
notching of the disc rim [20], and visual field defects. Visual field defects typical of 
glaucoma such as arcuate scotoma, nasal step and paracentral scotoma were determined 
with a Humphrey Field Analyzer (Zeiss Humphrey Systems, Dublin, CA, USA), and an 
open anterior chamber angle was confirmed with gonioscopy. Although high IOP is not 
part of the definition of glaucoma, we used strict criteria to exclude other types of 
glaucoma in our cohort.  Controls and cases were matched for age, gender and ethnicity. 
The same detailed ophthalmological examinations were done for the controls as for the 
glaucoma patients, and only control individuals without glaucoma were selected.  
 
DNA isolation and genetic analysis 
A conventional phenol-chloroform method was used for the extraction of genomic DNA 
from whole blood [21]. Primers flanking the entire coding sequence of ASB10 were 
designed with Primer3 software (primer sequences and PCR conditions are available on 
request). The amplified region covered at least 50 base pairs into each intron to screen for 
potential mutations affecting splicing. PCR products were visualized on 2% agarose gel 
and purified with PCR clean-up purification plates (NucleoFast® 96 PCR, MACHEREY-
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NAGEL, Germany), according to the manufacturer’s protocol. Purified PCR products 
were analyzed by Sanger sequencing in an automated DNA sequencer (Big Dye 
Terminator, version 3 on a 3730 DNA analyzer; Applied Biosystems, Inc., Foster City, 
CA). Sequencing results were aligned with the reference sequence (obtained from the 
hg19 human genome build) and analyzed using Vector NTI Advance (TM) 2011 software 
(Invitrogen).  
In silico analysis 
In addition, the pathogenicity of ASB10 missense variants was evaluated by publically 
available tools including PhyloP, Grantham, PolyPhen2, and SIFT [22].  Evolutionary 
conservation was determined for variants which were predicted pathogenic by PolyPhen2 
and SIFT, or had a high Grantham distance or PhlyoP score. To assess the amino acid 
conservation, orthologous ASB10 protein sequences of various species were aligned 
using Vector NTI Advance (TM) 2011 software.  The amino acid sequences were 
obtained from protein sequence database UniProt (http://www.uniprot.org).  
Statistical analysis 
The genotype frequency of individual sequence variants in the ASB10 gene was compared 
between POAG patients (probands of families and sporadic patients combined) and 
control individuals using a Fisher’s exact test for rare variants (n<5), and a Chi-square 
test for common variants. P-value ≤0.002 was considered significant after correction for 
multiple testing (α/number of variants).  
 
 Results 
Analysis of the ASB10 gene in 30 probands (one per family) of Pakistani glaucoma 
families revealed six nonsynonymous, two synonymous, and two intronic variants 
(Tables 1 and 2).  
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Of these variants, three nonsynonymous variants (p.Arg49Cys, p.Arg237Gly, 
p.Arg453Cys) were not detected in control individuals (Table 1).  However, all three 
variants did not segregate with the disease in family members of the probands (Figure 1). 
However individual II:2, who is homozygous for the pArg453Cys variant, has a more 
severe phenotype compared to his sibs. He was diagnosed with bilateral glaucoma in the 
age of 15 years. He was subjected to two trabeculectomies to control the IOP of both eyes 
(right 42mmHg; left 38mmHg). The cup-to-disc ratios of both eyes were also high (0.9). 
He lost the vision in both eyes at age 35, presenting visual acuities of 20/25 and 20/60 
with tubular visual fields (less than 10°). He still needs to use prostaglandin analogs to 
lower his IOP. 
 
 
 
Fig 1. Pedigrees of consanguineous Pakistani glaucoma families, with a probable 
autosomal dominant inheritance pattern. Segregation analysis of three nonsynonmous 
variants: (1A) represents segregation of p.Arg49Cys, (1B) segregation of p.Arg237Gly 
change, (1C) shows p.Arg453Cys variant segregation, Variant allele is indicated with an 
“M1(p.Arg49Cys), M2(p.Arg237Gly) and M3(p.Arg453Cys)”, and the wildtype allele 
indicated with “WT” for the three variations. This demonstrates that the variants do not 
segregate with the disease in the respective families. The proband is indicated with an 
arrow. 
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Sequence analysis of the ASB10 gene was further extended to a Pakistani cohort of 208 
sporadic POAG patients and 151 controls. In addition, to the above mentioned variants, 
14 additional variants were identified in sporadic POAG patients. Of these, seven variants 
were nonsynonymous, 4 synonymous and 3 were intronic variants (Tables 1 and 2). Five 
nonsynonymous variants (p.Val62Met, p.Gln295His, p.Arg296Gln, p.Arg304Cys, 
p.Arg447His) identified in POAG patients were not detected in control individuals. 
Conversely, no nonsynonymous, synonymous and intronic variants were identified that 
are present in control individuals but not in POAG patients.  
Association of each individual nonsynonymous, synonymous and intronic variant with 
POAG was assessed (Tables 1 and 2). One rare nonsynonymous variant (p.Arg453Cys) 
was detected in 6 sporadic POAG patients and 1 proband, but not in control individuals (p 
[uncorrected] = 0.04). However, this difference also did not remain significant after 
correction for multiple testing (p [corrected] = 0.96). One common synonymous variant 
(p.Ala290Ala) was detected heterozygously more frequently in POAG patients (49%) and 
probands (50%) compared to control individuals (33%), and the difference in genotype 
frequencies remained significant after correction for multiple testing (p [uncorrected] = 
0.002, p [corrected] = 0.048).  
One variant (c.1218+42T>C) was found more frequently in control individuals than in 
POAG patients but the frequencies of three genotypes in patients compared to controls 
shows a trend of difference in the frequencies (p [uncorrected] = 0.06), suggesting it 
might have a protective role, but this did not remain significant after correction for 
multiple testing (p [corrected] = 0.96). 
Collectively, nonsynonymous variants were detected in 106/1468 (7.2%) patients, and in 
18/694 (2.6%) controls after excluding the common variants (c.1075 G>A, c.1114 C>T, 
c.1204C>A).  A significant difference in number of variants in patients compared to 
controls was observed (p-value 0.0005) upon combing the number of patients and 
controls of the current and previous two studies (Table 3). 
 
3
167
 
 
 
 
Table 3. Burden test for rare nonsynonymous variants identified in POAG patients and 
controls in different cohorts. 
 Pakistan Iowa [19] 
Germany and 
US [18] 
Combined form 
3 studies 
Patient  23/238 (9.7%) 13/158 (8.2%) 70/1172 (6.0%) 106/1468 (7.2%) 
Control  2/151 (1.3%) 3/82 (3.7%) 13/461 (2.8%) 18/694 (2.6%) 
p-value 0.0005 0.27 0.008 0.000006 
 
Six of the 10 rare, nonsynonymous variants are predicted to be pathogenic by at least 2 
pathogenicity prediction tools (p.Arg49Cys, p.Val62Met, p.Arg237Gly, p.Arg304Cys, 
p.Leu342Pro, p.Arg447His) (Table 1). In addition, seven variants (p.Glu229Asp, 
p.Arg296Gln, p.Val359Ile, p.Arg372Cys, p.Pro420Thr, p.Arg447His, p.Arg453Cys) 
affect amino acids that are highly conserved during evolution (Figure 2).  
 
 
Fig 2. Amino acid conservation of amino acids of ASB10 in different species. Mutated 
amino acids conserved in humans and other species are shown in blue color. 
 
Discussion 
In a recent study, ASB10 was identified as a novel gene for glaucoma at the GLC1F locus. 
A synonymous variant (c.765C>T; p.Thr255Thr) was identified in a large family with 
POAG, which was found to segregate with the disease. Further support was provided by 
the identification of ASB10 variants in POAG patients from Oregon and Germany [18]. A 
few additional variants were identified in POAG patients from Iowa, but they were 
reported not to be significantly associated with POAG [19]. In the current study 10 rare 
amino acid changes were identified in 23/238 (9.7%) patients (Table 1) which compared 
to 2/151 (1.3%) of the population matched controls (p-value 0.0005). Similarly, in the 
study performed by Pasutto et al 70 patients were identified with 26 (6.0%) rare amino 
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acid changes compared to 9 amino acid changes in 13 controls (2.8%) (p-value 0.008). 
However, in the Iowa cohort rare 11 amino acid substitutions were detected in 13/158 
(8.2%) patients compared to 3/82 (3.7%) controls, and the difference was not statistically 
significant (p-value 0.27). Taken together, the burden of rare amino acid changes among 
all three cohorts are significantly associated with POAG (p-value 0.000006)    
The synonymous variant p.Thr255Thr identified by Pasutto et al. [18] was not found in a 
subsequent study from Iowa nor in the current study of Pakistani POAG patients. This 
suggests that Thr255Thr is a rare variant that may be population- or region-specific. The 
Thr255Thr was reported to affect an exonic splice enhancer, leading to aberrant splicing 
of the ASB10 transcript.  
In the current study we detected a significant association of another synonymous variant 
(c.870G>C; p.Ala290Ala), which was also reported previously in POAG patients from 
Germany, Oregon and Iowa. In the Iowa cohort the p.Ala290Ala variant (labeled as 
p.Ala275Ala) was also present at a higher frequency in POAG patients compared to 
controls with a marginally significant p-value 0.05 [19]. In Pakistani POAG patients a 
similar frequency of the heterozygous genotype (49%) was observed, and the frequency 
in controls (33%) was slightly lower than in the Iowa cohort (p-value 0.01; OR 1.76 [95% 
CI 1.10-2.83]). However, in the German cohort the frequency of the heterozygous 
genotype was higher in controls (57%) compared to POAG patients (47%) [18]. 
Therefore, the significance of this association in the pathogenicity of POAG is unclear.  
Interestingly, both synonymous variants, p.Thr255Thr [18] and p.Ala290Ala, are located 
in one of the ankyrin repeats. The ankyrin repeat structure and number is an important 
determinant of the target substrate to which ASB10 protein is bound. Disruption of the 
repeat structure by altered splicing may thus affect the substrate binding of ASB10 [23]. 
Based on an in silico analysis of exonic splice enhancer sites, we assume that the effect of 
the p.Ala290Ala variant may be subtle as the affinity for SRp55 is predicted to be 
reduced by approximately 40%, while the splice enhancer (SF2/ASF) site affected by the 
p.Thr255Thr variant was completely lost. In a survey by Chen et al it has been observed 
that both nonsynonymous and synonymous polymorphisms have an equal probability of 
their association with the disease (1.46 % versus 1.26% respectively) [24].  
Three rare nonsynonymous variants were analyzed in family members, and did not 
segregate with the disease in these families. The ASB10 protein is expressed in the retina, 
the retinal ganglion cells, the trabecular meshwork, and the ciliary body. The ciliary body 
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is involved in the production of aqueous humor, and the trabecular meshwork plays a 
phagocytic role to clear and regulate the outflow of aqueous humor. In the study of 
Pasutto et al, silencing of the ASB10 gene was shown to lead to a higher resistance in the 
outflow of aqueous humor in a perfused segment organ culture [18]. Recently, evidence 
has also been provided for the involvement of ASB10 in the ubiquitin-mediated 
degradation pathways in trabecular meshwork cells [23].  
In summary, the current study demonstrates that variants in ASB10 are significantly 
associated with POAG in the Pakistani population. This supports previous findings that 
sequence variants in the ASB10 gene may act as a risk factor for glaucoma. Further 
studies in other populations are required to better understand the role of ASB10 gene 
variants in glaucoma.  
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Abstract  
Background: Anterior segment dysgenesis (ASD) disorders are a group of clinically and 
genetically heterogeneous phenotypes in which frequently cornea, iris, and lens are 
affected. This study aimed to identify novel mutations in PAX6, PITX2 and FOXC1 in 
families with anterior segment dysgenesis disorders. 
Methods: We studied 14 Pakistani and one Mexican family with Axenfeld Rieger 
syndrome (ARS; n = 10) or aniridia (n = 5). All affected and unaffected family members 
underwent full ophthalmologic and general examinations. Total genomic DNA was 
isolated from peripheral blood. PCR and Sanger sequencing were performed for the exons 
and intron-exon boundaries of the FOXC1, PAX6, and PITX2 genes. 
Results: Mutations were identified in five of the 15 probands; four variants were novel 
and one variant was described previously. A novel de novo variant (c.225C>A; p.Tyr75*) 
was identified in the PAX6 gene in two unrelated probands with aniridia. In addition, a 
known variant (c.649C>T; p.Arg217*) in PAX6 segregated in a family with aniridia. In 
the FOXC1 gene, a novel heterozygous variant (c.454T>C; p.Trp152Arg) segregated with 
the disease in a Mexican family with ARS. A novel homozygous variant (c.92_100del; 
p.Ala31_Ala33del) in the FOXC1 gene segregated in a Pakistani family with ARS and 
congenital glaucoma. 
Conclusions: Our study expands the mutation spectrum of the PAX6 and FOXC1 genes 
in individuals with anterior segment dysgenesis disorders. In addition, our study suggests 
that FOXC1 mutations, besides typical autosomal dominant ARS, can also cause ARS 
with congenital glaucoma through an autosomal recessive inheritance pattern. Our results 
thus expand the disease spectrum of FOXC1 and may lead to a better understanding of 
the role of FOXC1 in development.  
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Introduction 
Anterior segment dysgenesis (ASD) disorders encompass a wide variety of 
developmental conditions in which multiple tissues such as the cornea, iris, and lens are 
affected [1]. The anterior segment consists of the anterior chamber and the posterior 
chamber, which are separated by the iris. In the posterior chamber, the ciliary body 
produces the aqueous humor which provides essential nutrients to the tissues of the 
anterior segment [2-4]. The aqueous humor is partially drained by the trabecular 
meshwork, and Schlemm's canal drainage structures located at the anterior segment angle 
where the iris and cornea meet. These structures that regulate the aqueous humor flow can 
be affected in patients with anterior segment dysgenesis, which leads to glaucoma in 
approximately 50% of the cases. These abnormalities may result from the abnormal 
differentiation of the mesenchymal cells which are responsible for the cornea, iris, and 
drainage structures development [2-4].  
ASD have been classified into different subtypes: aniridia, Axenfeld-Rieger 
syndrome (ARS), Peters' anomaly (PA), iridogoniodysgenesis, and posterior 
embryotoxon. They can be inherited either through autosomal recessive or autosomal 
dominant modes of inheritance, often with incomplete penetrance. Aniridia is a rare 
congenital disorder of either partial or complete hypoplasia of the iris, and can be 
associated with other eye defects such as corneal opacification, cataract, glaucoma, lens 
dislocation, ciliary body hypoplasia, foveal hypoplasia, strabismus, and nystagmus [5-7]. 
In about two-third of cases it is inherited as an autosomal dominant trait [8, 5]. ARS is a 
heterogeneous disorder characterized by a broad range of ocular and systemic 
abnormalities. Ocular features observed in ARS patients include iris stromal hypoplasia, 
polycoria, corectopia, iridogoniodysgenesis, posterior embryotoxon and iris strands 
bridging the iridocorneal angle to the trabecular meshwork. The various systemic features 
observed in ARS patients include facial dysmorphisms (e.g. hypertelorism, prominent 
forehead, telecanthus), dental anomalies (e.g. hypodontia, microdontia) and a redundant 
preumbilical skin [9, 10]. Mutations in the PAX6, PITX2, and FOXC1 genes have been 
associated with aniridia and ARS in an autosomal dominant manner [11-16] .  
The aim of the current study was to identify the genetic causes of aniridia and ARS in 15 
Pakistani and Mexican families.   
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Materials and Methods 
Ethics statement 
This study was approved by the Institutional Review Board of the Pediatric 
Glaucoma department of Al-Shifa Eye Trust Hospital, Pakistan and the Genetics 
department of the Asociación Para Evitar la Ceguera en México, Mexico. Written 
informed consent that complied with the tenets of the Declaration of Helsinki was 
obtained from every affected and unaffected individual (or his/her guardian) before they 
were enrolled into the study.  
Subjects 
Blood samples were collected from affected and unaffected siblings, and from the parents 
of 14 Pakistani and one Mexican family with anterior segment dysgenesis disorders (ARS 
n=10, aniridia n=5). Genomic DNA was extracted using AutoPure LS DNA Extractor and 
PUREGEN reagents (Gentra Systems Inc, Minneapolis, Minnesota, USA). 
Polymerase chain reaction and Sanger Sequencing 
All coding exons and intron-exon boundaries of the PAX6, PITX2 and FOXC1 
genes were amplified by standard polymerase chain reaction (PCR) (primer sequences 
available on request). The PCR products were Sanger sequenced using ABI BigDye 
chemistry (Applied Biosystems Inc, Foster City, California, USA), and were processed 
through an automated ABI 3730 Sequencer (Applied Biosystems, Inc. The sequencing 
results were aligned with the consensus sequences using Vector NTI Advance™ 2011 
software from Life Technologies/Invitrogen (Bleiswijk, Netherlands), by assembling 
the sequenced contigs. Variants were named according to the nomenclature 
recommended by the Human Genomic Variation Society (HGVS). Cosegregation 
analysis was carried out in available family members. The possible effects of 
variants were predicted by Polymorphism Phenotyping (PolyPhen-2, http://
genetics.bwh.harvard.edu/pph2/) and Sorting Intolerant Form Tolerant (SIFT; http://
sift.jcvi.org/), PhyloP, Grantham, and MutationTaster.   
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Results 
Identification of PAX6 mutations in three probands with aniridia 
The proband (II:3) of family 1 (Figure 1) from Pakistan was a 5-year old girl affected 
with bilateral aniridia, glaucoma, superiorly subluxated lenses, and cataract in the left eye 
(Figure 1). She underwent bilateral glaucoma surgery and lensectomy. Both parents had 
normal ocular examinations with 6/6 vision in both eyes.  A novel heterozygous nonsense 
mutation (c.225C>A; p.Tyr75*) in the PAX6 gene was identified in the proband. The 
variant was not detected in parents, suggesting that it arose de novo in the proband (Figure 
1).  
 
Figure 1: Family 1 from Pakistan with aniridia due to a de novo heterozygous PAX6 
mutation. (A) Pedigree and segregation of a novel mutation (c.225C>A; p.Tyr75*) in the 
PAX6 gene.  (B). Clinical presentation of the affected proband (II:3), corneal 
neovascularization and opacification in the right and left eyes. (C). DNA sequence 
chromatogram of PAX6.    
The same variation (c.225C>A; p.Tyr75*) was identified in another unrelated 2-year-old 
girl from Pakistan with bilateral aniridia, corneal opacity and buphthalmos. Her left eye 
was prosthetic after enucleation. Unfortunately DNA samples of her parents were not 
available.  
Proband II:1 of family 2 (Figure 2) from Pakistan was an 8-year-old boy presenting with 
aniridia, foveal hypoplasia, aphakia, hazy cornea, cataract and nystagmus. He also had 
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signs of limbal stem cell deficiency and was mentally retarded. His 30-year-old brother 
(II:2) had similar clinical findings except mental retardation. The mother (I:2) of the 
proband had no vision in the left eye and had complete aniridia of the right eye. A 
heterozygous nonsense mutation (c.649C>T; p.Arg217*) in the PAX6 gene was detected 
in the proband, and segregated with the disease in the affected mother and brother of the 
proband (Figure 2).  
 
Figure 2. Family 2 from Pakistan with aniridia due to a heterozygous PAX6 mutation. (a) 
Pedigree and segregation of a previously described mutation (c.649C>T; p.Arg217*) in 
the PAX6 gene.  (b). DNA sequence chromatogram of PAX6 for the variant c.649C>T 
Identification of FOXC1 mutations in two probands with ARS 
The proband (II:1) of family 3 (Figure 3A) from Mexico was diagnosed with ARS and 
congenital glaucoma at the age of 6 years. She had a prosthesis of her left eye (Figure 3B, 
C). At the age of 13 years, physical examination showed midface hypoplasia, a flat nose, 
hypertelorism, telecanthus, enamel hypoplasia and mild deafness. Her 9-year-old brother 
(II:2) (Figure 3D, E) and father (I:1) had similar clinical characteristics. A novel missense 
variant (c.454T>C; p.Trp152Arg) was identified in the FOXC1 gene (Figure F). The 
PhyloP score was 4.16 and the Grantham distance was 101. The mutated tryptophan 
amino acid was conserved among different species (Figure 3G).  
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Figure 3. Family 3 from Mexico with ARS due to a heterozygous FOXC1 mutation. (A) 
Pedigree and segregation of a novel missense mutation (c.454T>C; p.Trp152Arg) in the 
FOXC1 gene.  (B). Systemic and ocular characteristics of patient II.1 (C). Slit lamp 
photograph of right eye with posterior embriotoxon, polycoria, corectopia and iris 
atrophy. (D). Systemic and ocular characteristics of patient II.2, Midface hypoplasia, 
thelecantus and broad nasal bridge. (E). Slit lamp photographs of the right eye with 
posterior embriotoxon, polycoria, corectopia and iris atrophy. (F).  Sequence 
chromatograph of the FOXC1 variant. (G). Multiple sequence alignment of the region of 
the FOXC1 protein surrounding the novel p.Trp152Arg mutation in various species. The 
tryptophan residue (indicated with an arrow) is highly conserved among all species 
analyzed.    
Proband II:1 of family 4 (Figure 4A) from Pakistan was a 4-year-old boy with partial 
aniridia, aphakia, microcornea, cataract, and congenital glaucoma. His 9-year-old brother 
(II:2) had the similar clinical findings of microcornea, poor vision, and glaucoma. He also 
had sclerocornea and nystagmus and his left eye was phthisical after surgery for 
glaucoma. The anterior chamber was not visible due to the corneal opacity. In this family 
a novel homozygous deletion (c.92_100del; p.Ala31_Ala33del) in the FOXC1 gene 
segregated with the disease (Figure 4A, B). The mutation leads to an in-frame deletion of 
three conserved alanine amino acids (Figure 4C).   
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Figure 4. Family 4 from Pakistan with ARS and congenital glaucoma due to a 
homozygous FOXC1 mutation. (a) Pedigree and segregation of a novel deletion 
(c.92_100del; p.Ala31_Ala33del) in the FOXC1 gene.  (b). DNA sequence chromatogram 
of FOXC1 demonstrating loss of codons Ala31-33.   
The variants identified in PAX6 and FOXC1 were predicted to be deleterious by SIFT, 
damaging by Polyphen-2, and disease causing by MutationTaster. In addition, the variants 
were absent in public databases, including the dbSNP132, and Exome Aggregation 
Consortium (ExAC).  
Sanger sequencing of PITX2 gene did not revealed any variant in all the probands tested.  
Discussion 
In the current study we report PAX 6 mutations in two families and one unrelated proband 
with aniridia. A novel de novo mutation (c.225C>A; p.Tyr75*) was identified in the 
PAX6 gene in one family, and the same mutation was identified in an unrelated 2-year old 
girl with aniridia. In addition, a previously reported mutation (c.649C>T; p.Arg217*) was 
identified in the PAX6 gene [17] in another Pakistani family. PAX6 encodes a 
transcription factor consisting of three domains; a paired domain at the NH2-terminus, a 
homeodomain in the middle, and a transactivation at the COOH-terminus enriched with 
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proline/serine/threonine. Pax6 is widely expressed during normal eye development, [18] 
however, absence of Pax6 causes anophthalmia in mice [19] and humans [20]. The 
normal development anterior segment of the eye is dependent on the dose of the Pax6.  
Therefore, the PAX6+/− heterozygous null mutations responsible for the 
haploinsufficiency in humans are characterized by aniridia and other ocular abnormalities 
due to insufficient dose of Pax6 [14, 11, 21].  
The majority (92%) of mutations identified to be associated with aniridia in the PAX6 
gene includes; one or two base pair deletions and insertions resulting a change in the 
reading frame of the protein, nonsense, and splice site mutations [22-24]. In addition, a 
minority of mutations are missense mutations (2%), which often cause different 
phenotypes than null mutations, such as Peters anomaly [25], uveal ectropion [26], 
ectopia pupillae, cataracts, vascularized cornea, elliptical anterior iris stromal defects and 
iris hypoplasia. One-third of mutations identified in PAX6 are de novo 
(http://pax6.hgu.mrc.ac.uk/).   
 
In this study we also identified two novel mutations in the FOXC1 gene in two families 
with ARS: a heterozygous missense mutation (c.454T>C; p.Trp152Arg), and a 
homozygous in-frame deletion (c.92_100del; p.Ala31_Ala33del). In addition to the novel 
mutations in the FOXC1 gene segregating with the disease, two known GGC triplet 
insertions polymorphisms (rs545470261; p.Gly380dup and rs572346201; p.Gly456dup) 
that lead to a glycine incorporation have been identified in four probands, but none of 
them were segregating with the disease.  
The FOXC1 gene encodes a member of the forkhead box (FOX) family of transcription 
factors that are responsible for wide range of important roles such as embryogenesis, 
tissue-specific gene expression, and tumor development [27]. All forkhead transcription 
factors contains a highly conserved forkhead DNA-binding domain (FHD). The wing-like 
structure of the FHD is due to the particular arrangement of the alpha-helixes and beta-
sheets. FOXC1 activates the target genes by recognizing and binding to specific DNA 
sequences in the target genes through the conserved 110-amino-acid FHD [27].  The 
novel missense mutation (p.Trp152Arg) identified in this study affects a conserved amino 
acid residue in the second β-strand of the FOXC1 FHD. This mutation affects the same 
amino acid as the previously reported p.Trp152Gly mutation in a patient with aniridia 
[28].  The p.Try152Gly mutation has a severe effect on FOXC1 function, affecting its 
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phosphorylation, protein folding, DNA-binding ability, and nuclear localization [28].  The 
p.Trp152Arg mutation may have a similar consequence on the function of FOXC1. 
However, it is difficult to explain why there is a difference in the phenotypes of the 
patients with these mutation as p.Trp152Arg mutation leads to ARS, while the previously 
reported mutation p.Trp152Gly causes aniridia. Another FOXC1 mutation (p.Met161Lys) 
has been reported to cause both aniridia [12] and ARS [13, 29]. The phenotypic 
variability of overlapping FOXC1 mutations suggests that perhaps other factors influence 
the disease outcome. 
In this study, we also identified a homozygous in-frame deletion (p.Ala31_Ala33del) of 
three conserved alanine residues in a family with ARS and congenital glaucoma. These 
three amino acids are located in the activation domain 1 (AD1) of the FOXC1 protein at 
the amino terminus, which may affect the binding of FOXC1 with other interactors and 
may lead to irresponsiveness to ligands that trigger the activation upon binding to the 
AD1. To date, only heterozygous FOXC1 mutations have been reported in anterior 
segment dysgenesis disorders in humans; the family described in this study is the first 
with a mutation segregating homozygously.  Previously, it has been reported that mice 
with heterozygous (Foxc1-/+) and homozygous loss of Foxc1 (Foxc1-/-) have anterior 
segment abnormalities similar to those reported in humans with ASD and congenital 
glaucoma, such as iris hypoplasia, small or absence of Schlemm’s canal, severely 
eccentric pupils, displaced Schwalbe’s line, and aberrantly developed TM [30]. However 
heterozygous (Foxc1-/+) mice had a milder phenotype of ARS compared to the mice with 
homozygous mutations (Foxc1-/-). Homozygous mice exhibit excessive growth of corneal 
blood and lymphatic vessels which is associated with disorganization of the extracellular 
matrix (ECM) and increased expression of multiple matrix metalloproteinases [31]. In the 
current study the patients with the homozygous in-frame deletion of three conserved 
alanine amino acids were also affected by congenital glaucoma, high IOP (which might 
be due to the disorganized ECM), pupil corneal vascularization, and mild central corneal 
opacification at the level of post stroma. 
Our study expands the mutation spectrum of the PAX6 and FOXC1 genes in individuals 
with anterior segment dysgenesis disorders. In addition, our study suggests that FOXC1 
mutations, besides typical autosomal dominant ARS, can also cause ARS with congenital 
glaucoma through an autosomal recessive inheritance pattern. Our results thus expand the 
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disease spectrum of FOXC1, and may lead to a better understanding of the role of FOXC1 
in development. 
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Abstract: 
Purpose: To describe a novel mutation in the fibrillin-1 (FBN1) gene in a large Pakistani 
family with autosomal dominant Marfan syndrome (MFS).  
Methods: Blood samples were collected of 11 family members affected with Marfan 
syndrome, and DNA was isolated by phenol-extraction. The coding exons of the FBN1 
gene were analyzed by polymerase chain reaction (PCR) and direct sequencing. 130 
controls were screened for a mutation in the FBN1 gene that was identified in this family 
by restriction fragment length polymorphism (RFLP) analysis.  
Results: A novel heterozygous missense mutation c.2368T>A; p.Cys790Ser was 
observed in exon 19. This mutation substitutes a highly conserved cysteine residue by 
serine in a calcium binding epidermal growth factor-like domain (cbEGF) of FBN1. This 
mutation was present in all affected members and absent from unaffected individuals of 
the family in addition to 130 healthy Pakistani controls. Interestingly all affected family 
members presented with ectopia lentis, myopia and glaucoma, but lacked the cardinal 
cardiovascular features of MFS. 
Conclusion: This is a first report of a mutation in FBN1 in MFS patients of Pakistani 
origin. The identification of a FBN1 mutation in this family confirms the diagnosis of 
MFS patients and expands the worldwide spectrum of FBN1 mutations.   
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Introduction 
Marfan syndrome (MFS) is an autosomal dominantly inherited syndrome with a 
prevalence of 1 in 5,000-10,000 individuals. The major clinical manifestations of the 
syndrome include three major systems according to the Ghent criteria i.e. the ocular, 
skeletal and cardiovascular systems [1, 2]. 
Ocular features mainly involve ectopia lentis, which is observed in around 80% of MFS 
patients. Ectopia lentis is characterized by the dislocation of the lens, which typically 
occurs in patients between birth and 20 years of age after the lens is stabilized. Other 
features include high myopic eyes and retinal detachment in individuals aged 50-59 years 
[3, 4]. According to the new Ghent criteria another cardinal feature of MFS is aortic root 
aneurysm/dissection. The most common physical features were craniofacial 
characteristics, high-arched palate, positive thumb and wrist signs. If the family history of 
the patient is not positive, the involvement of at least two organ systems is required to 
establish the diagnosis. Genetic screening of MFS can aid the diagnosis MFS, as the 
presence of a mutation in the fibrillin-1 gene (FBN1)  in the presence of a major 
manifestation of one organ system is sufficient to make the diagnosis  [5].  
There are three types of fibrillins in humans: FBN1, FBN2 and FBN3. Fibrillins are 
extracellular matrix fibrillar components which are essential for the correct function of 
elastic and nonelastic tissues including blood vessels, bone and eye [6]. Fibrillin-1 is a 
350-kDa protein responsible for head-to-tail assembly of 10-12-nm fibrillin monomers in 
presence of calcium-constituting microfibrils. FBN1 forms a large multimeric protein 
complex by interacting with transforming growth factor beta (TGFβ), (latent TGFb 
binding protein (LTBPs) and microfibrils that interacts with bone morphogenetic proteins 
(BMP) complexes. Depending on the requirements of a cell or tissue the FBN1 complex 
can activate extracellular matrix (ECM) sequestered growth factors or inhibit activated 
growth factors. Thereby defects in fibrillin and its associated structure e.g. due to 
mutation, potentially could activate the growth factor signaling pathway, that can lead to 
MFS and related disorders of the connective tissue [7]. 
 FBN1 is composed of three types of repeated modules. The epidermal growth factor 
(EGF)-like modules contain six highly conserved cysteine residues, which form 
disulphide bonds with each other and are critical for the stabilized folding of the domain. 
FBN1 has 47 such modules, and 43 of them contain a calcium binding (cb) consensus 
sequence and are known as cbEGF-like modules [8]. The calcium ion bound in the 
3
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cbEGF-like domain performs a crucial structural role in restricting the interdomain 
flexibility, which might have a role in protein-protein interaction [9]. The second type of 
module of FBN1 are transforming growth factor β1-binding (or TB) protein-like module 
(TGF β1-BP-like module, or 8- Cys/TB), which is found seven times in FBN1. This 
module contains eight cysteine residues that form four disulfide bonds. The third type of 
module is a hybrid module, which occurs twice [5].  
Currently more than 1,200 mutations are known in the FBN1 gene and missense 
mutations account for a major proportion (60%) of these mutations [10]. The majority of 
these mutations affect one of the cbEGF domains; often involving one of the six highly 
conserved cysteine residues within the cbEGF domains. Most mutations leading to a 
severe disease are found to be clustered in exons 24-32, which encodes a central stretch 
of 12 cbEGF repeats. This stretch is important in the formation of a rigid rod-like 
structure, which might be involved in the formation of microfibril assembly [11].  
In this study we analyzed a five-generation family from Pakistan. All eleven affected 
family members lacked the cardinal cardiovascular features, but the diagnosis of MFS 
was confirmed by the identification of a novel mutation in the FBN1 gene.  
 
Methods 
Patients and clinical data 
In this study we recruited a five-generation consanguineous family with two loops, one 
from central Punjab and the other from the Azad Jamu and Kashmir area of Pakistan. 
Eleven out of 14 affected individuals and 5 of 6 normal healthy individuals participated in 
the study. 130 additional normal healthy controls were recruited for the study. After 
obtaining informed consent, thorough physical, ocular and cardiovascular examinations 
were performed for all participating family members.  
 
Molecular genetic analysis 
Genomic DNA was extracted from whole blood using a conventional phenol-chloroform 
method [12]. PCR amplification of the 65 coding exons and flanking regions of the FBN1 
gene was performed in the proband (IV:13) using a PE 9700 thermocycler (Applied 
Biosystems Forster City, CA). Primers and conditions are give in table 1. Briefly for all 
amplicons the following cycling conditions were applied: initial denaturation at  94 °C for 
5 min followed by 35 cycles of 94 °C for 30 s, 64 °C for 30 s, and 72 °C for 30 s. 
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Sequencing reactions were performed using an ABI 3730 DNA analyzer from Applied 
Biosystems (Foster City, CA). For the detection of deletions and duplications, the SALSA 
MLPA kits P065 and P066 from MRC (Amsterdam, the Netherlands) were used 
(http://www.mrc-holland.com). 
Segregation of a novel missense change in exon 19 was performed by direct sequencing 
of this exon in other family members using standard conditions. The forward primer 5′-
CAGGAGTTTTGCCTTTTTGC-3′ and reverse primer 5′-
TGCCATGTAGAACCACAGAA-3′ were used to amplify a 394 base pair (bp) product 
containing exon 19. PCR products were visualized on 2% agarose gel and purified by 
using PCR clean-up purification plates (NucleoFast® 96 PCR, MACHEREY-NAGEL, 
Düren Germany), according to the manufacturer’s protocol. Purified PCR products were 
analyzed by Sanger sequencing in an automated DNA sequencer (Big Dye Terminator, 
version 3 on a 3730 DNA analyzer; Applied Biosystems, Inc., Foster City, CA). 
Sequencing results were assembled and analyzed by using Vector NTI Advance (TM) 
2011 software from Life echnologies/Invitrogen (Bleiswijk, The Netherlands).  
Unrelated control individuals were analyzed for the novel mutation by restriction 
fragment length polymorphism (RFLP) analysis using the restriction enzyme AlwNI 
(New England Biolabs, Ipswich, MA). PCR products were digested by using 2 U of 
enzyme, 1X PCR buffer 4 (20 mM Tris-acetate, 50 mM potassium acetate, 
10 mM Magnesium Acetate, 1mM Dithiothreitol pH 7.9) and 16 µl of amplified PCR 
product and incubated for 2 hours at 37 0C. After heat inactivation at 650C the product 
was separated on a 3% agarose gel.  
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Results 
Clinical characteristics 
Eleven affected individuals of the family including 8 males and 3 females participated in 
the study (Figure 1). All patients showed similar clinical symptoms. In all affected 
members bilateral lens dislocation occurred and lenstectomy was performed. Other ocular 
symptoms included high myopia and glaucoma. None of them displayed any 
cardiovascular system abnormalities on echocardiography. Abnormalities of the skeletal 
system in MFS such as tall stature, long limbs, joint hypermobility, long narrow head, 
arachnodactyly, flat feet and medial displacement of medial malleoli, hollow cheeks and 
recessed or protruding jaw were noted in all individuals (Table 2).     
Identification of a novel FBN1 mutation 
Direct sequencing of FBN1 revealed a novel heterozygous mutation (c.2368T>A) in exon 
19 which results in a change from a cysteine to a serine (p.Cys790Ser) (Figure 2A, B). 
This missense mutation was present heterozygously in all affected members of the family 
while it was absent from normal individuals of the family as well as 130 unrelated healthy 
controls.  
 
Figure 1. Pedigree of a Pakistani family with MFS. Squares indicates males and circles 
females, black symbols represents affected and white unaffected individuals, gray 
symbols indicates unknown affection status. Slashed symbols represent the deceased 
subjects. + indicates the normal allele, and M indicates the Cys790Ser mutation.
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Figure 2. Sequence traces of the novel FBN1 missense mutation Cys790Ser in exon 19. 
A: A heterozygous change T>A (indicated by arrow) is identified in an affected family 
(IV:13) member. B: The corresponding normal sequence in an unaffected family member 
(IV: 10). 
The p.Cys790Ser mutation resides in the 12th cbEGF domain, where it affects one of the 
highly conserved cysteine residues. Cys790 is the 4th cysteine residue of this cbEGF 
domain, which is predicted to form a disulphide bond with the 2nd cysteine residue 
(Cys776) (Figure 3).  
 
 
Figure 3. A schematic representation of the consensus secondary structure of a 
prototypical cbEGF-like domain. Calcium binding in the NH2-terminal region of the 
wild-type domain is mediated by the highly conserved amino acids highlighted in blue. 
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The highly conserved cysteines of the cbEGF-like domain are marked with a C, and the 
lines between the cysteine residues represent disulfide bridges. The mutation Cys790Ser 
affects the 4th cysteine residue, which is predicted to form a disulfide bridge with the 2nd 
cysteine residue (Cys776). The mutation abolishes the disulfide bond formation and thus 
causes misfolding of the protein. 
 
Discussion 
Of all mutations that have globally been identified in the FBN1 gene, 38.6% result in a 
truncated FBN1 protein, and 60.3% represent missense mutations and of which most 
(78%) are localized in the cbEGF-like modules [13]. In the 43 cbEGF domains each have 
six highly conserved cysteine residues (C1-C6), which form disulphide bonds among 
each other (C1-C3, C2-C4, C5-C6). We identified a novel mutation in exon 19 of the 
FBN1 gene in a large MFS family from Pakistan, which, is predicted to abolish the C2-C4 
(Cys776-Cys790) disulphide bond of the 12th cbEGF domain, as the 4th cysteine residue 
is replaced with serine (Cys790Ser). Missense mutations in FBN1 that affect the 
cysteines, which are essential for the correct EGF-like domain structure, act in a dominant 
negative manner. Since the monomers from the mutated allele are folded incorrectly, they 
assemble with the normal monomers from the other allele creating abnormal multimers 
[14, 15].  
So far, no clear genotype-phenotype correlations in FBN1 have yet been established, 
though some correlations have been suggested in some studies, which included a large 
number of individuals (n= 101, 93, 57, 81 and 76 patients). Interestingly, a higher 
frequency of cysteine substitutions was observed in MFS patients with ectopia lentis, 
opposed to premature termination codon mutations [16-20]. This is in line with the 
clinical findings in the family described in this study, as all affected family members 
developed ectopia lentis.  
Previously most of the FBN1 mutations were found in other exons rather than exon 19. 
To date only four mutations have been identified in exon 19: a frameshift mutation 
observed in one Italian patient with clinical symptoms mainly involving the skeletal and 
cardiovascular systems [21], and three missense mutations in 3 sporadic patients from 
Belgium with classical MFS and involvement of the cardiovascular system [1]. All three 
missense mutations were present in the 8th cbEGF domain affecting the 2nd and 3rd 
cysteine residues. Though all mutations identified in exon 19 have so far been associated 
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with involvement of the cardiovascular system, this is not in the case in the family 
described in this study, as none of the affected family members showed cardiovascular 
system abnormalities on echocardiography.  
It has been reported that mutations in exons 24-32 are found in MFS individuals with a 
more severe and complete phenotype, including a younger age at diagnosis and a higher 
probability of developing ectopia lentis, ascending aortic dilatation, aortic surgery, mitral 
valve abnormalities, scoliosis, and shorter survival [11]. The ocular manifestations in this 
family, carrying a mutation in exon 19 of FBN1, were severe. All patients, including 4 
young children, developed ectopia lentis, myopia and glaucoma. However, no 
cardiovascular system defects have been developed in the affected individuals so far. 
Moreover, among skeletal manifestations no pectus abnormalities or scoliosis have been 
noted.  
Loeys et al did not find distinguishing features in patients with MFS with or without a 
FBN1 mutation except for the presence of ectopia lentis, which was significantly higher 
in individuals with mutations in FBN1[1]. A significant difference was observed between 
the clinical phenotype of patients carrying a missense mutation in 11th and 12th EGF-like 
domains compared with patients carrying a missense mutation in EGF-like domains 13-
18. Patients with mutations in EGF-like domains 11 and 12 have a shorter survival, a 
younger age at diagnosis, a higher probability of neonatal presentation, and a higher risk 
of developing ascending aortic dilatation than patients with a missense mutation affecting 
EGF-like domains 13–17 [11]. In the Pakistani family, carrying a mutation in the 12th 
EGF-like domain, patients were also diagnosed at a young age and some of them have a 
neonatal presentation, but no cardiovascular symptoms were observed.  
Marfan syndrome is characterized by a high clinical heterogeneity. The presentation of 
cardinal symptoms varies among families but also within families. The prevalence of 
cardiovascular features such as mitral valve prolapse is 43% and ascending aortic dilation 
is 53% in individuals in the age group <30. It increases steadily with age to 75% and 
96%, respectively, in individuals of ≤60 years with FBN1 mutations [22].  The affected 
individuals of the 5-generation family we present here lack the cardinal cardiovascular 
features of MFS, but do have the typical skeletal and ocular symptoms. The novel 
mutation in the FBN1 gene identified in this family supports the diagnosis of MFS.  
Although cardiovascular features are absent in the family, it has been reported that in 
some cases these features may not manifest until adulthood. Black et al reported the 
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development of aortic root dilatation in the fifth decade of life in patients presenting 
familial ectopia lentis at the age of 58 and 70 years. In the present family only one 
affected individual has reached age 50, whereas three are in the age group of 30-40 years, 
four affected individuals are in their childhood and 3 are infants. Therefore the young age 
might explain the absence of cardiovascular manifestation in these individuals. The study 
of Black et al confirms the need for life-long screening in adult patients carrying a FBN1 
mutation in the absence of major manifestations [23]. 
In this family of Pakistani origin affected individuals experience major involvement of 
the ocular and skeletal systems. Interestingly, all patients in this family developed ectopia 
lentis, had high myopia and glaucoma. In literature it has been reported that glaucoma 
occurs in 64% of patients with MFS and in 10% of patients with isolated ectopia lentis 
[24]. Glaucoma has been observed more frequently in spontaneous late subluxation of the 
lens than in the congenital type. However, in the family described here glaucoma was 
been observed in combination with early sublaxation of the lens in all affected 
individuals, suggesting that predisposing factors may be present in this family, adding to 
the risk of developing glaucoma.  
To the best of our knowledge this is the first report of a family with FBN1 mutations, in 
which all affected individuals developed glaucoma and myopia. The presence of these 
particular clinical features in all affected individuals might be due to the novel mutation 
p.Cys790Ser, or alternatively may be associated with additional genetic factors that 
contribute to the disease phenotype in this family. We believe that the p.Cys790Ser 
mutation affects the structure of the protein by disturbing the arrangement of the 
microfilaments, and acts in a dominant negative manner. Although more the 1,200 
mutations in the FBN1 gene have been identified for MFS, this is a first report from 
Pakistan, which expands the worldwide mutation spectrum and adds to the existing 
knowledge of genotype-phenotype comparisons for MFS.      
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Abstract 
Myocilin and optineurin are two candidate genes in which mutations are known to cause 
glaucoma. To determine their role in Pakistani familial and sporadic glaucoma cohorts the 
current genetic study was conducted on 32 families, 402 patients with primary open angle 
glaucoma, 135 patients with primary angle closure glaucoma, 155 patients with 
pseudoexfoliative glaucoma and 165 population-matched control individuals. In this 
multicenter study the cases were selected on the basis of raised intra ocular pressure, 
visual field damage and gonioscopic findings. Age matched controls with no signs of 
glaucoma were also recruited. The exons and intron-exon boundaries of myocilin and 
optineurin were sequenced in family probands. Additionally, using Taqman allelic 
discrimination and restriction fragment length polymorphism assays, association analysis 
was conducted for single nucleotide polymorphisms (SNPs) of myocilin: rs2234926, 
(exon 1), and optineurin: rs10906308 and rs11258194 (intron 13 and exon 5, 
respectively). Sequence analysis of probands revealed no pathogenic mutation in 
myocilin and optineurin. A non-synonymous SNP in myocilin (rs2234926) was detected 
in 16 probands, and a non-synonymous SNP (rs11258194,) in optineurin was found in 2 
probands. Association analysis of sporadic cases did not reveal the risk allele of 
rs11258194 or any of the other SNPs to be associated with increased risk for glaucoma. 
However, haplotype A-G (rs11258194-rs10906308) was found to be significantly 
associated with increased risk of POAG. In addition, although rs11258194 did not 
segregate with the disease in 2 glaucoma families, it was found at a higher frequency 
among family members, suggesting that it might play a role in the progression of the 
disease. 
Key words: 
Glaucoma; Myocilin; Normal Tension Glaucoma; Retinal Ganglion Cells 
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Introduction 
Glaucoma is a multifactorial optic neuropathy, in which combination of genetic and 
environmental factors are responsible for irreversible vision loss [1]. Clinically, two 
major types of primary glaucoma can be distinguished; primary open angle 
glaucoma (POAG) and primary angle closure glaucoma (PACG) [2]. A major form of 
secondary glaucoma is pseudoexfoliative glaucoma (PEXG) [3]. POAG is the most 
prevalent type of glaucoma, with higher incidence of sporadic as well as familial 
cases being reported worldwide [4]. Sporadic forms of glaucoma (POAG, PACG, 
PEXG, normal tension glaucoma) is believed to be manifested by a combination 
of genetic as well as environmental factors. Genetic variants associated with 
glaucoma have been identified using genome-wide and candidate gene association 
studies in sporadic cases [5]. As opposed to the sporadic cases the familial cases 
generally follow a Mendelian inheritance pattern, being either dominantly or recessively 
inherited [6, 7]. 
To date 20 loci (GLC1A to GLC1N, GLC3A to GLC3D) have been reported to 
be associated with familial glaucoma. Of these loci, two have the myocillin (MYOC) 
and optineurin (OPTN) genes that have been reported to be one of the causative 
factors of familial glaucoma [8]. Worldwide more than 70 point mutations in MYOC 
have been found to be associated with POAG (predominantly with JOAG), with a 
3-5% overall association with POAG [9] including: p.(Gln368*) (Caucasians), p.
(Thr377Met) (Greek and Australian populations) [10, 11], p.(Gln48His) (Indians) 
[12], p.(Pro370Leu) (Chinese) [13] and p.(Arg46*) (Asians) [14]. MYOC encodes a 
570kDa protein, spans a 17kb genome region and has 3 exons. The MYOC protein has a 
C-terminal olfactomedin-like domain and an N-terminal myosin-like domain [15]. In the 
eye it has been reported to be present in the TM, aqueous humor [15] and in the sheath of 
the optic nerve fibers [16]. Different mutations in MYOC have been reported to 
interfere with aqueous humor outflow and thus increase the IOP. However, the 
mechanism of the rise in IOP has not been clearly defined yet [11, 17]. OPTN has been 
reported to be associated with a late age of disease onset, but it has been found to 
account for only about 1% of glaucoma mutations. Polymorphisms in the gene have 
been shown to be associated with NTG, and the Glu50Lys variant has been reported in 
POAG cases [18]. The Met98Lys variant is also associated with NTG [19]. The gene 
encodes a 577-kDa protein expressed in the 
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TM, ciliary muscle and retina, and has been shown to have a protective role in the eye, 
being expressed in response to stress [20]. 
The current study was conducted to evaluate the role of genetic variants in MYOC and 
OPTN in the etiology of glaucoma in Pakistan. Mutation analysis of both genes was 
conducted in glaucoma families, and association analyses were performed for selected 
variants in sporadic cases of POAG, PACG and PEXG. 
 
Materials and methods 
 
Sample collection and DNA isolation 
The current study was approved by the COMSATS Institute of Information 
Technology, Department of Biosciences “Ethics Review Board” and conforms to the 
tenets of the Helsinki Declaration. After obtaining informed written consent venous blood 
samples were collected from all participants, and DNA was isolated by a standard organic 
extraction method [22]. Unaffected and affected members of 32 families underwent 
clinical tests necessary for the diagnosis of glaucoma. The diagnosis of glaucoma 
included detailed history, complete eye examination, retinal imaging and visual field 
testing. While taking history of patient, special emphasis was placed on presenting 
complaints that included pain in eyes, episodes of blurred vision with colored halos for 
primary closed angle glaucoma and risk factors such as family history of glaucoma, high 
myopia, for the diagnosis of open angle glaucoma. Complete eye examination was 
conducted including slit lamp examination to exclude all findings of secondary glaucoma 
such as lens induced glaucoma, inflammatory glaucoma, etc. Intraocular pressure was 
measured by tonometry (patients with intraocular pressure more than 21 mm were 
included in the study), eye drainage angle was measured by gonioscopy to diagnose open 
and closed angle, inspection of pupil and lens was done to identify the presence of 
pseudo-exfoliation, ophthalmoscopy was done to inspect the optic nerve changes 
(increased cup:disc ratio-more than 0.5, splinter hemorrhage at disc margin). Retinal 
imaging included Ocular Coherence Tomography (OCT) and Heidelberg Retinal 
Tomography (HRT) to measure nerve fiber layer thickness at the optic disc level, which 
is decreased in glaucoma specially in superior and inferior quadrants. Finally, Humphrey 
visual field testing was done to evaluate field defects characteristic of glaucoma. 
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Sequence analysis of MYOC and OPTN 
The coding exons and splice junctions of MYOC (NM_000261) and OPTN 
(NM_001008213) were amplified in the probands of the 32 glaucoma families. PCR 
amplification was performed by an initial denaturation at 92 oC for 5 min, followed by 30 
cycles of denaturation at 95 oC for 30 sec, annealing at 58 oC for 30 sec, and extension for 
30 sec at 72 oC, followed by a final extension step at 72 oC for 10 min. The PCR products 
were separated on 2% agarose gels, purified using PCR purification plates (NucleoFast™ 
96 PCR, MACHEREY-NAGEL, Düren, Germany) followed by Sanger sequencing (Big 
Dye Terminator chemistry, version 3, on a 3730 DNA analyzer; Applied Biosystems, 
Foster City, CA). The sequencing results were analyzed using Vector NTI Advance™ 
software (Life Technologies/Invitrogen, Carlsbad, CA). Identified variants were 
evaluated using SIFT (Sorting intolerant from tolerant) and Polyphen (polymorphism 
phenotyping). 
 
Genotyping of SNPs in MYOC and OPTN 
Genotyping was conducted for three SNPs: rs2234926 in exon 1 of MYOC, 
rs10906308 in intron 13 of OPTN, and rs11258194 in exon 5 of OPTN, in 402 patients 
with POAG, 135 patients with PACG, 155 patients with PEXG and 165 population-
matched control individuals. Two variants (rs2234926 and rs11258194) were selected 
because they were found recurrently in familial cases in the current study. The third 
variant, rs10906308, was selected because it was found to be associated with POAG in a 
previous study [22]. Taqman allelic discrimination assays were performed for rs2234926 
and rs10906308 using a real-time PCR (Applied Biosystems 7900HT Fast System and 
Sequence Detection Systems Software v2.3) with 10ng of genomic DNA in a 4µl reaction 
mixture. After an initial denaturation step of 12 min at 95 oC, 50 cycles of amplification 
were performed for 15 sec at 92 oC and 90 sec at 60 oC. The SNP rs11258194 in OPTN 
was analysed with a restriction fragment length assay, briefly the target sequence was 
amplified using the primers for exon 5, and the amplified product was digested with 
restriction enzyme Stu1 (Fermentas, Waltham, MA).  
Multivariate logistic regression analysis was conducted to determine the association of 
genotype frequencies between the different groups, after adjusting for age and gender. R 
software (R Core Team (2012). R: A language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL 
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http://www.R-project.org/) was used to perform the logistic regression analysis, and 
univariate logistic regression was done to determine the association of the allele 
frequencies using online statistical software http://statpages.org/ctab2x2.html in POAG, 
PACG and PEXG patients, and population-matched control individuals. A p value of 
≤0.05 was considered statistically significant. The intraocular pressure (IOP) was 
compared between cases and controls using a 2-tailed t-test. Haplotype analysis of the 
two OPTN SNPs was done for POAG samples using the online software 
http://bioinfo.iconcologia.net/SNPstats.  
 
Results 
Screening families for variants in MYOC and OPTN  
Several known and novel variants in MYOC and OPTN were found in the probands of the 
32 families. Segregation analysis of only known nonsynonymous SNPs and all novel 
variants was checked but these variants did not segregate with the disease in the 
respective families (Table 1). However, a non-synonymous SNP in MYOC (rs2234926 
c.227G>A, p.(Arg76Lys)) was found in 50% of the probands, and an intronic SNP 
(rs2032555, c.730+35G>A) was found in 13% of the probands. In OPTN three variants 
were identified in the families: of these, the synonymous SNP rs2234968 (c.102G>A, 
p.(=)), c.293T>A, p.Met98Lys) was identified in 6% probands. In addition a novel variant 
(M2: c.283G>C, p.(Glu95Gln)) in exon 5 of OPTN was found in one proband, however, 
none of these variants segregated with the disease in the families (segregation is shown in 
Fig. 1 A, B, C & D).  
 
Association analysis of sporadic glaucoma patients 
The genotype and allele frequencies of the SNP rs11258194 in OPTN were determined. 
As the AA genotype was present at a low percentage (0% in controls, and 1% in cases; 
data not shown) therefore it was merged into the TA genotype for logistic regression 
analysis. Both the genotype and allele frequencies were not found to be significantly 
associated with increased risk of POAG after correction of p values for multiple testing, 
(p*=0.07, OR=2.85 [95% CI=1.15-7.06]; p*=0.06, OR=2.68 [95% CI=1.07-7.12], 
respectively; Table 2). Similarly, no significant associations were observed for PACG 
(p*=0.60, OR=2.05 [95% CI=0.05-7.14]; p*=0.66, OR=1.96 [95% CI=0.58-6.68], 
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respectively; Table 2) or PEXG (p*=0.72, OR=1.76 [95% CI=0.56-5.51]; p*=0.15, 
OR=1.96 [95% CI=0.67-6.11], respectively; Table 2). Moreover, the mean IOP of POAG 
patient’s carrying the variant allele rs11258194 (23.6±9.2 mmHg) was not significantly 
different from the mean IOP in POAG patients who had the ancestral allele (25.2±10.1 
mmHg p>0.05). 
 
Figure 1. Segregation analysis and sequencing chromatogram of identified variants 
of OPTN in POAG families. Pedigrees A, B & C. with segregation of rs11258194 (M1: 
c.293T>A, p.[Met98Lys]) and D of a novel variant (M2: c.283G>C p.[Glu95Gln]). 
Generation numbers in the pedigrees are indicated by roman numerals. Filled squares and 
circles are affected males and females, respectively, while the unfilled symbols are 
unaffected individuals. Probands are indicated by an arrow, and all the individuals that 
underwent molecular genetic analysis are indicated by their mutation pattern, ‘+’ 
indicating wild type allele, ‘M’ indicating the variant allele. Individuals indicated with 
+|+ carry homozygous wild type genotype, those indicated by +|M are heterozygotes 
carrying one wild type and the other variant allele and M|M carry the variant allele 
homozygously. 
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In addition, rs10906308 in OPTN and rs2234926 in MYOC were not found to be 
significantly associated with POAG, PACG, or PEXG (Table 2). Haplotype analysis of 
the two SNPs in OPTN was also conducted, which was found to be significantly 
associated with the disease (overall haplotype p value=0.0082), where the haplotype A-G 
(rs11258194-rs10906308) was significantly associated with increased risk of 
POAG (p=0.019, OR=2.96 [95% CI=1.20-7.31]; Table 3).  
Table 3. Haplotype analysis of OPTN SNPs rs11258194 and rs10906308 in Pakistani 
POAG cohort 
rs11258194 rs10906308 Frequency OR (95%CI) p value 
1 T G 0.6733 1.00 --- 
2 T A 0.2789 1.10 (0.80-1.51) 0.55 
3 A G 0.0398 2.96 (1.20-7.31) 0.019 
Haplotype association p value=0.0082 
Discussion 
All the glaucoma families in the current study were screened for candidate glaucoma 
genes MYOC and OPTN. Though MYOC is known to be involved in disease progression 
in 2.6% to 4.4% of POAG cases [23], no pathogenic variant in the gene was found in the 
current cohort with the exception of a non-synonymous SNP (rs2234926). This variant 
was identified in 16 probands, and was therefore screened in a panel of unrelated POAG, 
PACG and PEXG patients. However, no significant association was found for rs2234926 
with the different types of glaucoma. This polymorphism is a recurrent SNP among 
MYOC variations and being the most common SNP it is reported to be disease-associated 
in various populations [24, 25]. In addition, mutations in MYOC occur in various 
populations of the world with varying frequency; 8% of Italian glaucoma patients carry 
MYOC variants [23, 24, 25], in the Indian population, mutations in the gene are reported 
to be responsible for 2% of POAG cases [26]. Although no disease-causing mutation was 
found in the current cohort, recently the c.1130C>T, p.(Thr377Arg) variant in MYOC has 
been reported to be a disease-causing mutation in a Pakistani family [27]. This indicates 
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the possibility that the gene might be involved in the pathogenesis of glaucoma in the 
Pakistani population, but is probably a rare cause of the disease. 
In vivo studies of MYOC have shown that it does not seem to play a role in the 
pathogenesis of glaucoma, which could be a coincidental finding, or the gene might be 
acting in tandem with another gene. For examples, the Gly399Val mutation in MYOC has 
been reported to cause late-onset POAG (mean age 51 years), however, when it occurs in 
combination with the Arg368His mutation in CYP1B1, the age of onset of the disease 
decreases to a mean age of 27 years [9]. In vivo analysis of MYOC mutations in double 
mutant mice revealed that the gene is not associated with IOP maintenance, since no TM 
abnormalities were seen in transgenic mice after the introduction of these mutations [28].  
Similarly, in the current cohort only a known pathogenic SNP, Met98Lys, was found in 
OPTN in three probands. The result is not surprising as the association of the SNPs and 
mutations in OPTN varies among various populations of the world [18, 29]. The original 
study that highlighted OPTN as a candidate gene for glaucoma described the Met98Lys, 
to be associated with NTG [30]. Although subsequent studies showed conflicting results 
about the involvement of the variant in glaucoma, meta-analysis did indicate association 
of the Met98Lys, with the disease. In addition in various Asian populations the variant 
has been shown to only have a weak association with glaucoma [8, 26, 29, 31, 32]. 
Keeping in view the diversity of the association of this SNP with different populations, 
Ayala-Luogo et al (2007) proposed that the involvement of rs11258194 might be 
evaluated in glaucoma families as well as in sporadic cases. Thus in the current study the 
segregation of rs11258194 was checked in the families of the 3 probands (in whom it was 
initially identified), as well as its association was determined with sporadic POAG, 
PACG and PEXG cohorts. Although the SNP did not segregate in the 3 POAG families, 
an interesting pattern of inheritance was seen when the overall frequency distribution of 
the alleles was calculated in the affected as well as unaffected family members. In this 
analysis it was observed that of the total 30 individuals: 10 (33%) had the ancestral TT 
genotype, 18 (60%) were heterozygous (TA) and 2 (7%) had the homozygous variant 
allele (AA). This pattern was not seen in unaffected controls (TT=96.4%, TA=3.6%, 
AA=0%), or sporadic cases of POAG (TT=90.8%, TA=9%, AA=0.2%). Although this 
variant did not segregate in the families, the preponderance of the TA genotype in the 
families suggests a possible role in the progression of the disease. It could thus be that 
this genotype maybe is interacting with some other unknown gene and thus increasing the 
3
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risk of glaucoma in the families carrying this variant. In order to preclude the possibility 
that the high prevalence in the affected families was by chance, we also analyzed two 
other POAG families in which this variant was not found in the probands, but none of the 
members of these families were found to carry the variant ‘A’ allele. This further 
strengthens our conjecture that when present, this variant might play a role in the 
initiation or progression of the disease in the affected families in tandem with some other 
gene or environmental factor. In addition, this SNP has previously been reported to be 
associated with low IOP, and thus has a modifying effect on the glaucoma phenotype. 
OPTN increases the sensitivity of glial neuronal cells to risk factors of glaucoma, even at 
normal IOP [11]. In the current study no difference was detected between the IOP in 
patients with and without this variant, which is in agreement with the previous work of 
Ayala-Luogo et al. (2007), who also did not find an IOP lowering effect of the variant 
allele of this SNP. However, its role in an increased risk due to sensitivity of glial cells at 
normal IOP cannot be ruled out, thus studies of NTG patients are required to further 
validate this observation. 
Based upon the varying results in different populations and our observation that 
rs11258194 might be acting in tandem with some other genetic element, we hypothesize 
that in populations where this SNP has shown association with the disease it is probably 
present in linkage disequilibrium with these elements. Whereas, in populations where this 
SNP shows no association some completely different element might be responsible for 
the disease, or in other words the presence of rs11258194 alone is not causative of the 
disease. This could very well be due to different times of fixation of this SNP in different 
populations, or an earlier fixation and subsequent dispersal into extant populations such 
as European (Australians), Indians, Chinese and other Asians, which effect possibly does 
not predominate in Pakistani ethnic groups that have seen subsequent replacement with 
populations from Levant and the Central Asian States, an effect that is visible in genetic 
clines tailing into Pakistan from those regions [33, 34]. In addition the dissimilarity in 
genetic susceptibility between the neighbors: India and Pakistan is not surprising as 
previously also we have found differences between these two populations while studying 
the association of LOXL1 with PEXG [35]. 
In conclusion this study describes MYOC and OPTN screening in familial as well as 
sporadic glaucoma patients. Our findings suggest that factors other than MYOC and 
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OPTN may possibly contribute to the pathogenesis of glaucoma in the analyzed families 
and sporadic cases. 
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Abstract: 
Background: CYP1B1 is the most commonly mutated gene in primary congenital 
glaucoma (PCG), and mutations have also been identified in primary open-angle 
glaucoma (POAG). This study was undertaken to describe mutations in CYP1B1 in 
patients and families with PCG and POAG from Pakistan. 
Design: Case-control series. 
Participants:Forty families, 190 sporadic POAG cases and 140 controls from Pakistan. 
Methods: Patients and healthy individuals of one consanguineous Pakistani family were 
genotyped with high-resolution single nucleotide polymorphism microarrays. 
Homozygosity mapping was performed using Homozygosity Mapper. Direct sequencing 
of CYP1B1 gene was performed in probands of the families, sporadic POAG cases and 
control individuals. 
Main Outcome Measures : Mutations in the CYP1B1 gene in PCG and POAG patients. 
Results: Homozygosity mapping in a consanguineous Pakistani family revealed one 
11-Mb homozygous region encompassing the CYP1B1 gene. A 
homozygous CYP1B1 missense mutation (p.Arg390His) was identified in this family. 
Sequence analysis of CYP1B1 in 39 additional families revealed one known and three 
novel homozygous mutations in PCG (p.Ala288Pro, p.Asp242Ala, p.Arg355* and 
p.Arg290Profs*37). In POAG, one novel heterozygous missense mutation (p.Asp316Val) 
was identified in one family and a previously reported mutation (p.Glu229Lys) was 
identified in three families. Analysis of CYP1B1 in a panel of 190 sporadic POAG 
patients revealed three novel heterozygous variants (p.Thr234Lys, p.Ala287Pro and 
p.Gln362*) and three previously reported heterozygous variants (p.Gly61Glu, 
p.Glu229Lys and p.Arg368His). The p.Glu229Lys variant was significantly associated 
with POAG (P = 0.03; odds ratio 2.49). 
Conclusions: This study confirms that CYP1B1 mutations are associated with POAG and 
PCG in the Pakistani population. 
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Introduction 
CYP1B1 (OMIM 601771) encodes cytochrome P4501B1, an enzyme belonging to the 
cytochrome P450 super-family. CYP1B1 is localized in the endoplasmic reticulum and is 
involved in the metabolism of endogenous and exogenous substrates. CYP1B1 
metabolizes procarcinogens such as polycyclic aromatic hydrocarbons and 17-β-estradiol. 
It is also involved in the synthesis of steroid hormones and lipid molecules, which 
contribute in various signaling pathways that regulate growth and differentiation, 1.  
CYP1B1 is highly expressed in the iris and ciliary body of the human eye, and it has been 
proposed that it is involved in the development of the iridocorneal angle, 2, 3. Alterations 
in CYP1B1 may lead to a reduced or absent metabolism of essential endogenous 
substrates in the ciliary epithelium. Since the ciliary body is primarily involved in the 
production of aqueous humor,4 such alterations might directly lead to an abnormal 
elevation of the intraocular pressure of the eye, or indirectly affect the aqueous outflow by 
disrupting the proper development of trabecular meshwork in glaucoma patients. 
CYP1B1 plays a major role in the etiology of glaucoma and other disorders of the anterior 
segment. CYP1B1 mutations have been identified in primary congenital glaucoma (PCG), 
5, 6 primary open angle (POAG), 7-9, juvenile open angle glaucoma, 10, and other anterior 
chamber disorders such as Rieger’s anomaly (RA) and Peters anomaly (PA).11, 12 
Mutations in CYP1B1 have been identified in families where PCG and POAG co-exist, 
indicating that these two forms of glaucoma may also have a common or overlapping 
CYP1B1-mediated pathophysiological mechanism. 13  
Different CYP1B1 mutations have been identified among diverse ethnic groups, some of 
which may be population-specific. 14,15. In the present study we investigated the CYP1B1 
mutation spectrum in families and sporadic POAG patients from Pakistan.  
Methods 
Patients and clinical data 
The study adhered to the guidelines of the Declaration of Helsinki and was approved by 
the Institutional Review Board of Al-Shifa Eye Trust Hospital. After signed informed 
consents were obtained, blood samples were collected for DNA isolation. Affected and 
unaffected family members of 40 glaucoma families (12 PCG and 28 POAG), 190 
sporadic POAG patients and 140 healthy controls were included in this study. The 
3
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diagnosis of PCG was made according to the following criteria: age at onset less than 3 
years; megalocornea or buphthalmos (horizontal corneal diameter >13 mm); corneal haze; 
breaks in Descemet membrane; raised intraocular pressure (>21 mmHg); cup–disc ratio of 
the optic nerve >0.6; and the presence of additional symptoms such as blepharospasm and 
photophobia. Patients were diagnosed with POAG based on an increased intraocular 
pressure, optic nerve damage, visual field changes and fundoscopy. Juvenile-onset POAG 
was diagnosed between age 4 years and early adulthood. Adult-onset POAG was 
diagnosed at adulthood, usually after 35 years of age.  
 
Molecular genetic analysis 
A conventional phenol-chloroform method was used for the extraction of genomic DNA 
from whole blood. 16  
DNA samples of 8 affected (PCG, juvenile-onset or adult-onset POAG) and 5 unaffected 
family members of a large consanguineous family (Glu1) were genotyped with 
Affymetrix 250K SNP microarray, and genotype data were analyzed for homozygous 
regions using the online mapping tool Homozygosity Mapper 
(http://www.homozygositymapper.org/).  
Both coding exons of the CYP1B1 gene were amplified in the probands of 40 glaucoma 
families (12 PCG and 28 POAG), 190 sporadic POAG patients and 140 healthy controls. 
Primers were designed using Primer 3 (primer sequences and PCR conditions are 
available on request). PCR products were visualized on 2% agarose gel and purified with 
PCR clean-up purification plates (NucleoFast® 96 PCR, MACHEREY-NAGEL, 
Germany), according to the manufacturer’s protocol. Purified PCR products were 
analyzed by Sanger sequencing in an automated DNA sequencer (Big Dye Terminator, 
version 3 on a 3730 DNA analyzer; Applied Biosystems, Inc., Foster City, CA). 
Sequencing results were aligned with the reference sequence (obtained from the hg19 
human genome build) and analyzed using Vector NTI Advance (TM) 2011 software 
(Invitrogen). In addition, the pathogenicity of CYP1B1 missense variants was evaluated 
by publically available tools including PhyloP (nucleotide conservation in various 
species), Grantham (amino-acid conservation), PolyPhen2, and SIFT.  
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Results 
Identification of a homozygous CYP1B1 mutation in family segregating PCG, juvenile-
onset and adult-onset POAG 
Homozygosity mapping in 8 affected and 5 unaffected individuals of a large 
consanguineous family (Glu1) revealed only one homozygous region of 11 Mb containing 
the CYP1B1 gene (Figure 1). Sequence analysis of the coding exons of CYP1B1 revealed 
a homozygous missense mutation (c.1169G>A; p.Arg390His) segregating with the 
disease in the family (Figure 2). The variant is predicted to be pathogenic by 
pathogenicity programs, and was not found in 140 control individuals.  
Affected individuals of this family were diagnosed with PCG, juvenile-onset or adult-
onset POAG. Individuals III:2 and III:5 have a late onset form of POAG, with an onset of 
the disease in their forties. Individuals IV:2, IV:5, IV:7, IV:8 and IV:10 have a juvenile-
onset form of POAG. Patient III:2 has poor vision, a phthisical left eye, nystagmus, and 
optic disc neuropathy with a pigmentary mottling of the fundus in the macula of her right 
eye. Her son (IV:2) has a phthisical left eye, a peripheral iris defect, aniridia and anterior 
and posterior synechia, and a high IOP (44 mmHg) of the right eye. Individual IV:5 has 
megalocornea, nystagmus, raised IOP in both eyes (35 and 30 mmHg) and a CDR of 1.0 
in both eyes. Patient IV:13 was diagnosed at 2 years of age with PCG. She has a 
megalocornea, hazy cornea, edema, raised IOP (32 mmHg) and nystagmus.   
 
Figure 1. Homozygosity mapping in eight affected and five unaffected individuals of 
family Glu1. One 11-Mb homozygous region was identified on chromosome 2 
encompassing the CYP1B1 gene. Glu1, a large consanguineous Pakistani family with 
glaucoma. 
3
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Figure 2. Pedigree of a large consanguineous Pakistani family with glaucoma (Glu1). The 
c.1169G>A; p.Arg390His mutation is indicated with an M, and the wild-type allele with a 
+. All affected individuals carry the mutation homozygously, whereas the unaffected 
individuals are heterozygous. This demonstrates that the mutation segregates with the 
disease in the family through a recessive inheritance pattern. 
 
Identification of homozygous CYP1B1 mutations in four PCG families  
Sequence analysis of CYP1B1 in 39 additional families revealed four homozygous 
mutations in consanguineous PCG families. One nonsense mutation (p.Arg355*) was 
previously described to cause PCG, while three mutations (p.Ala288Pro, p.Asp242Ala 
and p.Arg290Profs*37) are novel. All four mutations segregate with the disease in the 
respective families (Figure 3).  
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Figure 3. Pedigrees of consanguineous families with primary congenital glaucoma 
(PCG). Mutations are indicated with an M, and the wild-type allele with a +. All affected 
individuals carry the mutation homozygously, whereas the unaffected individuals carry 
the mutation heterozygously. This demonstrates that the mutations segregate with the 
disease in the families through a recessive inheritance pattern. 
 
The age of individuals diagnosed with glaucoma was before 2 years. All affected 
individuals have bilateral congenital glaucoma with buphthalmos due to increased IOP, 
and a horizontal corneal diameter >13mm (Figure 4). Cup-to-disc ratio in all affected 
individuals was >0.7, and individual IV:1 of family C (Figure 3C) has a cloudy cornea of 
the right eye (Figure 4A).    
 
Figure 4. (a) Patient IV:1 of primary congenital glaucoma (PCG) family C at 5 years of 
age. Horizontal corneal diameters were 13 mm in both eyes, and the cornea of the right 
eye is cloudy. (b) Patient IV:1 of family D at 3 years of age. Horizontal corneal diameters 
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were 14 mm in both eyes, and corneas were clear without breaks or scars. No iris atrophy 
was noted. 
 
Identification of a heterozygous CYP1B1 mutation in a JOAG/POAG family 
A novel heterozygous missense mutation (c.947A>T; p.Asp316Val) was identified in a 
large consanguineous POAG family (Glu2; Figure 5). Pathogenicity programs predict the 
variant to be pathogenic (Table 1). The mutation was not identified in 140 ethnically-
matched controls. The myocilin gene (MYOC) in the current family was excluded by 
Sanger sequencing. 
Affected individuals of family Glu2 were diagnosed with both JOAG and adult-onset 
POAG. Individual IV:1 has POAG with an age of onset in his late sixties, myopic 
retinopathy, optic atrophy, tessellated fundus and raised IOP in both eyes, even after 
treatment. Individuals V:1, V:2, V:4, V:8 and V:9 were diagnosed with bilateral JOAG 
before 35 years of age. Patient V:1 has a high IOP (26 mmHg) and a CDR of 0.9 in both 
eyes and a pale optic disc with peripapillary atrophy and extensive chorioretinal atrophy. 
V:2 and V:7 also have a bullous superior retinal detachment; therefore a 3-port pars plana 
vitrectomy was performed in both of them. The IOP was elevated in both eyes (30 and 26 
mmHg, respectively) after treatment and the CDR was 0.9 and 1.0, respectively. 
Individuals V:5, V:6 and V:7 were diagnosed with JOAG at the age of 20 years. Both V:5 
and V:6 have myopic degeneration, mild chorioretinal atrophy, raised IOP in both eyes 
and a 0.9 for (V:5) and CDR of 0.6 (V:6).  
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Figure 5. Pedigree of a large consanguineous family with individuals affected by juvenile 
open-angle glaucoma (JOAG) or primary open-angle glaucoma (POAG) (Glu2). The 
c.947A>T; p.Asp316Val mutation is indicated with an M, and the wild-type allele with a 
+. All affected individuals carry the mutation heterozygously, whereas the unaffected 
individuals do not carry the mutation. This demonstrates that the mutation segregates with 
the disease in the family through a dominant inheritance pattern. 
 
Identification of a heterozygous p.Glu229Lys CYP1B1 variant in 3 families 
Sequence analysis of CYP1B1 in the 39 probands also identified a previously reported 
variant (p.Glu229Lys) in 3 POAG families. Pathogenicity programs predict the variant to 
be pathogenic (Table 1). However, this variant does not segregate with the disease in the 
family members of the 3 probands (Figure 6). 
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Figure 6. Pedigrees of three large consanguineous Pakistani families with primary 
open-angle glaucoma (POAG). The c.685G>A; p.Glu229Lys variant is indicated with an 
M, and the wild-type allele with a +. The variant does not segregate with the disease in 
these families. 
 
Identification of heterozygous CYP1B1 variants in sporadic POAG patients 
Direct sequencing of 190 sporadic POAG patients revealed two novel heterozygous 
missense variants (c.701C>T; p.Thr234Met, c.859G>C; p.Ala287Pro) and one novel 
heterozygous nonsense variant (c.1084C>T; p.Gln362*). In addition, three heterozygous 
variants were identified (c.182G>A; p.Gly61Glu, c.1103G>A; p.Arg368His, c.685G>A; 
p.Glu229Lys), which have previously been reported in PCG and POAG patients of 
various populations. The p.Gly61Glu variant was found heterozygously in 2 of 190 
POAG cases, while it was not observed in 140 control individuals. The p.Arg368His 
variant was observed in 8 of 190 cases and 5 of 140 controls, and is therefore not 
significantly associated with POAG in this cohort (Table 1).   
The p.Glu229Lys variant was found in 22 of 190 POAG patients, and 7 of 140 controls. 
Using a chi square test, this variant was found to be significantly associated with the 
disease (p = 0.03; OR 2.49[0.97-6.62]). All variants were analyzed in 140 ethnically 
matched controls, and all were predicted to be pathogenic (Table 1).  
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Identification of common SNPs in the CYP1B1 gene in sporadic POAG patients 
In addition to the above described variants, 5 common coding SNPs (c.514 C>G; 
p.Arg48Gly, c.727 G>T; p.Ala119Ser, c.1666 C>G; p.Leu432Val, c.1719 C>T; 
p.Asp449Asp, and c.1730 A>G; p.Asn453Ser) and one intronic SNP c.-1-12C>T were 
found in both patients and controls (Table 2).  Two coding SNPs detected in exon 2, 
p.Arg48Gly and p.Ala119Ser, were found to be in perfect linkage disequilibrium. A 
significant difference in genotype and allele frequencies between POAG cases and 
controls was observed for p.Arg48Gly (p=0.00002; OR[95% CI] 1.95[1.38-2.74]), 
p.Ala119Ser (p=0.00002); OR[95% CI] 1.95[1.38-2.74]), and c.-1-12C>T (p=0.0002; 
OR[95% CI] 1.81[1.28-2.54]) (Tables 2 and 3). A significant difference in genotype 
frequencies was observed for SNP p.Asn453Ser (p=0.0008), while the allele frequency 
was not significantly different (p=0.07) between POAG patients and controls (Tables 2 
and 3).   
3
231
   
 
 
Ta
bl
e 
1:
 V
ar
ia
nt
s d
et
ec
te
d 
in
 C
YP
1B
1 
in
 3
0 
pr
ob
an
ds
 o
f m
ul
tip
le
x 
fa
m
ili
es
 a
nd
 1
90
 sp
or
ad
ic
 P
O
A
G
 p
at
ie
nt
s f
ro
m
 P
ak
is
ta
n 
N
uc
le
ot
id
e 
ch
an
ge
  
A
m
in
o 
ac
id
 c
ha
ng
e 
 P
ro
ba
nd
s  
(n
 =
 4
0)
 
Pa
tie
nt
s 
(n
=1
90
)  
C
on
tro
ls
 
(n
=1
40
) 
Ph
yl
oP
 G
ra
nt
ha
m
 
di
st
an
ce
 
SI
FT
 
Sc
or
e*
 P
ol
yP
he
n*
* 
 
Pr
ev
io
us
 re
po
rts
 
db
SN
P 
c.
18
2G
>A
 
p.
G
ly
61
G
lu
 
0 
2 
0 
3.
34
 
98
 
0.
00
 
1.
00
 
PC
G
 [3
,8
], 
PO
A
G
 [2
0]
 
rs
28
93
67
00
 
c.
68
5G
>A
 
p.
G
lu
22
9L
ys
 
3 
22
 
7 
3.
60
 
56
 
0.
03
 
0.
99
 
PC
G
 [8
], 
PO
A
G
 [1
2]
 
rs
57
86
50
60
 
c.
70
1C
>T
 
p.
Th
r2
34
M
et
 
0 
1 
0 
2.
38
 
81
 
0.
00
 
1.
00
 
N
ov
el
 
N
/A
 
c.
72
5A
>C
 
p.
A
sp
24
2A
la
××
 
1 
0 
0 
2.
63
 
12
6 
0.
00
 
1.
00
 
N
ov
el
 
 
c.
85
9G
>C
 
p.
A
la
28
7P
ro
 
0 
2 
0 
0.
37
 
27
 
0.
02
 
0.
99
 
N
ov
el
 
N
/A
 
c.
86
2G
>C
 
p.
A
la
28
8P
ro
××
 
1 
0 
0 
-0
.1
2 
27
 
0.
19
 
0.
00
3 
N
ov
el
 
 
c.
86
8d
up
 
p.
A
rg
29
0P
ro
fs
*3
7×
×  
1 
0 
0 
N
/A
 
N
/A
 
N
/A
 
N
/A
 
N
ov
el
 
 
c.
94
7A
>T
 
p.
A
sp
31
6V
al
 
1 
0 
0 
0.
69
 
15
2 
0.
03
 
0.
98
 
N
ov
el
 
N
/A
 
c.
10
63
C
>T
 
p.
A
rg
35
5*
 ××
 
1 
0 
0 
N
/A
 
N
/A
 
N
/A
 
N
/A
 
PC
G
 [2
1,
 2
2]
 
 
c.
10
84
C
>T
 
p.
G
ln
36
2*
 
0 
1 
0 
N
/A
 
N
/A
 
N
/A
 
N
/A
 
N
ov
el
 
N
/A
 
c.
11
03
G
>A
 
p.
A
rg
36
8H
is
 
0 
8 
5 
5.
53
 
29
 
0.
01
 
1.
00
 
PC
G
 [8
], 
PO
A
G
 [1
2,
 
22
] 
rs
79
20
43
62
 
c.
11
69
G
>A
 
p.
A
rg
39
0H
is
××
 
1 
0 
0 
5.
69
 
29
 
0.
01
 
1.
00
 
PC
G
 [3
], 
PO
A
G
 [1
1]
 
N
/A
 
 *S
ub
st
itu
tio
ns
 w
ith
 a
 S
IF
T 
sc
or
e 
<0
.0
5 
ar
e 
pr
ed
ic
te
d 
to
 b
e 
de
le
te
rio
us
, *
*P
ol
yp
he
n 
sc
or
es
 n
ea
r 1
 a
re
 c
on
fid
en
tly
 p
re
di
ct
ed
 to
 b
e 
pa
th
og
en
ic
,  
××
M
ut
at
io
ns
 w
er
e 
de
te
ct
ed
 in
 h
om
oz
yg
ou
s s
ta
te
; a
ll 
ot
he
r v
ar
ia
nt
s w
er
e 
he
te
ro
zy
go
us
.  
232
   
 
 
Ta
bl
e 
2:
 G
en
ot
yp
e 
fr
eq
ue
nc
ie
s o
f c
om
m
on
 S
N
Ps
 d
et
ec
te
d 
in
 C
YP
1B
1 
in
 1
90
 sp
or
ad
ic
 P
O
A
G
 p
at
ie
nt
s a
nd
 1
40
 c
on
tro
ls
  
N
uc
le
ot
id
e 
ch
an
ge
 
A
m
in
o 
ac
id
 
ch
an
ge
 
Pa
tie
nt
 n
=1
90
 
(%
) 
C
on
tro
l 
n=
14
0 
(%
) 
P- va
lu
e 
Ph
yl
oP
 
G
ra
nt
ha
m
 
di
st
an
ce
 
SI
FT
 
Sc
or
e*
 P
ol
yP
he
n*
* 
db
SN
P 
c.
-1
-1
2C
>T
 
N
/A
 
C
C
=5
9 
(3
0.
0)
 
C
T=
10
1 
(5
3.
1)
 
TT
=3
0 
(1
5.
8)
 
C
C
=7
5 
(5
3.
6)
 
C
T=
49
 (3
5.
0)
 
TT
=1
6 
(1
1.
4)
 
0.
00
02
 
N
/A
 
N
/A
 
N
/A
 
N
/A
 
rs
26
17
26
6 
c.
14
2C
>G
 
p.
A
rg
48
G
ly
 
C
C
=5
4 
(2
8.
4)
 
C
G
=1
04
 (5
4.
7)
 
G
G
=3
2 
(1
6.
9)
 
C
C
=7
5 
(5
3.
6)
 
C
G
=4
9 
(3
5.
0)
 
G
G
=1
6 
(1
1.
4)
 
0.
00
00 2 
-1
.2
5 
12
5 
0.
38
 
0.
00
 
rs
10
01
2 
c.
35
5G
>T
 
p.
A
la
11
9S
er
 
G
G
=5
4 
(2
8.
4)
 
G
T=
10
4 
(5
4.
7)
 
TT
=3
2 
(1
6.
9)
 
G
G
=7
5 
(5
3.
6)
 
G
T=
49
 (3
5.
0)
 
TT
=1
6 
(1
1.
4)
 
0.
00
00 2 
-0
.2
8 
99
 
0.
79
 
0.
00
 
rs
10
56
82
7 
c.
12
94
C
>G
 
p.
Le
u4
32
V
al
 
C
C
=1
37
 (7
2.
1)
 
C
G
=4
4 
(2
3.
2)
 
G
G
=0
9 
(4
.7
) 
C
C
=1
01
 (7
2.
1)
 
C
G
=3
3 
(2
3.
6)
 
G
G
=0
6 
(4
.3
) 
0.
97
 
1.
09
 
32
 
0.
90
 
0.
00
 
rs
10
56
83
6 
c.
13
47
T>
C
 
p.
A
sp
44
9A
sp
 
TT
=0
5 
(2
.6
) 
TC
=5
3 
(2
7.
9)
 
C
C
=1
32
 (6
9.
5)
 
TT
=0
5 
(3
.6
) 
TC
=3
5 
(2
5.
0)
 
C
C
=1
00
 (7
1.
4)
 
0.
76
 
N
/A
 
N
/A
 
N
/A
 
N
/A
 
rs
10
56
83
7 
c.
13
58
A
>G
 
p.
A
sn
45
3S
er
 
A
A
=7
4 
(3
8.
9)
 
A
G
=1
06
 (5
5.
8)
 
G
G
=1
0 
(5
.3
) 
A
A
=7
8 
(5
5.
7)
 
A
G
=4
9 
(3
5.
0)
 
G
G
=1
3 
(9
.3
) 
0.
00
08
 
4.
73
 
46
 
0.
02
 
0.
68
 
rs
18
00
44
0 
3
233
 
 
 
 
Table 3. Allele frequencies of common SNPs detected in CYP1B1 in 190 sporadic POAG 
patients and 140 controls 
Nucleotide 
change 
Patient 
n=190 
(%) 
Control 
n=140 
(%) 
OR 95% CI P-value 
c.-1-12C>T 
C=219 (57.6) 
T=161 (42.4) 
C=199 (71.1) 
T=81 (28.9) 
1.81 (1.28-2.54) 0.0003  
p.Arg48Gly 
C=212 (55.8) 
G=168 (44.2) 
C=199 (71.1) 
G=81 (28.9) 
1.95 (1.38-2.74) 0.00006  
p.Ala119Ser 
G=212 (55.8) 
T=168 (44.2) 
G=199 (71.1) 
T=81 (28.9) 
1.95 (1.38-2.74) 0.00006  
p.Leu432Val 
C=318 (83.7) 
G=62 (16.3) 
C=235 (83.9) 
G=45 (16.1) 
0.98 (0.63-1.52) 0.93  
p.Asp449Asp 
T=63 (16.6) 
C=317 (83.4) 
T=45 (16.1) 
C=235 (83.9) 
1.04 (0.67-1.61) 0.86  
p.Asn453Ser 
A=254 (66.8) 
G=126 (33.2) 
A=205 (73.2) 
G=75 (26.8) 
1.36 (0.95-1.93) 0.07  
 
Discussion 
Extensive analysis of the CYP1B1 gene in PCG and POAG patients of various 
populations around the world have revealed a great diversity with respect to the mutation 
spectrum of the CYP1B1 gene in the pathogenesis of the disease. PCG is a recessive 
disease, with patients often carrying homozygous mutations in CYP1B1.2 In the current 
study, CYP1B1 was sequenced in probands of 12 PCG families, of which 4 PCG families 
were solved with homozygous mutations p.Ala288Pro, p.Asp242Ala, p.Arg355* and 
p.Arg290Profs*37.  
Previous studies from France, Canada and Spain described heterozygous CYP1B1 
mutations in POAG patients.9,17,18. In the present study all identified mutations in POAG 
patients were present in heterozygous state, except for the homozygous mutation 
p.Arg390His detected in family Glu1. The age of onset of the disease ranged widely in 
this family, from adult-onset POAG diagnosed around age 40 to PCG at 2 years of age. 
This demonstrates that POAG can be caused by homozygous CYP1B1 mutations. The 
wide variability in disease expression suggests that other factors may contribute to the 
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disease outcome in this family. The p.Arg390His has previously been found 
homozygously in PCG patients from different populations,19,20 while it has been reported 
heterozygously in 1 POAG patient from France,9 and homozygously in one JOAG patient 
from Tehran.19 It was suggested that gene dosage is unlikely to be a general mechanism 
for delayed expression in POAG patients, since parents of PCG patients do not develop 
glaucoma.9 Possible explanations may be the involvement of a modifier locus, an 
alteration of the dopamine pathway, or exposure to environmental factors such as 
xenobiotics or mutagenic chemicals.9 The p.Arg390His mutation affects an arginine 
residue in a conserved motif (GluXXArg) in the helical turn of the K-helix of CYP1B1. 
Arg390 is proposed to be involved in the formation of salt bridges, which is disrupted by 
the introduction of a histidine at this position.21  
In the current study a significant association was observed for the p.Glu229Lys variant in 
POAG. Interestingly, in Indian POAG patients the frequency of this variant was almost 
similar in patients (5.12%) compared to controls (5.0%),22 while in the current Pakistani 
cohort a significantly higher percentage (13%) of POAG patients carry this variant 
compared to 5.0% of Pakistani controls. The p.Glu229Lys variant changes a basic to an 
acidic amino acid in the SRS2 region of CYP1B1. Glu229 is localized at the periphery of 
the active site at the COOH terminal of the F helix, and it forms a charged pair with 
Arg233.23 Replacement of Glu229 by a lysine residue leads to a charge repulsion, which 
is expected to have an effect on the structure of the substrate binding region and thus may 
influence metabolite formation. Choudhary et al observed that the presence of the 
p.Glu229Lys variant destabilizes the holoenzyme, involving a decline of 25% in the 
enzyme activity as compared to wild type. The mutant protein significantly impaired the 
ability of CYP1B1 to metabolize metabolites generated by the arachidonic acid 
metabolism, with a decrease of up to 75%.24 
In the current study we report 4 novel heterozygous mutations in POAG patients, 
expanding the mutation spectrum of the CYP1B1 gene: p.Asp316Val in a family with 
adult-onset POAG, and p.Thr234Lys, p.Ala287Pro and p.Gln362* in 3 sporadic POAG 
patients. All novel variants are predicted to be pathogenic and were not identified in 140 
ethnically matched control individuals. To date only one study has reported two nonsense 
mutations in POAG patients from France; all other nonsense mutations have been 
reported in PCG patients.9 This study thus further supports a role for CYP1B1 nonsense 
mutations in the pathogenesis of POAG.  
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Previous studies revealed that the common variants p.Asn453Ser and p.Leu432Val are 
significantly associated with POAG in French,9 and Indian, 25 populations. However, 
contradictory results for association of the p.Leu432Val SNP have been observed in the 
Indian population belonging to two different regions. This SNP was not associated with 
JOAG in patients residing in the Eastern part of India,10 and complete linkage 
disequilibrium was observed between p.Arg48Gly and Ala119Ser, similar to our 
observation in the Pakistani population. In the current study we observed a significant 
association of p.Asn453Ser with POAG, which strengthens the findings of Melki et al,9 in 
French POAG patients. In addition, significant associations were observed between the 
c.-1-12C>T, p.Arg48Gly, and p.Ala119Ser and p.Asn453Ser SNPs and POAG in 
the Pakistani cohort, whereas no association was observed with p.Leu432Val 
and p.Asp449Asp. The contradictory associations observed for variants in CYP1B1 
gene suggest that either these alleles have a different effect in different populations, 
possibly by the involvement of other contributing factors, or that they might be 
in linkage disequilibrium with a yet unidentified causative variant in or near the 
CYP1B1 gene. Only a limited number of studies have described the spectrum of 
CYP1B1 mutations in adult-onset POAG. Additional studies are required to better 
understand the role of CYP1B1 mutations in this type of glaucoma.
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Abstract 
Background: CYP1B1 is the most commonly mutated gene in primary congenital 
glaucoma (PCG). This study was undertaken to identify mutations in CYP1B1 in the 
Western region of Saudi Arabia. 
Methods: Blood of patients who had typical findings of PCG, were screened by direct 
sequencing of all coding exons and splice junctions of the CYP1B1 gene. 
Results: 34 patients were studied; 18 patients belonged to 8 families, and 16 patients 
were non-familial, isolated PCG. Consanguinity was found in 27/34 (79.4%) of cases. All 
patients were diagnosed to have bilateral PCG at birth except one child, who had 
glaucoma in the right eye. More males (61.8%) were affected than females (38.2%). 
79.4% (27/34) of patients were solved with pathogenic mutations and 20.6% (7/34) 
remained unsolved. Of the solved ones, 22.2% (6/27) of patients carry a pathogenic allele 
on one allele while the other allele remained yet to be determined. Direct sequencing of 
exon 2 revealed two pathogenic variants (p.Gly61Glu, p.Glu229Lys). P.Gly61Glu 
substitution was found both homozygously in 63% (17/27) of cases, and heterozygously 
in one patient. P.Glu229Lys variant was found heterozygous in 3.7% (1/27) of cases. One 
pathogenic variant (p.Arg469Trp) was found in exon 3, and is present homozygously in 
14.8% (4/27) of cases while four patients have this variant heterozygously. All mutations 
were reported previously in the Saudi population, except p.Glu229Lys. Severe cases were 
associated with p.Gly61Glu, and p.Arg469Trp in 50% and 30% of ten patients 
respectively. 
Conclusions: This study confirms that CYP1B1 mutations are the most frequent cause of 
PCG in the Saudi population, with p.Gly61Glu being the major disease-associated 
mutation. P.Glu229Lys is a newly discovered mutation in our PCG patients. Patient 
lacking mutation in CYP1B1 gene seems likely, to have another genetic loci involved in 
the pathogenesis of the disease, and need further study. Genetic studies of recessive 
diseases such as PCG is important in consanguineous populations, since it will increase 
awareness and allows genetic counseling to be offered to patients and their relatives. This 
will not only reduce the disease to be inherited to future generations but will also reduce 
the disease burden in the community. 
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Introduction 
Primary congenital glaucoma (PCG) refers to a glaucoma occurring within the first 
3 years of life, due to isolated trabeculodysgenesis [1]. It is relatively common in Saudi 
Arabia (SA), with an estimated incidence of 1: 2500 live births, secondary to a high 
prevalence of consanguinity in Saudi families [2]. It is the second most common cause of 
blindness in schools of the blind in SA [3]. The congenital glaucoma registry at King 
Khaled Eye Specialist Hospital showed that PCG geographic distributions in SA is: south 
region (27.8%), western province (23.6%), central region (22.2%), eastern province 
(11.1%), and north province (9%) [4]. 
The link between PCG and gene abnormalities is the initial step in the establishment of 
the pathophysiology of the disease. Three previous major studies [5-7] were conducted in 
SA, to identify the abnormal genes associated with PCG. So far CYP1B1 was the only 
gene found to be associated with bilateral PCG in consanguineous Saudi Arabian 
families. CYP1B1 mutations were identified in 96% of cases of the study described by 
Bejjani et al. [6] and in 75.9% of cases of the study described by Abu-Amero et al. [7]. 
Unilateral PCG were studied by Khan et al. [8] but was not associated 
with CYP1B1mutations. Expatriates were excluded from all previous gene studies [4-8]. 
This study was conducted to identify CYP1B1 mutations in Saudi PCG patients with 
various ethnic backgrounds, and to identify those patients who carry novel mutations. 
Patients were collected at King Abdulaziz University Hospital, one of the major hospitals 
in the Western province of Saudi Arabia and a main referral centre for congenital 
glaucoma in the province. 
Methods 
Patients and clinical data 
The study adhered to the guidelines of the Declaration of Helsinki and was approved by 
King Abdulaziz University Research ethics committee (Reference No. 922–12). 
After signed informed consents were obtained, blood samples were collected for DNA 
isolation from 34 patients with PCG. 
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Patients were recruited from the glaucoma clinic at King Abdulaziz University Hospital 
(KAUH) and the pediatric ophthalmology clinic at King Fahd Armed Forces Hospital 
(KFAFH), in Jeddah, Kingdom of Saudi Arabia. The diagnosis of PCG was established 
by the following signs: (1) increased intraocular pressure (IOP) (>21 mmHg), (2) cornea 
diameter (>10 mm) and changes (oedema, Haab’s striae, scar), (3) optic nerve 
glaucomatous cupping, and by the following symptoms: photophobia, epiphora, and/or 
blephrospasm [1]. The medical history of all participants was taken and the family 
pedigrees were drawn. Patients with other ocular and systemic abnormalities were 
excluded. 
Molecular genetic analysis 
Primers were designed for the two coding exons and splice site junctions of 
the CYP1B1 gene using Primer 3 (primer sequences and PCR conditions are available on 
request). PCR products were visualized on 2% agarose gel and purified with PCR clean-
up purification plates (NucleoFast® 96 PCR, MACHEREY-NAGEL, Germany), 
according to the manufacturer’s protocol. Purified PCR products were analyzed by 
Sanger sequencing in both directions using both forward and reverse primers in an 
automated DNA sequencer (Big Dye Terminator, version 3 on a 3730 DNA analyzer; 
Applied Biosystems, Inc., Foster City, CA). Sequencing results were aligned with the 
reference sequence (obtained from the hg19 human genome build) and analyzed using 
Vector NTI Advance (TM) 2011 software (Invitrogen). In addition, the pathogenicity 
of CYP1B1 missense variants was evaluated by publically available in silico tools 
including PhyloP, Grantham, PolyPhen2, and SIFT. 
Data collection and statistical analysis 
Data were collected from the medical records in a special form and then entered and 
stored in computer Microsoft ward. Graph Prism 5 software (GraphPad Software Inc, La 
Jolla, Ca USA) was used to analyze the data. Frequency distribution tables were used to 
present the data. Mean, standard deviation and (student’s) t-test were used to compare 
continuous variables. 
All tests were two sided and at a 5% level of statistical significance. Fisher’s exact test 
also used to compare the real values of native and non-native Saudi groups. 
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Results 
Demographic and medical data 
Our study included 34 PCG patients: 23 patients from KAUH and 11 patients from 
KFAFH. 18 patients belonged to 8 families with consanguineous parents, while9 patients 
were unrelated, non-familial, isolated PCG cases belonging to consanguineous parents. 7 
patients were unrelated, non-familial, isolated PCG belonging to non-consanguineous 
parents. Consanguinity was reported in 27/34 (79.4%) of cases. 
All 34 patients were diagnosed to have bilateral PCG at birth except one child, who had 
glaucoma only in the right eye. More males (21/34) were affected than females (13/34). 
At presentation, the mean IOP +/− standard deviation (SD) was 30.48+/−6.93 (range 20 – 
47) mmHg, the mean corneal diameter +/− SD was 12.71 +/−1.26 (range 10 – 17) mm. 
The mean cupping +/− SD and mean refraction +/− SD of 23 eyes with clear cornea was 
0.47 +/− 0.29 (range 0.1 - 1.0), and - 4.92 +/− 5 (range +2.3 to −16) D respectively.
Twenty three cases were native Saudi, of which 21 (91%) were positive 
for CYP1B1 mutations, and 2 (9%) were negative. Eleven patients were non-native Saudi, 
originating from Yemen (4), Sudan (3), Afghanistan (2), Burma (1), and Syria (1). Of the 
non-native cases, 6 (54.5%) were positive for CYP1B1 mutations, and 5 (45.5%) were 
negative. Overall 27/34 (79.4%) cases carried CYP1B1 mutations and 20.6% (7/34) 
patients remained unsolved. Table 1, present a comparison of demographic, medical 
and CYP1B1mutations between native and non-native Saudis. No significant differences 
were observed between the 2 groups, except for the mean C/D ratio, which was higher in 
the non-native Saudi group. 
Ten patients were classified to have severe glaucoma on presentation (based on IOP level, 
corneal diameter and clarity) according to Al-Hazmi et al. [9] classification. 5 (50%) 
patients were associated with G61E, and 3 (30%) patients with R469W mutations 
Table 2. 
244
 
 
 
 
 
CYP1B1 mutation analysis 
DNA samples of all patients were screened for mutations in the CYP1B1 gene. 
Pathogenic variants were detected in CYP1B1 gene in 27 patients. 77.8% (21/27) patients 
were completely solved with pathogenic mutations, while 22.2% (6/27) patients were 
carrying a pathogenic allele on one allele while the other allele remained yet to be known. 
Direct sequencing of exon 2 revealed two pathogenic variants (c.182G > A: p.Gly61Glu, 
and c.685G > A: p.Glu229Lys). The p.Gly61Glu substitution was found homozygously in 
63% (17/27) patients, of which 10 cases belong to 4 consanguineous families. The 
p.Glu229Lys variant was found heterozygously in 3.7% (1/27) of cases Table 3. 
Similarly, one pathogenic variant (c.1405C > T: p.Arg469Trp) was detected in exon 3. 
The p.Arg469Trp was found in 29.6% (8/27) patients. The p.Arg469Trp substitution was 
found homozygously in four patients belonging to two consanguineous families. 
The probable pathogenic mutations of the 22.2% (6/27) patients were, p.Arg469Trp in 
four patients, p.Gly61Glu in one patient and p.Glu229Lys in one patient, heterozygously. 
These six patients might have a second variant in the same gene that lies in the noncoding 
region i.e. intron or promoter Table 3. 
In addition to those pathogenic variants, 6 other common SNPs (rs2617266, rs10012, 
rs1056827, rs9341249, rs4986888 and rs1056837) were also found either homozygously 
and heterozygously, that were not predicted to be pathogenic Table 3. 
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Discussion 
The populations of the Arabian Peninsula descend from a small number of founders. 
Their descendants established various tribes that dispersed across the kingdom. Therefore, 
the majority of native Saudi Arabians living today have common ancestors [5]. This is 
may be true in all parts of SA except the Western region, where the population consists of 
a different ethnic groups due to the presence of the two holy cities, Makkah and Madinah, 
and immigration of people from Arabic and Islamic countries to this region over the last 
14 centuries. Jeddah is the sea port of the two holy cities, and thus also has a population 
with a high cultural and ethnical diversity. Non-native Saudi PCG patients were excluded 
from all previously published gene studies, and only conducted on native patients from 
various tribes and regions of SA [4-8]. To the best of our knowledge this is the only gene 
study in SA, which addresses the effect of ethnicity on gene anomalies in PCG. 
The CYP1B1 gene was selected to screen for mutations in our PCG patients, since it was 
considered the main candidate gene for PCG in Saudi Arabia. CYP1B1 mutations were 
found in 79.4% of our patients, which is higher than that reported by Abu-Amero et al. [7] 
and lower than that reported by Bejjani et al. [6]. 
We detected CYP1B1 mutations in 91% and 54.5% of native and non-native Saudi 
Arabian PCG patients, respectively. This difference in rate of mutations could be 
secondary to the lower consanguinity rate in the non-native Saudi population (54.6%) 
compared to the native population (91.3%). The rate of CYP1B1mutations in our non-
native Saudi cases is low and comparable to populations with low consanguinity rates like 
India (44%) [10] and Brazil (50%) [11]. In addition, the high rate of CYP1B1 mutations in 
the native Saudi PCG cases may be explained by the population structure. Since the 
native Saudi population descended from a limited number of founders, it is likely that one 
of a small number of founder mutations have arisen that explain the majority of the cases 
among the native Saudi populations. Two of the pathogenic variants (p.Gly61Glu, 
p.Arg469Trp) identified in our cases were previously reported in the literature in PCG 
patients of various populations (ethnic groups), including native Saudi Arabians [5-7]. 
The Gly61Glu mutation is the most frequent mutation in the Saudi patients of our current 
study as well as in patients from Kuwait. Both SA and Kuwait share a common genetic 
background because of the neighborhood and frequent migration routes between the two 
populations [12]. We identified a missense mutation (p.Glu229Lys) in one of our non-
3
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native Saudi PCG patients. This patient’s family is originally from Burma. This mutation 
has not been reported previously in native Saudi Arabian PCG patients [5-7], but it has 
been reported in Turkish [13], Indian [10], Iranian [14] patients, and in an index patient of 
family from Oman in heterozygous manner [15]. 
In a previous study of CYP1B1 analysis by Bejjani et al. [6] in PCG patients from SA a 
haplotype was constructed for the six SNPs. We also constructed haplotypes ie 
C/C/G/G/T/A using the same SNPs which includes one intronic c.-1-12C > T and five 
exonic SNPs i.e. c.142C > G; R48G, c.355G > T; A119S, c.1294C > G; V432L, 
c.1347T > C; D449D and c.1358A > G; N453S. In their study they had observed that this 
distinctive haplotype is associated with the five different mutations and we also saw a 
same haplotype C/G/G/T/A in case of the two mutations Gly61Glu and Arg469Trp in 27 
patients. This same haplotype C/C/G/G/T/A was associated with at least seven separate 
mutations and appears to be common in all the individuals carrying the most frequent 
mutation, 4340delG in CYP1B1 in Brazilian PCG patients [11, 16]. However, in the 7 
patients which remained unsolved with CYP1B1 in the current study, 4 patients had this 
haplotype T/G/T/C/C/A while three individuals were heterozygous for all these five 
SNPs. Bejjani et al. [6] also found that the three families unsolved with CYP1B1 
mutations has a heterozygous haplotype for these five SNPs. It seems likely, that 
individuals lacking haplotype C/C/G/G/T/A have another genetic loci involved in the 
pathogenesis of PCG. We are currently exploring this possibility. 
In the literature, there has not been a consistent correlation between the severity of PCG 
and presence and types of CYP1B1 mutations [17]. Hollander et al. [18] found a 
correlation between the type of CYP1B1mutations and the severity of glaucoma on the 
basis of anterior chamber angle histological changes and difficulty in controlling IOP. 
Panicker et al. [19] found that severe cases (using severity index) of PCG associated with 
ins376A (100%), E229K (80%), E368H (72%), G61E (66.7%), and P193L (62.5%). The 
severity of PCG in our patients was assessed on the basis of clinical assessment of IOP 
level, corneal diameter, and corneal clarity at the time of presentation. We did find severe 
cases of PCG associated with two mutations, G61E (50%), and R469W (30%), in ten of 
our patients. 
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Conclusions 
This study confirms that CYP1B1 mutations are the most frequent cause of PCG in the 
Saudi Arabian population, with p.Gly61Glu being the major disease-associated allele. The 
p.Glu229Lys is a new mutation in Saudi Arabian PCG patients. Genetic studies of 
recessive diseases such as PCG is important in consanguineous populations, since it will 
increase awareness and allows genetic counseling to be offered to patients and their 
relatives. This will not only reduce the disease to be inherited to future generations, but 
will also reduce the disease burden in the community.
Acknowledgement
This research project was funded by the Deanship of Scientific Research (DSR), King 
Abdulaziz University, under Grant No. (575/140/1433). The authors, therefore 
acknowledge with thanks DSR for supporting this scientific research. We thank all the 
patients and families for their enthusiastic involvement.
Footnotes
Competing interests 
The authors declare that they have no competing interests. 
Authors’ contributions 
OB is the principal investigator of this research project. He wrote the proposal and 
obtained the grant from King Abdulaziz University. He enrolled patients in the study at 
King Abdulaziz university hospital. He analyzed the clinical data and wrote the 
manuscript. SM and AH carried the Gene studies at the Human Genetic lab at Radboud 
University Medical Centre. They analyzed and wrote the gene results and revised the 
manuscript. RK assisted in writing the proposal, analyzed the results, and revising the 
manuscript. MH enrolled patients in the study from King Fahd Armed Forces Hospital. 
All authors read and approved the final manuscript. 
3
251
 
 
 
 
References 
1. Badeeb OB. Congenital Glaucoma in Saudi Arabia. Jeddah: King Abdulaziz University 
press; 2011. 
2. Jaafar M. Care of the infantile glaucoma patients. New York: Raven Press; 1988. 
3. Al-Rajhi A, Awad A, Badeeb O, Bukhari A, Al-Qahtani S, Mulla I, Jabak M, Selleck 
C. Causes of blindness in students attending school for the blind in Saudi Arabia. Saudi J 
Ophthalmol. 2003;17:276–280. 
4. Alanazi FF, Song JC, Mousa A, Morales J, Alshahwan S, Aldohayb S, Aljadaan I, Al-
Turkmani S, Edward DP. Primary and secondary congenital glaucoma: baseline features 
from a registry at King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Am J 
Ophthalmol. 2013;155:882–889.  
5. Bejjani BA, Lewis RA, Tomey KF, Anderson KL, Dueker DK, Jabak M, Astle WF, 
Otterud B, Leppert M, Lupski JR. Mutations in CYP1B1, the gene for cytochrome 
P4501B1, are the predominant cause of primary congenital glaucoma in Saudi 
Arabia. Am J Hum Genet. 1998;62:325–333. 
6. Bejjani BA, Stockton DW, Lewis RA, Tomey KF, Dueker DK, Jabak M, Astle WF, 
Lupski JR. Multiple CYP1B1 mutations and incomplete penetrance in an inbred 
population segregating primary congenital glaucoma suggest frequent de novo events and 
a dominant modifier locus. Hum Mol Genet. 2000;9:367–374. 
7. Abu-Amero KK, Osman EA, Mousa A, Wheeler J, Whigham B, Allingham RR, 
Hauser MA, Al-Obeidan SA. Screening of CYP1B1 and LTBP2 genes in Saudi families 
with primary congenital glaucoma: genotype-phenotype correlation. Mol 
Vis. 2011;17:2911–2919.  
8. Khan AO, Aldahmesh MA, Mohamed JY, Hijazi H, Alkuraya FS. CYP1B1 analysis of 
unilateral primary newborn glaucoma in Saudi children. J AAPOS. 2012;16:571–572. 
9. Al-Hazmi A, Awad A, Zawaan Z, Al-Mesfer SA, Al-Jadaan I, Al-Mohammed A. 
Correlation between surgical success rate and severity of congenital glaucoma. Br J 
Ophthalmol. 2005;89:449–453. 
252
 
 
 
 
10. Reddy AB, Kaur K, Mandal AK, Panicker SG, Thomas R, Hasnian SE, 
Balasubramanian D, Chakrabarti S. Mutation spectrum of the CYP1B1 gene in Indian 
primary congenital glaucoma patients. Mol Vis. 2004;10:696–702.  
11. Stoilov IR, Costa VP, Vanscocellos JP, Melo MB, Betinjane AJ, Carani JC, Oltrogge 
EV, Safarazi M. Molecular genetics of primary congenital Glaucoma in Brazil. Invest 
Ophthalmol Vis Sci. 2002;43:1820–1827.  
12. Alfadhli S, Behbehani A, Elshafey A, Abdelmoaty S, Al-Awadi S. Molecular and 
clinical evaluation of primary congenital glaucoma in Kuwait. Am J 
Ophthalmol. 2006;141:512–515.  
13. Bagiyeva S, Marfany G, Gonzalez-Angulo O, Gonzalez-Duarte R. Mutational 
screening of CYP1B1 in Turkish PCG families and functional analyses of newly detected 
mutations. Mol Vis. 2007;13:1458–1468. 
14. Chitsazian F, Tusi BK, Elahi E, Saroei HA, Sanati MH, Yazdani S, Pakravan M, 
Nilforooshan N, Eslami Y, Mehrjerdi MA, Zareei R, Jabbarvand M, Abdolahi A, 
Lasheyee AR, Etemadi A, Bayat B, Sadeghi M, Banoei MM, Ghafarzadeh B, Rohani MR, 
Rismanchian A, Thorstenson Y, Sarfarazi M. CYP1B1 mutation profile of Iranian 
primary congenital glaucoma patients and associated haplotypes. J Mol 
Diagn. 2007;9:382–393. 
15. El-Gayar S, Ganesh A, Chavarria- Soley G, Al-Zuhaibi S, Al-Mjeni R, Raeburn S, 
Bialasiewicz AA. Molecular analysis of CYP1B1 in Omani patients with primary 
congenital glaucoma: a pilot study. Mol Vis. 2009;15:1325–1331.  
16. Chavarria-Soley G, Rautenstrauss KM, Pasutto F, Flikier D, Flikier P, Cirak S, 
Bejjani B, Winters DL, Lewis RA, Mardin C, Reis A, Rautenstrauss B. Primary 
congenital glaucoma and Rieger’s anomaly: extended haplotypes reveal founder effects 
for eight distinct CYP1B1 mutations. Mol Vis. 2006;12:523–531.  
17. Kaur K, Mandal AK, Chakrabari S. Primary congenital glaucoma and the involvement 
of CYP1B1. MEAJO. 2011;18:7–16.  
  
3
253
 
 
 
 
18. Hollander DA, Sarfarazi M, Stoilov I, Wood IS, Fredrick DR, Alvarado JA. Genotype 
and phenotype correlations in congenital glaucoma: CYP1B1 mutations, goniodysgenesis, 
and clinical characteristics. Am J Ophthalmol. 2006;142:993–1004. 
 19. Panicker SG, Mandal AK, Reddy AB, Gothwal VK, Hasnain SE. Correlations of 
genotype with phenotype in India patients with primary congenital glaucoma. Invest 
Ophthalmol Vis Sci. 2004;45:1149–1156. doi: 10.1167/iovs.03-0404.  
 
 
254
  
 
Chapter 4 
 
 
 
Whole exome sequencing 
for identification of novel 
genes 
 
 
  
4.1 Identification of mutations in the PRDM5 gene in brittle 
cornea syndrome.  
 
Shazia Micheal1, Muhammad Imran Khan2, Farah Islam3, Farah Akhtar3, Raheel 
Qamar4,5, Marie-José Tassignon6, Bart Loeys2,7, Anneke I. den Hollander1,2§ 
 
1Department of Ophthalmology, Radboud University Medical Center; Nijmegen, the 
Netherlands. 2Department of Human Genetics, Radboud University Medical Center, 
Nijmegen, the Netherlands. 3Al-Shifa Eye Trust Hospital Jhelum Road, Rawalpindi, 
Pakistan. 4Department of Biosciences, COMSATS Institute of Information Technology, 
Islamabad-44000, Pakistan. 
5Al-Nafees Medical College and Hospital, Isra University, Islamabad, Pakistan.6 
Department of Ophthalmology, Antwerp University Hospital/University of Antwerp, 
Antwerp, Belgium. 
7Center for Medical Genetics, Antwerp University Hospital/University of Antwerp, 
Antwerp, Belgium.  
 
ACKNOWLEDGEMENTS 
This study was supported by the Stichting Blindenhulp, a Shaffer grant from the 
Glaucoma Research Foundation, the Glaucoomfonds, Oogfonds, and the Algemene 
Nederlandse Vereniging ter Voorkoming van Blindheid (awarded to A. den Hollander 
and S. Micheal).  
 
CONFLICT OF INTEREST 
The authors declare no conflict of interest. 
 
Adapted from Cornea 2016; 35(6):853-9 
256
 
 
 
 
Abstract  
Background: Brittle cornea syndrome (BCS) is a rare autosomal recessive connective 
tissue disease characterized by variable combinations of corneal thinning and fragility, 
corneal ruptures either spontaneously or after minor trauma, blue sclerae, keratoconus, 
keratoglobus, and high myopia. So far, mutations in two genes, PRDM5 and ZNF469, 
have been associated with BCS. The purpose of this study is to describe novel mutations 
in the PRDM5 gene in patients with BCS.  
 
Methods and results: Using homozygosity mapping with SNP markers followed by 
whole exome sequencing we identified a novel homozygous splice site variant 
(c.93+5G>A) in the PRDM5 gene in a consanguineous Pakistani family with four 
affected individuals. RT-PCR analysis from lymphocyte-derived RNA failed to reveal 
any exon skipping due to this splice site variant. A homozygous variant (c.11T>G; 
p.Gln4Pro) in SEC24D also segregated with the  disease in this particular family. One 
previously known mutation (c.974del; p.Cys325LeufsX2) was identified in a sporadic 
patient with BCS from Serbia.  
 
Conclusions: The current study revealed a novel mutation in the PRDM5 gene in a BCS 
family and recurrent mutation in a sporadic BCS patient. A variant in the SEC24D gene 
also segregated in the BCS family, although its role in the disease remains unclear. 
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Introduction 
Brittle cornea syndrome (BCS; MIM 229200; Online Mendelian Inheritance in Man) is a 
rare autosomal recessive connective tissue disorder with a striking ocular phenotype [1-
3]. Marked corneal thinning, fragility, and blue sclerae are cardinal features of the 
disorder. Concomitant keratoconus, keratoglobus, and high myopia are present in many 
cases. The diagnosis is often suspected following corneal rupture, either spontaneously or 
due to minor trauma, particularly in the context of a family history of recurrent ocular 
trauma. Corneal ruptures lead to blindness in most cases. Prior to rupture, visual acuity in 
BCS patients is often already significantly affected by keratoconus and high myopia. 
Non-specific features of generalized connective tissue disorders are often also present and 
may include joint hypermobility, skin hyperelasticity, kyphoscoliosis, osteopenia, hearing 
defects, dental abnormalities, hernias, and in rare cases mental retardation [1-3] Increased 
awareness of the condition, however, has recently led to the description of a number of 
cases of BCS with ocular signs only. Genetically BCS is heterogeneous and can be 
caused by mutations in either ZNF469 (MIM 612078) 4-6 or PRDM5 (MIM 614161) [7, 
8]. PRDM5 (also known as PFM2) maps to 4q25- 26 [ 9], and belongs to the PRDM 
(PRDI-BF1 and RIZ domain containing) family of transcription factor proteins, harboring 
an evolutionarily conserved N-terminal PR domain followed by 16 zinc finger repeats 
[10]. PRDM5 has been reported to act as a tumor suppressor in a number of human cancer 
cell lines, and a role in extracellular matrix physiology has been suggested by the recent 
characterization of a PRDM5 conditional knock-out mouse [11, 12].  ZNF469 is a very 
poorly characterized single exon zinc finger protein of unknown function. How both 
genes cause BCS is not yet understood, but experimental evidence supports the 
involvement of both of them in the same pathway regulating extracellular matrix proteins 
[5]. Disruption in the expression of several key components of the extracellular matrix 
was observed 84 in fibroblasts with mutations in PRDM5. Similarly, in patients with 
ZNF469 mutations skin derived fibroblasts show down-regulation of the extracellular 
matrix [7]. Most individuals with BCS have been born to consanguineous parents [7, 8], 
and most published disease-causing mutations in both PRDM5 and ZNF469 are 
homozygous mutations [8, 13]. In this study, we combined homozygosity mapping with 
whole exome sequencing to find the pathogenic variant associated with disease in a 
Pakistani BCS family. The PRDM5 gene was sequenced in an additional index patient 
from Serbia. 
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Methods  
Patients and clinical data  
The study adhered to the guidelines of the Declaration of Helsinki and was approved by 
the Institutional Review Board of Al-Shifa Eye Trust Hospital. Informed consent was 
obtained from all individuals in the study. Ophthalmic and systemic examinations were 
carried out by ophthalmologists and clinical geneticists, respectively, in both affected and 
unaffected individuals. Anterior segment examination was carried out by slit-lamp 
biomicroscopy with measurements of intra-ocular pressures by applanation tonometer, 
central corneal thickness was assessed by Pachymetry (measured in microns), Pentacam 
(Oculus Optikgeräte GmbH, Wetzlar, Germany) was used for corneal topography for 
mapping the surface curvature of the cornea, and visual field defects were evaluated with 
a Humphrey Field Analyzer (Zeiss Humphrey Systems, Dublin, CA, USA). 
Homozygosity Mapping  
Blood samples were collected for DNA isolation, and a conventional phenol-chloroform 
method was used for the extraction of genomic DNA from whole blood [14] In the BCS 
family from Pakistan a genome-wide single nucleotide polymorphism (SNP) scan was 
performed with Affymetrix 250K SNP microarrays (Affymetrix, Santa Clara, CA), and a 
search for regions of homozygosity was performed with the online tool Homozygosity 
Mapper. Haplotypes of affected and unaffected individuals were compared amongst 
family members to identify identical homozygous regions shared by all affected 
individuals.  
Exome sequencing 
To identify the underlying genetic cause of the disease in the BCS family, whole exome 
sequencing (WES) was performed using genomic DNA of the proband (IV:5). 
Enrichment of exonic sequences was achieved by using the SureSelectXT Human All 
Exon V.2 Kit (50 Mb), (Agilent Technologies, Inc, Santa Clara, California, USA). 
Sequencing was performed on a SOLiD 4 sequencing platform (Life Technologies, 
Carlsbad, California, USA). The hg19 reference genome was aligned with the reads 
obtained using SOLiD LifeScope software V.2.1 (Life Technologies). Filtering of the 
exome data was conducted as described previously [15, 16]. 
Sequence Analysis 
Conventional polymerase chain reaction (PCR) followed by Sanger sequencing was 
undertaken to assess the lower coverage regions of the PRDM5 and ZNF469 genes. In 
4
259
 
 
 
 
addition, one patient from Belgium was analyzed for all coding exons of the PRDM5 
gene [7].  
Sanger sequencing was performed with an automated DNA sequencer (Big Dye 
Terminator version 3, 3730 DNA analyzer, Applied Biosystems, Inc., Foster City, CA). 
Sequencing results were aligned with the reference sequence (obtained from the hg19 
human genome build) and analyzed using Vector NTI Advance (TM) 2011 software 
(Invitrogen). For analysis of variants identified in PRDM5, the coding sequence of this 
gene was evaluated in control data sets including dbSNP (Build 137), the May 2012 
release of the 1000 Genomes Project, and the NHLBI Exome Sequencing Project (ESP). 
Only the variants with minor allele frequency of <0.5 were considered for further 
analysis. In addition, the pathogenicity of missense variants was evaluated by publically 
available tools including PhyloP, Grantham, polymorphism phenotyping v-2 (PolyPhen-
2), and sorting intolerant from tolerant (SIFT). To evaluate splice site mutations, we used 
five prediction programs (SpliceSite-Finder-like, MaxEntScan, NNSPLICE, Gene splicer, 
and Human Splicing Finder) in Alamut Software. 
RNA extraction and cDNA preparation 
Five milliliter of whole blood was collected in PAX gene blood RNA tubes. The 
PAXgene 96 Blood RNA Kit was used for the isolation of total RNA. Total RNA was 
reverse-transcribed using the iScript™ cDNA Synthesis Kit (BIO-RAD). The entire 
PRDM5 cDNA was amplified for all the exons in overlapping fragments (primer 
sequences will be provided on request). The thermal profile used for PCR reactions was 
initial denaturation at 94°C for 5 min, 35 cycles of 94°C for 45 s, 58°C for 45 s and 72°C 
for 60 s, and a final extension at 72°C for 7 min under standard conditions, except for 3 
mM MgCl2. The size of the PCR products was verified by electrophoresis in 2% agarose 
gels followed by Sanger sequencing. 
 
Results 
Clinical details 
Family 1  
 A detailed history and clinical examination was performed for 4 affected individuals of 
the BCS family (two females and two males) originating from the central Punjab area of 
Pakistan (Fig. 1) (Table 1). 
Sibling IV:1 is a 17-year-old girl, with a history of corneal perforation on minor blunt  
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trauma in her left eye. She had a surgical repair and lensectomy following lens 
dislocation. Pupil were oval (Fig. 2A), she had nystagmus, and a clear view of the fundus 
could not be obtained. Intraocular pressures (IOP) were 14 mmHg after using IOP-
lowering medications. Systemic examination revealed Marfanoid habitus with tall stature, 
long limbs, joint hypermobility, a long narrow head, arachnodactyly, flat feet, bilateral 
medial displacement of medial malleoli, and a protruding jaw. She also had hirsuitism 
and history of irregular menstraul cycles. No cardiovascular abnormalities were noted 
upon echocardiography. 
 
 
Figure 1. Segregation of genetic variants in an autosomal recessive BCS family. PRDM5 
(c.93+5G>A) is indicated with the M1 allele and SEC24D (p.Gln4Pro) is indicated with 
the M2 allele. The proband is indicated with an arrow. 
 
Sibling IV:2 is a 14-year-old girl who suffered recurrent bilateral corneal ruptures on 
trivial blunt traumas at the age of 5 years. Following several attempts of corneal repair, 
phthisis bulbi ensued (Fig. 2B). 
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Figure 2. (A): Clinical photo of patient IV:1 with ectopia lentis (B): Phthisical eye in 
patient IV:2, (C): Corneal haze due to scars in patient IV:2. (Systemic features of BCS 
present in patient IV:4 includes: (D) Hyperextensibility of joints: Wrist (WALKER) sign, 
(E) thumb (STEINBERG) sign and joint laxity, particularly in large joints of the upper 
extremities and (F) pes planus. 
 
IV:4 is a 13-year-old male with a history of trauma following a stick injury to his right 
eye. He had corneoscleral repair done and the fundus view was hazy. On examination, 
nystagmus and corneal scarring were present in the left eye following corneal repair. 
There was also posterior synechiae and traumatic cataract in the left eye (Fig. 2C). 
IV:5 was 11-year-old male who presented with corneal perforation on minor blunt 
trauma. He had corneoscleral repair done in right eye. The examination of right eye 
revealed blue sclera, posterior subcapsular cataract, and significant corneal scarring. Left 
eye also had blue sclera and corneal thinning with keratoconus. He had a abdominal 
hernia repair done at 4 year of age. Like individual IV:1, sibling IV:5 demonstrated tall 
stature, long limbs, joint hypermobility, a long narrow head, arachnodactyly, flat feet, and 
a medial displacement of medial malleoli upon systemic examination (Fig. 2D-F). The 
echocardiogram was normal. 
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Patient 1  
A male BCS patient from Serbia was born from non-consanguineous parents. He was 
diagnosed with congenital hip dislocation requiring surgery. He had a history of bilateral 
ocular trauma at the age of five years. He sustained bilateral corneal perforations, and 
retinal detachments in both eyes. Other significant ocular findings included high myopia. 
Systemic examination revealed macrocephaly, enlarged arm span, pectus carinatum, 
arachnodactyly, pes plani, scoliosis, and hearing loss. The echocardiogram was 
unremarkable with normal aortic root measurements. 
Mutation Detection  
Family 1  
In total 4 homozygous regions were obtained in the affected individuals of the BCS 
family with a size >2Mb (Fig. 3). Among the homozygous regions obtained, the largest 
homozygous region was identified on chromosome 4, spanning 46.7Mb. Two variants 
remained after filtering of the exome data; one in PRDM5 (c.93+5G>A), a gene known to 
be involved in BCS, and another in the SEC24D gene (c.11T>G; p.Gln4Pro). Both 
variants segregate with the disease in the family 1 (Fig. 1), were excluded from 180 
population-matched controls, and were absent from the exome variant server, 1000 
genomes, and dbSNP databases.  
 
 
Figure 3. Shared homozygous regions identified in four affected individuals of the BCS 
family. The numbers on top indicate the chromosomes. Bars extending above 0.8 
represents putative homozygous regions in all affected individuals. A 46.7-Mb 
homozygous region was identified on chromosome 4 encompassing the PRDM5 and 
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SEC24D genes. 
The PRDM5 (c.93+5G>A) splice site variant was analyzed with Alamut Mutation 
Interpretation software, and scores for the wildtype and the mutant alleles predicted by 
SpliceSiteFinder-like, MaxEntScan, NNSPLICE, Gene splicer, and Human Splicing 
Finder are given in supplementary Fig 1. This variant decreases the scores for the natural 
splice donor site of exon 1. 
The PRDM5 variant (c.93+5G>A) in intron 1 is present 5 bp upstream of the splice donor 
site, therefore, exon skipping of exon 2 may occur. RT-PCR analysis was performed on 
RNA isolated from patients’ lymphocytes to determine the effect of the c.93+5G>A 
variant on splicing. The forward primer was designed in exon 1 while the reverse primers 
were present in exon 2 and 3 (Fig. 4). RT-PCR analysis of the PRDM5 gene did not 
reveal exon skipping due to this variant. 
 
Figure 4. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of the 
novel variant (c.93+5G>A) in the PRDM5 gene. Forward primer was positioned in exon 
1 and the reverse primers in exons 2 and 3. No exon skipping was revealed by RT-PCR 
analysis of the PRDM5 variant. 
 
In-silico analysis of the variant (c.11T>G; p.Gln4Pro) in SEC24D revealed it to be 
pathogenic by SIFT (deleterious) and Polyphen (damaging), with a high Grantham score 
of 76 and PhlyoP score 3.7. The mutated amino acid residue is highly conserved in all 
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SEC24D homologs and orthologs (supplementary Fig. 2). 
Patient 1 
Sequence analysis of the PRDM5 gene in the sporadic BCS patient revealed a 
homozygous frameshift variant (c.974del; p.Cys325Leufs*2) in exon 9. Due to this 
deletion, the reading frame is shifted, introducing a stop codon 1 position downstream. 
Consequently, a truncated protein 11 may be synthesized, or the mRNA produced might 
be targeted for nonsense-mediated decay (NMD). 
 
Discussion 
Previously, mutations in the PRDM5 gene have been reported in two Pakistani families, 
one patient from Saudi Arabia [7, 8] and five additional BCS families. Individuals of two 
of these Middle Eastern families had previously been published as cases of Ehlers-Danlos 
syndrome (EDS) type VIA underlining the clinical similarities between EDS VIA and 
BCS [17]. A firm clinical diagnosis of BCS was difficult due to the presence of clinical 
variability. Therefore, early genetic testing to establish the diagnosis of BCS at an early 
age will help to prevent the devastating sequelae of corneal rupture by providing them 
with protective glasses and educating the families about eye protection measures. It will 
also help to identify individuals at risk for the associated systemic features of this 
condition. 
In the current study, we identified a novel homozygous splice site variant (c.93+5C>T) 
222 by combining WES and homozygosity mapping in a Pakistani family. In addition, a 
recurrent mutation (c.974del; p.Cys325Leufs*2) in a patient from Serbia was identified 
by Sanger sequencing. Analysis of the PRDM5 gene was performed in lymphocyte RNA 
samples from the Pakistani family to determine whether the splice site variant 
(c.93+5C>T) induced any exon skipping. The results of the analysis did not reveal exon 
skipping. Although we did not identify evidence of a splice defect in lymphocytes, we 
cannot exclude that the variant may result in exon skipping in eye tissues. Previously, two 
splice site variants, c.93+1G>A and c.93+2T>C [7, 8] have been identified close to the 
splice site variant c.93+5C>T described in this study. The natural splice donor site for 
exon 1 was abolished by the c.93+2T>C mutation, which was confirmed by 12 RT PCR 
analysis from blood [8]. However, for the, c.93+1G>A variant no such analysis was 
performed. In addition to these splice site variants, a deletion of exons 9–14, a nonsense 
mutation in exon 16 (c.1768C>T; p.Arg590X), a missense mutation (c.320A>G; 
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p.Tyr107Cys), and three frameshift mutations (c.711_714delTGTT; p.Val238AlafsX35, 
c.974delG; p.Cys325LeufsX2, and c.1517_1527del TTCATATCCGG; 
p.Val506GlufsX5) have been identified [7, 8]. The frameshift mutation (c.974delG; 
p.Cys325LeufsX2) is a recurrent mutation as it was also identified in the Serbian patient 
in the current study. 
Next to the splice site variant (c.93+5C>T) in the PRDM5 gene, we also identified variant 
(c.11T>G; p.Gln4Pro) in the SEC24D gene. This variant also segregates with the disease, 
and in-silico modeling by polyphen-2, SIFT, and MutationTaster analyses predicts the 
variant to be pathogenic. The glutamine is a highly conserved amino acid up-to zebrafish. 
The Sec24D protein is an important component of the coat protein II (COPII) complex, 
which is responsible for anterograde protein trafficking, and vesicle budding from the 
endoplasmic reticulum (ER) to the Golgi apparatus [18]. Previously, missense mutations 
in SEC24D binding partner SEC23A have been indentified, which leads to cranio-
lenticulo-sutural-dysplasia (CLSD), characterized by the late closing fontanels in 
childhood, development of cataracts in the eye, facial dysmorphisms, and skeleton 
defects. In zebrafish craniofacial defects were observed in the absence of SEC24D, which 
are proposed to be due to defects in the transport of extracellular matrix proteins such as 
type II collagen and matrilin [19]. Therefore, we cannot exclude that the disease 
phenotype observed in the Pakistani BCS family may be influenced by the SEC24D 
missense variant identified in this family, next to the splice site variant in the gene. 
In conclusion, by combining the IBD mapping and whole exome data we identified novel 
variants in PRDM5 and SEC24D genes in a Pakistani BCS family. RNA analysis of the 
PRDM5 variant did not identify splice defects, leaving it uncertain whether the PRDM5 
variant, the SEC24D variant or both variants contribute to the disease phenotype in this 
family. In addition, one recurrent variant in the PRDM5 gene was identified in a sporadic 
BCS patient. 
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Figure 2. Amino acid sequence conservation of the SEC24D missense variant in 
homologs and orthologs. The glutamine amino acid at this is completely conserved 
up-to Zebrafish. 
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Abstract  
 
Background: Glaucoma is an important cause of irreversible blindness affecting 70 
million people worldwide. The most common type is primary open-angle glaucoma 
(POAG), characterized by excavation of the optic nerve head, visual field defects, and an 
open anterior chamber angle. So far linkage and whole exome sequencing (WES) studies 
in families have identified more than 10 genes that are associated with POAG. However, 
these genes explain only a small proportion of the heritability of the disease.  
Objective: The aim of the current study is to identify the genetic cause of POAG in a 
large consanguineous family with 8 affected individuals.  
Methods: Homozygosity mapping and WES were performed to find the causative variant 
in this family. Variants identified by WES were validated by Sanger sequencing and 
segregation analysis was performed in all affected and unaffected family members. 
Results: We identified a homozygous missense variant (c.467G>A; p.Cys156Tyr) in the 
DBX2 gene that cosegregates with the disease in the family. The variant is absent in 150 
ethnically matched controls and in the publically available databases. The mutated 
cysteine amino acid residue is highly conserved among orthologous species and alteration 
to a tyrosine residue is predicted to be pathogenic by in-silico analysis.  
Conclusions: This study identified the DBX2 gene as a new genetic cause of POAG. 
DBX2 encodes a homeobox transcription factor that plays an important role in the 
development of the vertebrate central nervous system. DBX2 is a downstream target of 
PAX6, a homeobox transcription factor that has been associated with various eye 
anomalies. Further studies are required to shed light on the role of DBX2 in POAG.   
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Introduction 
Glaucoma is a leading cause of irreversible and devastating vision loss, affecting 70 
million people worldwide. The disease is characterized by progressive degeneration of 
retinal ganglion cells (RGCs) and damage to the optic nerve [1-2]. The exact cause of 
death of the RGCs is not known, but an increased intraocular presence (IOP) is 
considered to play a fundamental role in this process. Normally the IOP is a homeostasis 
between the production of the aqueous humor (AH) by the ciliary body in the posterior 
part of the eye and its drainage into the anterior chamber [3, 4]. The normal range of the 
IOP is between 14 to 21 mmHg, but under unfavorable circumstances the balance 
between the two processes is disturbed which leads to raised IOP >21 mmHg, resulting in 
progressive vision loss and blindness if not controlled. The trabecular meshwork (TM) is 
a key player in the drainage of AH. Multiple factors could disturb this transport, such as 
oxidative stress, mechanical stress and genetic factors [4, 5].    
Glaucoma is classified into two main types: primary open-angle glaucoma (POAG) and 
primary angle-closure glaucoma (PACG). POAG is the most common type, accounting 
for approximately 95% of primary glaucoma among Caucasians [6]. POAG is 
characterized by excavation or “cupping” of the optic nerve head, the presence of visual 
field defects, and an open anterior chamber angle [7]. POAG is principally caused by 
obstruction of the aqueous outflow deep within the TM, resulting in an increase of the 
IOP causing damage to the optic nerve. As the early stages of POAG are usually 
asymptomatic, most patients are not diagnosed until the disease has progressed to an 
advanced stage [1]. 
 The molecular disease mechanisms of POAG are poorly understood. Genome-wide 
association studies in case-control cohorts, and linkage analysis and whole exome 
sequencing (WES) studies have identified >20 genes that are associated with POAG, 
including CAV1/CAV2 [8], TMCO1 [9], CDKN2B-AS1 [10], CDC7-TGFBR3 [11], 
SIX1/SIX6 [12], GAS7, ATOH7, TXNRD2, ATXN2, FOXC1 [13], MYOC [14, 15], OPTN 
[16], WDR36 [17], ASB10 [18] and EFEMP1 [19]. Together, these genes explain only a 
small proportion of the heritability of the disease. Therefore, more studies using high-
throughput technologies should be performed to determine the unknown causes of the 
disease. In the current study, we aimed to identify the genetic cause in a large 
consanguineous POAG family using WES.  
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Materials and Methods  
A large POAG family with 8 unaffected and 8 affected individuals (5 male, 3 female) was 
recruited from the Punjab district (Figure 1A). The age of onset of POAG in the affected 
individuals ranged from 10 to 35 years. The study was approved by the Institutional 
Review Board of the Al-Shifa Eye Trust hospital, and adhered to the tenets of the 
Declaration of Helsinki. Written informed consent was obtained from the participants/or 
their parents, as appropriate. Blood samples were collected from affected and unaffected 
siblings, and from the parents. Genomic DNA was extracted using AutoPure LS DNA 
Extractor and PUREGEN reagents (Gentra Systems Inc, Minneapolis, Minnesota, USA). 
Genomic DNA of three affected (IV:3, IV:5, IV:10) and two unaffected (III:1, III:4) 
individuals were genotyped using Affymetrix 250K SNP array analysis (Affymetrix: 
Santa Clara, CA, USA). Array experiments were performed according to the 
manufacturer’s protocol. The genotype data obtained from the 250K SNP arrays for five 
individuals was analyzed for homozygous regions using the online mapping tool 
Homozygosity Mapper (http://www.homozygositymapper.org/).  
WES was performed in four affected subjects (III:3, IV:3, IV:7, IV:10) (Figure 1A). 
Briefly, exonic sequences were enriched using the SureSelectXT Human All Exon V.2 
Kit (50 Mb) (Agilent Technologies, Inc, Santa Clara, California, USA). All variants 
obtained through WES were first filtered against in-house and public databases 
(dbSNP132 and Exome Aggregation Consortium (ExAC) databases) to select variants 
with a minor allele frequency (MAF) < 0.5%. Subsequently, only coding nonsynonymous 
variants, frameshift, and splice site variants were analyzed. The functional impact and 
pathogenicity of coding nonsynonymous variants were evaluated by in-silico analysis 
using publically available tools. Variants that were predicted to be pathogenic by all 
prediction programs that includes polymorphism phenotyping v-2 (PolyPhen-2), 
MutationTaster, and sorting intolerant from tolerant (SIFT), and that had a PhyloP score 
>2.7, and a Grantham score >80 were retained.  Homozygous variants that passed the 
filtering criteria, were shared between the four affected individuals, and were present in 
the homozygous region identified by homozygosity mapping were considered for further 
evaluation.
Validation and segregation analysis of variants identified by WES were carried out by 
performing standard PCR and Sanger sequencing using ABI BigDye chemistry (Applied 
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Biosystems Inc, Foster City, California, USA), processed through an automated ABI 
3730 Sequencer (Applied Biosystems, Inc).  
The project HOPE (http://www.cmbi.ru.nl.ru.idm.oclc.org/hope/home) server was used to 
predict the structural effect of the variant in the DBX2 gene segregating with the disease 
[20].  
Results  
The proband of the family (IV:11) was a 12-year-old boy diagnosed with bilateral 
glaucoma. He had leticular myopia in both eyes, microspherophakia and iridodonesis. 
The IOP was 44 mmHg in the right eye and 52 mmHg in the left eye. After using 
medication, the IOP was lowered to 28 mmHg in the right and 32 mmHg in the left eye. 
His optic discs were fully cupped in both eyes with a cup-disc ratio (CDR) of 1.0. 
Trabeculectomy was performed multiple times to control the IOP of his eyes.  
All affected individuals of this family have similar clinical findings, with IOP >30mmHg, 
CDR >0.8, myopia, open angle with the age of onset ranged from 10-35 years and 
microspherophakia.  
A single large homozygous region of ≈35 Mb (genomic position 20,021,125 – 
54,976,112 of the human genome build Hg19) localized at chromosome 12 (Figure 1B) 
was revealed by homozygosity mapper. Filtering of the WES data for homozygous 
variants shared between four affected individuals and residing within this homozygous 
region identified only a single homozygous variant.  The homozygous missense variant 
(c.467G>A; p.Cys156Tyr) was identified in the DBX2 gene, and was found to segregate 
with the disease in the family (Figure 1A, 1C). This variant was predicted to be 
deleterious by SIFT, damaging by Polyphen-2, and disease-causing by MutationTaster. 
The PhyloP score was 5.53 and Grantham distance was 194. The mutated cysteine amino 
acid in DBX2 is conserved among different species (Figure 1D).  
The DBX2 variant segregating with the disease in the family was excluded from 150 
ethnically matched healthy controls and was absent in the dbSNP132 and Genome 
Aggregation Database (gnomAD) databases.  
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Figure 1: (a) Pedigree of a consanguineous family with POAG, and segregation of a 
novel missense mutation (c.467G>A; p.Cys156Tyr) in the DBX2 gene. (b). 
Homozygosity mapping results. The thick red line indicates a homozygous region of ≈35 
Mb on chromosome 12 encompassing the DBX2 gene. (c) DNA chromatogram of a 
fragment of the DBX2 gene of a healthy individual (IV:1) carrying the variant 
heterozygously (represented by R) and of an affected individual (IV:2) carrying the 
variant homozygously. (d). Multiple sequence alignment of the region of the DBX2 
protein surrounding the Cys156Tyr variant in orthologous species. The cysteine residue 
(indicated with a red box) and surrounding residues are highly conserved among all 
species analyzed. 
 
Discussion 
In the current study, a novel homozygous missense variant (c.467G>A; p.Cys156Tyr) in 
the DBX2 gene was identified in a consanguineous family with POAG. The affected 
individuals presented with the age of onset of POAG ranging from 10-35 years and an 
IOP ranging from 30 to 55mmHg. Recently, a de novo deletion of 3 genes, including 
DBX2 was identified in a patient with moderate intellectual disability (ID) and 
psychomotor delay [21]. It was suggested that haploinsufficiency of DBX2 and the 
neighboring gene NELL2 may have led to the ID and psychomotor delay in this patient. 
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No signs of ID or psychomotor delay were noted in the individuals in this study who were 
homozygous for the missense variant p.Cys156Tyr in DBX2.    
DBX2 encodes a homeobox transcription factor, which highly expressed during neuronal 
development and regulates differentiation of interneurons in the brain and spinal cord 
[22]. Several members of the family of homeobox transcription factors play an important 
role in the development of the vertebrate forebrain and eye [23-26]. In the eye these 
transcription factors are required for the determination of progenitor cell fate, 
differentiation and survival of retinal cells, specifications of the eye field and the optic 
cup [23-26]. Since they play a critical role in eye development, several of the homebox 
genes (RAX, PAX6) are known for their association with various eye anomalies such as 
coloboma, aniridia, Peter׳s anomaly, and anophthalmia [27-32].     
Overexpression of PAX6 results in an increased expression of DBX2, and in Pax6 mutant 
mice the expression of DBX2 is decreased, demonstrating that DBX2 is a downstream 
target of PAX6. Perturbation of DBX2 may thus alter the progenitor cell fate and 
differentiation of retinal cells [33]. DBX2 expression is regulated by retinoic acid (RA), 
which has also been shown to regulate CYP1B1, a gene that has been associated with 
glaucoma. RA plays an important role in the appropriate arrangement and patterning of 
numerous tissues such as the hindbrain, eye, and spinal cord [34].  Taken together, these 
findings support that the variant detected in the DBX2 gene may cause glaucoma in this 
family.  
In conclusion, we report a novel homozygous missense variant in the DBX2 gene in a 
large consanguineous family with POAG. Further studies are required to shed light on the 
involvement of DBX2 in POAG. This will support the design of novel therapeutic 
strategies for potential intervention in glaucoma. 
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Abstract  
 
Background: Primary congenital glaucoma (PCG) is the most common form of 
glaucoma in children.  PCG occurs due to the developmental defects in the trabecular 
meshwork and anterior chamber of the eye. The purpose of this study is to identify the 
causative genetic variants in three families with developmental and primary congenital 
glaucoma (PCG) with a recessive inheritance pattern.  
Methods: DNA samples were obtained from consanguineous families of Pakistani 
ancestry. The CYP1B1 gene was sequenced in the affected probands by conventional 
Sanger DNA sequencing. Whole exome sequencing (WES) was performed in DNA 
samples of four individuals belonging to three different CYP1B1-negative families. 
Variants identified by WES were validated by Sanger sequencing.  
Results: WES identified potentially causative novel mutations in the latent transforming 
growth factor beta binding protein 2 (LTBP2) gene in two PCG families. In the first 
family a novel missense mutation (c.4934G>A; p.Arg1645Glu) co-segregates with the 
disease phenotype, and in the second family a novel frameshift mutation 
(c.4031_4032insA; p.Asp1345Glyfs*6) was identified. In a third family with 
developmental glaucoma a novel mutation (c.3496G>A; p.Gly1166Arg) was identified in 
the PXDN gene, which segregates with the disease.   
Conclusions: We identified three novel mutations in glaucoma families using WES; two 
in the LTBP2 gene and one in the PXDN gene. The results will not only enhance our 
current understanding of the genetic basis of glaucoma, but may also contribute to a better 
understanding of the diverse phenotypic consequences caused by mutations in these 
genes.   
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Introduction 
Childhood or infantile glaucoma include primary congenital glaucoma (PCG) and 
developmental glaucoma, which can be associated with syndromes (e.g. Axenfeld Rieger 
syndromes) or can lead to defects only in the eye. The majority (about 60%) of patients 
with these types of glaucoma are diagnosed by the age of 6 months, and 80% are 
diagnosed within the first year of life. PCG usually leads to permanent visual impairment, 
and accounts for 0.01–0.04% of total blindness [1,2]. The incidence of PCG, however, 
varies among different populations: 1 in 2,500 in Saudi Arabians, 1 in 3,300 in southern 
Indians, 1 in 1,250 in Slovakian gypsies [3], and from 1 in 10,000 to 1 in 20,000 in 
Western populations [4]. In most cases, developmental anomalies affect the anterior 
chamber and the trabecular meshwork. PCG is characterized by an elevated intraocular 
pressure (IOP), an increased corneal diameter, and optic disc damage [4,5]. The clinical 
features of PCG include buphthalmos, corneal edema and opacification with rupture of 
the Descemet membrane, thinning of the anterior sclera, iris atrophy, and an anomalously 
deep anterior chamber. In addition, less common features include epiphora, 
blepharospasm, and photophobia.  
Three chromosomal locations have been associated with PCG: GLC3A at 2p21, GLC3B 
at 1p36.2-1p36.1, GLC3C at 14q24.3, and thus far only two causative genes (CYP1B1, 
LTBP2) have been identified [6]. The CYP1B1 gene is frequently mutated, ranging 20-
100% in PCG cases from Japan, Saudi Arabia and Slovakian gypsies [7]. Mutations in the 
PXDN gene are known to cause developmental glaucoma with opacification/clouding of 
the cornea, cataract, and developmental glaucoma in Pakistani and Cambodian families 
[8].  
In the current study, we aimed to identify novel mutations in three CYP1B1-negative 
glaucoma families from Pakistan using whole-exome sequencing (WES).  
Materials and Methods  
Subjects  
The participants were recruited at the pediatric glaucoma department of Al-Shifa Eye 
Trust Hospital, Rawalpindi, Pakistan. Blood samples were collected from affected and 
unaffected siblings, and from the parents. Genomic DNA was extracted using AutoPure 
LS DNA Extractor and PUREGEN reagents (Gentra Systems Inc, Minneapolis, 
Minnesota, USA). 
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Ethics statement 
This study was approved by the Institutional Review Board of the Al-Shifa Eye Trust 
hospital, and adhered to the tenets of the Declaration of Helsinki. Written informed 
consent was obtained for study participation from the participants and/or their parents, as 
appropriate.  
WES and Sanger Sequencing 
WES was employed to identify the disease-associated genes in four subjects, belonged to 
three families. Genomic DNA was prepared from peripheral venous blood, and was 
randomly fragmented into 200-400 base pair (bp) fragments with the Covaris Acoustic 
System according to the manufacturer’s instructions (Covaris, Inc., Woburn, MA). Kapa 
Library preparation (Kapa Biosystems, Inc., Wilmington, MA) was performed on a 
Caliper Sciclone NGS workstation (Caliper Life Sciences, Hopkinton, MA) followed by 
capture using the Nimblegen SeqCap EZ V2 kit (Roche Nimblegen, Inc., Madison, WI). 
Each captured library was then loaded on an Illumina HiSeq2000 sequencer using 
Illumina TruSeq V3 chemistry (Illumina, Inc., San Diego, CA). 
Downstream analyses included demultiplexing (CASAVA software, Illumina), alignment 
to the human reference genome (GRCh37, UCSC hg19) using the Burrows-Wheeler 
alignment (BWA)[9] tool. Alignments were sorted by Picard 
(http://broadinstitute.github.io/picard) and subsequently processed by GATK [10].  
Finally, the mean depth of coverage was determined using GATK, and Free mix values 
were estimated through verify BAMid [11]. Samples that passed technical QC metrics 
were genotyped to gVCF level through GATKs Haplotype Caller. Indels, SNVs, 
microinsertions and microdeletions were filtered separately using GATKs Variant-
Quality Score Recalibration. Both the SNV and indel sets were annotated using 
ANNOVAR [12].Only mapped reads were used for subsequent analysis. They were 
annotated with information from the University of California, Santa Cruz genome 
annotation database (http://genome.ucsc.edu/index.html), consensus coding sequence 
(http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi), Ensembl 
(http://www.ensembl.org), RefSeq (http://www.ncbi.nlm.nih.gov/RefSeq/), MirBase 
(http://www.mirbase.org/), & EntrezGene 
(www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene).  
All variants obtained through WES were first filtered against several public databases for 
the minor allele frequency (MAF) < 0.5%, including dbSNP135, 1000 Genomes Project 
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databases (http://www.1000genomes.org/, 1000g2012April_all version), NHLBI GO 
Exome Sequencing Project (ESP6500, http://evs.gs.washington.edu/EVS/, esp6500si_all 
version) and the Human Genetic Variation Database 
(HGVD,http://www.genome.med.kyoto-u.ac.jp/SnpDB/). Subsequently, only coding 
nonsynonymous variants, frameshift, and splice site variants were analyzed. To predict 
the functional impact of the sequence variants on the encoded protein, the pathogenicity 
of missense variants was evaluated by publically available tools including PhyloP, 
Grantham, polymorphism phenotyping v-2 (PolyPhen-2) (version 2.1.0 
r367; http://genetics.bwh.harvard.edu/pph2/), MutationTaster, and sorting intolerant from 
tolerant (SIFT; http://sift.jcvi.org/). 
Variant validation and segregations analysis of variants identified by WES were carried 
out by performing standard PCR and Sanger sequencing using ABI BigDye chemistry 
(Applied Biosystems Inc, Foster City, California, USA), and was processed through an 
automated ABI 3730 Sequencer (Applied Biosystems, Inc).  
Results  
Family 1  
Proband IV:1 was a 5-year-old boy with buphthalmos in both eyes. He had a corneal 
diameter of 14.5 mm in the right eye and 13.5 mm in the left eye. The corneal thickness 
was 0.625 mm and 0.733 mm in the right and left eyes, respectively. Axial lengths were 
26.32 mm in the right and 21.22mm in the left eye. Intraocular pressures (IOP) were 24 
mmHg in the right and 25 mmHg in the left eye. In the left eye he had a persistant 
pupillary membrane which was removed by surgery. He had subluxated lenses in both 
eyes. The cup-disc ratio (CDR) was 0.7 in the right eye and 0.2 in the left eye.  
Sibling IV:2 was a 3-year-old boy with a phthisical right eye after surgery for glaucoma, 
and a left eye with buphthalmos. The IOP of the left eye was 13 mmHg after surgical 
treatment and topical drops with a vision of 6/ 96, and the CDR was 0.9. He had 
microspherophakia (a small spherical lens) and an iridogoniodysgenesis (IGDS)-like iris 
pattern.  
WES in DNA samples of the two affected children of the family revealed a novel 
pathogenic missense variant (c.4934G>A; p.Arg1645Glu) in LTBP2 (Figure 1a, b). This 
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particular variant was predicted to be deleterious by SIFT, damaging by Polyphen-2, and 
disease causing by MutationTaster. The PhyloP score was 3.64 and Grantham distance 
was 43. The mutated arginine amino acid was conserved among PRDM5 orthologs from 
different species (Figure 1c).  
Figure 1. (a) Sanger sequencing chromatograms showing III:1 carrier and IV:1 
homozygous mutant (b). Family pedigree and segregation of a novel missense mutation 
(c.4934G>A; p.Arg1645Glu) in the LTBP2 gene in a PCG family. (c). Multiple sequence 
alignment of the   region of the LTBP2 protein surrounding the novel Arg1645Glu 
mutation in various species. The arginine residue (indicated with an arrow) is highly 
conserved among all species analyzed.  
Family 2  
Proband IV:2 was a 4-year-old boy who visited the hospital with the complaint of 
watering eyes. On examination he had a hazy cornea, buphthalmos, and poor vision in 
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both eyes. He had four surgeries for glaucoma. The IOP was 24 mmHg and 30 mmHg 
and the CDR was 0.7 and 0.9 for the right and the left eye, respectively.  
In this family a novel homozygous frameshift mutation (c.4031_4032insA; 
p.Asp1345Glyfs*6) segregates with the disease (Figure 2a, b). Due to this single base pair 
insertion the reading frame is shifted leading to a premature stop codon, which may result 
in a truncated protein, or the the mRNA may be subjected to nonsense-mediated decay.
Figure 2. (a) Sanger sequencing chromatograms for the carrier III:1 and affected 
individual IV:2 homozygous for the mutation. (b). Family pedigree and segregation of a 
novel frameshift mutation (c.4031_4032insA; p.Asp1345Glyfs*6) in the LTBP2 gene in a 
PCG family.  
Family 3  
Proband IV:2 was a 9-year-old girl with a hazy cornea. Axial lengths were 19.7 mm and 
17.3 mm with a horizontal corneal diameter of 11.5 mm and 10 mm for the right and the 
left eyes, respectively. 
Sibling IV:3 was a 6-month old girl having a severe bilateral corneal haze, due to which 
detailed clinical evaluation of the anterior chamber was not possible. Her left eye was 
phthisical, and the right eye had poor vision due to corneal opacity. The IOP of the right 
eye was within normal range after surgery for glaucoma.  
WES identified a novel missense variant (c.3496G>A; p.Gly1166Arg) in the PXDN gene 
(Figure 3a, b). This variant segregates with the disease phenotype in the family and is 
predicted to be deleterious, damaging and disease causing by SIFT, Polyphen-2, and 
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MutationTaster, respectively, with a Grantham score of 125 and a PhyloP score of 6.10. 
The Gly1166Arg variant affects a glycine residue in the haem peroxidase domain of the 
protein, which is a highly conserved amino acid among PXDN orthologs of different 
species (Figure 3c).   
The novel variants segregating with disease in LTBP2 and PXDN have been excluded 
from 150 Pakistani healthy controls.  
 
Figure 3. (a) DNA chromatogram of the relevant PXDN fragment for the carrier and 
homozygous variant are shown. (b). Family pedigree and segregation of a novel missense 
mutation (c.3496G>A; p.Gly1166Arg) in the PXDN gene (c). Multiple sequence 
alignment of the region of the PXDN protein surrounding the novel Gly1166Arg 
mutation in various species. The glycine residue (indicated with an arrow) is highly 
conserved among all species analyzed.   
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Discussion 
In the current study we identified two novel potentially pathogenic mutations 
(c.4934G>A; p.Arg1645Glu and c.4031_4032insA; p.Asp1345Glyfs*6) in the LTBP2 
gene in two PCG families from Pakistan. In the PXDN gene a novel mutation 
(c.3496G>A; p.Gly1166Arg) was identified in a family with developmental glaucoma. 
Previously, mutations in the LTBP2 gene have been identified in the four recessive 
Pakistani families with PCG: a homozygous single base pair deletion in exon 1 (c.412 del 
G; p.Ala138Profs*278), a homozygous nonsense mutation in exon 4 (c.895C >T; 
p.Arg299X), a homozygous 14-base pair deletion in exon 6 (c.1243-1256 del; 
p.Glu415Argfs*596), and a homozygous nonsense variant in exon 1 (c.331C>T; 
p.Gln111X).  In European Gypsies a recurrent founder mutation (c.895C >T; p.Arg299X) 
was identified in 8 patients, which was initially identified in a Pakistani PCG family, 
suggesting that they may have a common ancestry [13]. More recently, loss of function 
mutations (c.1415delC; p.Ser472Trpfs*3 and c.5376delC; p.Tyr1793Alafs*55) in the 
LTBP2 gene have been identified in Iranian families [14].  In PCG patients from the 
United States, WES revealed 3 nonsynonymous and 11 synonymous sequence variants in 
the LTBP2 gene in heterozygous state  but since a second variant remained unidentified 
these variants are unlikely to be causative[15]. On the contrary, no variants in the LTBP2 
gene were identified in 54 Saudi Arabian families [16], in Turkish and British PCG 
families [17] nor in North Indian patients [18]. This suggests that LTBP2 mutations are a 
relatively rare cause of PCG.  
The LTBP2 protein is expressed in the trabecular meshwork and ciliary processes 
involved in the regulation and production of the aqueous humor. In other 
tissues, LTBP2 is involved in tissue repair and cell adhesion [19]. Mutations in LTBP2 
were identified in PCG families and patients from Pakistan and Gypsies [13]. The 
mechanism behind the pathogenic involvement of the LTBP2 gene in glaucoma is not 
clearly established, but it has been demonstrated that the LTBP2 protein is associated 
with elastic fibers in developing elastic tissues [20]. Furthermore, LTBP2 interacts with 
fibrillin 1 (FBN1), which is required for its integration into the extracellular matrix [21]. 
The LTBP2 protein binds directly to FBN1 and competes with LTBP1 for this interaction 
[22]. Mutations in the FBN1 gene are known to cause Marfan syndrome, and a number of 
studies have linked homozygous mutations in the LTBP2 gene with a syndrome including 
megalocornea, microspherophakia, lens dislocation, and secondary glaucoma developing 
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after the age of 3 years [23]  and in isolated microspherophakia/lens dislocation [24]. In 
addition to involvement in PCG, pathogenic mutations in the LTBP2 gene have also been 
linked to Weill-Marchesani syndrome characterized by abnormalities of the lens of the 
eye, proportionate short stature, brachydactyly, and joint stiffness [25]. These reports, 
together with the current study, and the LTBP2 expression pattern in the trabecular 
meshwork, ciliary body and ciliary process[13], shows underlying pathophysiology of 
LTBP2 in different eye diseases.  
Peroxidasin protein (PXDN) is localized to the cornea and in the layers of the lens 
epithelial. Previous studied identified that it is required for the normal development of the 
anterior chamber of the eye [8]. Therefore, any pathogenic change or mutations affect the 
normal development of the eye and results in various congenital eye anomalies. 
Previously, mutations in PXDN have been reported in families and patients with 
congenital cataracts, microcornea, sclerocornea, developmental glaucoma, and anterior 
segment dysgenesis [8,26] 
In the current study, a novel missense mutation (c.3496G>A; p.Gly1166Arg) is identified 
in the PXDN gene in a Pakistani family with the developmental glaucoma. Mutations 
in the PXDN were previously reported to cause severe inherited eye diseases, such as 
congenital cataract, corneal opacity and developmental glaucoma in Pakistani 
[(c.2638C>T; p.Arg880Cys), (c.2568delC; p.Cys857Alafs*5)] and Cambodian 
(c.1021C>T; p.Arg341X) families [8]. In addition to homozgous mutations identified in 
the current and previous studies, recently, mutations in the PXDN have been identified 
compound heterozygously in a non-consanguineous family with two children who had 
anterior segment dysgenesis, sclerocornea, microphthalmia, hypotonia and developmental 
delays. Both siblings carried a heterozygous nonsense mutation (c.1021C>T; p.Arg341*) 
and a heterozygous 23-basepair deletion leading to a frameshift (c.2375_2397del23; 
p.Leu792Hisfs*67). In addition, a sporadic male patient carried a heterozygous frameshift 
mutation (c.1192delT; p.Tyr398Thrfs*40) and a heterozygous missense substitution 
(c.947 A>C; p.Gln316Pro) [26].  
A Pxdn mutant mouse carrying a premature stop codon mutation was described to have a 
severe anterior segment dysgenesis and microphthalmia, resembling the phenotype in 
patients with PXDN mutations. In the mutant mice, proliferation and differentiation of the 
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lens is disrupted due to the extrusion of lens material outside the lens, and aberrant 
expression of Pax6 and Foxe3 was observed. The defective peroxidasin was described to 
affect the structural integrity of the ocular basement membrane, causing damage to the 
anterior segment of the eye and leading to developmental eye defects. Moreover, the 
PXDN mutants exhibited an early-onset glaucoma and progressive retinal dysgenesis 
[27,28].  
Both affected siblings in the current study had corneal opacity, glaucoma, and 
buphthalmos. The homozygous missense mutation (c.3496G>A; p.Gly1166Arg) affects a 
highly conserved glycine reside in the haem peroxidase domain of the protein. Therefore, 
it is likely that this variant affects the peroxidase activity of the protein, potentially 
leading to impaired integrity of the basement membrane. In summary, we identified two 
novel mutations (c.4934G>A; p.Arg1645Glu and c.4031_4032insA; p.Asp1345Glyfs*6) 
in the LTBP2 gene and one novel mutation (c.3496G>A; p.Gly1166Arg) in the PXDN 
gene in Pakistani families with the PCG and developmental glaucoma. Our study, 
together with previous published studies, suggests that both LTBP2 and PXDN are 
essential for eye development, and are important members of the extracellular matrix 
essential for basement membrane integrity and cell adhesion during the eye development. 
Mutations in both LTBP2 and PXDN can cause diverse phenotypic consequences, 
therefore, more studies are required to contribute to an accurate phenotypic classification 
based on the genetic diagnosis.  
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Abstract: 
Axenfeld–Rieger syndrome (ARS) is a disorder affecting the anterior segment of the eye, 
often leading to secondary glaucoma and several systemic malformations. It is inherited in an 
autosomal dominant fashion that has been associated with genetic defects in PITX2 and 
FOXC1. Known genes CYP1b1, PITX2, and FOXC1 were excluded by Sanger sequencing. 
The purpose of current study is to identify the underlying genetic causes in ARS family by 
whole exome sequencing (WES). WES was performed for affected proband of family, and 
variants were prioritized based on in silico analyses. Segregation analysis of candidate 
variants was performed in family members. A novel heterozygous PRDM5 missense variant 
(c.877A>G; p.Lys293Glu) was found to segregate with the disease in an autosomal dominant 
fashion. The novel missense variant was absent from population-matched controls, the 
Exome Variant Server, and an in-house exome variant database. The Lys293Glu variant is 
predicted to be pathogenic and affects a lysine residue that is conserved in different species. 
Variants in the PRDM5 gene were previously identified in anterior segment defects, i.e., 
autosomal recessive brittle cornea syndrome and keratoconus. The results of this study 
suggest that genetic variants in PRDM5 can lead to various syndromic and nonsyndromic 
disorders affecting the anterior segment of the eye. 
Keywords: Axenfeld-Rieger syndrome, whole exome sequencing, PRDM5.   
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Introduction 
Axenfeld–Rieger Syndrome (ARS; OMIM 180500) is a rare developmental disorder 
inherited in an autosomal dominant manner with an incidence of 1:200,000. ARS is a part of 
phenotypically heterogeneous group of conditions involving anterior segment dysgenesis, 
constituting a wide spectrum of developmental anomalies that may affect the cornea, iris, 
lens, and angle [1] ARS is characterized by a broad range of abnormalities, with evident 
ocular and systemic manifestations.  
Ocular features observed in ARS patients include iris stromal hypoplasia, polycoria, 
corectopia, iridogoniodysgenesis, posterior embryotoxon and iris strands bridging the 
iridocorneal angle to the trabecular meshwork.[2] Increased ocular pressure (IOP) leading to 
glaucoma is the major consequence of the anterior segment dysgenesis observed in ARS, 
with approximately half of the patients developing secondary glaucoma.[3] In addition, ARS 
patients sometimes present with various systemic abnormalities including facial 
dysmorphisms (e.g. hypertelorism, telecanthus, maxillary hypoplasia with flattening of the 
mid-face, prominent forehead, and a broad, flat nasal bridge) and dental abnormalities (e.g. 
microdontia or hypodontia). In the abdominal region, a failure of involution of the skin 
results in redundant periumbilical skin. Hypospadia in males, anal stenosis, pituitary 
abnormalities and growth retardation may also be observed. Systemic changes other than 
these are usually not considered as the classical features of ARS.[4] 
ARS has been associated with mutations in the pituitary homeobox 2 (PITX2; OMIM 
601542) gene at 4q25 [5], and  the forkhead box C1 (FOXC1; OMIM 601090) gene at 6p25. 
[6,7] A third locus was suggested on 13q14, but a disease-causing gene has not yet been 
identified.[8,9]  In two isolated ARS cases, deletion of the 16q23-q24 region [10] and deletion 
of the PAX6 gene at 11p13[11], have been reported.  
The goal of this study was to identify the underlying genetic cause in an autosomal dominant 
ARS family by whole exome sequencing (WES).  
Methods 
Clinical evaluation 
A Pakistani family of Punjabi origin with four affected individuals was included in the study 
(Figure 1). The study adhered to the principles of the declaration of Helsinki, and was 
approved by the institutional ethical review board of Al-Shifa Eye Trust Hospital in 
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Rawalpindi. Blood samples were drawn from affected and unaffected family members, after 
obtaining written informed consent. DNA was extracted using a standard phenol-chloroform 
method.[12] 
Clinical characterization of affected individuals included funduscopy, and measurement of 
intraocular pressure (IOP) with Goldmann applanation tonometry. Assessment of visual field 
defects was performed with a Humphrey Visual Field Analyzer (Carl Zeiss Humphrey 
Systems, Dublin, CA, USA). Anterior insertion of the iris into the trabecular meshwork with 
prominent iris processes was observed by gonioscopic examination. All participants were 
examined by a general physician for the presence or absence of systemic abnormalities.  
Sanger Sequencing  
Known genes cyp1b1, Pitx2, and Foxc1 were excluded by direct Sanger sequencing of the 
coding exonic and flanking intronic regions of the respective genes. Conditions used to 
amplify these genes can be provided on request. 
Exome sequencing and analysis 
To identify the underlying genetic cause of the disease in this family, WES was performed 
using genomic DNA of the proband (VI:3). Enrichment of exonic sequences was achieved by 
using the SureSelectXT Human All Exon V.2 Kit (50 Mb), (Agilent Technologies, Inc, Santa 
Clara, CA, USA). Sequencing was performed on a SOLiD 4 sequencing platform (Life 
Technologies, Carlsbad, CA, USA). Hg19 reference genome was aligned with the reads 
obtained using SOLiD LifeScope software V.2.1 (Life Technologies).  
To evaluate the pathogenicity of the variants obtained from WES, bioinformatic analysis was 
performed using PhyloP (nucleotide conservation in various species), Grantham score (amino 
acid conservation), SIFT (Sorting Intolerant from Tolerant), MutationTaster and PolyPhen2 
(http://genetics.bwh.harvard.edu/pph2/). The presence of potential pathogenic variants was 
confirmed and segregation checked by PCR and Sanger sequencing. Sequencing was 
performed using the Big Dye Terminator Cycle Sequencing-Ready Reaction Kit (Applied 
Biosystems) on a 3130 DNA automated sequencer (Applied Biosystems, Foster City, CA, 
USA) using standard protocols.  
Protein conservation:  PRDM5 protein sequences from different species were aligned to 
study the evolutionary conservation of the mutated amino acid Lys293 using Vector NTI 
Advance 2011. 
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Protein structure prediction: Homology based modeling using HOPE [13] was performed to 
assess the possible structural changes in the mutant protein. The human PDRM5 protein 
sequence (NM_018699, UniProt ID: Q9NQX1) was used to predict the wild-type and mutant 
protein structure 
 
Results 
Clinical characterization  
The proband (VI:3) has an affected father (V:2) and aunt (V:1), and one affected sister (VI:5) 
(Figure 1). The proband was diagnosed at age 4 years. Ocular abnormalities included 
bilateral buphthalmos, correctopia, iris atrophy, corneal opacity, embryotoxon, posterior 
subcapsular cataract and mild vitreous condensation. Funduscopy showed glaucomatous 
atrophy of the optic nerve with a cup-disc ratio (CDR) of 0.7 and 0.6 for the right and left 
eyes, respectively, and IOP measured by Goldmann applanation tonometry was 32 mmHg in 
the right eye, and 36mmHg for the left eye.  
 
Figure 1. Segregation of a PRDM5 missense variant in a family with Axenfeld-Rieger 
syndrome. The c.877A>G; p.Lys293Glu variant is indicated with an M, and the wild-type 
allele with a +. All affected individuals carry the variant heterozygously, while the unaffected 
individuals do not carry the variant. The proband is indicated with an arrow.  
4
303
 
 
 
 
The proband underwent several surgeries for the right eye, including trabeculectomy with 
mitomycin C (MMC) when he was 6 years old. For the left eye cryopexy was done. At 7 
years of age cataract surgery was performed in the right eye, followed by parsplana 
viterectomy with silicone oil as he developed retinal detachment after trauma. He has typical 
facial features of ARS such as telecanthus, a broad nasal bridge, micrognathia, and 
microdontia. His abdominal features included redundant periumbilical skin. Facial 
dysmorphism in individuals VI:3 and VI:5 included flattening of the mid-face, a broad 
forehead, a broad nasal bridge, a thin upper lip with a long philtrum, a protruding lower lip 
and a receding chin  (Figure 2A-F). Both individuals V:1 and V:2 have hearing defects and 
hip joint anomalies. None of the affected individuals have cardiovascular defects. 
 
Figure 2. Ocular and systemic characteristics of the family with Axenfeld-Rieger syndrome 
(a) Eyes of the proband (VI:3) presented bilateral buphthalmos, corectopia, polycoria, 
corneal edema, posterior embryotoxon, posterior subcapsular cataract, vascularized corneal 
opacity and iris atropy patches in the left eye. (b) Both eyes of individual (VI:5) showed 
megalocornea, and posterior embryotoxon. The right eye shows polycoria, and the left eye 
corectopia (c) Facial dysmorphism in individuals VI:3 included flattening of the mid-face, a 
broad forehead, a broad nasal bridge, a thin upper lip with a long philtrum, a protruding 
lower lip and a receding chin (d) Microdontia (e) Micrognathia (F) redundant periumbilical 
skin. Detailed clinical features of the proband &  the other affected individuals are 
summarized in Table 1.   
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Table 1. Clinical evaluation of affected family members 
affected family members V:1 V:2 VI:3 VI:5 
Age (years) 
 
55 60 10 20 
Gender 
 
F M M F 
Eye  
 Iris dysplasia (goniodysgenesis) + + + + 
 Iris hypoplasia + + + + 
 Glaucoma + + + + 
 Early development of nuclear cataract - - + - 
 Polycoria - - + + 
 Corectopia  + + + + 
 Megacornea (Displaced pupils) - - - + 
 Cataract - - + - 
 Telecanthus - - + + 
 Vitreous condensation  + + + + 
Ear  
 
Abnormal ear, Hearing defect + + - - 
Nose  
  Broad nasal bridge + + + + 
Teeth  
  Microdontia  - + + - 
  Micrognatia + + + - 
Abdomen  
  Umbilical defect (redundant periumbilical skin) + + - + 
Joints 
  Congenital hip anomalies + + - - 
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WES Variant selection and segregation analysis of the candidate variants identified 
Variants obtained by WES analysis of the proband were prioritized based upon a dbSNP 
frequency <0.5, nucleotide and amino acid conservation, and by in silico analyses using 
online databases. No variants were present in the known ARS genes PITX2 and FOXC1. 
Therefore, candidate variants present in known genes involved in autosomal dominant 
anterior segment defects and glaucoma [1] (Table 2), were screened for segregation in the 
family.  
A novel, heterozygous missense variant (c.877A>G; p.Lys293Glu) in the PRDM5 gene was 
found to segregate with the disease in the family (Figure 1). The variant (c.877A>G; 
p.Lys293Glu) was absent in population matched controls, and is also absent in the Exome 
Variant Server database (http://eversusgs.washington.edu/EVS/) and in the 1000 Genomes 
Project (http://browser.1000genomes.org/index.html). The variant was predicted to be 
pathogenic by most in silico analyses and is present in a Cys2His2 zinc finger protein domain 
of PRDM5. The lysine residue affected by the variant (c.877A>G; p.Lys293Glu) is conserved 
in all species analyzed (Figure 3).  
 
Figure 3. PRDM5 protein sequence alignment (amino acids 283-303) across species, 
indicating evolutionary conservation of lysine at position 293 in human PRDM5.   
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Protein structure prediction 
Hope project analysis predicted that the lysine residue at position Lys293 is located in the 
linker between two Zn-finger domains (Figure 4). The side chain seems to be completely 
exposed to the exterior surface. The lysine residue is large in size, is basic and is positively 
charged, while the mutant glutamic acid (Glu) is smaller in size, is acidic and is negatively 
charged. The wild-type Lys residue might have been involved in electrostatic interactions 
with other domains of the same protein, or with other molecules in a complex. The mutation 
introduces a residue with a sidechain that is smaller and that carries an opposite charge, and 
therefore the interactions may be lost. 
 
 
Figure 4. Secondary structure of the PRDM5 protein. The Lys residue in the linker region 
between two Zn-finger domains is represented with the green color, and the mutant Glu 
variant is indicated with a red color .  
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Discussion 
In the current study WES identified a novel pathogenic missense variant (c.877A>G; 
p.Lys293Glu) in the PRDM5 gene segregating with the disease in a family with 
autosomal dominant ARS. Previously, variants in the PRDM5 gene have been identified 
in autosomal recessive brittle cornea syndrome (BCS), and an enrichment of potentially 
pathogenic heterozygous variants have been observed in keratoconus.[4,14] In BCS 
patients carrying PRDM5 mutations, a relationship was noted between the zygosity of the 
mutation (homozygous/heterozygous) and the clinical features of the patients and age of 
onset of keratoconus. Heterozygous carriers of PRDM5 mutations have mildly reduced 
central corneal thickness, mild keratoconus, and blue sclera compared to individuals with 
homozygous mutations, who have more severe features. Individuals with BCS who carry 
a homozygous deletion of exons 9-14 have an earlier age of onset and more severe 
keratoconus compared to individuals carrying a mutation heterozygously.[4] A recent 
study proposed that heterozygous variants in PRDM5 and ZNF469 predisposed the 
patients towards the development of isolated keratoconus.[15] These studies support that 
a range of ocular phenotypes are associated with variants in the PRDM5 gene, and the 
current study extends the spectrum to autosomal dominant ARS.  
PRDM5 localizes to human chromosome 4q26 and encodes a member of the family of 
PRDM proteins [16]. PRDM proteins constitute a family of transcription regulators 
characterized by the presence of variable number of zinc finger repeats typically involved 
in protein–DNA or protein–protein interaction,[17] and an N-terminal PR domain which 
shares similarity to the SET domain of histone methyltransferases. PRDM proteins play a 
vital role in gene expression regulation, either directly or indirectly by modifying the 
structure of chromatin i.e. through the intrinsic methyltransferase activity, or via the 
recruitment of chromatin remodeling complexes, respectively. PRDM proteins typically 
display tissue-specific patterns of expression and are often involved in the differentiation 
of specific cell lineages. [18] 
PRDM5 is involved in the development and maintenance of the extracellular matrix 
(ECM), which explains its involvement in BCS and ARS syndromes, which represent 
multisystemic connective tissue disorders. Quantitative PCR analysis of fibroblast RNA 
from BCS patients and control individuals identified significant differences in genes 
involved in the ECM. In particular, genes encoding fibrillar collagens (e.g., COL4A1 and 
COL11A1), connective tissue components (e.g., HAPLN1), and molecules regulating cell 
4
309
 
 
 
 
migration and adhesion (e.g., EDIL3 and TGFB2) were significantly downregulated. 
EDIL3, HAPLN1, and COL11A1 each demonstrated a greater than 30-fold decrease in 
mutant lines relative to controls [4].  
A phenotypic overlap is also present to some extent in BCS and ARS. For example, in 
BCS, sensorineural hearing loss is a prominent feature and was observed in families with 
mutations in PRDM5 described previously by Burkitt Wright et al 2011 [4]. In the current 
study patients V:1 and V:2 with ARS, a progressive sensorineural hearing loss was 
apparent at young age and became severe in adulthood, especially in individual V:2. In 
addition to this most of the affected individuals with BCS described previously had 
experienced hip problems, similar to the patients V:1 and V:2 with ARS in current study. 
The central corneal thickness is reduced in patients with BCS, which is also reported 
previously in patients with ARS who underwent a corneal transplantation and carry 
mutations in PITX2 gene [19]. 
In zebrafish, Prdm5 expression was observed in specific tissues including intestinal 
mucosa, ventral spinal cord and ciliary zone by in-situ hybridization [16]. In addition, 
Prdm5 is highly expressed in the osteoblast region of developing bones in mice [20]. Loss 
of Prdm5 results in delayed ossification, involving a prominent impairment in the 
assembly of fibrillar collagens. The presence of Prdm5 is therefore vital for the proper 
assembly of the osteoblastic extracellular matrix [20]. 
To study the role of Prdm5 during zebrafish development, both loss of function and gain 
of function approaches have been used. Two morpholino oligonucleotides were designed 
to obtain a depletion of Prdm5 protein: one targeting the region comprising the start 
codon (ATGmo), and one targeting the exon1/intron1 splice site (splice blocking or 
SBmo). The ATGmo induced cyclopia, while the SBmo induced closer, smaller eyes and 
marked axial mesendodermal defects in the jaw, heart and blood [16]. This is in line with 
the eye, jaw and heart defects and hip anomalies seen in individuals affected by ARS.  
Other genes involved in ARS, FOXC1[6,7,1] and PITX2[5], also encode transcription 
factors. In addition, mutations in transcription factor PITX3 have been identified in 
anterior segment dysgenesis and congenital cataracts.[5,21] These studies, together with 
the results presented here, support an important role for transcription factors and 
regulators in the development of anterior segment defects. 
Notably, nearly all homozygous PRDM5 mutations detected in BCS patients disrupt the 
open reading frame, suggesting that BCS is associated with loss of function of 
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PRDM5[4]. In this study a heterozygous missense variant in the linker region between 
two zinc finger domains of PRDM5 was identified in autosomal dominant ARS. 
Although the exact mechanism of action of this variant is unknown, it might have a 
dominant negative effect, leading to distinct ocular and extra-ocular features than 
observed in BCS. Mutations in the PITX2 gene are associated with autosomal dominant 
ARS, but both autosomal dominant and recessive mutations have been identified in 
another anterior segment defect (i.e. ring dermoid of the cornea).[22] Both PRDM5 and 
PITX2 are involved in Wnt signaling pathways and are involved in the development of 
multiple organs [16,23]. This suggests that PRDM5 and PITX2 mutations can lead to a 
spectrum of syndromic and nonsyndromic anterior segment defects, with autosomal 
dominant and recessive inheritance patterns. In summary, we describe a novel association 
of a PRDM5 missense variant with autosomal dominant ARS.  
 
Acknoweledgements 
This study was supported by the Stichting Blindenhulp, a Shaffer grant from the 
Glaucoma Research Foundation, the Glaucoomfonds, Oogfonds, and the Algemene 
Nederlandse Vereniging ter Voorkoming van Blindheid (awarded to A. den Hollander 
and S. Micheal).  
 
Conflict of interest 
The authors declare no conflict of interest. 
 
  
4
311
 
 
 
 
References 
1. Ito YA, Walter MA. Genomics and anterior segment dysgenesis: a review. Clin 
Experiment Ophthalmol. 2014; 42:13-24. 
2. Tumer Z, Bach-Holm D. Axenfeld-Rieger syndrome and spectrum of PITX2 and 
FOXC1 mutations. Eur J Hum Genet. 2009:17:1527-1539. 
3. Idrees F, Vaideanu D, Fraser SG, Sowden JC, Khaw PT. A review of anterior segment 
dysgeneses. Surv Ophthalmol. 2006;51:213-231. 
4. Burkitt Wright EM, Spencer HL, Daly SB, Manson FD, Zeef LA, Urquhart J, Zoppi N, 
Bonshek R, Tosounidis I, Mohan M, Madden C, Dodds A, Chandler KE, Banka S, Au L, 
Clayton-Smith J, Khan N, Biesecker LG, Wilson M, Rohrbach M, Colombi M, Giunta C, 
Black GC. Mutations in PRDM5 in brittle cornea syndrome identify a pathway regulating 
extracellular matrix development and maintenance. Am J Hum Genet. 2011;88:767-777. 
5. Semina EV, Reiter R, Leysens NJ, Alward WL, Small KW, Datson NA, Siegel-Bartelt 
J, Bierke-Nelson D, Bitoun P, Zabel BU, Carey JC, Murray JC. Cloning and 
characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, 
involved in Rieger syndrome. Nat Genet. 1996;14:392-399. 
6. Mears AJ, Jordan T, Mirzayans F, Dubois S, Kume T, Parlee M, Ritch R, Koop B, Kuo 
WL, Collins C, Marshall J, Gould DB, Pearce W, Carlsson P, Enerback S, Morissette J, 
Bhattacharya S, Hogan B, Raymond V, Walter MA. Mutations of the forkhead/winged-
helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly. Am J Hum Genet. 
1998;63:1316-1328. 
7. Nishimura DY, Swiderski RE, Alward WL, Searby CC, Patil SR, Bennet SR, Kanis 
AB, Gastier JM, Stone EM, Sheffield VC . The forkhead transcription factor gene 
FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet. 
1998;19:140-147. 
8. Stathacopoulos RA, Bateman JB, Sparkes RS, Hepler RS. The Rieger syndrome and a 
chromosome 13 deletion. J Pediatr Ophthalmol Strabismus. 1987;24:198-203. 
9. Phillips JC, del Bono EA, Haines JL, Pralea AM, Cohen JS, Greff LJ, Wiggs JL. A 
second locus for Rieger syndrome maps to chromosome 13q14. Am J Hum Genet. 
1996;59:613-619. 
312
 
 
 
 
10. Werner W, Kraft S, Callen DF, Bartsch O, Hinkel GK. A small deletion of 16q23.1--
>16q24.2 [del(16)(q23.1q24.2).ish del(16)(q23.1q24.2)(D16S395+, D16S348-, P5432+)] 
in a boy with iris coloboma and minor anomalies. Am J Med Genet. 1997;70:371-376. 
11. Riise R, Storhaug K, Brondum-Nielsen K. Rieger syndrome is associated with PAX6 
deletion. Acta Ophthalmol Scand. 2001;79:201-203. 
12. Sambrook J, Russell D (2000) Molecular Cloning: A Laboratory Manual. 3rd edn. 
Cold Spring Harbor Laboratory New York 
13. Venselaar H, Te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure 
analysis of mutations causing inheritable diseases. An e-Science approach with life 
scientist friendly interfaces. BMC Bioinformatics. 2010;11:548. 
14. Aldahmesh MA, Mohamed JY, Alkuraya FS. A novel mutation in PRDM5 in brittle 
cornea syndrome. Clin Genet. 2012;81:198-199. 
15. Lechner J, Porter LF, Rice A, Vitart V, Armstrong DJ, Schorderet DF, Munier FL, 
Wright AF, Inglehearn CF, Black GC, Simpson DA, Manson F, Willoughby CE. 
Enrichment of pathogenic alleles in the brittle cornea gene, ZNF469, in keratoconus. 
Hum Mol Genet. 2014;23:5527-5535. 
16. Meani N, Pezzimenti F, Deflorian G, Mione M, Alcalay M. The tumor suppressor 
PRDM5 regulates Wnt signaling at early stages of zebrafish development. PLoS One. 
2009;4:e4273. 
17. Fog CK, Galli GG, Lund AH. PRDM proteins: important players in differentiation 
and disease. Bioessays. 2012;34:50-60. 
18. Kinameri E, Inoue T, Aruga J, Imayoshi I, Kageyama R, Shimogori T, Moore AW. 
Prdm proto-oncogene transcription factor family expression and interaction with the 
Notch-Hes pathway in mouse neurogenesis. PLoS One. 2008;3:e3859. 
19. Kelberman D, Islam L, Holder SE, Jacques TS, Calvas P, Hennekam RC, Nischal 
KK, Sowden JC. Digenic inheritance of mutations in FOXC1 and PITX2 : correlating 
transcription factor function and Axenfeld-Rieger disease severity. Hum Mutat. 
2011;32:1144-1152. 
4
313
 
 
 
 
20. Galli GG, Honnens de Lichtenberg K, Carrara M, Hans W, Wuelling M, Mentz B, 
Multhaupt HA, Fog CK, Jensen KT, Rappsilber J, Vortkamp A, Coulton L, Fuchs H, 
Gailus-Durner V, Hrabe de Angelis M, Calogero RA, Couchman JR, Lund AH. Prdm5 
regulates collagen gene transcription by association with RNA polymerase II in 
developing bone. PLoS Genet. 2012;8:e1002711. 
21. Aldahmesh MA, Khan AO, Mohamed J, Alkuraya FS. Novel recessive BFSP2 and 
PITX3 mutations: insights into mutational mechanisms from consanguineous populations. 
Genet Med. 2011;13:978-981. 
22. Xia K, Wu L, Liu X, Xi X, Liang D, Zheng D, Cai F, Pan Q, Long Z, Dai H, Hu Z, 
Tang B, Zhang Z, Xia J. Mutation in PITX2 is associated with ring dermoid of the 
cornea. J Med Genet. 2004;41:e129. 
23. Gage PJ, Suh H, Camper SA. Dosage requirement of Pitx2 for development of 
multiple organs. Development. 1999;126:4643-4651. 
 
314
  
4.5. Variants in the PRPF8 gene are associated with glaucoma.  
 
Shazia Micheal PhD1,2, Barend F. Hogewind MD PhD1, Muhammad Imran Khan PhD3, 
Sorath Noorani Siddiqui FCPS4, Saemah Nuzhat Zafar FCPS4, Farah Akhtar FCPS4, 
Raheel Qamar PhD5,6, Carel B. Hoyng MD PhD1, Anneke I. den Hollander PhD1,3,* 
 
1Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, 
Radboud University Medical Center; Nijmegen, the Netherlands, 2Department of Clinical 
Genetics, Academic Medical Centre, Amsterdam, the Netherlands. 3Department of 
Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud 
University Medical Center, Nijmegen, the Netherlands, 4Department of Pediatric 
Ophthalmology, Al-Shifa Eye Trust Hospital Jhelum Road, Rawalpindi, Pakistan, 
5Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, 
Pakistan, 6Department of Biochemistry, Al-Nafees Medical College & Hospital, Isra 
University, Islamabad, Pakistan 
 
*corresponding author:  Anneke I. den Hollander, Department of Ophthalmology, 
Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical 
Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. E-mail: 
Anneke.denHollander@radboudumc.nl. 
 
Conflict of interest. 
The authors declare no conflict of interest. 
 
Adapted from Mol Neurobiol. 2018; 55(5): 4504–4510. 
4
315
 
 
 
 
Abstract: 
Glaucoma is the cause of irreversible blindness worldwide. Mutations in six genes have 
been associated with juvenile- and adult-onset familial POAG prior to this report but they 
explain only a small proportion of the genetic load.  The aim of the study is to identify the 
novel genetic cause of the POAG in the families with adult onset glaucoma. 
Whole exome sequencing (WES) was performed on DNA of two affected individuals, 
and predicted pathogenic variants were evaluated for segregation in 4 affected and 3 
unaffected Dutch family members by Sanger sequencing. 
We identified a pathogenic variant (p.Val956Gly) in the PRPF8 gene, which segregates 
with the disease in Dutch family. Targeted Sanger sequencing of PRPF8 in a panel of 40 
POAG families (18 Pakistani and 22 Dutch) revealed two additional nonsynonymous 
variants (p.Pro13Leu and p.Met25Thr), which segregate with the disease in two other 
Pakistani families. Both variants were then analyzed in a case-control cohort consisting of 
Pakistani 320 POAG cases and 250 matched controls. The p.Pro13Leu and p.Met25Thr 
variants were identified in 14 and 20 cases, respectively, while they were not detected in 
controls (p-values 0.0004 and 0.0001, respectively). Previously, PRPF8 mutations have 
been associated with autosomal dominant retinitis pigmentosa (RP). The PRPF8 variants 
associated with POAG are located at the N-terminus, while all RP-associated mutations 
cluster at the C-terminus, dictating a clear genotype-phenotype correlation. 
 
Key words: Primary open angle glaucoma, whole exome sequencing, variant, 
pathogenic, PRPF8.  
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Introduction 
Glaucoma is an irreversible optic neuropathy characterized by progressive degeneration 
of retinal ganglion cells (RGCs). It affects more than 70 million people worldwide with 
approximately 10% being bilaterally blind [1]. Glaucoma is also called a silent thief of 
the sight due to the damage of the peripheral vision first. Since glaucoma is typically 
asymptomatic until a substantial loss of vision has occurred, an even higher number of 
people is affected than the numbers estimated worldwide [2, 3]. Typically, glaucoma is 
classified as primary open angle (POAG) and angle closure glaucoma (PACG). POAG is 
the most common type of the glaucoma affecting about 1-2% of individuals over the age 
of 40, with a higher prevalence among African individuals [4-6].  
Despite the fact that glaucoma has different types and distinct etiologies, the death of the 
RGCs is a unifying theme, together with visual field defects and a characteristic optic 
nerve excavative atrophy [7, 8]. Since many years, research efforts have been made to 
elucidate the molecular mechanisms of the progressive optic nerve degeneration, but the 
underlying causes of the disease still remain poorly understood. Genome-wide association 
studies in case-control cohorts have identified several genetic variants associated with 
POAG, but they explain only a small proportion of the genetic load [9]. Although more 
than 15 loci have been identified for glaucoma till date, but only five genes have been 
identified with the causative mutations which includes: MYOC/TIGR,[10,11], 
OPTN,[12,13], ASB10,[14,15], WDR36,[16] EFEMP1,[17,18]. Mutations in sixth gene 
CYP1B1 were initially identified in the patients with the primary congenital glaucoma but 
later association have been reported in sporadic cases and families with both juvenile and 
adult-onset POAG. Mutations in MYOC are responsible for disease only in 4% of the 
JOAG and POAG cases with raised IOP in an autosomal dominant mode of inheritance 
[11]. The overall prevalence of OPTN mutations in POAG is 0.4% and the role of 
WDR36 is still contradictory in glaucoma, even no difference in the phenotype was 
observed between the wild type and heterozygous mice for the WDR36 which makes it a 
weaker candidate for glaucoma. However, ASB10 [14,15] and EFEMP1 [17,18] were 
recently identified and the prevalence of patients with mutations in these genes is difficult 
to conclude. Overall, it has been estimated that less than 10% of POAG cases have 
pathogenic mutations in one of these genes. This suggests that a substantial percentage of 
patients may carry mutations in genes yet to be identified [21].  
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Following this rationale, we performed whole-exome sequencing (WES) in 2 affected 
individuals of a family with adult-onset POAG to find the causative gene for this family.  
 
Materials and Methods 
Subjects 
Patients were recruited at the glaucoma departments of Radboud University Medical 
Center, The Netherlands and Al-Shifa Eye Trust Hospital, Pakistan. The study was 
approved by the Institutional Review Boards of the Department of Ophthalmology, 
Radboud University Medical Center and Al-Shifa Eye Trust Hospital, and adhered to the 
tenets of the Declaration of Helsinki. The families included in the study have at least two 
affected individuals in the family. The sporadic POAG patients were included based on 
the absence of any incidence of glaucoma among the relatives of the patient. Written 
informed consent was obtained from affected and unaffected participants and/or their 
parents to participate in the study and for blood withdrawal. Genomic DNA was extracted 
using AutoPure LS DNA Extractor and PUREGEN reagents (Gentra Systems Inc, 
Minneapolis, Minnesota, USA).  
Clinical Examination 
Complete ophthalmic examinations were performed for both sporadic and familial 
patients. The diagnosis of the POAG was made when the following criteria were met: 
Briefly, absence of secondary glaucoma, an open anterior chamber angle by gonioscopy 
(Shaffer grade III or IV), higher IOP (>22 mmHg) measured using Goldmann applanation 
tonometry, a cup-to-disc ratio (CDR) >0.7 with thinning or notching of the disc rim, and 
nerve fiber layer defects. Visual field defects typical of glaucoma were determined with a 
Humphrey Field Analyzer (Zeiss Humphrey Systems, Dublin, CA, USA) and includes 
arcuate scotoma, nasal step, paracentral scotoma, and generalized depression. Only 
individuals affected with advanced primary open angle glaucoma were included in the 
study while normal tension glaucoma patients were excluded. The controls included in 
the study also underwent the clinical examination and only individuals with the normal 
vision without any eye anomaly and no family history of glaucoma were included in the 
study.  
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Whole-Exome and Sanger Sequencing 
Whole-exome sequencing (WES) was performed in 2 affected individuals of family A, 
(II:3 and II:4, Figure 1a) with adult-onset POAG. The study adhered to the principles of 
the declaration of Helsinki. Written informed consent was obtained prior to the study. 
Genomic DNA was extracted from the peripheral leukocytes of the family members. 
Enrichment of exonic sequences was achieved by using the SureSelectXT Human All 
Exon V.2 Kit (50 Mb), (Agilent Technologies, Inc, Santa Clara, California, USA). 
Sequencing was performed on a SOLiD 4 sequencing platform (Life Technologies, 
Carlsbad, California, USA). The hg19 reference genome was aligned with the reads 
obtained using SOLiD LifeScope software V.2.1 (Life Technologies). The identified 
variants were validated and segregation analysis was performed in all available family 
members using standard PCR and Sanger sequencing. Sequencing was performed using 
the Big Dye Terminator Cycle Sequencing-Ready Reaction Kit (Applied Biosystems) on 
a 3730 DNA automated sequencer (Applied Biosystems, Foster City, CA, USA) using 
standard protocols. 
 
Figure 1. Segregation of PRPF8 variants in glaucoma families. (A). Family A with the 
heterozygous mutation c.2894T>G; p.Val965Gly (M1) in the PRFP8 gene. (B). Family B 
segregating the variant (c.38C>T; p.Pro13Leu (M2). (C). Family C with the heterozygous 
variant c.74T>C; p.Met25Thr (M3) segregating with the disease. 
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Data processing 
To identify the causative variant in this family, only variants shared by both affected 
individuals were considered for further analysis. All variants present within intergenic, 
intronic and untranslated regions and synonymous substitutions were excluded. In 
addition, variants with an allele frequency >0.5 in public databases, including the 
dbSNP132 (http://www.ncbi.nlm.nih.gov/projects/SNP/) and Exome Aggregation 
Consortium (ExAC http://exac.broadinstitute.org/) databases, were excluded. Variants 
that were predicted not to be pathogenic by in-silico prediction including Sorting 
Intolerant from Tolerant (SIFT http://sift.bii.a-star.edu.sg/), MutationTaster 
(http://www.mutationtaster.org/), and Polymorphism Phenotyping (PolyPhen-2 
http://genetics.bwh.harvard.edu/pph2/), variants with a low PhyloP score (<2.7) or a low 
Grantham score (<80) were also excluded. The variants that remained after these filtering 
steps were validated by Sanger sequencing, and segregation analysis was performed in 
the family. Amino acid conservation of mutated residue among the orthologous species 
was assessed by performing the aligned using Vector NTI Advance (TM) 2011 software.  
The amino acid sequences were obtained from protein sequence database UniProt 
(http://www.rcsb.org/pdb/protein/Q6P2Q9). 
 
Results 
Mutation Identification 
Only the rare variants shared between two affected individuals of the family were further 
considered for validation by Sanger sequencing (Table 1). Segregation analysis was 
performed for >20 variants based on the in-silico prediction and expression in the eye. 
Only one novel variant (c.2894T>G; p.Val965Gly) in the PRPF8 gene was identified that 
segregates with the disease in family A (Figure 1a). This variant was predicted to be 
deleterious by SIFT, probably damaging by PolyPhen-2 and disease-causing by Mutation 
Taster. The wildtype nucleotide was highly conserved (phyloP score 5.13), and the amino 
acid residue p.Val965 was highly conserved among different orthologues (Figure 2a). The 
p.Val965Gly variant was not present in the dbSNP132 or ExAc databases, nor was it 
identified in 150 Dutch control individuals.  
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Table 1. Number of variants identified by WES in in two affected individuals of family A 
 Filtering Steps 
Individual 
 II:3 
Individual 
 II:4 
Shared variants for 
both individuals 
Total Variants 45.953 46.860 31.622 
SNP frequency<0.5 29.020 29.688 16.645 
In-house frequency<0.5 2.431 2.519 476 
exonic and canonical splice sites 887 900 175 
Nonsynonmous 646 638 123 
Grantham Score>80 281 274 41 
Phylop>2.7 234 231 46 
 
 
Figure 2. (A). Multiple sequence alignment of PRPF8 orthologues. Conserved amino 
acids are shaded and the positions of mutated amino acids p.Pro13Leu (P), p.Met25Thr 
(M), and p.Val965Gly (V) are indicated with an arrow. (B). Distribution of PRPF8 
mutations in different domains. Conserved domains, PrP8 N-terminal domain (PRO8NT), 
central N-terminal domain in pre-mRNA splicing factors of PRO8 family (PROCN), 
Reverse transcriptase homology domain (RT), Restriction endonuclease homology 
domain (Endo), Ribonuclease H homology domain (RNase H), JAB1/Mov34/MPN/PAD-
1 ubiquitin protease (JAB), C-terminal domain in pre-mRNA splicing factors of PRO8 
family (PROCT). Mutations (indicated in red) associated with autosomal dominant (ad) 
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POAG are all located at the C-terminus of the protein while adRP mutations (indicated in 
black) are all located at the N terminus. 
 
Clinical findings of Family A 
The four affected individuals of family A (Figure 1a) were diagnosed with POAG. They 
all had bilateral glaucomatous optic neuropathy with a cup-to-disc-ratio (CDR) >0.7 on 
fundoscopy with compatible glaucomatous visual field loss. The intraocular pressure 
(IOP) was >22 mmHg and the anterior chamber angles were open in all affected 
individuals. They also showed abnormal results on Heidelberg Retina Tomography 
(HRT) II testing. The visual field and the HRT analysis of the 67-year-old proband 
(family A, individual II:3) and those of a 60-year-old, unaffected male sibling (family A, 
individual II:2) are shown in figure 3. The three unaffected siblings did not show any 
(glaucomatous) optic neuropathy nor visual field loss as present in the four affected 
siblings. 
 
 
Figure 3. Phenotypic characterization of the right eyes of two representative individuals 
of family A with the pathogenic variant in the PRPF8 gene. Each panel has two parts; the 
upper part depicts the visual field printouts of the Humphrey Field Analyzer (HFA) and 
the lower part shows screenshots from Heidelberg Retina Tomograph II (HRT) analysis 
to detect loss of the papillary neuro-retinal rim. (A). HFA and HRT results for the 67-
year-old proband (individual II-3 of family A) are shown. The large dark areas in the 
HFA results correspond to glaucomatous scotomas due to nerve fiber layer defects. HRT 
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scans demonstrate glaucomatous increased optic disc cupping and suspect (exclamation 
marks) or manifest pathological (crosses) neuro-retinal rim measures (according to the 
Moorfield’s regression analysis) within the different quadrants of the optic disc. (B). HFA 
and HRT results for a 61-year-old, unaffected sibling (individual II-2 of family A) of the 
proband are shown for comparison. HFA results indicate that there is no darkening due to 
glaucomatous defects on HFA. The small temporal black area corresponds to the 
physiological blind spot. HRT results (with only green tick marks) show no thinning of 
the neuro-retinal rim. 
 
Panel screening for PRPF8  
Sanger sequencing of the entire open reading frame of PRPF8 in a cohort of 40 adult 
onset POAG families (n=18 Pakistani and n=22 Dutch) having at least two affected 
individuals was performed. Sequencing identified two additional nonsynonymous 
variants, c.38C>T; p.Pro13Leu and c.74T>C; p.Met25Thr, which segregate with the 
disease in families B and C, respectively (Figure 1b, c). Affected individuals in both 
families were diagnosed with adult-onset POAG, with an IOP >21 mmHg and a CDR 
>0.7.  
Both variants are localized in exon 2 of the PRPF8 gene. Therefore, exon 2 was Sanger 
sequenced in a case-control cohort consisting of 320 Pakistani POAG patients and 250 
Pakistani controls. The p.Pro13Leu and p.Met25Thr variants were identified in 14 and 20 
cases, respectively, while they were not detected in controls (p-values 0.0004 and 0.0001, 
respectively). The p.Pro13Leu and p.Met25Thr variants were present in the ExAC 
database, with allele frequencies of 0.00014 (16/113928 individuals) for p.Pro13Leu and 
0.00002 (3/115076 individuals) for p.Met25Thr, respectively. The wildtype nucleotide 
and amino acid residues are highly conserved among different orthologues (Figure 2a).  
Discussion 
The precursor mRNA-processing factor 8 (PRPF8) is the core component of the U5 
snRNP. It is the largest and most evolutionarily conserved protein, central to the 
dynamics of the spliceosome [22,23]. As a key part of the catalytic core of the 
spliceosome, it not only makes direct interactions with the 5′ splice site, branch point, and 
3′ splice site in the pre-mRNA, but also engages the U5 and U6 snRNAs and the excised 
intron [24, 25]. Previous studies have indicated a crucial role of PRPF8 in the vast 
majority of pre-mRNA splicing and its requirement in all tissues [26, 27].  PRPF8 is 
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responsible for processing of the majority of intron-containing transcripts, including 
alternatively spliced mRNAs in higher eukaryotes [28]. Mutations in human PRPF8 that 
affect spliceosome assembly and function are found in autosomal dominant retinitis 
pigmentosa (RP) (OMIM 600059), characterized by a progressive degeneration of the rod 
and cone photoreceptors in the retina [29-31]. All germline mutations reported in the 
PRPF8 gene in patients with RP are clustered at the C-terminus of the protein.    
PRPF8 interacts with other proteins at both the N-terminal and C-terminal of the protein. 
Mutations previously identified in RP are all localized at the C- terminus of the protein 
and affect the binding of the interacting partners with the C-terminus of the PRPF8 
protein. Pathogenic mutations in the Jab1/MPN domain of human PRPF8 have been 
described in RP [29], and mutations of equivalent residues in the yeast Jab1/MPN domain 
disrupt its interaction with Brr2 [32]. Brr2 is involved in catalyzing the separation of the 
U4/U6 snRNA duplex [33]. In addition, the prp8–1 allele G2347D was observed to have 
a detrimental effect on the interaction of Prp8p with Brr2 in yeast two-hybrid and 
coimmunoprecipitation assays [34].  These studies helps to elucidate that mutations 
involved in RP at the C-terminus of the PRPF8 disrupts the interactions with the 
interacting partners important for the splicing.  
In the current study, we identified mutations located at the N-terminus of PRPF8 
associated with glaucoma. We postulate that these variants can disrupt the interaction of 
PRPF8 with its interacting partners at the N-terminus of the protein, such as PRP39 and 
PRP40 [23]. All three variants identified in glaucoma are predicted to be pathogenic 
using different pathogenicity programs and reside within these interacting domains. 
Biochemical studies are needed to determine whether these variants indeed interrupt these 
interactions.  
Human mRNA expression studies have shown that PRPF8 is highly expressed in the 
retinal inner nuclear layer containing the bipolar cells, horizontal cells, amacrine cells and 
Müller glia cells, as well as in the retinal ganglion cell layer. In the photoreceptor cells 
the expression of PRFP8 is comparatively lower [35]. POAG is characterized by loss of 
retinal ganglion cells (RGCs), large and complex cells extending from the inner retina. 
The convergence of the axons of RGCs at the optic disc creates the neuroretinal rim. In 
POAG, the loss of the RGC axons leads to progressive thinning of this neuroretinal rim of 
the optic nerve, thereby enlarging the optic nerve cup. Since PRPF8 is highly expressed 
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in RGC axons, pathogenic variants in PRPF8 could affect the function of the 
spliceosomal machinery in these cells and thus induce POAG.  
The identification of three variants in PRPF8 suggests that POAG may be a splicing 
disease. The PRPF8 variants associated with POAG are located at the N-terminus, while 
all RP-associated mutations cluster at the C-terminus, dictating a clear genotype-
phenotype correlation. 
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Abstract: 
Primary open angle glaucoma (POAG) is a major type of glaucoma characterized by 
progressive loss of retinal ganglion cells with associated visual field loss without an 
identifiable secondary cause. Genetic factors are considered to be major contributors to 
the pathogenesis of glaucoma. The aim of the study was to identify the causative gene in a 
large family with POAG by applying whole exome sequencing (WES). 
WES was performed on the DNA of four affected family members. Shared variants 
among them were filtered for rare, pathogenic variants. Polymerase chain reaction and 
Sanger sequencing were used to analyze variants for segregation with the disease in 
additional family members. WES analysis identified a variant in TP53BP2 (c.109G>A; 
p.Val37Met) that segregated heterozygously with the disease. In silico analysis of the 
substitution predicted it to be pathogenic. The variant was absent in public databases and 
in 180 population-matched controls.  
A novel genetic variant in the TP53BP2 gene was identified in a family with POAG. 
Interestingly, it has previously been demonstrated that the gene regulates apoptosis in 
retinal ganglion cells. This supports that the TP53BP2 variant may represent the cause of 
POAG in this family. Additional screening of the gene in patients with POAG from 
different populations is required to confirm its involvement in the disease.  
 
Keywords: Primary open angle glaucoma, whole exome sequencing, TP53BP2. 
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Introduction 
Glaucoma is a leading cause of irreversible blindness worldwide, affecting more than 60 
million people around the world[1]. Glaucoma comprises a group of heterogeneous optic 
neuropathies, characterized by progressive optic nerve degeneration. The diagnosis of 
glaucoma is usually late since the loss of vision often starts in the periphery and 
progression to the loss of central vision is late. Due to this glaucoma is also called a silent 
thief of sight, with devastating consequences to the patient’s quality of life. Glaucoma is 
classified into two main types; primary and secondary glaucoma. Among primary 
glaucoma subtypes, primary open angle glaucoma (POAG) represent the major type of 
glaucoma affecting about 35 million people worldwide, and is characterized by a juvenile 
or adult onset. Patients with POAG have characteristic glaucomatous optic nerve damage 
with corresponding visual field defects and an open anterior chamber angle at 
gonioscopy, but no other (congenital) anomalies[2,3]. One of the significant risk factors 
for POAG is elevation of intraocular pressure (IOP). However, POAG also occurs in 
patients without elevated IOP, and an elevated IOP does not necessarily lead to POAG[4]. 
The gradual loss of the retinal ganglion cells (RGCs) is a hallmark of the disease along 
with the increased IOP, but the exact pathophysiological mechanisms of the disease are 
not fully understood. Well-studied risk factors associated with POAG include age, family 
history, gender, ethnicity, central corneal thickness, and myopia. In addition, genetic 
factors play an important role in the disease etiology. To date more than 15 loci have been 
identified for glaucoma, and the causative gene has been identified for 5 of these loci: 
GLC1A (MYOC/TIGR)[5,6], GLC1E (OPTN)[7,8], GLC1F (ASB10) [9,10], GLC1G 
(WDR36)[11] GLC1H (EFEMP1)[12,13] In addition, mutations in the CYP1B1[14] gene 
were identified in primary congenital, juvenile onset and adult onset POAG [15-17]. 
Finding the genes that cause glaucoma is the first step in improving early diagnosis and 
treatment of patients suffering from glaucoma. However, only less than 10% of POAG 
cases have pathogenic mutations in these disease-causing genes. It is therefore likely that 
the hereditary aspect of many of the remaining cases of POAG is either in the unidentified 
genes or due to the combined effects of several single nucleotide polymorphisms (SNPs). 
In recent years several genome-wide association studies (GWAS) have identified several 
SNPs at different loci including CAV1/CAV2[18], TMCO1[19], CDKN2B-AS1[20], 
CDC7-TGFBR3[21], SIX1/SIX6[22], GAS7, ATOH7, TXNRD2, ATXN2,  FOXC1[23], to 
be associated with POAG, but they explain only a fraction of the disease heritability. In 
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addition, the mechanisms how the associated loci influence the development of disease 
are often unclear. Therefore, additional genetic studies are required to explain the 
heritability, to gain a better understanding in  the disease etiology, and to define new 
targets for treatment.  
The goal of the current study was to identify the genetic cause of POAG in a large 
multiplex family using whole exome sequencing (WES). 
 
Materials and Methods 
Clinical evaluation 
A large family with 8 individuals affected by POAG and one unaffected individual was 
ascertained. Affected and unaffected individuals were examined by an ophthalmologist at 
the Radboud University Medical Center in Nijmegen, the Netherlands. The study adhered 
to the principles of the declaration of Helsinki, and was approved by the institutional 
ethical review board. Blood samples were drawn from the family members, after 
obtaining written informed consent. DNA was extracted using standard methods.  
Clinical characterization of the affected individuals included slit-lamp examination for iris 
diaphany, funduscopy, and intraocular pressure (IOP) measurement with Goldmann 
applanation tonometry. Assessment of visual field defects was performed with a 
Humphrey Visual Field Analyzer (Carl Zeiss Humphrey Systems, Dublin, CA, USA). 
The decisions about glaucomatous damage on visual fields were based on the diagnostic 
criteria of the Hodapp et al classification[24]. Evaluation of the anterior chamber angle 
was performed by gonioscopy and corneal thickness was calculation by ultrasound 
pachymetry. In addition, a morphometric analysis of the optic disc was carried out by the 
Heidelberg Retina Tomograph II (HRT II; Heidelberg Engineering, Heidelberg, 
Germany), as described elsewhere[25]. An ophthalmic photographer masked to the results 
of the previous tests conducted the examination. The HRT Moorfields regression analysis 
(MRA) was used for classification of the optic disc[26]. The diagnosis of POAG was 
made when the following criteria were met: IOP higher than 22 mmHg (as measured by 
applanation tonometry in both eyes), glaucomatous optic neuropathy present in both eyes 
at funduscopy, visual field loss consistent with assessed optic neuropathy in at least one 
eye, and an open anterior chamber angle by gonioscopy.  
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Whole exome sequencing and analysis 
To identify the underlying genetic cause of the disease in this large family with POAG, 
WES was performed using genomic DNA of four affected individuals (III:1, III:5, III:6, 
and III:8) (Fig. 1). Enrichment of exonic sequences was achieved by using the 
SureSelectXT Human All Exon V.2 Kit (50 Mb) (Agilent Technologies, Inc, Santa Clara, 
California, USA). Sequencing was performed on a SOLiD 4 sequencing platform (Life 
Technologies, Carlsbad, California, USA). The hg19 reference genome was aligned with 
the reads obtained using SOLiD LifeScope software V.2.1 (Life Technologies).  
To identify the causative variant, only the variants shared by the four affected individuals 
were included for further analysis. All variants present within intergenic, intronic and 
untranslated regions and synonymous substitutions were excluded. Variants present in the 
public genetic variant databases, including the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/), dbSNP132 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?build_id=132), and 1000 
Genomes (http://www.1000genomes.org/) with an allele frequency >0.5% were excluded. 
To evaluate the pathogenicity of the variants obtained from WES, bioinformatic analysis 
was performed using the PhyloP (nucleotide conservation in various species) and 
Grantham scores (difference in physicochemical nature of amino acid substitutions). 
Functional predictions were performed using publically available tools i.e. SIFT 
(http://sift.bii.a-star.edu.sg/ Sorting Intolerant from Tolerant), MutationTaster 
(http://www.mutationtaster.org/), and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/ 
Polymorphism Phenotyping). Confirmation of variants and segregation analysis in all 
available family members was performed using PCR and Sanger sequencing. Sequencing 
was performed using the Big Dye Terminator Cycle Sequencing-Ready Reaction Kit 
(Applied Biosystems) on a 3730 DNA automated sequencer (Applied Biosystems, Foster 
City, CA, USA) using standard protocols. Segregating variants were analyzed in 180 
population-matched controls by restriction fragment length analysis.  
Linkage Analysis 
Microsatellite markers with a genetic heterogeneity >60% were selected from the UCSC 
database. Microsatellite markers D1S2655, D1S2891, D1S2629, D1S229 were amplified 
with M13 tailed primers, followed by a second PCR with fluorescently labelled M13 
primers. Fluorescent amplification products were visualized on the ABI-310 genetic 
analyzer, the size of the alleles were determined with 500LIZ (Applied Biosystems, 
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Bleiswijk, the Netherlands) and analyzed with the GeneMapper software version 3.7 
(Applied Biosystems, Bleiswijk, the Netherlands). Multipoint linkage analysis was 
performed for informative markers to determine the Logarithm of the odds (LOD) score 
using the GeneHunter program (version 2.1).11 in the easyLINKAGE Software package 
(http://nephrologie.uniklinikum-
leipzig.de/nephrologie.site,postext,easylinkage,a_id,797.html). For linkage analysis, and 
autosomal dominant inheritance was assumed, with a disease-allele frequency of 0.0001, 
and 95% penetrance. 
 
Results 
Clinical Evaluation 
Table 1 provides detailed clinical information of the 8 affected family members diagnosed 
with POAG. All individuals had open drainage angles on gonioscopy (at least Shaffer 
grade III) and normal results of corneal thickness evaluation. The mean age at diagnosis 
was 54.8 years (range 49–60 years), with a mean IOP of 13.2 ± 2.2 mmHg (after use of 
IOP lowering medications). All individuals had bilateral glaucoma: they had 
glaucomatous optic neuropathy on fundoscopy with reproducible compatible 
glaucomatous visual field loss, and all individuals showed abnormal results on Heidelberg 
Retina Tomograph II testing. A representative color photo of the optic disc of individual 
III-10 with POAG, with the corresponding superior arcuate scotoma on Humphrey visual 
field testing are shown in Fig. 2. From the medical charts we distilled that the mean 
highest IOP recorded on diurnal testing was 23.6 ± 4.7 mmHg. 
Mutation Detection 
In Table 2 the number of variants that passed the various filtering steps per individual for 
the four affected individuals, as well as the variants shared by all four affected individuals 
are shown. The mean coverage of the WES data was 100X. Filtering for variants shared 
between all four affected individuals (III:1, III:5, III:6, and III:8) resulted in nine variants 
for further analysis (Table 3). Segregation analysis was performed for nine variants with a 
phyloP >2.7 or a Grantham score >80 (Table 3). Two novel heterozygous variants in the 
TP53BP2 and MAPKAPK2 genes were found to segregate with the disease in the family 
(Fig.1). 
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Fig. 1. Pedigree of a family with individuals affected by normal pressure glaucoma. The 
(c.109G>A; p.Val37Met) variant in the TP53BP2 gene is indicated with M2, the variant 
(c.305G>A; p.Arg102His) in the MAPKAPK2 gene is indicated with M1, and the wild 
type allele is indicated with WT for both genes together with microsatellite markers 
haplotype. All affected individuals carry both variants heterozygously, while the 
unaffected individuals do not carry the variant.  
 
Fig. 2. Photograph of the optic disc (A) and Humphrey visual field testing (B) of the left 
eye in a 76 year old patient (III-9) with POAG and a corresponding visual acuity of 20/32. 
(A) Photography shows a pallor, glaucomatous excavated optic disc. (B) Visual field 
testing shows a superior arcuate scotoma as well as inferior defects that are congruent 
with the excavation of the optic disc. 
The variant in the TP53BP2 gene (c.109G>A; p.Val37Met) was predicted to be 
deleterious by SIFT, probably damaging by PolyPhen-2 and disease-causing by Mutation 
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Taster (Table 3). The wildtype nucleotide was highly conserved (phyloP score 4.08), and 
the amino acid residue p.Val37 was completely conserved among vertebrates (Fig. 3A). 
The second variant that segregated with the disease in the family was identified in the 
MAPKAPK2 gene (c.305G>A; p.Arg102His) (Fig. 1). This variant was also predicted to 
be deleterious by SIFT, probably damaging by PolyPhen and disease-causing by Mutation 
Taster (Table 3). The wildtype nucleotide was highly conserved (phyloP score 5.69), and 
the amino acid residue p.Arg102 is completely conserved among vertebrates (Fig. 3B).  
Both variants were not identified in 180 population-matched controls and were not 
present in the Exome Variant Server, dbSNP132 and 1000 Genomes. 
 
Fig. 3. 3a: Evolutionary conservation of valine at position 37 is represented by alignment 
of the human TP53BP2 (ASPP2) protein sequence to orthologous protein sequences of 
various vertebrate species. 3b: Evolutionary conservation of arginine at position 102 is 
represented by alignment of the human MAPKAPK2 protein sequence to orthologous 
protein sequences of various vertebrate species.  
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Linkage Analysis 
Twelve microsatellite markers were used for linkage analysis of the genomic region 
encompassing the MAPKAPK2 and TP53BP2 genes, but only four markers were 
informative. A multi-point LOD score of 2.48 was obtained for markers D1S2655 and 
D1S2891, which is suggestive of linkage and is in accordance with the maximum LOD 
score that can be achieved considering the structure of the pedigree. The disease-
associated haplotype encompasses markers D1S2655, the MAPKAPK2 variant, D1S2891, 
D1S2629, D1S229 and the TP53BP2 variant. All affected individuals carry the disease 
haplotype that includes both genetic variants, which indicates that both variants are in the 
same linkage interval and are in an in cis configuration.  
Discussion 
In the current study, we used WES to identify the genetic defect in a large family with 
POAG. We identified potentially pathogenic variants in the TP53BP2 (c.109G>A; 
p.Val37Met) and MAPKAPK2 (c.305G>A; p.Arg102His) genes, which both segregated 
with the disease in the family. A disease-haplotype carrying both variants segregates with 
the disease, with a maximum LOD score of 2.4. Variants in both TP53BP2 and 
MAPKAPK2 are segregating with the disease since both of them are on the same 
haplotype therefore, the segregation of the MAPKAPK2 is a co-incidental finding.  
Since the inheritance pattern was not obvious from the pedigree, we considered both 
recessive and dominant inheritance patterns during the variant prioritization process. 
However, no homozygous or compound heterozygous variants were identified among the 
putative pathogenic variants that were shared between affected individuals, and this thus 
does not support recessive inheritance. Since phenotype data and DNA was not available 
from the deceased parents, we can only speculate that the inheritance pattern may be 
autosomal dominant.  
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 TP53BP2 encodes a member of the ASPP (apoptosis-stimulating protein of p53) family 
of p53-interacting proteins comprised of three members: ASPP1, ASPP2 and iASPP. 
Both ASPP1 and ASPP2 are pro-apoptotic proteins involved in the regulation of the 
apoptosis, and are encoded by the TP53BP2 and iASPP is encoded by PPP1R13B genes, 
respectively [27]. ASPP2 is well known for its binding and activation of the apoptotic 
function of p53, p63, and p73 by selectively enhancing their DNA-binding and 
transactivation activities on pro-apoptotic genes such as BAX and PIG3 [28,27]. 
Apoptosis is tightly regulated during normal development. In the case of abnormal 
regulation, it mediates cell death of neuronal cells in neurodegenerative diseases such as 
Alzheimer's disease or Parkinson’s disease, or death of retinal ganglion cells (RGCs) in 
glaucoma due to over-expression of p53 [29-31]. Recently, the role of ASPP1 and ASPP2 
proteins in neuronal apoptosis and their involvement in the regulation of adult RGCs after 
injury has been investigated. The results indicated that both ASPP1 and ASPP2 are highly 
expressed in RGCs and contribute to  p53-dependent death of RGCs. In glaucoma the cell 
death of the post-mitotic neurons i.e. RGCs occurs due to increased rate of apoptosis. The 
ASPP proteins are involved in the regulation of the apoptosis by activating the P53. Since 
the expression of ASPP2 affects the DNA binding activity of the P53 on the Bax 
promoter/ or downstream targets involved in apoptosis [32]. In the current study, we 
speculate that binding between the ASPP2 and P53 could be affected due to the presence 
of the pathogenic mutation (c.109G>A; p.Val37Met) in the ASPP2 which leads to the 
increased accumulation of the P53 followed by the increase in the cell death of the RGCs 
leading to glaucoma.  Previously, it has been reported that normal ASSP2 protein is 
required for the activation of the apoptosis in the controlled manner. It was observed that 
the blockade of the ASPP-p53 pathway is important for the survival of neurons after 
axonal injury [33]. The results of Wilson et al. are further supported by a recent study in 
an in vivo model of acute optic nerve damage, in which it was shown that iASPP is 
expressed by injured RGCs and short interference RNA (siRNA)-induced iASPP 
knockdown exacerbates RGC death, while RGC survival was enhanced by adeno-
associated virus (AAV)-mediated iASPP expression. Increased expression of iASPP in 
RGCs downregulates p53 activity and blocks the expression of pro-apoptotic targets 
PUMA and Fas/CD95 [34].  
In a recent study , it has been observed that the siRNA interfering the ASPP2 is involved 
in the development of the proliferative vitreoretinopathy (PVR).  Using the epiretinal 
membranes of PVR patients they have examined the expression of ASPP2 using 
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immunohistochemistry and observed reduced expression of the ASPP2 in PVR 
membranes.  In addition, the knockdown of the ASPP2 is involved in increased 
expression of the cytokines such as TGF-β, CTGF, VEGF, TNF-α, and interleukins [35]. 
In glaucoma,  the role of inflammatory cytokines is well known and it could be that the 
pathogenic mutation identified in the ASPP2 is affecting the expression of the 
inflammatory cytokines and interleukins which are mediating the apoptosis of the retinal 
ganglion cells in glaucoma. In another recent study the neuroprotective effect of 
minocycline in rats with glaucoma was evaluated, and downregulation of TP53BP2 was 
observed upon treatment [36]. Minocycline is a tetracycline with anti-inflammatory and 
anti-apoptotic properties. In previous studies it has been shown that minocycline 
significantly delays RGC death in models of experimental glaucoma and optic nerve 
transaction [37].  
Taken together, these studies support the involvement of the TP53BP2 gene in glaucoma, 
and suggest that the genetic variant identified by WES in the large POAG family may be 
relevant to the disease. 
The second variant that segregates with the disease in the family was identified in 
MAPK-activated protein kinase 2 (MAPKAPK2, also known as MK2), which is one of 
the downstream targets of p38 MAPK. The Ocular Tissue Database 
(OTDB, http://genome.uiowa.edu/otdb/) demonstrates a minimal expression in the eye for 
MAPKAPK2 in contrast to TP53BP2. Therefore, TP53BP2 gene seems to be the 
strongest candidate to be associated with the disease in this particular family.  
In conclusion, through WES in a large POAG family we identified a novel genetic variant 
in the TP53BP2 gene, which is predicted to be pathogenic and affects a highly conserved 
amino acid residue., Since it has been demonstrated that the gene regulates apoptosis in 
RGCs and is downregulated upon minocycline-treatment in a glaucoma rat model, 
TP53BP2 may represent a novel gene associated with POAG. Additional screening of the 
TP53BP2 gene in other familial and sporadic patients with POAG from different 
populations is required to confirm its  involvement in the disease.  
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Chapter 5 
 
Discussion
5.1 Genetic studies in glaucoma 
Glaucoma is a multifactorial disease, caused by a combination of genetic and 
environmental factors. In this thesis two approaches were used to identify genes and 
genetic variants associated with glaucoma. In the first part of this thesis, single nucleotide 
polymorphisms (SNPs) with modest effect were assessed for their association with 
different types of glaucoma in case-control cohorts. These variants were selected from 
previous association studies, genome-wide association studies, and from candidate genes.  
Besides its multifactorial nature, glaucoma can also present as a hereditary disease 
in some cases and families. Both dominant and recessive modes of inheritance are known 
in glaucoma. Dominant inheritance is predominant in juvenile onset, adult onset, and 
developmental glaucoma. In congenital glaucoma, however, the recessive pattern of 
inheritance is predominant. In the second part of this thesis, we used different techniques 
for identification of rare variants, mainly using families: homozygosity mapping (in 
recessive families), Sanger sequencing to analyze known glaucoma genes, and next 
generation sequencing to find novel genes. 
Primary open angle glaucoma (POAG) is largely genetically determined, with a 
very high heritability (0.81)[1]. To date, only a small portion of the variation in POAG is 
explained by the genetic variants identified. Yet, combining effects of common and rare 
variants improves discrimination of high-risk groups as measured by the area under the 
curve (AUC) of receiver-operator-curve. The AUC for age, sex, and intraocular pressure 
(IOP) is 0.68, and rare variants improve the AUC significantly by 2%. A similar modest 
but significant increase is achieved by adding common variants, raising the AUC to 0.72 
[2]. It is important to search for new genetic variants and improve discrimination of high-
risk groups further, in order to allow early screening before irreversible vision loss has 
occurred. Another step towards clinical translation will be to improve our understanding 
of the molecular pathogenesis of POAG, allowing the development of new treatments and 
interventions based on molecular evidence. 
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5.2 Common variants in glaucoma 
Patients who do not have a family history of glaucoma are assumed to have a 
multifactorial susceptibility to the disease. During the past years, many loci have been 
identified through with genome-wide association studies (GWAS). The variants identified 
through GWAS studies are relatively common in the population and have relatively 
modest effects sizes, meaning that they are not highly penetrant. The genetic risk of 
glaucoma is due to the combined effect of multiple low-frequency variants present in 
different genes. Each variant confers a moderate effect and is, therefore, considered as a 
risk factor for disease onset. GWAS studies have been performed on the different types of 
glaucoma, and more that 15 loci have been identified for POAG [3-9], eight for primary 
angle closure glaucoma (PACG) [10-12], and two major loci for pseudoexfoliative 
glaucoma (PEXG) [13].[14] 
 In this thesis, we performed replication studies for some of the variants that had 
previously been reported to be associated with POAG and were identified through GWAS 
studies, as well as some SNPs reported to be associated with glaucoma in different 
populations. The patient cohorts on which these replication studies were performed 
included Pakistani POAG, PACG, and PEXG glaucoma patients and controls.  
 In Chapter 2, sections 2.1 and 2.2, eight SNPs from GWAS studies were 
evaluated: CDKN2B-AS1 (rs4977756), CDKN2B (rs1063192), ATOH7 (rs1900004), 
CAV1 (rs4236601), TMCO1 (rs4656461), SIX1 (rs10483727), PDIA5 (rs11720822), and 
BIRC6 (rs2754511). Statistically significant associations of the ATOH7 SNP rs1900004 
with PACG (p=0.03) and of the CAV1 SNP rs4236601 with POAG (p=0.02) were 
detected. However, the frequency of the minor allele (G) of the TMCO1 SNP rs4656461 
was significantly lower in POAG (p=0.003), PACG (p=0.009), and PEXG (p=0.01) 
patients than in controls, which indicates a protective role of this variant in glaucoma. 
Similarly, the minor allele (A) of the rs2754511 SNP in BIRC6 was found to have a 
protective role in PEXG. We were unable to confirm an association of CDKN2B-AS1, 
CDKN2B, and SIX1 SNPs with any type of glaucoma. 
 In section 2.3, the association of SNPs in the matrix metalloprotease genes 
MMP1 (rs1799750), MMP7 (rs11568818), and MMP9 (rs17576) with POAG and PACG 
patients was evaluated comparative to controls. A significant association of the MMP1 
SNP (rs1799750) with POAG (p=0.001) and of the MMP9 SNP (rs17576) with PACG 
(p<0.001) was detected. 
5
351
 
 
 
 
 
 In section 2.4, a significant association of LOXL1 polymorphisms (rs1048661 
and rs3825942) with PEXG was observed, with an odds ratio (OR) of 2.98 (95% CI 1.94-
4.57) and 6.83 (95% CI 2.94-16.67), respectively, for the minor allele.  
 In section 2.5, the association of glutathione S-transferase GSTT1 and GSTM1 
polymorphisms with PEXG was evaluated. A significant association of the three null 
genotype combinations (i.e., T1M0, T0M1, and T0M0) was detected with PEXG. 
 In section 2.6, the association of the tumor necrosis factor alpha (TNF-α) gene 
polymorphism -308G>A (rs1800629), which was previously reported in POAG, was 
evaluated in PEXG patients. We found a significant association of the TNF-α -308G>A 
(rs1800629) polymorphism (p<0.001) with PEXG in Pakistani patients compared to 
controls.  
In summary, we identified significant associations of common variants in ATOH7 
(rs1900004), CAV1 (rs4236601), MMP1 (rs1799750), MMP9 (rs17576), LOXL1 
(rs1048661 and rs3825942), glutathione S-transferases GSTT1 and GSTM1, and TNF-α (-
308G>A) (rs1800629) with different types of glaucoma. On the other hand, common 
variants in TMCO1 (rs4656461) and BIRC6 (rs2754511) were found to be protective for 
glaucoma. Contradictory reports about the association of these common variants with 
glaucoma have been published in previous studies. For instance, in the case of LOXL1 
polymorphisms, replication studies have been successful in finding an association with 
glaucoma in Caucasians from the US [15] and Europe [16], Asians [17-20], and Africans 
[21]. In a few populations, however, the risk alleles in LOXL1 were inverted for their 
association with glaucoma [17, 21].  
We did not find an association with the common variants in the CDKN2B-AS1 
(rs4977756), CDKN2B (rs1063192), SIX1 (rs10483727), PDIA5 (rs11720822), and 
MMP7 (rs11568818) genes, previously reported for their association with different types 
of glaucoma in different populations.  
In addition, new loci have been published in recent years for their association with 
POAG (ABCA1, PMM2, GAS7, TGFBR3, TXNRD2, ATXN2, and FOXC1) [3, 4, 22, 23] 
and PEXG (CACNA1A) [13], which we have not analyzed in our Pakistani cohorts. 
Recently, DNA samples of our Pakistani glaucoma patients were included in a large 
multicenter GWAS with 10,503 PACG cases and 29,567 controls, which identified five 
novel genetic loci that are associated with PACG: EPDR1 (rs3816415), CHAT 
(rs1258267), GLIS3 (rs736893), FERMT2 (rs7494379), and DPM2-FAM102A 
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(rs3739821). In addition, the association of three previously identified loci (PLEKHA7, 
COL11A1, and PCMTD1-ST18) [10]. Rather than studying common variants for their 
association with glaucoma in individual populations, it would be a better approach to 
collaborate worldwide and analyze large global cohorts using robust techniques such as 
GWAS to prove the involvement of a variant in the disease with strong evidence and 
reproducible results. 
5.3 Rare variants in glaucoma 
Rare variants have been associated with different types of glaucoma, anterior segment 
dysgenesis (ASD), and developmental glaucoma. Rare variants can be inherited in a 
Mendelian fashion, either dominantly or recessively, and are usually fully or highly 
penetrant. Rare variants in MYOC, OPTN [24], WDR36, TBK1 [25], ASB10 [26], and 
NTF4 [27] explain less than 10% of POAG cases; the remaining POAG patients are so 
far unexplained and may be multifactorial. On average, MYOC mutations cause 2-4% 
glaucoma; the prevalence of OPTN mutations varies from 0-6%; WDR36 variants occur 
in about 3.7% of patients [28], NTF4 variants occur in 1.7% of patients [27], and about 
1.2% of patients are explained with variants in TBK1 [25, 29, 30]. However, the 
prevalence or frequencies of variants in the ASB10 and EFEMP1 genes in glaucoma is 
not clear yet, as only two studies have been published for the ASB10 gene [26] and one 
for the EFEMP1 gene [31]. Therefore, more studies need to be performed for the 
association of ASB10 and EFEMP1 variants with glaucoma before any conclusion can be 
reached.  
 In congenital glaucoma patients, the CYP1B1 gene is frequently mutated, 
ranging between 20-100% in primary congenital glaucoma (PCG) cases from Japan, 
Saudi Arabia, and Slovakian gypsies [32]. Rare variants in LTPB2 explain only a small 
number of Pakistani and gypsy families [33], while variants in this gene have not been 
found in other populations. 
Homozygosity mapping 
In inherited disorders, the recessive mode of inheritance is more frequent in African and 
Asian populations (http://www.consang.net/index.php/Global_prevalence) because of 
high rates of consanguinity [34]. In countries with a high rate of consanguinity, such as 
Pakistan and Saudi-Arabia, autosomal recessive inheritance forms are very prevalent. The 
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rate of consanguineous marriages in Pakistan ranges between 31% to 62%, and it can be 
as high as 80% in some areas [35]. Pakistan may have the largest number of 
consanguineous families in the world. Similarly, consanguineous marriages are very 
common in Saudi Arabia: 50% of the marriages in Riyadh are between cousins, and 30-
40% of these are between first cousins [36, 37]. Consanguineous families with 
recessively inherited disease are very suitable for finding novel genetic causes of disease, 
and identification of novel loci could help to understand the underlying mechanisms of 
the disease. Gene discoveries in many diseases have been made possible by using 
homozygosity mapping either alone or in combination with next- generation sequencing 
[38]. 
Most families included in the current study were recruited from Pakistan. The 
families were clinically diagnosed with PCG and juvenile-onset open angle glaucoma 
(JOAG). The pedigree structure of many of these families suggested disease transmission 
in an autosomal recessive manner due to frequent consanguineous marriages. In a 
recessive family, a single affected child can give as much information for linkage of the 
disease trait to a genetic locus as three children in a non-consanguineous family. In 
children born from consanguineous marriages, the causative mutation in the majority of 
families is located in a homozygous chromosomal segment shared between the affected 
individuals of the family because they are descendants of a common ancestor. An 
approach that can effectively be used in such families to identify the genetic defect is 
homozygosity mapping. The algorithm Homozygous Mapper can be used for identifying 
homozygosity or autozygosity in recessive families [39].  
In sections 3.6, 4.1, and 4.2, homozygosity mapping was used to map the 
causative defects in families with recessive forms of glaucoma. As a next step, we 
searched for the causative genetic defects using Sanger sequencing and next-generation 
sequencing (NGS). In section 3.6, homozygosity mapping revealed a large homozygous 
region of 11-Mb on chromosome 2 harboring CYP1B1 gene, therefore, the exon-intron 
boundaries of the gene were sequenced. A homozygous variant 
(c.1169G>A;p.Arg390His) was identified in CYP1B1 and found to segregate with the 
disease phenotype within the family.  In section 4.1, in a family with brittle cornea 
syndrome, several homozygous regions were identified. The largest homozygous region 
of 46.7 Mb encompassing the PRDM5 gene was on identified on chromosome 4. A novel 
homozygous splice site variant (c.93+5C.T) in the PRDM5 gene and a homozygous 
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missense variant (c.11T.G; p.Gln4Pro) in the SEC24D gene were found to segregate with 
the disease phenotype. In section 4.6, a combination of both homozygosity mapping and 
NGS helped to identify a variant in novel DBX2 gene located in the homozygous region 
on chromosome 12.   
Sanger sequencing  
In this thesis, Sanger sequencing of genes that were previously found to harbor rare 
variants in glaucoma was performed. Sanger sequencing was carried out for the CYP1B1, 
MYOC, OPTN, WDR36, ASB10, FOXC1, PAX6, PITX2, and FBN1 genes using probands 
of the families and, in some cases, in sporadic patients as well. Upon identification by 
Sanger sequencing, segregation analysis of the pathogenic variant was performed in the 
families. 
In Chapter 3, section 3.1, Sanger sequencing of the ASB10 gene was performed in 
probands of 30 Pakistani families. Three missense variants (p.Arg49Cys, p.Arg237Gly, 
and p.Arg453Cys) were identified in the probands of three families, but none of these 
were found to segregate with the disease. However, sequencing of additional POAG 
patients and controls revealed a significant association of rare variants in the ASB10 gene 
with glaucoma, and were considered risk factors for the disease. 
In section 3.2, Sanger sequencing of the FOXC1 gene revealed a homozygous 
deletion (c.92_100del; p.Ala31_Ala33del) in a family with PCG and Axenfeld-Rieger 
syndrome (ARS). Previously, FOXC1 mutations were associated only with ARS in an 
autosomal dominant manner, and in this study, we for the first time reported an autosomal 
recessive inheritance pattern for FOXC1 mutations. In addition, a novel variant 
(c.454T>C; p.Trp152Arg) was found to segregate in a Mexican family with ARS. A 
novel de novo mutation (c.225C>A; p.Tyr75*) in PAX6 was found to segregate in a 
family with aniridia and was also identified in one proband from Pakistan. A recurrent 
variant (c.649C>T; p.Arg217*) was also found to segregate with the disease in a family 
with aniridia. 
In section 3.3, Sanger sequencing of the FBN1, TGFBR1, and TGFBR2 genes was 
performed in a proband of a large family affected with Marfan syndrome and glaucoma. 
A heterozygous mutation was identified in the FBN1 gene that segregated with the 
disease in the family. The pathogenic mutation (p.Cys790Ser) changes a cysteine residue 
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localized in the 12th cbEGF domain, required for forming a disulphide bridge by bonding 
with a second cysteine residue in this domain.  
In section 3.4, 32 probands with POAG were sequenced for the MYOC and OPTN 
genes, and sequencing did not reveal any pathogenic variations. However, screening of 
additional glaucoma patients with POAG, PACG, and PEXG revealed an association of 
rs11258194 in the OPTN gene (OR 2.85 [95% CI=1.15-7.06]; p=0.02) with POAG. 
Sanger sequencing of WDR36 and PITX2 in families with glaucoma and ASD, 
respectively, did not reveal any pathogenic variant. 
In section 3.5, 34 Saudi Arabian PCG patients were sequenced for the CYP1B1 
gene, and 79.4% of patients were solved with pathogenic mutations, while 20.6% 
remained unsolved. Among these 34 patients, 18 patients belonged to eight different 
families, and all except one individual had bilateral PCG. In Saudi Arabia, 80% of the 
PCG patients were previously solved with mutations in the CYP1B1 gene [40]. The 
results of the current study are therefore consistent with previously published studies, 
demonstrating that CYP1B1 mutations are the major cause of PCG in Saudi Arabia.  
In section 3.6, we employed homozygosity mapping to find the genetic defect in a 
family with congenital to juvenile onset glaucoma. Homozygosity mapping identified an 
11-Mb homozygous region on chromosome 2, which encompassed the CYP1B1 gene, and 
subsequent Sanger sequencing identified a homozygous CYP1B1 mutation that 
segregated with the disease in this family. 
Next-generation sequencing 
In Chapter 4, section 4.1, a combination of homozygosity mapping and NGS was used to 
identify the causative gene in a family with brittle cornea syndrome (BCS). A novel 
variant was identified in the PRDM5 gene in this family. The variant is located near a 
splice site (c.93+5G>A), but cDNA analysis not did identify exon skipping or intron 
retention. Subsequent NGS analysis revealed a homozygous variant in the SEC24D gene, 
which is located in the same homozygous region as PRDM5, and which also segregates 
with the disease in this family. It therefore remains unclear whether the PRDM5 or the 
SEC24D variant is the cause of BCS in this family. 
In section 4.2, a large family with nine affected and eight unaffected individuals, 
with an age of onset of glaucoma ranging between 10-70 years, was analyzed using 
combination of  homozygosity mapping and NGS to identify the genetic defect 
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underlying the disease. Both affected and unaffected members of the family were 
genotyped with SNP microarrays, and subsequent homozygosity mapping identified a 
large homozygous region of 35 Mb on chromosome 12. This region contains many genes, 
and whole exome sequencing (WES), therefore, was performed for the four affected 
individuals of the family. As WES yields millions of variants per patient, only shared rare 
variants were considered for further analysis after discarding common SNPs, variants 
present in the publically available databases, and non-coding and synonymous variants. 
More than 100 plausible candidate variants needed further evaluation by filtering for 
pathogenic variants. When the filter was applied to the homozygous region revealed by 
homozygosity mapping analysis, this revealed a homozygous variant in the DBX2 gene, 
which segregated with the disease in the family. This study demonstrates that the 
combination of homozygosity mapping and NGS is a powerful approach to identify new 
disease genes, and this approach has helped to identify novel genes in many diseases in 
recent years [41-43]. 
In section 4.3, novel mutations were identified in families with PCG and 
developmental glaucoma using WES. A novel missense mutation (c.4934G>A; 
p.Arg1645Glu) and a novel frameshift mutation (c.4031_4032insA; p.Asp1345Glyfs*6) 
in the LTBP2 gene were identified to segregate with the disease in two PCG families. In a 
family with developmental glaucoma, a novel mutation (c.3496G>A; p.Gly1166Arg) was 
identified in the PXDN gene. 
In section 4.4, a novel heterozygous variant in the PRDM5 gene was identified in 
a family with ARS, segregating with the disease in an autosomal dominant manner. 
Previously, mutations in the gene were known for BCS in recessive families, but this 
study for the first time identified autosomal dominant inheritance of a PRDM5 mutation.   
In section 4.5, NGS identified variants in the PRPF8 gene in glaucoma families. 
The mutations segregate with glaucoma in families with POAG (c.2894T>G; 
p.Val965Gly, c.38C>T; p.Pro13Leu, and c.74T>C; p.Met25Thr). In addition, two of 
these variants were also found to be associated with glaucoma in a case-control cohort. 
Interestingly, the risk alleles for glaucoma are located at the N-terminus of the protein 
(c.38C>T; p.Pro13Leu, and c.74T>C; p.Met25Thr), while mutations previously identified 
in retinitis pigmentosa (RP) are located at the C-terminal of the protein. 
In section 4.6, WES was performed in a family with POAG. Filtering for rare 
pathogenic variants identified a variant in the TP53BP2 gene that was found to segregate 
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with the disease in this family. The identification of potential novel glaucoma disease 
genes and novel genotype phenotype associations in this chapter demonstrates that WES 
is a powerful technique for finding novel targets and pathways involved in the 
pathogenesis of glaucoma.  
5.4 Understanding the disease mechanisms of glaucoma 
Over the last two decades, genetic studies have made significant progress in revealing the 
genetic basis of various types of glaucoma considering the monogenic/Mendelian 
transmission (mainly in families with glaucoma) and the multifactorial nature of the 
disease due to the combined effect of the multiple common variants (mainly in sporadic 
cases with glaucoma). These genetic studies have contributed to a better understanding of 
the disease mechanisms, which are outlined in this section. In addition, these genetic 
studies have clinical relevance, such as establishing a more accurate diagnosis or enabling 
early disease detection, and for developing new treatments based on the disease 
mechanisms (discussed in section 5.5).  
Glaucoma is a complex disease, and the mechanism of the pathogenesis of glaucoma is 
not completely understood, although many disease genes have been identified through 
genetic studies. The genetic causes of glaucoma and associated developmental disorders 
can be categorized based on their functional effects, which include structural defects in 
the extracellular matrix and basement membranes, defects in pathways leading to 
apoptosis, and defects in gene transcription.   
Structural defects in the extracellular matrix and basement membranes 
In multicellular organisms, the extracellular matrix (ECM) is the key component that is 
responsible for making a complex network of different proteins (Figure 1) [44], involved 
in filling the extracellular spaces and maintaining the organization of tissues by providing 
structural support. In addition, the ECM is important for providing flexibility and 
elasticity to the tissues, anchorage, and vital information required for cellular functions, 
including proliferation, migration, differentiation, and death. 
Pathogenic changes in the components of ECM have been reported in different types of 
glaucoma, both dominantly and recessively, which results in degeneration of the RGCs. 
The main constituents of the ECM include fibronectin, collagenous and elastic fibers, and 
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microfibrils. Both elastic and non-elastic tissues contain microfibrils, which are essential 
for the formation of elastic fibers and play a vital role in the transforming growth factor 
beta (TGFβ) signaling pathway [45, 46]. The pathogenic involvement of microfibrils in 
glaucoma has been suggested, as LOXL1 is strongly associated with PEXG. LOXL1 is a 
member of the lysyl oxidase family of enzymes and is involved in the crosslinking of 
collagens, elastin, and tropoelastin as well as in the formation of the ECM [47]. 
 
Figure 1. Schematic illustration of the ECM and its components (Ref. 44). 
  
Fibullin proteins also play an important role in the ECM. The family of fibullin proteins 
(fibullin 1-6) is characterized by tandem arrays of calcium-binding epidermal growth 
factor-like domains (cbEGF) and a fibulin-type module at the C-terminus, which is shared 
with the fibrillins. Fibullin-3 (also called EFEMP1) is connected to tropoelastin and 
involved in the assembly of the elastic fibers. EFEMP1 plays a vital role in maintaining 
the integrity and stability of both the basement membrane and the ECM. Mutations have 
recently been identified in the EFEMP1 gene at the GLC1H locus for glaucoma [31]. A 
GWAS also identified the association of EFEMP1 variants with optic nerve changes, 
which are characteristic for glaucoma [48]. Although the exact mechanism of EFEMP1 
involvement in glaucoma is not known, the structure of the basement membrane/ ECM 
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may be interrupted due to the impaired function of the protein, leading to changes in the 
drainage of the aqueous humor, which results in glaucoma. 
Recessive mutations in LTBP2 have been identified in families with congenital 
glaucoma, [33] and more than 3,000 dominant mutations have been revealed in the FBN1 
gene in Marfan syndrome [49]. FBN1 belongs to a family of fibrillin proteins constituting 
the main component of the microfibrils in both elastic and non-elastic tissues in the ECM 
[50]. In addition, mutations in transforming growth factor beta receptor 1 (TGFβR1) and 
TGFβR2 are known to cause Marfan syndrome, and variants in transforming growth 
factors TGFβ1, TGFβ2 and TGFβ3 are associated with glaucoma [51-53]. In glaucoma, 
an increased IOP of the eye, due to the deposition of the damaged ECM in the trabecular 
meshwork (TM) and Schlemm’s canal, results in scarring and fibrosis of the TM. This is 
also mediated by TGFβ, as higher levels were observed in the aqueous humor of 
glaucoma patients [54-56]. In the ECM, TGFβ is also involved in modulating the 
expression of other proteins, such as matrix metalloproteinases (MMPs), well known for 
their association with glaucoma [57]. MMP-2 and MMP-9 are involved in the degradation 
and activation of the latent TGFβ [58]. MMP-9 is specifically involved in TGFβ1-
mediated fibrosis, which results in a higher IOP in mice. 
LTBP2, known for pathogenic mutations in PCG, is also involved in ECM 
maintenance. The C-terminal region of LTBP2 interacts with the N-terminus of fibrillin 
1, a constituent of the microfibrils [59]. In addition, LTBP2 plays an important role in the 
TGFβ signaling pathway and interacts with TGFβ1 to avoid excessive TGFβ1 signaling. 
Upon the binding of TGFβ1 to TGFBR2, phosphorylation and activation of TGFBR1 
takes place, which results in downstream signaling and activation of transcription factors 
(Figure 2) [60]. LTBP2 is implicated in the formation of elastic fibers in developing 
elastic tissues [61]. In the presence of mutations in LTBP2, it fails to bind with FBN1, 
which may be due to changes in the structure of the protein [61]. In addition, lens 
dislocation was observed in LTBP2 null mice, which could be due to interrupted 
organization of ciliary zonules, comprising microfibrils [61]. When the shape of the 
ciliary processes and surrounding tissues/structures is disturbed, this leads to a high IOP 
and apoptosis of RGCs due to glaucoma. 
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Figure 2.  Genetic defects in components of the TGF-β signaling pathway (Ref. 60) 
 
Basement membranes support many ocular tissues, such as the cornea, the lens, the retina, 
and vasculature [62]. Basement membranes are specialized structures of the ECM 
constituted of laminin-entactin/nidogen complexes and proteoglycans. Type IV collagens 
(COL4A1-COL4A6), however, are most abundant and have gained much attention for 
their involvement in ASD and glaucoma [63-65]. In ENU-induced mutant mice, 
heterozygous missense mutations in the col4a1 gene cause ARS including all typical 
ocular phenotypes, such as iris defects, corneal opacity, iris/corneal adhesions, 
buphthalmos, cupping of the optic nerve, and glaucoma [66]. 
 In the basement membrane, collagen IV is assembled into sheet-like networks 
through the sulfilimine bond catalyzed by peroxidasin (PXDN) through the synthesis of 
hypohalous acid [67]. Mutations in PXDN have been identified in recessive families with 
developmental glaucoma. In zebrafish, morpholino knockdown of peroxidasin shows that 
the collagen IV cross-link plays an essential role in the ECM and organogenesis [67, 68]. 
The exact mechanism of PXDN involvement in glaucoma is unknown. However, 
peroxidases are important in catalyzing the oxidation reaction of various compounds to 
avoid oxidative stress due to the production of reactive oxygen species in the aqueous 
humor, which affects the development of anterior segments of the eye and increases IOP 
[69].  
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Defects in pathways leading to apoptosis  
Cell death/apoptosis of the retinal ganglion cells in response to elevated IOP is a hallmark 
of glaucoma, resulting in progressive vision loss. As glaucoma is a complex disease, 
multiple pathways have been found to be responsible for programmed cell death in 
glaucoma. These pathways are triggered by both intrinsic and extrinsic factors and cause 
cell death either alone or in interaction. The most common pathways include: deprivation 
of neurotrophic factor, oxidative stress and ischemia, mitochondrial/endoplasmic 
reticulum-related stress and dysfunction, axonal transport failure, improper glial 
activation, loss of synaptic connectivity, and excitotoxicity. In glaucoma, communication 
between the survival promoters such as neurotrophins and proapoptotic signals involved 
in the activation of the caspase pathway or impaired function of the mitochondria are 
important in determining the fate of the RGCs [70, 71]. 
Neurotrophins are growth factors involved in the regulation of neuronal growth, 
survival, and synaptic plasticity. They play a key role in the activation of members of the 
tropomyosin-related kinase (Trk) family of receptor tyrosine kinases and a member of the 
tumor necrosis factor receptor superfamily, p75 neurotrophin receptor [72]. In glaucoma, 
the proper functioning of neurotrophins is pivotal; in animal models, for instance, Brain-
Derived Neurotrophic Factor (BDNF) protects the RGCs from injury and disease [73, 
74]. Pathogenic variants in the NTF-4 neurotrophic factor are considered to be a rare 
cause of glaucoma [75]. NTF-4 is involved in the activation of the TrkB receptor and in 
protection of the RGCs, and decreased expression of TrkB is related to the loss of RGCs 
[76-78]. In addition, it has been observed in vitro that mutated NTF4 induces impaired 
TrkB signaling and neuronal growth [27].  
In glaucoma, apoptosis is also induced by oxidative stress due to the excessive 
production of nitric oxide (NO) or reactive oxygen species (ROS). A significant amount 
of DNA damage has been observed in the TM of glaucoma patients compared to controls 
due to oxidative stress. Staining of nitrotyrosine in the optic nerve heads of glaucoma 
patients indicates that reactive nitrogen species might cause the programmed death of the 
retinal ganglion [79]. Under normal conditions, a state of equilibrium exists between the 
production of ROS and anti-oxidation, but in glaucoma the two processes are disturbed, 
and excessive production of free radicals takes place mostly in the mitochondria. These 
ROS act as the second messengers in the downstream signaling pathways and affect the 
signaling cascade. 
362
 
 
 
 
 
MYOC, known to be involved in glaucoma, also interacts with the mitochondria 
in the TM. The most frequent mutation associated with glaucoma (Pro370Leu) is 
responsible for changing the membrane potential of the mitochondria as it alters the Ca2+ 
concentration and ATP production. These changes in the mitochondria affect the TM 
function and lead to cell death [80]. MYOC mutations also induce ER stress, which leads 
to impaired function of the TM [81]. ER stress is also responsible for ROS accumulation, 
causing oxidative stress as well. Both ER and oxidative stress in mitochondria impair the 
essential functions and render them incapable of performing the normal physiological 
functions, causing disease [82]. Different enzymes are involved in the regulation of 
oxidation, detoxification to remove toxic compounds, and anti-oxidation: superoxide 
dismutase, catalase, glutathione peroxdiase, and glutathione transferase, such as GSTT1 
and GSTM1. Polymorphisms in enzymes involved in the detoxification process have 
been associated with increased risk of glaucoma [69, 83].  
Another gene associated with glaucoma, OPTN, is also involved in apoptosis [24]. 
It has been observed that the variant E50K induces cell death in the RGCs due to 
excessive production of ROS, disturbance in the membrane potential of the mitochondria, 
lower levels of bcl-2, and higher levels of Bax, leading to cytochrome c release from the 
mitochondria, activation of caspase-9 and caspase-3, and apoptosis [24, 84]. This 
indicates that a mitochondrial caspase-dependent cell death pathway is involved in 
glaucoma patients carrying OPTN mutations. In addition, it has been proposed that cell 
death due to mutations in OPTN might be induced by oxidative stress, and experiments 
have been performed showing that cell death was inhibited by the addition of antioxidants 
[85]. The expression of OPTN is also induced by TNF-α, which is therefore also 
considered to be a part of the TNF-α-induced signaling pathway leading to cell death 
[86]. In addition, there is also a negative feedback regulation through which TNF-α-
induced NF Kappa B activity mediates expression of OPTN. Polymorphisms in TNF-α 
are considered to be risk factors for glaucoma, especially for PEXG. 
 
Pathogenic mutations in WDR36 have been associated with glaucoma, and are also 
related to the apoptosis pathway. The loss of function of WDR36 activates the p53 stress-
response pathway, which plays a crucial role in apoptosis [87, 88]. Apoptotic cell death 
and upregulation of mRNA expression of Bax, TP53, and CDKN1A was reported in the 
cultured human TM cells deprived of WDR36 mRNA [89]. 
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In the current thesis, a novel pathogenic variant in the TP53BP2 gene was 
identified in a large Dutch POAG family. TP53BP2 is a member of the apoptosis-
stimulating protein family of p53 and is involved in the regulation of apoptosis and cell 
growth by interacting with other members of the p53 family. TP53BP2, also known as 
ASPP2, is the common activator of all p53 proteins together with ASPP1 [90]. The p53 
family proteins, such as TP53 and p21, have been associated with glaucoma in different 
populations [91, 92]. Both ASPP1 and ASPP2 bind to p63 and p73 in vitro and in vivo 
and activate the transactivation function of p63 and p73 on the promoters of the Bax, 
PIG3, and PUMA genes and boost the apoptotic function of p63 and p73 by inducing the 
expression of p53 target genes [90]. 
Defects in gene transcription  
The development of the human eye is a complex process involving multiple factors, such 
as growth hormones, proteins, enzymes, and transcription factors regulating the 
expression of different genes. For proper development of the eye, the normal expression 
and function of these regulatory proteins is very important. However, impaired function 
of these proteins due to deleterious mutations or other changes could hamper their normal 
function, which could result in developmental eye anomalies or defects at a later age. 
Numerous transcription factors have been implicated in the development of the eye, such 
as PITX2 and FOXC1, which are involved in early embryogenesis. In the mouse, at 
E10.5, which is equal to the fifth week of human gestation, Pitx2 is activated in the 
anterior-most cells, and Foxc1 is expressed in the posterior periocular cells around the 
optic stalk [93]. 
 Pathogenic mutations have been identified in genes encoding transcription 
factors in different eye anomalies, in particular in PITX2, PAX6, and FOXC1 in glaucoma 
and ASD [94, 95]. Normally, transcription factors regulate gene expression by binding to 
enhancers and recruiting the cofactors and RNA polymerase II to the target genes. 
Transcription is a complicated procedure involving multiple components, and can be 
deregulated by defects in transcription factors, the splicing factors, binding of 
transcription factors to specific DNA sequences, recruitment and regulation of the 
transcription machinery. Due to pathogenic changes in genes regulating these functions, 
pathological conditions can occur. In the current thesis, we identified novel and known 
mutations in transcription factors in families with glaucoma and ASD. In addition, a 
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novel mutation was identified in transcription factor PRDM5 in a family with autosomal 
dominant ARS, while mutations in PRDM5 were previously identified in BCS with an 
autosomal recessive mode of inheritance.  
 We also identified pathogenic variants in the PRPF8 gene, encoding an 
important player in the splicing machinery, in POAG families. Previously, mutations in 
the PRPF8 gene were identified in retinitis pigmentosa patients which are localized at the 
C-terminus of the protein, while the variants identified in glaucoma are located at the N-
terminus of the protein. Therefore, a potential novel genotype-phenotype correlation of 
PRPF8 has been established. PRPF8 is one of the major proteins of the spliceosome 
complex involved in pre-mRNA splicing. The splicing event in eukaryotes removes the 
intervening introns and joins the exons to form the mature mRNA for translation. 
Splicing involves a complex of five small nuclear ribonucleoproteins (snRNPs) U1, U2, 
U4, U5, and U6 as well as additional factors to catalyze the transesterification reactions. 
PRPF8 is a component of U5 snRNP as well as U4/U5/U6 tri-snRNP and interacts with 
the 5’ splice site, the branch point adenosine, and the 3’ splice site in pre-mRNA, 
suggesting that PRPF8 plays a role as a cofactor in the catalytic domain of the 
spliceosome [96-98]. 
 
5.5 Clinical relevance of genetic studies in glaucoma 
Establishing a more accurate diagnosis and enabling early disease detection 
Genetic studies have led to the identification of genetic causes of inherited forms of 
glaucoma, now allowing genetic counseling in families with glaucoma mainly for the 
PCG with the recessive mode of inheritance. In case of the consanguineous marriages it is 
important to inform the family members about the transmission of the genetic risk within 
their next generations. Especially in Pakistani population people prefer to marry within 
their own families due to religious and social set-up which needs to be changed to 
decrease the risk of the inherited diseases. In the families with such diseases physico-
educational sessions should be arranged for the disease intervention. Genetic counseling 
should be an integral component of the health system to provide an adequate information 
to the family for their decision making and betterment.  
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In addition, the identification of the genetic causes of glaucoma can enable a better 
clinical diagnosis. Some diseases can have a clinical overlap making it difficult to 
establish an accurate diagnosis, for example in Marfan syndrome and BCS. The proband 
of the Pakistani family described in section 4.1 was originally diagnosed with Marfan 
syndrome, but the genes known to be involved in Marfan syndrome were excluded for 
this family. After a variant in the PRDM5 gene had been identified in this family using 
WES, clinical re-examination was done by the ophthalmologist. The family was then 
diagnosed with BCS instead, with frequent corneal ruptures and perforations in the 
affected members of the family due to minor injuries or trauma. Therefore, genetic 
analysis can help in establishing the correct diagnosis of the disease phenotype. 
Genetic studies including large GWAS studies have led to the identification of SNPs that 
are associated with multifactorial forms of glaucoma. However, these SNPs account for 
only a small proportion of the genetic variability of glaucoma. Therefore, reliable genetic 
testing for multifactorial forms of glaucoma cannot yet be offered. Additional genetic 
studies are needed to identify SNPs that account for a larger proportion of the genetic 
variability. This would then allow early disease detection, allowing treatments to be 
initiated before irreversible vision loss has occurred.   
Developing new treatments based on disease mechanisms 
Glaucoma is a complex disease, and its main determinant is increased IOP. Conventional 
glaucoma treatments, therefore, focus on decreasing IOP through different strategies, 
including lowering aqueous humor production, enhancing the outflow through the TM, 
and/or modulating the outflow through the uveoscleral pathway. Numerous IOP-lowering 
eye drops are available for topical use. Reducing IOP using these drops decreases loss of 
vision by 20-40%. Typically, IOP-lowering drugs are divided into five groups (Table 1A) 
[99]. 
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Table 1. Glaucoma therapies used in the clinic 
(A) IOP-Lowering Drugs 
Class Example Method of IOP reduction 
Parasympathomimetic 
Cholinomimetics (cholinergic agonists) 
Pilocarpine Increase Aqueous Humor (AH) 
outflow 
Sympathomimetics 
Adrenergic receptor agonists 
Brimonidine  Reduce AH production; increase 
outflow 
β-Adrenergic receptor antagonists (β-
blockers) 
Timolol Reduce AH production 
Carbonic anhydrase inhibitors Dorzolamide Reduce AH production 
Prostaglandin analogues Latanoprost Increase uveoscleral outflow 
(B) Surgery 
Type Purpose 
Primary angle closure glaucoma 
Laser peripheral iridotomy (LPI) To widen the iridocorneal angle 
Iridoplasty To widen the iridocorneal angle 
Argon laser peripheral iridoplasty (ALPI) To create space between the anterior iris surface and the 
TM by contraction burns 
Phacoemulsification cataract extraction 
(phaco/IOL) 
To alleviate pressure by removal of lens 
Primary open angle glaucoma 
Glaucoma filter, surgery/trabeculectomy To allow AH to bypass TM and alleviate pressure by 
partial removal of drainage angle 
Trabeculectomy with shunt/stent To alleviate pressure by trabeculectomy with addition of 
shunt or stent  
Trabeculoplasty To alleviate pressure by opening drainage channels 
Footnote: Adapted from Donegan et al. 2016 
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These medications can be used alone, or a combination can be used in patients in which a 
single drug does not have an effect. The fixed combinations used include prostaglandin 
analogs with β-blockers, carbonic anhydrase inhibitors with β-blockers, α2-adrenergic 
agonists with β-blockers, and carbonic anhydrase inhibitors with α2-adrenergic agonists. 
The only exception is Mexico, where a fixed combination of three drugs can be used for 
treatment, including prostaglandin analogs, α2-adrenergic agonists and β-blockers. All 
these drugs were approved for use by the US Food and Drug Administration (FDA).  
Patients in whom eye drops are not effective for lowering IOP are treated surgically to 
lower IOP. Various surgical methods are available for treating the different types of 
glaucoma (Table 1B) [100].  
In addition to eye drops and surgical treatments, therapeutic approaches have been 
designed for the different disease mechanisms involved in glaucoma. Some have been 
discontinued after the first or second phase of clinical trials, such as a selective inhibitor 
for Rho- associated protein kinases (ROCKs) [101], while some have been approved for 
treating glaucoma, such as Ripasudil in Japan [102]. Additional targets are also being 
considered for reducing IOP and for establishing neuroprotection (Table 2). Recent 
studies have also identified novel targets involved in different pathways for treatment of 
glaucoma.  
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Table 2: Therapeutic strategies under consideration for glaucoma 
Drug target Proposed therapeutic mode of action 
Angiopoietin-like 
molecules 
Increase TM outflow through reorganization of the ECM 
Cannabinoids Decrease AH production and increase TM outflow; may also 
be neuroprotective 
Cochlin Regulation may modulate TM outflow 
CTGF Increase TM outflow by modification of TM actomyosin 
cytoskeleton 
Endothelin 1 Increase TM outflow by relaxation of TM; also shown to be 
neuroprotective of RGCs 
Ghrelin Increase TM outflow by relaxation of the TM 
Latrunculins Increase TM outflow by reducing cell contractility and cell-
cell and cell-matrix adhesions; drugs have reached human 
trials 
MMP-2, MMP-9 Increase TM turnover; possible neuron regeneration in retina 
Melatonin Increase TM outflow through adrenoceptor and 
cholinoceptor modulation 
Myocilin Decrease TM cell stress and death 
Nerve Growth Factor  Protect RGCs from neurodegeneration 
Nitric oxide (NO) Increase TM outflow by relaxation of the TM and ciliary 
muscle; a NO-donating prostaglandin drug has entered 
clinical trials 
Transforming growth 
factor β (TGF-β) 
 
Increase TM outflow through ECM remodeling or 
modification of the actin cytoskeleton 
Footnote: Adapted from Donegan et al. 2016  
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In addition to the topical eye drops and surgery for high pressure glaucoma to reduce 
IOP, a gene therapy approach could also potentially spur progress in treating glaucoma by 
delivering anti-apoptotic and anti-inflammatory genes into the retinal cells to arrest the 
progression of the disease. In glaucoma, however, only a few genes are known 
accounting for a small percentage of cases, and discovery of novel genes is relatively 
slow. In the current thesis, we have identified potential novel glaucoma genes, such as 
TP53BP2 for autosomal dominant POAG. TP53BP2 is involved in the apoptosis 
pathway, mediating the death of the RGCs as well as facilitating the increased expression 
of TGF-β, CTGF, VEGF, TNF-α, and interleukins, which mediate cell death in 
glaucoma. Another potential novel glaucoma gene, DBX2, was identified in a large 
consanguineous JOAG family. DBX2 is involved in the development of the eye and 
neurogenesis, and expression of the gene is regulated by retinoic acid (RA), which is 
also involved in the regulation pathway of the CYP1B1 gene. 
In addition, a potential novel genotype-phenotype correlation was established 
for the PRPF8 gene. PRPF8 is an important component of the splicing machinery, 
and mutations are known in retinitis pigmentosa, affect the transitions between the 
splicing steps, and influence splicing efficiency [103]. The results of the current thesis 
helped to identify potential novel therapeutic targets for glaucoma, which could be 
targeted by gene therapy in the future. 
However, a bottleneck of gene-therapy-based experiments is a safe and efficient 
method for drug delivery to the optic nerve. Currently, the clinically feasible option for 
gene delivery to the RGCs is through either intravitreal or subretinal injections. These 
methods, however, lead to many complications, such as hemorrhages, retinal detachment, 
and pre-retinal fibrosis [104, 105]. Therefore, other noninvasive and pain-free methods 
should be considered for gene therapy. In a mouse model with high IOP, successful 
adeno-associated virus-mediated gene delivery of the soluble Fas ligand to the retina has 
recently helped in neuroprotection, mediated by the membrane-bound Fas ligand, which 
is pro-inflammatory and pro-apoptotic. Neuroprotection was correlated with decreased 
production of the inflammatory cytokine TNF-α, inhibition of glial activation, decreased 
rate of cell death of RGCs, and loss of axons [106].  
The advent of the possibility to generate patient-specific induced pluripotent stem 
cells (iPSCs) and their differentiation into tissues of the eye, has opened up a new door 
for glaucoma treatment. In addition, such cells can be used to confirm the pathogenesis of 
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the mutations responsible for the disease and to test the effect of new treatments. 
Recently, the pathogenic effect of the most frequent variant in OPTN (E50K) was 
determined in iPSCs from a patient and an unaffected individual of the family. As the 
mutated protein forms aggregates and is less soluble, the expression of OPTN protein in 
the affected individual was lower than that in the normal control. The successful 
generation of TM from iPSCs was also shown [107], which could be used to study 
MYOC-associated mutations and to design disease mechanism-specific therapeutics.  
Recently, iPSC-derived TM cells were transplanted into the anterior chamber of a 
mouse model of glaucoma, which decreased IOP by improving the aqueous humor 
outflow, stimulated the survival of the RGCs, and helped to improve vision. Both in vivo 
and in vitro experiments showed higher TM cellularity in treated mice than in littermate 
controls. The results of this study help to demonstrate the in vivo regeneration of 
glaucomatous TM, rendering this a potential novel treatment option for glaucoma [108]. 
Taken together, these studies create opportunities to improve our understanding of the 
mechanisms of the disease and to take one step further to advance glaucoma treatment. 
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5.6 Final remarks and future perspectives 
The genomic revolution over the last decades has led to tremendous achievements in 
finding novel genes and pathways involved in glaucoma, which could be targeted in 
novel therapeutic approaches to glaucoma. In this thesis, we used the power of previous 
techniques, such as homozygosity mapping, to find novel mutations in known genes and 
to identify novel genes by combining the results with new methods, such as NGS. The 
combination of two techniques helps to reduce the number of variants identified through 
WES and to pinpoint the causative genetic defects. 
 The results of this thesis will improve the molecular diagnostics of different 
types of glaucoma and ASD, will improve the identification of high-risk groups, and will 
improve our understanding of the known and novel mechanisms involved in the 
pathogenesis of the disease. Genetic counseling in families with inherited forms of 
glaucoma should be done for awareness-raising purposes about the risks involved in 
consanguineous marriages, particularly in countries such as Pakistan, where cousin 
marriages are very common. Large consortiums for family-based studies and GWAS in a 
large number of populations should be established to find additional genetic causes of the 
disease. 
The susceptibility genes for glaucoma identified in this study and in other familial and 
GWAS studies worldwide will help to provide novel targets for gene-based and cellular 
therapies for glaucoma. New model systems for glaucoma are now emerging, including 
patient-specific iPSCs that can be differentiated into cell types relevant for the disease, 
which can be used to increase our understanding of the disease pathways and to test novel 
targets for treatment. 
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Summary 
Glaucoma is a complex neurodegenerative disorder and the leading cause of irreversible 
blindness worldwide. The disease is genetically, physiologically, and phenotypically 
complex. Glaucoma is subdivided into primary and secondary types which may be 
associated with additional systemic anomalies causing different syndromic phenotypes. In 
this thesis, Chapter 1 (Introduction) explains the structure of the eye and related tissues 
involved in the pathogenesis of disease, different types of glaucoma, associated 
syndromes, genetic risk factors and their heritability.  
In addition, Chapter 1 explains the different techniques and approaches used in this thesis 
to identify genetic risk factors and novel candidate genes for glaucoma. Since glaucoma 
is a multifactorial disease, in particular in sporadic cases, analysis of single nucleotide 
polymorphisms (SNPs) in cases-control studies is described. In addition, the use of 
unbiased approaches through genome-wide association studies (GWAS) is explained. 
Next-generation sequencing offers new ways to identify rare variants causing disease. 
These rare variants may have a large effect size compared to the common variants and 
may in particular be involved in familial and/or Mendelian forms of glaucoma. We 
reviewed all potential candidate genes involved in different types of glaucoma identified 
through case-control studies, genome-wide association studies and by combining high-
throughput technologies such as linkage analysis, homozygosity mapping and next-
generation sequencing. The function and disease pathobiology of all genes identified in 
families with different types of glaucoma, anterior segment dysgenesis and 
developmental glaucoma are explained briefly. Mutations in the known genes for 
glaucoma are estimated to explain only 5% of the causes glaucoma. Other causes may be 
explained by a combination of genetic and environmental factors.  
Chapter 2 (Association of glaucoma with single nucleotide polymorphisms) explains 
genetic risk factors in different types of glaucoma taking into consideration the common 
variant model for sporadic patients. However, SNPs identified in previous studies explain 
only less than 2-fold risk effect of the disease. In Chapter 2 we aimed to replicate the 
results of SNPs identified through GWAS studies using our Pakistani cohort of primary 
open angle glaucoma (POAG), primary angle closure glaucoma (PACG) and 
pseudoexfoliative glaucoma (PEXG) patients. We confirmed the association of a number 
of SNPs in the Pakistani case-control cohort, however, others were not associated. This 
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lack of association could be due to the different environmental and genetic background of 
the Pakistani population.  
In Chapter 3 (Candidate gene sequencing), we performed Sanger sequencing of genes 
previously associated with glaucoma and associated syndromes (CYP1B1, MYOC, OPTN, 
ASB10, FOXC1, PAX6, PITX2, FBN1) in families from Pakistan. Novel rare pathogenic 
variants were identified in the analyzed genes in Pakistani families with PCG, POAG, 
anterior segment dysgenesis and Marfan syndrome. In addition, in Chapter 3 we 
demonstrate that homozygosity mapping is a powerful tool to locate the position of the 
genetic defect in recessive consanguineous families.  
In Chapter 4 (Whole exome sequencing for identification of novel genes), comprised of 
six subchapters. Using high-throughput sequencing technology (whole exome 
sequencing, WES) all coding exons in the genome were sequenced, which identified rare 
variants in known glaucoma genes (LTBP2, PRDM5, PXDN) in consanguineous Pakistani 
families and in a novel gene (TP53BP2) in a dominant Dutch POAG family. 
Homozygosity mapping together with WES identified a novel candidate gene, DBX2, in a 
large consanguineous family with JOAG, and rare variants in the PRDM5 gene in a 
family with brittle cornea syndrome. PRDM5 gene variants were also identified in 
Axenfeld Rieger’s syndrome. A novel genotype-phenotype association was found for 
variants in the PRPF8 gene in large Dutch and Pakistani families with glaucoma.  
In Chapter 5 the main findings, future prospective and implications of this thesis are 
discussed. The power of combining homozygosity mapping and next-generation 
sequencing to identify disease-causing mutations in recessive families is underlined. 
Disease mechanisms involved in the neurodegeneration in glaucoma and developmental 
syndromes with secondary glaucoma are also elaborated. The major pathways involved in 
glaucoma are categorized into three main subcategories, which includes defects in 
basement membranes and extracellular matrix, defects in apoptosis/cell death 
mechanisms, and defects in transcription regulation based on previous studies and results 
of this thesis. The challenges in clinical diagnosis using limited resources in Pakistan are 
highlighted, and the value of the identification of the genetic defect to help establish the 
proper diagnosis is discussed. In addition, past and present treatment strategies for 
glaucoma are explained. In future research, patient-specific induced pluripotent stem cells 
can be used to differentiate cells relevant to the disease site in the eye, which can help to 
understand the disease mechanisms and to design new treatment options. 
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 Samenvatting 
Glaucoom is een complexe neurodegeneratieve aandoening en de belangrijkste oorzaak 
van onomkeerbare blindheid wereldwijd. De ziekte is genetisch, fysiologisch en 
fenotypisch complex. Glaucoom is onderverdeeld in primaire en secundaire typen die 
gepaard kunnen gaan met bijkomende systemische anomalieën die verschillende 
syndromische fenotypen veroorzaken. In dit proefschrift wordt in hoofdstuk 1 (Inleiding) 
de structuur van het oog en verwante weefsels beschreven die betrokken zijn bij de 
pathogenese van ziekten, verschillende soorten glaucoom, geassocieerde syndromen, 
genetische risicofactoren en hun erfelijkheid. 
Daarnaast worden in hoofdstuk 1 de verschillende technieken en benaderingen 
beschreven die in dit proefschrift worden gebruikt om genetische risicofactoren en 
nieuwe kandidaatgenen voor glaucoom te identificeren. Aangezien glaucoom een 
multifactoriële ziekte is, in het bijzonder in sporadische gevallen, wordt de analyse van 
single nucleotide polymorphisms (SNPs) in case-control studies beschreven. Daarnaast 
wordt het gebruik van objectieve benaderingen via genoom-brede associatiestudies 
(GWAS) uitgelegd. Next-generation sequencing biedt nieuwe manieren om zeldzame 
varianten te identificeren die de kunnen veroorzaken. Deze zeldzame varianten kunnen 
een groot effect hebben in vergelijking met de gangbare varianten en kunnen met name 
betrokken zijn bij familiale en / of Mendeliaanse vormen van glaucoom. We hebben alle 
potentiële kandidaat-genen onderzocht die betrokken zijn bij verschillende soorten 
glaucoom. Deze genen waren geïdentificeerd door case-control studies, genoom-brede 
associatiestudies en door het combineren van high-throughput technologieën zoals 
linkage-analyse, homozygosity mapping en next-generation sequencing. De functie en 
pathobiologie van alle genen die geïdentificeerd waren in families met verschillende 
soorten glaucoom, anterieure segment dysgenese en ontwikkelingsglaucoom worden kort 
uitgelegd. Mutaties in de bekende genen voor glaucoom verklaren naar verwachting 
slechts 5% van de verklaren. Andere gevallen zouden kunnen worden verklaard door een 
combinatie van genetische en omgevingsfactoren. 
Hoofdstuk 2 (Vergelijking van glaucoom met single nucleotide polymorfisms) verklaart 
genetische risicofactoren in verschillende soorten glaucoom, rekening houdend met het 
gebruikelijke variantmodel voor sporadische patiënten. SNP's die in eerdere onderzoeken 
werden geïdentificeerd, verklaren echter slechts een minder dan twee voudig risico effect 
op de ziekte. In Hoofdstuk 2 hebben we de resultaten van de SNP's die geïdentificeerd 
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werden door middel van GWAS-onderzoeken met behulp van ons Pakistaans cohort van 
primaire openhoek glaucoom (POAG), primaire hoeksluiting glaucoom (PACG) en 
pseudoexfoliatieve glaucoom (PEXG) patiënten. We bevestigden de associatie van een 
aantal SNP's in het Pakistaanse case-control cohort, maar anderen waren niet 
geassocieerd. Dit gebrek aan associatie kan te wijten zijn aan de verschillende milieu- en 
genetische achtergrond en van de Pakistaanse bevolking. 
In Hoofdstuk 3 (Kandidaat gen sequencing) hebben we Sanger sequencing uitgevoerd van 
genen die eerder geassocieerd waren met glaucoom en geassocieerde syndromen 
(CYP1B1, MYOC, OPTN, ASB10, FOXC1, PAX6, PITX2, FBN1) in families uit 
Pakistan. Nieuwe zeldzame pathogene varianten werden geïdentificeerd in de 
geanalyseerde genen in Pakistaanse families met PCG, POAG, anterieure segment 
dysgenese en Marfan syndroom. In hoofdstuk 3 demonstreren we bovendien dat 
homozygosity mapping een krachtig hulpmiddel is om de positie van het genetische 
defect in recessieve bloedverwanten te lokaliseren. 
In Hoofdstuk 4 (Whole exome-sequencing voor de identificatie van nieuwe genen), 
bestaat uit zes subhoofdstukken. Met behulp van de high-throughput sequence 
technologie (whole exome sequencing, WES) werd van alle coderende exonen in het 
genoom de sequentie bepaald. Zeldzame varianten warden geidentificeerd in bekende 
glaucoomgenen (LTBP2, PRDM5, PXDN) in consanguine Pakistaanse families. Ook 
werd een nieuw gen (TP53BP2) geidentificeerd in een dominante Nederlandse POAG-
familie. Homozygosity mapping samen met WES identificeerde een nieuw kandidaat-
gen, DBX2, in een grote consanguine familie met JOAG, en zeldzame varianten in het 
PRDM5-gen in een familie met bros hoornvlies syndroom. PRDM5-genvarianten werden 
ook geïdentificeerd in het Axenfeld Rieger-syndroom. Een nieuwe genotype-fenotype 
associatie werd gevonden voor varianten in het PRPF8-gen in grote Nederlandse en 
Pakistaanse families met glaucoom. 
In hoofdstuk 5 worden de belangrijkste bevindingen, toekomstverwachtingen en 
implicaties van dit proefschrift besproken. De kracht van het combineren van 
homozygosity mapping en NGS om ziekteverwekkende mutaties in recessieve families te 
identificeren, is onderstreept. Ziektemechanismen die betrokken zijn bij de 
neurodegeneratie bij glaucoom en ontwikkelingssyndromen met secundair glaucoom 
worden ook uitgewerkt. De belangrijkste pathways betrokken bij glaucoom zijn 
onderverdeeld in drie hoofd categorieën, waaronder defecten in basaalmembranen en 
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extracellulaire matrix, defecten in apoptose / celdoodmechanismen en defecten in 
transcriptieregulatie op basis van eerdere studies en resultaten van dit proefschrift. De 
uitdagingen in de klinische diagnose met behulp van beperkte middelen in Pakistan 
worden benadrukt, en de waarde van de identificatie van het genetische defect om te 
helpen bij het vaststellen van de juiste diagnose wordt besproken. Bovendien worden 
vroegere en huidige behandelingsstrategieën voor glaucoom uitgelegd. In toekomstig 
onderzoek kunnen patiëntspecifieke geïnduceerde pluripotente stamcellen worden 
gebruikt om cellen te differentiëren die relevant zijn voor de ziekte in het oog, die kunnen 
helpen de ziektemechanismen te begrijpen en nieuwe behandelingsopties te ontwerpen. 
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